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Abstract 
Systematic problems in the supply chain of second-line anti-TB drugs (SLDs) for multi-
drug-resistant tuberculosis (MDR-TB) are well documented and contribute significantly 
to the comprehension of the difficulties preventing successful control of the disease. 
Though literature contains a wealth of proposed changes to global SLD supply chain 
policies, there is a significant research gap related to quantitative modelling of the SLD 
supply chain to accurately predict the expected impact of these proposed changes on 
the availability of SLDs.  
The global SLD supply chain consists of two components: (i) the ‘upstream’ component 
which includes all activities from the manufacturing of the active pharmaceutical 
ingredient through to the warehousing of drugs prior to shipment; and (ii) the 
‘downstream’ component which includes in-country warehousing and delivery of drugs 
to various healthcare facilities. A prominent problem in the supply chain, is the erratic 
demand patterns, since these prohibit accurate forecasting and effective planning. 
Consequently, manufacturers are forced to produce drugs in inefficient batch sizes, 
causing higher prices and longer, inconsistent lead times. A possible solution to address 
this problem, is the implementation of a large buffer stockpile directed at (i) preventing 
stock-outs and treatment interruptions, and (ii) combining and timing orders to permit 
current manufacturers to produce medicines more efficiently. 
The aim of this study is to model a part of the upstream supply chain of MDR-TB SLDs 
and to evaluate the impact of implementing such a buffer stockpile. The supply chain is 
modelled using system dynamics and the model is used to evaluate the likely impact 
of a range of alternative inventory management policies on the supply chain 
performance. Three different SLD formulations are included in the model to ensure that 
the recommendations based on this research are robust. These formulations, namely 
capreomycin, kanamycin and cycloserine, account for approximately 58% of the total 
procurement costs of the current supply chain.  
The modelling results indicate that the inventory policies that will most likely lead to the 
most significant improvement in the supply chain performance, are the policies that 
implement a reorder quantity based on an exponential smoothing forecast of previous 
demand, specifically when a smoothing factor of either 0.1 or 0.5 and a high reorder 
point are implemented.  
This research contributes to the current academic literature by increasing the 
understanding of the upstream SLD supply chain, by providing a quantitative evaluation 
of the expected impact of suggested changes to the supply chain, and by presenting 
an example of an application of the system dynamics modelling approach that is not 
common in literature.  
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Opsomming 
Sistematiese probleme in die voorsieningsketting van tweede lyn anti-TB-middels 
(SLDs) vir multi-weerstandbiedende tuberkulose  (MDR-TB) is goed gedokumenteer en 
maak ‘n aansienlike bydrae om die probleme wat die suksesvolle beheer van die siekte 
voorkom, te verstaan. Alhoewel literatuur 'n rykdom van voorgestelde wysigings aan 
die globale SLD voorsieningsketting bevat, is daar 'n beduidende navorsing gaping wat 
verband hou met die kwantitatiewe modellering van die SLD voorsieningsketting om 
die verwagte impak wat hierdie voorgestelde wysigings aan die beskikbaarheid van 
SLDs sal hê, akkuraat te voorspel. 
Die globale SLD voorsieningsketting bestaan uit twee komponente: (i) die 'stroomop’ 
komponent wat alle aktiwiteite van die vervaardiging van die aktiewe farmaseutiese 
bestanddeel, tot die verpakking van die teenmiddels vir distribusie, insluit; en (ii) die 
‘stroomaf’ komponent wat die binnelandse (nasionale) pakhuise en die aflewering van 
teenmiddels na verskeie gesondheidsorg fasiliteite insluit. 'n Prominente probleem in 
die voorsieningsketting is die dinamiese en wisselvallige aanvraag patrone vir die 
teenmiddels, aangesien dit akkurate vooruitskatting en effektiewe beplanning verhoed. 
Gevolglik word vervaardigers gedwing om die teenmiddels in onekonomiese 
hoeveelhede te vervaardig wat hoër pryse en langer wagtye tot gevolg het. 'n 
Moontlike oplossing om hierdie probleem aan te spreek, is die implementering van 'n 
groot buffer voorraad wat gerig is op: (i) die voorkoming van onderbrekings in die 
behandeling van MDR-TB, deur te verseker dat daar altyd teenmiddels op voorraad is; 
asook (ii) om beter tydsberekening toe te laat om die verskeie bestellings te kombineer, 
sodat huidige vervaardigers die teenmiddels meer doeltreffend kan produseer. 
Die doel van hierdie navorsing is om 'n deel van die ‘stroomop’ voorsieningsketting van 
MDR-TB SLDs te modelleer en om die impak wat 'n buffer voorraad op die 
voorsieningsketting kan hê, te evalueer. Die model is ontwikkel deur ‘n Stelsel Dinamika 
Modellering benadering en word gebruik om die moontlike impak van 'n 
verskeidenheid alternatiewe voorraadbestuur beleide op die voorsieningsketting te 
evalueer. Drie verskillende SLD formulerings is ingesluit in die model om te verseker 
dat die aanbevelings, op grond van hierdie navorsing, robuus is. Hierdie formulerings, 
naamlik capreomycin, kanamycin en cycloserine, is verantwoordelik vir ongeveer 58% 
van die totale aankoopkoste van die huidige voorsieningsketting. 
Die resultate van die modellering dui daarop dat die voorraadbestuur beleid wat meer 
waarskynlik sal lei tot die mees beduidende verbetering in die voorsieningsketting, is 
die beleide waar die herbestel hoeveelheid bepaal word op grond van 'n 
eksponensiële ‘gladstryking’ voorspelling van vorige aanvraag, spesifiek wanneer ‘n 
‘gladstryking’ faktor van óf 0.1 of 0.5 en 'n hoë herbestelvlak geïmplementeer word. 
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Hierdie navorsing dra by tot die huidige akademiese literatuur deur die begrip van die 
stroomop SLD voorsieningsketting te verbeter, deur 'n kwantitatiewe evaluering van die 
verwagte impak van voorgestelde wysigings aan die voorsieningsketting te verskaf en 
deur 'n voorbeeld van ‘n Stelsel Dinamika Modellering te verskaf, wat nie algemeen in 
die literatuur is nie. 
Stellenbosch University  https://scholar.sun.ac.za
Page | vii 
Acknowledgments 
I am immeasurably grateful to my study leader, Louzanne Bam. Without her dedication, 
guidance, direction and support this research would not have been possible.  
I give a special note of thanks to Prashant Yadav for steering us in the right direction, 
with regard to data as well as our understanding of the supply chain. 
To Adam de Beer, who supported me throughout this thesis more than anyone could 
realise, I give very special thanks for the constant encouragement and support in the 
preparation of this final report.  
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
Table of contents  Page | ix 
Stellenbosch University 
Table of contents 
Declaration .................................................................................................................................................. i	
Abstract ....................................................................................................................................................... iii	
Opsomming ................................................................................................................................................ v	
Acknowledgments .................................................................................................................................. vii	
Table of contents ..................................................................................................................................... ix	
List of figures .......................................................................................................................................... xvii	
List of tables ............................................................................................................................................ xxi	
Nomenclature ....................................................................................................................................... xxv	
Chapter 1: Introduction ............................................................................................................................. 1	
1.1 Background information ................................................................................................................ 1	
1.2 Problem statement ....................................................................................................................... 3	
1.3 Aim and objectives ....................................................................................................................... 3	
1.4 Boundaries and limitations ........................................................................................................ 4	
1.5 Expected contributions ............................................................................................................... 5	
1.6 Research design ........................................................................................................................... 5	
1.6.1 Research category ................................................................................................................ 6	
1.6.2 Research purpose ................................................................................................................ 6	
1.6.3 Data acquisition ..................................................................................................................... 6	
1.6.4 Data analysis .......................................................................................................................... 7	
1.7 Research methodology ................................................................................................................ 7	
1.8 Structure of the report ................................................................................................................. 9	
1.9 Conclusion: Introduction ............................................................................................................ 10	
Chapter 2: Overview of MDR-TB ........................................................................................................ 11	
2.1 An introduction to TB and MDR-TB ......................................................................................... 11	
2.2 Advancement of MDR-TB ........................................................................................................ 12	
2.3 Diagnosis of TB and MDR-TB ................................................................................................. 14	
2.4 Treatment of TB and MDR-TB ................................................................................................ 14	
2.4.1 Directly Observed Therapy Short Course ................................................................... 18	
Stellenbosch University  https://scholar.sun.ac.za
Page | x Table of contents 
Department of Industrial Engineering 
2.5 Other factors fuelling the disease ........................................................................................ 19	
2.5.1 Diabetes .................................................................................................................................. 19	
2.5.2 Human Immunodeficiency Virus (HIV) ....................................................................... 20	
2.6 Areas of infection ...................................................................................................................... 20	
2.7 Funding for TB and MDR-TB .................................................................................................. 22	
2.8 Conclusion: Overview of MDR-TB ........................................................................................ 23	
Chapter 3: Supply chains .................................................................................................................... 25	
3.1 Defining supply chains and supply chain management ............................................... 25	
3.2 Levels of supply chain management decision making ................................................ 26	
3.2.1 Strategic level ...................................................................................................................... 27	
3.2.2 Tactical level ....................................................................................................................... 27	
3.2.3 Operational level ............................................................................................................... 27	
3.3 Importance of supply chains .................................................................................................. 27	
3.4 Measuring supply chain performance ................................................................................ 28	
3.4.1 Measures and metrics ....................................................................................................... 28	
3.4.2 Supply Chain Operations Reference (SCOR) ........................................................... 30	
3.5 Demand Forecasting ................................................................................................................. 31	
3.5.1 Time series ............................................................................................................................. 31	
3.5.2 Causal analysis .................................................................................................................. 34	
3.5.3 Forecasting quality ........................................................................................................... 34	
3.6 Push and pull systems ............................................................................................................. 35	
3.7 Inventory management ............................................................................................................ 35	
3.7.1 Single period inventory models ..................................................................................... 36	
3.7.2 Base stock policy ............................................................................................................... 36	
3.7.3 Continuous review policies ............................................................................................. 36	
3.7.4 Periodic review policy ...................................................................................................... 37	
3.8 Conclusion: Supply chains ..................................................................................................... 38	
Chapter 4: Supply chain modelling ................................................................................................. 39	
4.1 Supply chain modelling and analysis .................................................................................. 39	
4.1.1 Supply chain perspectives ................................................................................................ 40	
Stellenbosch University  https://scholar.sun.ac.za
Table of contents  Page | xi 
Stellenbosch University 
4.1.2 Classification of modelling approaches and techniques ..................................... 40	
4.1.3 Operations research .......................................................................................................... 44	
4.1.4 Statistical models ................................................................................................................ 44	
4.1.5 Supply chain analytics ...................................................................................................... 44	
4.1.6 Analytical measures and modelling: verdict ............................................................. 45	
4.2 Computer simulation ................................................................................................................. 45	
4.2.1 Discrete-event simulation ................................................................................................ 46	
4.2.2 Business games ................................................................................................................. 47	
4.2.3 Agent-based simulation .................................................................................................. 47	
4.2.4 Continuous simulation ...................................................................................................... 48	
4.2.5 Hybrid simulation ............................................................................................................... 48	
4.2.6 Computer simulation: verdict ......................................................................................... 48	
4.3 Selection of modelling approach ......................................................................................... 49	
4.3.1 Structure ................................................................................................................................ 50	
4.3.2 General procedure ........................................................................................................... 50	
4.3.3 Underlying principles ........................................................................................................ 51	
4.3.4 Mapping of systems ........................................................................................................... 51	
4.3.5 Validity ................................................................................................................................... 52	
4.3.6 Application to supply chain levels ............................................................................... 52	
4.3.7 Comparison conclusion ................................................................................................... 52	
4.4 Overview of system dynamics ............................................................................................... 54	
4.4.1 Policy resistance ................................................................................................................. 55	
4.4.2 Dynamic complexity ......................................................................................................... 56	
4.4.3 Systems thinking ................................................................................................................ 57	
4.4.4 Causal-loop diagrams ...................................................................................................... 57	
4.4.5 Feedback thinking ............................................................................................................. 59	
4.4.6 Stocks and flows ............................................................................................................... 60	
4.4.7 Modelling procedure ......................................................................................................... 61	
4.4.8 Conclusion: System dynamics ...................................................................................... 63	
4.5 Conclusion: Supply chain modelling .................................................................................. 63	
Stellenbosch University  https://scholar.sun.ac.za
Page | xii Table of contents 
Department of Industrial Engineering 
Chapter 5: Mapping the upstream MDR-TB SLD supply chain .............................................. 65	
5.1 Unique characteristics of the supply chain ........................................................................ 65	
5.1.1 Structure and components ............................................................................................... 68	
5.1.2 Price and demand elasticity ........................................................................................... 69	
5.1.3 Demand and forecasting ................................................................................................. 70	
5.1.4 Market constraints .............................................................................................................. 70	
5.2 Initiatives to address TB and MDR-TB ................................................................................ 70	
5.2.1 The Green Light Committee ............................................................................................ 70	
5.2.2 The Global Partnership to Stop TB .............................................................................. 71	
5.2.3 The Global Drug Facility .................................................................................................. 71	
5.2.4 The Global Fund to Fight Aids, Malaria and TB ...................................................... 71	
5.2.5 UNITAID ................................................................................................................................ 72	
5.2.6 Relationship between the different initiatives .......................................................... 72	
5.3 MDR-TB SLD supply chain flows .......................................................................................... 73	
5.3.1 Information flow ................................................................................................................... 73	
5.3.2 Financial flow ...................................................................................................................... 74	
5.3.3 Product flow ......................................................................................................................... 75	
5.4 Other important concepts and entities in the MDR-TB SLD supply chain .............. 77	
5.4.1 The price and quality reporting tool ............................................................................ 77	
5.4.2 Manufacturers ..................................................................................................................... 77	
5.4.3 The strategic rotating stockpile .................................................................................... 78	
5.4.4 Projects outside the GLC initiative ............................................................................... 79	
5.5 Map of the MDR-TB SLD supply chain ............................................................................... 79	
5.6 Challenges in the supply chain ............................................................................................ 80	
5.6.1 High prices ............................................................................................................................. 81	
5.6.2 Limited availability of quality assured SLDs ............................................................ 82	
5.6.3 Causes of difficulties and challenges ........................................................................ 82	
5.7 Improving the MDR-TB SLD supply chain .......................................................................... 83	
5.8 Conclusion: Mapping the upstream MDR-TB SLD supply chain ............................... 85	
Chapter 6: Dynamic model development ..................................................................................... 87	
Stellenbosch University  https://scholar.sun.ac.za
Table of contents  Page | xiii 
Stellenbosch University 
6.1 Defining the problem and its boundaries ........................................................................... 87	
6.1.1 Problem area ......................................................................................................................... 87	
6.1.2 Data and information ......................................................................................................... 89	
6.1.3 Time horizon ......................................................................................................................... 95	
6.2 Understanding the model ....................................................................................................... 96	
6.2.1 Key variables and concepts ........................................................................................... 97	
6.2.2 Historical and possible future behaviour .................................................................. 97	
6.2.3 Causal-loop diagram ..................................................................................................... 105	
6.3 Simulating the model .............................................................................................................. 108	
6.3.1 Modelling software ........................................................................................................... 108	
6.3.2 Level of detail ................................................................................................................... 109	
6.3.3 Model A ................................................................................................................................ 110	
6.3.4 Stabilising Model A .......................................................................................................... 112	
6.3.5 Model B ................................................................................................................................. 113	
6.3.6 Model C ................................................................................................................................. 117	
6.4 Testing and validating the models ..................................................................................... 121	
6.4.1 CLD validity .......................................................................................................................... 121	
6.4.2 Parameter assessment ................................................................................................... 121	
6.4.3 Dimensional consistency .............................................................................................. 122	
6.4.4 Boundary adequacy ....................................................................................................... 122	
6.4.5 Structure assessment ..................................................................................................... 123	
6.4.6 Behaviour reproduction ................................................................................................. 123	
6.4.7 Extreme conditions .......................................................................................................... 126	
6.4.8 Sensitivity analysis .......................................................................................................... 126	
6.5 Identifying and implementing scenarios ........................................................................... 127	
6.6 Conclusion: Dynamic model development .................................................................... 128	
Chapter 7: Analysis and results ...................................................................................................... 129	
7.1 Evaluation criteria ..................................................................................................................... 129	
7.1.1 Stock performance ............................................................................................................ 130	
7.1.2 Order variability performance ...................................................................................... 130	
Stellenbosch University  https://scholar.sun.ac.za
Page | xiv Table of contents 
Department of Industrial Engineering 
7.1.3 Cost performance ............................................................................................................. 130	
7.2 Performance of base case ...................................................................................................... 131	
7.2.1 Stock performance ........................................................................................................... 132	
7.2.2 Order variability performance ..................................................................................... 132	
7.2.3 Cost performance ............................................................................................................. 133	
7.3 Scenario planning and modelling ....................................................................................... 134	
7.3.1 Inventory policies ............................................................................................................... 134	
7.3.2 Summary of inventory policy scenarios .................................................................... 137	
7.4 Scenario results ........................................................................................................................ 139	
7.4.1 Stock performance ........................................................................................................... 139	
7.4.2 Order variability performance ..................................................................................... 140	
7.4.3 Cost performance .............................................................................................................. 141	
7.4.4 Summary of scenario results ........................................................................................ 142	
7.5 Analysis of scenario results .................................................................................................. 143	
7.5.1 Analysis methodology ..................................................................................................... 143	
7.5.2 Capreomycin ...................................................................................................................... 144	
7.5.3 Kanamycin .......................................................................................................................... 146	
7.5.4 Cycloserine ........................................................................................................................ 149	
7.6 Research findings ..................................................................................................................... 151	
7.7 Conclusion: Analysis and results ........................................................................................ 152	
Chapter 8: Conclusions and summary ......................................................................................... 153	
8.1 Project summary ........................................................................................................................ 153	
8.2 Recommendations to stakeholders .................................................................................. 154	
8.3 Research contributions .......................................................................................................... 156	
8.4 Research limitations ................................................................................................................ 156	
8.5 Opportunity for further work .................................................................................................. 157	
8.6 Closing summary ..................................................................................................................... 158	
References ............................................................................................................................................. 159	
Appendix A	 Checklist ................................................................................................................... 171	
Appendix B	 Characteristics of Dynamic Complexity ........................................................ 173	
Stellenbosch University  https://scholar.sun.ac.za
Table of contents  Page | xv 
Stellenbosch University 
Appendix C	 The SD Modelling Procedure ........................................................................... 175	
Appendix D	 Historical behaviour ............................................................................................. 179	
D.1 Kanamycin ................................................................................................................................... 179	
D.2 Cycloserine ............................................................................................................................... 180	
Appendix E	 Modelling details ...................................................................................................... 183	
E.1 Variable definitions .................................................................................................................. 183	
E.2 Modelling details of Model A .............................................................................................. 185	
E.2.1 Model A: Variable types ................................................................................................ 185	
E.2.2: Model A: Characteristics and equations of elements ........................................ 185	
E.3 Modelling details of Model B ............................................................................................... 194	
E.3.1 Model B: Variable types ................................................................................................. 194	
E.3.2 Model B: Characteristics and equations of elements ......................................... 195	
E.4 Modelling details of Model C .............................................................................................. 210	
E.4.1 Model C: Variable types ................................................................................................. 210	
E.4.2 Model C: Characteristics and equations of elements .......................................... 211	
Appendix F	 Validation results ..................................................................................................... 229	
F.1 Descriptive statistics of demand ......................................................................................... 229	
F.2 Sensitivity analysis results .................................................................................................... 231	
F.2.1 Model A ................................................................................................................................ 231	
F.2.2 Model B .............................................................................................................................. 232	
F.2.3 Model C .............................................................................................................................. 233	
Appendix G	 Summary of inventory policy scenarios ..................................................... 235	
G.1 (s,S) Policy scenarios .............................................................................................................. 236	
G.2 (R,S) Policy scenarios ............................................................................................................ 236	
G.3 (R,s,S) Policy scenarios ......................................................................................................... 236	
G.4 (s,Q) Policy scenarios ............................................................................................................ 237	
G.5 (R,s,Q) Policy scenarios ........................................................................................................ 237	
Appendix H	 Modelling results ................................................................................................ 239	
H.1 Modelling results of capreomycin ..................................................................................... 239	
H.2 Modelling results of kanamycin ........................................................................................ 245	
Stellenbosch University  https://scholar.sun.ac.za
Page | xvi Table of contents 
Department of Industrial Engineering 
H.3 Modelling results of cycloserine ........................................................................................ 251	
Appendix I	 SDM documents ....................................................................................................... 259	
I.1 SDM document for Model A ................................................................................................... 259	
I.2 SDM document for Model B ................................................................................................. 267	
I.3 SDM document for Model C .................................................................................................. 291	
Stellenbosch University  https://scholar.sun.ac.za
List of figures  Page | xvii 
Stellenbosch University 
List of figures 
Figure 1.1: Research process and tools. ........................................................................................... 8	
Figure 1.2: Breakdown of the study’s scope. .................................................................................. 9	
Figure 2.1: Flowchart of the selection of patients for the shorter treatment regimen ...... 18	
Figure 2.2: Number of people with diabetes per region in 2013 ............................................ 19	
Figure 2.3: Overlap of HBC lists ....................................................................................................... 22	
Figure 2.4: Spending categories for a full TB response ........................................................... 22	
Figure 3.1: Levels of supply chain management decision making. ...................................... 26	
Figure 3.2: Example of a push-pull hybrid system. .................................................................... 35	
Figure 3.3: (a) Example of an order-point, order quantity (s,Q) policy, (b) example of an 
order-point, order-up-to-level (s,S) policy. ............................................................................ 37	
Figure 3.4: Example of an order-up-to-level (R,S) policy. ......................................................... 37	
Figure 4.1: Taxonomy of supply chain modelling approaches and techniques. ............. 43	
Figure 4.2: Time bucket-driven discrete-event ............................................................................ 46	
Figure 4.3: Event-driven discrete-event simulation .................................................................... 46	
Figure 4.4: Application of simulation techniques for modelling more than one SCOR 
process ............................................................................................................................................. 49	
Figure 4.5: Example of policy resistance - evolution of drug-resistant pathogens ........ 55	
Figure 4.6: (a) Positive link between variables, (b) negative link between variables, (c) 
time delay between variables. ................................................................................................ 58	
Figure 4.7: Example of a causal-loop diagram ........................................................................... 58	
Figure 4.8: Example of an event-based view of a system ...................................................... 59	
Figure 4.9: Example of a system with feedback ......................................................................... 59	
Figure 4.10: Reinforcing (R) and balancing (B) loop. .................................................................. 60	
Figure 4.11: Example of a stocks and flows system ..................................................................... 61	
Figure 4.12: Example of a stock and flow diagram ..................................................................... 61	
Figure 4.13: System dynamics modelling procedure. ................................................................ 62	
Figure 5.1: Basic steps in a drug supply chain. ............................................................................ 68	
Figure 5.2: Upstream and downstream components ................................................................ 69	
Stellenbosch University  https://scholar.sun.ac.za
Page | xviii List of figures 
Department of Industrial Engineering 
Figure 5.3: Information flow diagram of the supply chain. ...................................................... 73	
Figure 5.4: Financial flow diagram of the supply chain. .......................................................... 75	
Figure 5.5: Product flow diagram of the supply chain. ............................................................. 76	
Figure 5.6: Map of the supply chain for SLDs for MDR-TB. ..................................................... 80	
Figure 5.7: Implementation of a buffer inventory ........................................................................ 85	
Figure 6.1: Fragment of the supply chain that falls within boundaries and limitations. . 89	
Figure 6.2: Conceptual model of the fragment of the supply chain to be modelled. .. 90	
Figure 6.3: Top 10 SLDs based on procurement values from 2012 and 2013 .................. 94	
Figure 6.4: Annual order percentages of cycloserine tablets and capsules. .................. 95	
Figure 6.5: Comparison of data entries for different time steps. ........................................... 96	
Figure 6.6: Frequency diagram of capreomycin. ....................................................................... 97	
Figure 6.7: Frequency diagram of kanamycin. ............................................................................ 98	
Figure 6.8: Frequency diagram of cycloserine. .......................................................................... 98	
Figure 6.9: Distributional choices ..................................................................................................... 99	
Figure 6.10: Visual assessment of trends in order timing for capreomycin. .................... 104	
Figure 6.11: Visual assessment of the average lead times and order sizes for 
capreomycin. ................................................................................................................................ 104	
Figure 6.12: Visual assessment of changes in lead time for capreomycin. ..................... 105	
Figure 6.13: Causal-loop diagram of the upstream supply chain. ...................................... 106	
Figure 6.14: Two balancing loops of the SRS stock on hand. .............................................. 106	
Figure 6.15: Balancing and reinforcing loop of SRS demand and supply line. .............. 107	
Figure 6.16: Balancing loop of normal orders. ........................................................................... 107	
Figure 6.17: Balancing loops of emergency orders. ................................................................ 108	
Figure 6.18: Stock and flow diagram of the main section of Model A. ............................... 110	
Figure 6.19: Stock and flow diagram of the cost section of Model A. ................................. 110	
Figure 6.20: The three major steps that summarises the ordering and manufacturing 
processes. ....................................................................................................................................... 113	
Figure 6.21: Stock and flow diagram of the main section of Model B. ................................ 114	
Figure 6.22: Stock and flow diagram of the cost section of Model B. ................................. 114	
Figure 6.23: Stock and flow diagram of the main section of Model C. ............................... 118	
Stellenbosch University  https://scholar.sun.ac.za
List of figures  Page | xix 
Stellenbosch University 
Figure 6.24: Stock and flow diagram of the cost section of Model C. ................................ 118	
Figure 6.25: Graph comparing the lead time of model output and historical data. ..... 125	
Figure 6.26: Comparison of the distribution of real-wold costs and base case costs. 126	
Figure 7.1: Base case order variability of capreomycin. .......................................................... 133	
Figure 7.2: Base case order variability of kanamycin. ............................................................. 133	
Figure 7.3: Base case order variability of cycloserine. ............................................................ 133	
Figure 7.4: Scatter plots of the scenario results for capreomycin. ..................................... 145	
Figure 7.5: Scatter plots of the scenario results for kanamycin. .......................................... 147	
Figure 7.6: Scatter plots of the scenario results for cycloserine. ........................................ 149	
Figure 8.1: Illustration of the different objectives associated with the supply chain 
segments. ...................................................................................................................................... 155	
Figure D.1: Visual assessment of trends in order timing for kanamycin. ........................... 179	
Figure D.2: Visual assessment of the average lead times and order sizes for kanamycin.
 .......................................................................................................................................................... 180	
Figure D.3: Visual assessment of changes in lead time for kanamycin. .......................... 180	
Figure D.4: Visual assessment of trends in order timing for cycloserine. .......................... 181	
Figure D.5: Visual assessment of the average lead times and order sizes for cycloserine.
 ............................................................................................................................................................ 181	
Figure D.6: Visual assessment of changes in lead time for cycloserine. ......................... 182	
Figure E.1: Demand section of Model A. ...................................................................................... 186	
Figure E.2: Manufacturing section of Model A. .......................................................................... 190	
Figure E.3: Country section of Model A. ...................................................................................... 192	
Figure E.4: Cost section of Model A. ............................................................................................. 193	
Figure E.5: Illustration of triangular distribution for order processing lead time. ........... 196	
Figure E.6: Illustration of triangular distribution for production and dispatch lead time.
 .......................................................................................................................................................... 196	
Figure E.7: Illustration of triangular distribution for country dispatch lead time. ............. 197	
Figure E.8: Normal orders section of Model B. ........................................................................... 197	
Figure E.9: Production of normal order drugs section of Model B. .................................... 199	
Figure E.10: Stockpile supply line section of Model B. ........................................................... 201	
Figure E.11: Stock rotation section of Model B. .......................................................................... 202	
Stellenbosch University  https://scholar.sun.ac.za
Page | xx List of figures 
Department of Industrial Engineering 
Figure E.12: Emergency order section of Model B. ................................................................. 206	
Figure E.13: Cost section of Model B. ........................................................................................... 208	
Figure E.14: Normal order section of Model C. .......................................................................... 212	
Figure E.15: Stockpile supply line section of Model C. ........................................................... 212	
Figure E.16: Cost section of Model C. ........................................................................................... 213	
Figure E.17: Stockpile section of Model C. .................................................................................. 214	
Figure E.18: Backlog section of Model C. ................................................................................... 220	
Figure F.1: Capreomycin order size comparison of model output and historical data.
 ......................................................................................................................................................... 229	
Figure F.2: Kanamycin order size comparison of model output and historical data. . 230	
Figure F.3: Cycloserine order size comparison of model output and historical data. . 231	
Stellenbosch University  https://scholar.sun.ac.za
List of tables  Page | xxi 
Stellenbosch University 
List of tables 
Table 1.1: Summary of the research design. ................................................................................... 5	
Table 2.1: Groups of drugs to treat MDR-TB .................................................................................. 15	
Table 2.2: List of the HBCs for TB, TB/HIV and MDR-TB ........................................................... 21	
Table 3.1: Description of SCOR attributes. .................................................................................... 30	
Table 3.2: Five components of time series. .................................................................................. 32	
Table 4.1: Criteria for comparing system dynamics and discrete-event simulation. ...... 53	
Table 4.2: Main differences between complex systems and traditional systems .......... 56	
Table 5.1: Summary of characteristics for commercial and donor funded supply chains
 ............................................................................................................................................................ 66	
Table 5.2: Evaluation criteria for manufacturers ........................................................................ 78	
Table 5.3: Summary of difficulties and challenges. ................................................................... 80	
Table 5.4: Summary of recommendations to improve the upstream segment of the 
supply chain. .................................................................................................................................. 83	
Table 6.1: Limitations and constraints of the database ............................................................ 92	
Table 6.2: Weibull parameters determined by distribution fitting software. .................... 101	
Table 6.3: Descriptive statistics of order size. ........................................................................... 102	
Table 6.4: Correlation tests results. .............................................................................................. 103	
Table 6.5: Final parameters for the demand input. .................................................................... 111	
Table 6.6: Number of orders placed per week for model output and historical data. 124	
Table 6.7: Total lead time for model output and historical data. ....................................... 125	
Table 6.8: Sensitivity analysis results for Model B, capreomycin. ...................................... 127	
Table 7.1: Order variability performance of base case. ......................................................... 132	
Table 7.2: Cost performance of base case during a five-year simulation. ....................... 134	
Table 7.3: Summary of equations for inventory policy variables. ...................................... 138	
Table 7.4: Scenario results – Capreomycin high stock performance policies. .............. 139	
Table 7.5: Scenario results – Capreomycin poor stock performance policies. ............. 140	
Table 7.6: Scenario results – Capreomycin high order variability performance policies.
 ............................................................................................................................................................ 141	
Stellenbosch University  https://scholar.sun.ac.za
Page | xxii List of tables 
Department of Industrial Engineering 
Table 7.7: Scenario results – Capreomycin poor order variability performance policies.
 ............................................................................................................................................................ 141	
Table 7.8: Scenario results – Capreomycin high cost performance policies. ................ 142	
Table 7.9: Scenario results – Capreomycin poor cost performance policies. ............... 142	
Table 7.10: Summary of Pareto optimal solutions for capreomycin. .................................. 146	
Table 7.11: Summary of Pareto optimal solutions for kanamycin. ....................................... 148	
Table 7.12: Summary of Pareto optimal solutions for cycloserine. ..................................... 150	
Table 7.13: Comparison of the procurement cost and holding cost range. ...................... 151	
Table 8.1: Summary of stock levels. .............................................................................................. 155	
Table A.1: Checklist for literature analysis. ................................................................................... 171	
Table B.1: Summary of dynamic complexity characteristics. ................................................. 173	
Table D.1: Definitions of variable types. ........................................................................................ 176	
Table E.1: Definition of variables. ................................................................................................... 183	
Table E.2: Variable types for Model A. ........................................................................................ 185	
Table E.3: Summary of probabilities of more than one order being placed. .................. 187	
Table E.4: Summary of costs from 2010 – 2014. ....................................................................... 193	
Table E.5: Variable types for Model B. ........................................................................................ 194	
Table E.6: Shelf lives of the dormulations. ................................................................................ 202	
Table E.7: Variable types for Model C. ........................................................................................ 210	
Table F.1: Descriptive statistics of capreomycin order size for model output and historical 
data. ............................................................................................................................................... 229	
Table F.2: Descriptive statistics of kanamycin order size for model output and historical 
data. ............................................................................................................................................... 230	
Table F.3: Descriptive statistics of cycloserine order size for model output and historical 
data. ............................................................................................................................................... 230	
Table F.4: Sensitivity analysis results for Model A, capreomycin. ..................................... 231	
Table F.5: Sensitivity analysis results for Model A, kanamycin. ........................................ 232	
Table F.6: Sensitivity analysis results for Model A, cycloserine. ....................................... 232	
Table F.7: Sensitivity analysis results for Model B, kanamycin. ......................................... 232	
Table F.8: Sensitivity analysis results for Model B, cycloserine. ....................................... 233	
Table F.9: Sensitivity analysis results for Model C, capreomycin. .................................... 233	
Stellenbosch University  https://scholar.sun.ac.za
List of tables  Page | xxiii 
Stellenbosch University 
Table F.10: Sensitivity analysis results for Model C, kanamycin. ....................................... 233	
Table F.11: Sensitivity analysis results for Model C, cycloserine. ....................................... 234	
Table G.1: Summary of reorder point alternatives. .................................................................. 235	
Table G.2: Summary of order-up-to-level alternatives. ......................................................... 235	
Table G.3: Summary of reorder frequency alternatives. ...................................................... 235	
Table G.4: Summary of the reorder quantity alternatives. ................................................... 235	
Table G.5: Summary of (s,S) policy scenarios. ......................................................................... 236	
Table G.6: Summary of (R,S) policy scenarios. ......................................................................... 236	
Table G.7: Summary of (R,s,S) policy scenarios. ...................................................................... 236	
Table G.8: Summary of (s,Q) policy scenarios. ........................................................................ 237	
Table G.9: Summary of (R,s,Q) policy scenarios. ..................................................................... 237	
Table H.1: Capreomycin - Summary of stock performance for the scenarios. .............. 239	
Table H.2: Capreomycin - Summary of order variability performance for the scenarios.
 .......................................................................................................................................................... 241	
Table H.3: Capreomycin - Summary of cost performance for the scenarios. ............... 243	
Table H.4: Kanamycin - Summary of stock performance for the scenarios. .................. 245	
Table H.5: Kanamycin - Summary of order variability performance for the scenarios.
 .......................................................................................................................................................... 247	
Table H.6: Kanamycin - Summary of cost performance for the scenarios. .................... 249	
Table H.7: Cycloserine - Summary of stock performance for the scenarios. ................ 252	
Table H.8: Cycloserine - Summary of order variability performance for the scenarios.
 ......................................................................................................................................................... 254	
Table H.9: Cycloserine - Summary of cost performance for the scenarios. .................. 256	
Stellenbosch University  https://scholar.sun.ac.za
Page | xxiv List of tables 
Department of Industrial Engineering 
Stellenbosch University  https://scholar.sun.ac.za
Nomenclature  Page | xxv 
Stellenbosch University 
Nomenclature 
Acronyms 
API Active Pharmaceutical Ingredient 
BRICS  Brazil, Russian Federation, India, China, South Africa 
CLD  Causal Loop Diagram 
DES  Discrete-Event Simulation 
DOT(S) Directly Observed Treatment (Short Course) 
FLD  First-line Drug 
FPP  Finished Pharmaceutical Product 
GDF  Global Drug Facility 
GLC Green Light Committee 
GPS Global Positioning System 
HBC High Burden Country 
HIV  Human Immunodeficiency Virus 
INH  Isoniazid 
IOM  Institute of Medicine  
K-S test Kolmogorov-Smirnov Goodness-of-fit Test 
LMIC  Low- and Middle Income Country 
LTBI  Latent Tuberculosis Infection 
MDR-TB Multidrug Resistant Tuberculosis 
M.TB  Mycobacterium tuberculosis 
PA Procurement agent 
RIF Rifampin 
SC Supply Chain 
SCM Supply Chain Management 
SD System Dynamics 
SDM System Dynamics Modelling 
SLD Second-line Drug 
TB Tuberculosis 
Stellenbosch University  https://scholar.sun.ac.za
Page | xxvi Nomenclature 
Department of Industrial Engineering 
UNITAID Not an acronym. Organisation cooperating with other organisations on 
the WHO millennium goals 
USAID United States Agency for International Development 
WHO World Health Organisation 
XDR-TB Extensively Drug Resistant Tuberculosis 
Greek Symbols 𝛼  Exponential smoothing factor 0 ≤ 𝛼 ≤ 1𝛽  Shape parameter or slope 𝛽& Exponential smoothing trend factor 0 ≤ 𝛽 ≤ 1  𝛽' Estimate of the intercept 𝛽(: Estimate of the slope for variable 𝑖 𝜂  Scale parameter or characteristic life 𝛾  Location parameter or failure free life 𝛾& Seasonality smoothing factor 0 ≤ 𝛾 ≤ 1  𝜇. Average demand  𝜇/0 Average lead time  𝜎23 Standard deviation of the order size for each individual order 𝜎34 Standard deviation of the volume of orders placed per month 𝜎. Standard deviation of the demand	𝜎/ Standard deviation of the lead time 
Roman Symbols 𝑎6 Estimated level at time 𝑡 𝑏6 Estimated trend at time 𝑡 𝐶: Holding costs 𝐶; Obsolescence costs 𝐶< Procurement costs 𝐶0 Total costs 
Stellenbosch University  https://scholar.sun.ac.za
Nomenclature  Page | xxvii 
Stellenbosch University 
𝐷 Demand  𝐸𝑂𝑄 Economic order quantity 𝑒6 Forecast error for time 𝑡 𝐹6 Multiplicative seasonal index appropriate for period 𝑡 𝑛 Number of data points or data entries   𝑃 Number of time periods within the seasonality 𝐹( = 𝑃<(FG𝑆𝑆 Safety stock 𝑡 Time period 𝑥6,6KG Forecast for period 𝑡 + 1 made during period 𝑡 𝑥6 Actual demand during time 𝑡 𝑥6MN Actual demand during time 𝑡 − 𝑛 𝑌( Demand for variable 𝑖 𝑧 Safety stock coverage factor based on the service level 
Terminology 
Bacilli  A rod-shaped bacterium that causes disease. 
Cross-resistance When resistant mutations to one drug may cause 
resistance to some of the other members in the same 
drug family. 
Pathogen A microorganism, such as a bacterium or virus, that 
can cause disease. 
Second-line Drug Any therapeutic drugs that is not the drug of choice 
or normally used for treatment. 
Subtherapeutic Not generating a therapeutic effect. 
Supply Chain A network of entities that supply products and/or 
services from the raw material phase to the end 
consumers through the flow of information, physical 
distribution, and finances. 
Syndemic The conversion of two or more epidemics that act 
together to aggravate the burden of one or more of 
the diseases.    
Stellenbosch University  https://scholar.sun.ac.za
Page | xxviii Nomenclature 
Department of Industrial Engineering 
Stellenbosch University  https://scholar.sun.ac.za
Page | 1 
Chapter 1:
Introduction 
 “The new numbers revealed what many of us had feared, that the TB epidemic is even bigger 
than we thought.” 
- October 2014, Dr Joanne Carter (Vice-chair, STOP TB Partnership) 
This study aims to model and analyse the upstream supply chain of second-line drugs 
for multi-drug resistant tuberculosis, through the use of data gathering, simulation, 
correlational analysis and statistical analysis. The intended goal of the model is to 
identify operational changes that will improve the management of the supply chain and 
to quantify the potential impact that these changes will have. 
This chapter serves as an introduction to the study. Background information on the 
underlying themes of the topic is shortly discussed and is followed by the formulation 
of the problem statement, objectives, expected contributions and the boundaries and 
limitations. Thereafter, the research process is explained through a detailed description 
of the research design and methodology, as well as the timeframe and scope of the 
study. 
1.1 Background information 
Tuberculosis (TB) is an airborne disease and is a foremost cause of death, disease and 
disability, especially in developing countries (Fraser et al., 2013). A report delivered by 
the World Health Organisation (WHO) in 2015, stressed that “TB now ranks alongside 
HIV as a leading cause of death worldwide” (World Health Organization, 2015a). 
According to the report, approximately 9.6 million cases of TB were reported in 2014 
and the death toll for that year was near 1.5 million.  
Efforts towards reducing the global occurrence of drug-susceptible TB have had a minor 
positive impact (Gandhi et al., 2010). The rate by which new infections are falling on a
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global scale, is 1,5% each year. There is no concrete evidence to suggest that this rate 
will improve in the near future (Senthilingam, 2014). The main challenge is the global 
control from the standpoint of diagnosis, treatment and the detection of drug-resistance 
(Wilson, 2011).  
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis have 
emerged over the last few decades and threaten to deteriorate any advances towards 
stabilising the TB epidemic (Gandhi et al., 2010). In 2013, an estimated 190,000 people 
died from MDR-TB, according to the aforementioned 2015 WHO report. It is believed 
that 75% of people carrying MDR-TB remain undetected and unreported (World Health 
Organization, 2015a). Finally, the increase of antimicrobial resistance places the global 
health risk posed by MDR-TB in even more stark light. According to Furin et al. (2016), 
“estimates indicate that unless the management of MDR TB changes radically, it will be 
one of the main drivers of antimicrobial resistance, which could kill more persons than 
cancer by 2050”. 
The management of MDR-TB is much more complex, costly, time-consuming and less 
effective than drug-susceptible TB (Gandhi et al., 2010). The treatment generally spans 
over a two-year period with complex and often toxic drug regiments (Fraser et al., 2013). 
It is therefore vital to exert all efforts in preventing the spread thereof. MDR-TB can be 
caused by the incorrect completion of TB treatment, poor adherence, poor drug quality, 
or transmission from one person to another (Gandhi et al., 2010). In most cases, a patient 
becomes drug-resistant due to TB treatment failures. Treatment failures are mostly 
ascribed to the lack of sufficient supplies, especially in poorer nations (De Lucia, 2014). 
APICS, The Association for Operations Management, defines a supply chain as: “The 
global network used to deliver products and services from raw materials to end 
customers through an engineered flow of information, physical distribution, and cash” 
(‘APICS Dictionary 10th Edition’, 2002). Disruptions and problems within the supply chain 
(especially with financing, production, supply and quality) are a main reason for the 
unavailability of the drugs. As previously stated, this contributes to the development of 
drug resistance. Even if patients are adhering to the treatment, problems within the 
supply chain, such as the absence of quality monitoring and maintenance, can cause 
the treatment to be sub-therapeutic (Gandhi et al., 2010).  
In the supply chains of critical medications, such as TB- and MDR-TB treatment drugs, 
there are severe risks attached to lengthy and slow-moving logistics, especially during 
the shipment from warehousing to various countries. This portion of the supply chain is 
defined as the ‘upstream’ segment of the supply chain by the Institute of Medicine 
(Nicholson et al., 2013).   
MDR-TB is a manmade occurrence, developed due to the inadequate treatment of TB. 
Recorded cases of drug resistance are increasing almost as fast as drugs come to the 
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market (Chang and Yew, 2012). The prospect of MDR strains becoming the leading form 
of TB will remain, unless the detection and treatment of drug-resistant cases is 
intensified (Gandhi et al., 2010). 
1.2 Problem statement 
Systemic problems in the supply chain for second-line drugs (SLDs) for MDR-TB are well 
documented and contribute significantly to the difficulties preventing successful control 
of the disease. Although literature contains a wealth of proposed changes to the 
management of the global SLD supply chain, there is a significant research gap related 
to quantitative modelling of the supply chain to accurately predict the expected impact 
of these proposed changes on the availability and delivery of SLDs. In this research, a 
model of a segment of the upstream MDR-TB SLD supply chain will be developed. This 
model will be used to evaluate the likely impact of some alternative approaches to 
managing and operating the supply chain. 
1.3 Aim and objectives 
The aim of this thesis is: (i) to model the upstream supply chain of MDR-TB SLD, and (ii) 
to use this model to identify potential improvements and quantify the expected impact 
of these improvements on the performance of the supply chain on a global scale.  
Achieving each of the two parts of the aim (i and ii) will demand different approaches 
throughout the research. To simplify the execution and understanding of the research 
approach, the aforementioned parts of the aim will from hereon be referred to as Phase 
A and Phase B, respectively.  
Each phase is associated with a separate set of objectives. For Phase A, the objectives 
are to: 
• provide accurate descriptions of the different supply chain aspects in all of their
complexity;
• define the limitations (that will be considered in this research) of the upstream
environment in which the supply chain operates;
• identify the prominent factors or variables within this environment and their
relevance to the research; and
• develop a descriptive model that accurately portrays the upstream supply chain.
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The objectives for Phase B are to: 
• simulate the model of the upstream MDR-TB SLD supply chain;
• identify problems and opportunities for improvement, and make associated
recommendations to address these;
• quantify the likely performance of the supply chain, using the simulation model, to
measure the expected impact of certain improvements; and
• make conclusions and recommendations on which changes will contribute most to
the strengthening of this supply chain.
1.4 Boundaries and limitations 
Boundaries are the result of specific decisions made and the deliberate exclusion and 
inclusion of certain aspects and elements. As stated in the title of this study, only the 
upstream component of the supply chain will be investigated. This research 
complements a similar study by Coetzee (2015) of the downstream component of the 
supply chain.  
Furthermore, the study will only consider the supply chain of MDR-TB drugs, and not 
that of drug-susceptible TB or XDR-TB drugs. The systematic problems in the MDR-TB 
SLD supply chain as well as suggestions for improvement have previously been 
discussed in literature, but the expected impact of these improvements are yet to be 
quantified. This study will aim to fill this gap in the MDR-TB research area. Additional 
boundaries of the study can be derived from Section 1.2 and Section 1.3, where problem 
statement and research objectives are provided, respectively.  
Limitations are effects, shortcomings or conditions that flow from implicit features of the 
chosen method and design. The availability of and access to data is the most prevailing 
limitation of this research. Only data that is publically available or provided by research 
partners and organisations can be used. As with any qualitative study, the validity and 
reliability of the study is a limitation. To try and uphold the external reliability, which is 
defined as “the degree to which a study can be replicated” (Bryman et al., 2014), the 
research approach will be carefully defined and described (see Section 1.6) and all the 
steps and actions taken during the progression of the study will be recorded in detail 
(Bryman et al., 2014). Another limitation of the study arises with the correlational 
analyses (see Section 1.6.4). This type of analysis merely demonstrates that two 
variables are associated with each other. There can, however, be other variables that 
have an influence on this association. Another reason for the association can be the 
situation or circumstance under which the correlation was analysed. Therefore, there is 
some uncertainty about the generalisability of the correlation. 
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1.5 Expected contributions 
The documentation of the upstream supply chain for MDR-TB SLDs can prove to be 
beneficial to further studies in this field. The expected contributions of this study are 
threefold: 
i. This study forms part of a larger project that incorporates both the upstream and
downstream components of the MDR-TB SLD supply chain. This global project
can be used to aid companies and organizations (that are a part of the supply
chain) in their decision making process and contribute to the sustainability of the
supply chain.
ii. The impacts of the various solutions suggested by professionals for improving
the operation of the upstream supply chain have not been quantitatively
analysed or evaluated to date. Therefore, another contribution of this study is
the quantification of the likely impact of one or more of these suggestions, to aid
in the strengthening of the global MDR-TB SLD supply chain.
iii. Lastly, the identification and modelling of the dynamic relations and associations
in the supply chain can provide support for decision making in other medical and
drug supply chains.
1.6 Research design 
The research design of this study will differ for each of the two phases of the aim, as 
defined in Section 1.3, and the designs will be discussed separately in subsequent 
subsections.  A summary of the research design is given in Table 1.1 for clarification and 
to illustrate how the design differs for the two phases. 
Table 1.1: Summary of the research design. 
Phase A Phase B 
Research 
Purpose 
Exploratory Descriptive Explanatory 
Research 
Category 
Basic Research Applied Research 
Research 
Methodology 
Mostly Qualitative,      
Inductive Study 
Mostly Quantitative, 
Deductive Study 
continued on next page 
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continued from previous page 
Data 
Acquisition 
Data, Documents (text, numerical, speech), 
Graphical modelling 
Previous studies, experiment 
with simulation and modelling 
Data Analysis Thematic Data Analysis 
Conceptual 
Description 
Statistical Analysis 
1.6.1 Research category 
For the modelling of the supply chain (Phase A) the purpose is to obtain new knowledge 
about and deepen understanding of the resources, manufacturers, suppliers, 
distributors etc. Their properties, structures and relationships need to be determined 
and analysed. The research will be carried out with the prospect of forming the basis of 
the next phase. The research category of the modelling phase is therefore oriented 
basic research. 
For the analysis and evaluation of the supply chain (Phase B), further research is carried 
out to build on the findings of the basic research in the previous phase. The research is 
directed primarily towards the specific aims and objectives as set out in Section 1.3, thus 
it falls into the category of applied research. 
1.6.2 Research purpose 
Due to the lack of existing research on the upstream supply chain for MDR-TB 
medication, an exploratory research approach will initially be followed. During this 
stage of the research, the key issues and variables will be identified. Thereafter, the 
research will follow a descriptive approach where an accurate and valid representation 
of the upstream supply chain will be provided.  
For the evaluation of the supply chain model, an explanatory research approach will 
be followed to identify any links between factors and variables. During this phase of the 
research, the effect that different changes have on the supply chain will be determined 
and assessed.  
1.6.3 Data acquisition 
The fundamental data to be used in Phase A will be obtained from research partners 
and publically available databases, such as the database of the Global Fund to Fight 
Aids, Malaria and TB. Any additional data will be acquired through documents (text, 
numerical or speech) and through explanation building.  
The evaluation of the supply chain (Phase B) will make use of simulation and modelling 
to experiment with changes made to the supply chain. These changes entail possible 
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improvements that were identified in the first phase of the study. The independent 
variable(s) will be manipulated, according to the improvements, to observe the effect on 
the dependent variable(s).  
1.6.4 Data analysis 
For both phases, the data analysis is an iterative process as the process can be 
adjusted to adapt to the outcomes. Constant comparison will be done to lead the 
process from analysis to results and back again.  During the exploratory research, a 
thematic data analysis will be done. Any fundamental or underlying topics and patterns 
observed in the literature and data will be identified. Coding will be used to define 
connections between different topics and patterns, and to attempt to develop networks 
between the patterns, processes and activities. The descriptive part of the research will 
involve a conceptual/thematic description that will comprise of the presentation of the 
networks and concepts developed during the exploratory research. This will form the 
foundation of the graphical model of the supply chain. During the explanatory phase of 
the research, recommended improvements and operational changes will be evaluated 
with simulation and modelling. The obtained results will be used to perform a statistical 
analysis to describe the effects of the improvements on the supply chain and to expand 
on the outcomes of the improvements. 
1.7 Research methodology 
As with the research design, the research methodology will be distinctive for every 
phase. The first phase of the study will involve qualitative research and follow an 
inductive approach.  It will aim to provide an in-depth and thorough model of the 
upstream supply chain. For the second and final phase of the study, the contextual 
framework (within which the research will be conducted) will be much clearer. Therefore, 
it will follow a deductive approach and primarily consist of quantitative research. The 
procedure to be followed is based on the abovementioned approaches and can be 
seen in Figure 1.1. The tools to be used with each of the steps are also provided in the 
figure. 
The procedure highlights the different steps and processes associated with each of the 
two phases mentioned in Section 1.3. As can be seen in the figure, both phases start 
with a literature review. Throughout the literature review process, the validity of the 
study is ensured by performing a critical analysis on each source before making 
assertions and conclusions based thereon. The evaluation method as laid out by 
Jonathan Paulo in the Madison Research Essentials Toolkit (Paulo, 2014) as well as the 
Critical Appraisal and Analysis technique from the Cornell University Library (Engle, 
Stellenbosch University  https://scholar.sun.ac.za
Page | 8 Chapter 1: Introduction 
Department of Industrial Engineering 
2015) were combined to develop a checklist, illustrated in Appendix A, which is used to 
analyse each source. Sources include electronic as well as printed resources. 
Figure 1.1: Research process and tools. 
After a source has been analysed and approved, it is imported into the ATLAS.ti 
software package. Various codes and code groups are created in ATLAS.ti and relevant 
information in the sources are coded. As indicated in Section 1.6.4, coding is used to 
define connections between the sources and to identify relevant themes that are used 
to develop descriptions and/or concepts. 
For the mapping of the supply chain, informal modelling software will be used. This step 
is limited to a graphical representation, software such as Microsoft Visio or PowerPoint 
can therefore be used. The simulation model of the supply chain will make use of 
software specific to the chosen technique. Similarly, analytics software such as SPSS 
and Microsoft Excel will be used for the assessment of the simulation results.  
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1.8 Structure of the report 
The scope of the study is summarised in the structure in Figure 1.2. The different 
chapters of the study can be grouped in three main research phases, namely the 
research orientation, research body and research outcomes, which will be discussed 
separately below. 
Figure 1.2: Breakdown of the study’s scope. 
The first four chapters form part of the research orientation. These chapters serve to 
acquire direction and become familiar with topics and themes relevant to the problem 
statement and objectives. This first chapter provides an introduction to the study by 
providing background information, the problem statement, objectives, expected 
contributions and the boundaries and limitations. The research process to be followed 
in the study is also given in this chapter.  
Chapter 2 provides an overview of the real-world problem through a discussion of the 
relevant aspects regarding TB and MDR-TB, such as (i) the advancement of the disease 
to its current status; (ii) the diagnosis and treatment of TB and MDR-TB; (iii) other factors, 
such as diabetes and HIV, fuelling the disease; (iv) the main areas of infection; and (v) 
funding for responding to the disease. 
Research 
Orientation
Chapter 1: Introduction
• Provide background
information on topic
• Formulate problem 
statement and 
objectives
• Specify research 
approach
Chapter 2: MDR-TB
• Gather more information 
on TB and MDR-TB
• Review key documents
about the disease
Chapter 3: Supply Chains 
• Gather information on 
supply chains
• Review key documents
about supply chain 
aspects
• Define and explain any 
terms/aspects needed to 
put research in context
Chapter 4: Supply Chain 
Modelling
• Review key documents
about supply chain 
modelling approaches 
and techniques
• Evaluate different 
approaches
• Outline chosen 
approach
Chapter 5: Mapping the 
upstream MDR-TB SLD 
Supply Chain
• Gather information –
both qualitative and 
quantitative – required 
to map the supply chain
• Identify participants and
stakeholders and outline 
their activities
• Categorise the activities
and map the flows
• Identify problems and
difficulties in the supply 
chain
• Conceptualise
preliminary suggestions 
for improving the supply 
chain, as concluded 
from previous research 
and the map
Chapter 6: Dynamic 
Model Development
• Develop a stock and
flow diagram of the map
• Develop a dynamic
model of the mapped 
supply chain on 
simulation software
• Test and validate the
model
• Choose scenarios to be 
modelled
Chapter 7: Analysis and 
Results
• Provide description of 
scenarios to be 
modelled
• Describe the
performance measures 
that will be used to 
quantify the impact
• Model scenarios and
quantify impact through 
performance measures
• Provide summary of 
scenario results
• Comment on results and
explain its meaning
Chapter 8: Conclusions 
and summary
• Interpret results in a
wider context
• Provide recommenda-
tions based on results
• Summarise the study
• Describe broader 
implications of results
• Propose future work for
related topics
Research  
Body
Research 
Outcomes
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In Chapter 3, selected aspects of a supply chain will be defined and discussed. This 
includes the levels of supply chain management related to decision making and 
measuring the performance of the supply chain. Furthermore, certain methods for 
demand forecasting and inventory management are also discussed.   
Chapter 4, the final chapter for research orientation, is concerned with supply chain 
modelling and determining the most appropriate modelling method for this study. A 
taxonomy of supply chain modelling approaches and techniques is provided and 
discussed, after which an overview of the chosen method is provided. 
Chapter 5 and 6 form part of the research body; the central part of the study. In Chapter 
5, a representation of the supply chain for SLDs for MDR-TB is provided, by describing 
some of the unique characteristics of the supply chain and the initiatives developed to 
address TB and MDR-TB. The supply chain flows (information flow, product flow and 
financial flow) are also discussed. The concepts are combined to map and describe the 
supply chain through a theoretical model, followed by a summary of the difficulties and 
challenges in the supply chain as well as recommendations to improve the supply 
chain. Chapter 6 presents the dynamic model of the supply chain and the modelling 
process followed to build the model. This includes a description of the available data, 
as well as the limitations and boundaries thereof. After the discussion of the models that 
were developed, the models are validated through various validation techniques. 
The final two chapters, contain the research outcomes. Chapter 7 present the analysis 
and results of the models and scenarios. It also includes a discussion of the results as 
well as general findings that were concluded from the results. Chapter 8 is the final 
chapter of the document and provides a summary of the research as well as 
recommendations to the stakeholders, the research contributions and opportunities for 
further research. 
These chapters and their sections are meant to be sequential, however, in some cases 
it will be necessary to revisit previous sections, as they are dependent on one another. 
1.9 Conclusion: Introduction 
This chapter served as an introduction to the research project by providing background 
information on the MDR-TB epidemic and problems faced in the supply of SLDs. The 
problem statement together with the aims and objectives for this project were provided, 
as well as the research design and methodology that will be followed in order to reach 
these objectives. This chapter also included a summary of how the project is structured. 
In Chapter 2, a more detailed description of TB and MDR-TB is provided. 
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Overview of MDR-TB 
"This threat has to be prevented and when it does occur, extraordinary measures must be put 
in place. It's a real threat and has to be taken extremely seriously." 
- 2014, Mario Raviglione (Director, WHO Global Tuberculosis Program) 
In the previous chapter, which served as an introduction to the research project, a short 
account of the TB and MDR-TB epidemic were provided. This chapter provides 
background to the project by providing more information on TB with the focus on MDR-
TB. The following topics will be discussed:  
1. The causes and advancement of TB and MDR-TB;
2. The diagnosis and treatment of the disease;
3. Other factors, such as Diabetes and HIV, fuelling the disease;
4. The main areas of infection; and
5. Funding for countering the epidemic.
2.1 An introduction to TB and MDR-TB 
TB is an infectious and airborne disease, spread easily through simple actions such as 
coughing, sneezing, laughing or talking. A person with the disease will most likely infect 
other people that are in contact with him/her for extended periods of time. 
Consequently, TB has long been associated with poverty, where the majority of the 
infected resides in informal settlements (En, 2014). 
The primary cause of TB is the pathogen Mycobacterium tuberculosis (M.TB). The two 
critical anti-TB drugs, isoniazid (INH) and rifampin (RIF), are essential in the effective 
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treatment for TB, since most M.TB strains are sensitive to these drugs (Rodwell, 2010). 
MDR-TB occurs when the M.TB strain is resistant to at least both INH and RIF and can 
be due to the incorrect completion of TB treatment or it can be transmitted from one 
person to another (Fraser et al., 2013). More specifically, drug resistance is a result of 
tubercle bacillus mutations. When the predominant bacilli are exposed to a single 
effective anti-TB drug and is sensitive to that drug, it is killed. The few drug resistant 
mutants are left to multiply freely (New Jersey Medical Shcool: Global Tuberculosis 
Institute, 2015). Genetic resistance to anti-TB drugs is a natural occurrence, resulting 
from chromosomal mutations that accompany mycobacterial replication (Chang and 
Yew, 2012). 
The treatment of a single case of TB spans over, at least, a six-month period of daily 
drug therapy. MDR-TB, on the other hand, can take two years or more to treat. Since 
none of the SLDs used to treat MDR-TB are as effective as INH and RIF, MDR-TB has a 
substantial impact on the course and outcome of the TB disease. As previously 
mentioned, the treatment of MDR-TB is also much more complex as SLDs are costlier 
and more toxic than first-line drugs (FLDs) (Atun et al., 2010).  
A study done by the University of Cape Town found that in South Africa, even though 
the MDR-TB cases comprised of only 2.2% of the case burden, it consumed 32% of the 
total estimated 2011 national TB budget. (Pooran et al., 2013). The high costs associated 
with the treatment of drug-resistant TB can drain much needed resources required for 
global TB control. Difficult drug-resistant TB can cripple all TB control efforts if 
preventative- and management strategies are not implemented timeously and 
effectively (Chang and Yew, 2012).  
2.2 Advancement of MDR-TB 
Drug-resistance began to develop over the last 100 years. When it was first discovered, 
there was no strategy that included a means of testing for this new strain of TB and no 
drugs were provided to countries for the treatment thereof. Consequently, MDR-TB 
began to spread across the globe (Wexlar, Rockwood and Childress, 2014). 
Over the last four to five decades, the MDR-TB burden has become worse. In 2007, a 
WHO global laboratory surveillance network revealed that the global caseload of 
MDR-TB increased from approximately 274,000 cases in 2000 to over half a million 
cases in 2007 (Dheda et al., 2010). Although these figures have recently declined to 
about 480,000 cases in 2014, it is estimated that only about a quarter (123,000) of these 
were detected and reported (World Health Organization, 2015a). The global epidemic 
of drug-resistant TB can be attributed to inadequate treatment, aggravated by a delay 
in diagnosis and by environments that increase the probability of transmission, infection 
and development of the disease (Chang and Yew, 2012).  
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Currently, the conditions for MDR-TB look promising. For the first time in more than four 
decades, two new drugs have been registered for MDR-TB - bedaquiline and delamanid 
(Burki, 2014). Furthermore, the global rate at which new cases of MDR-TB are being 
reported, remains stable at 3,5% (World Health Organization, 2014). These aspects 
might seem optimistic, but on closer inspection, the data is incomplete (Brigden, 2015). 
Several areas across the globe are dealing with a severe and increasing MDR-TB crisis. 
For example, in Belarus, Kyrgyzstan and Kazakhstan, more than 70% of patients that 
have been treated for TB, are now drug-resistant. Furthermore, 35% of people 
diagnosed with TB for the first time are already drug-resistant (Brigden, 2015). With a 
cure rate of only 50%, MDR-TB is a major threat to these areas, which run the risk of 
having MDR-TB being the predominant diagnosis (Brigden, 2015).  
The new drugs for treating MDR-TB, bedaquiline and delamanid, are not yet being 
distributed to the areas that require them the most (Brigden, 2015), even though they 
were approved for use in 2012 and 2013 respectively (Burki, 2014). Since the approval 
of bedaquiline by the Food and Drug Administration on 31 December 2012 (Field, 2013), 
only one thousand patients have had access to the drug as of March 2015 (Brigden, 
2015). Similarly, by December 2014 fewer than 10 patients had, had access to 
delamanid outside of clinical trials (Brigden, 2015), after its conditional approval by the 
European Medicines Agency in 2013 (Burki, 2014; Lessem, 2014). 
Delamanid has only been granted conditional approval, thus further studies need to be 
conducted to maintain the approval. Although this approval gives the manufacturer 
Otsuka permission to market delamanid in all European Union countries, they have only 
distributed the drugs in the United Kingdom and Germany, as of 2015. The drug has not 
been submitted for registration in any of the high burden countries and it is unclear 
whether Otsuka has sufficient drug supply to meet the high demand (Lessem, 2014). The 
country has recently announced a targeted access initiative, details have not yet been 
announced (Rustomjee and Zumla, 2015). 
The Johnson and Johnson affiliate, Janssen Therapeutics, has been more proactive in 
the registration of their drug, bedaquiline. However, despite a tiered pricing structure, 
there are concerns regarding the affordability for several high-burden countries 
(Brigden, 2015). In December 2014, Janssen signed a Memorandum of Understanding 
in an attempt to lift the price barrier, under which they will provide 30,000 treatment 
courses of bedaquiline over a 4-year period (Liden et al., 2014). This is unfortunately not 
a comprehensive solution, as only a portion of the global need will be fulfilled for a 
limited time (Brigden, 2015). 
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2.3 Diagnosis of TB and MDR-TB 
Correctly diagnosing a patient with TB is the critical first step towards a successful TB 
programme. The process starts with the bacteriological confirmation of TB, whereafter 
it is determined whether the patient is drug resistant (World Health Organization, 2014). 
A detailed description of various diagnosis methods, including their drawbacks and 
benefits, have been provided elsewhere (Unitaid, 2012; World Health Organization, 
2015b) and will not be repeated here.  
Although it is not recommended by WHO due to current insufficient evidence, Sputum 
smear microscopy, which was developed over 100 years ago, is the general method 
used to diagnose TB worldwide. In this method, a sputum sample is collected from the 
patient to observe bacteria under a microscope. The use of rapid molecular tests to 
diagnose TB and DR-TB, however, is continuing to increase in popularity (World Health 
Organization, 2014).  
According to the Global Tuberculosis Report 2015, of the 5.2 million patients that were 
diagnosed, only 58% were bacteriologically confirmed according to a WHO-
recommended diagnostic, while the remaining 42% were diagnosed clinically, i.e. 
based on symptoms, chest X-ray abnormalities or suggestive histology. Since X-ray 
screening has poor specificity and the symptoms associated with TB are fairly common 
(fatigue, coughing, weight loss, fever), false diagnosis is a strong possibility (World 
Health Organization, 2015a).  
Once the diagnosis confirms that the patient has TB, further investigation is required to 
determine whether the patient is drug-resistant (Fraser et al., 2013). The diagnostics for 
drug-resistance can be done through conventional culture-based methods, liquid 
culture-based methods, rapid phenotypic methods or rapid molecular methods 
(McNerney et al., 2015). Failure to test the patient for drug resistance can result in 
prescribing the wrong treatment plan and can cause further spread and development 
of the drug-resistant strains (World Health Organization, 2014).  
2.4 Treatment of TB and MDR-TB 
As previously mentioned, the treatment of TB spans over several months (typically six 
months for TB and up to 20 months for DR-TB) and often requires supervised treatment 
for maximum cure rates, reduced incidence and to minimise chances of developing drug 
resistance (Wells et al., 2011). The first effective drug treatments for TB, were developed 
in the 1940s, while rifampicin, the most effective first-line drug to date, became available 
in the 1960s. Success rates of approximately 85% are reported for the treatment of drug-
susceptible TB (World Health Organization, 2014). the success rate for MDR-TB is 
significantly lower at 50% globally (World Health Organization, 2015a). 
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The seven essential drugs in treatment policies of drug-susceptible TB are isoniazid 
(H/Inh), rifampicin/rifampin (R/Rif), pyrazinamide (Z/Pza), ethambutol (E/Emb), rifapentine 
(P/Rpt), rifabutin (Rfb) and streptomycin (S/Stm) (World Health Organization, 2010, 2015c). 
For the majority of the public sector, policies for the treatment for TB are based on WHO 
recommendations. For example, a typical first-line treatment adhered by most 
countries, is a 6-month regime denoted as 2HRZE/4HR. This translates to a treatment 
consisting of two months of isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol 
(E), followed by four months of isoniazid (H) and rifampicin (R). The Global Drug Facility 
(GDF), more detail in Section 5.2.3, supports the WHO recommendations by facilitating 
the purchase of TB treatment in these dosages (Wells et al., 2011).  
In countries with a high TB burden, the average cost of treatment for a patient with drug-
susceptible TB in 2014 was approximately US$100 – US$500, while for MDR-TB it varied 
between US$5,000 and US$10,000 per patient, with an average price of US$6,826 in 
low-income countries and US$21,265 in upper middle-income countries (World Health 
Organization, 2015a). As shown in Table 2.1, the drugs for MDR-TB are grouped 
according to their efficacy, experience of use and drug class, with Group 1 containing 
the most potent and best tolerated drugs – unless the bacillus have become resistant 
to these drugs (World Health Organization, 2010). 
Table 2.1: Groups of drugs to treat MDR-TB (Adapted from Caminero et al., 2010 and World Health 
Organization, 2011). 
Group Drugs 
1 First-line oral agents Pyrazinamide (Z/Pza) 
Rifabutin (Rfb) 
Ethambutol (E/Emb) 
2 Second-line parenteral 
agent (injectable anti-
tuberculosis drugs)  
Kanamycin (Km)  
Amikacin (Am)  
Capreomycin (Cm) 
Streptomycin (S/Stm)  
3 Fluoroquinolones Ofloxacin (Ofx)  
Levofloxacin (Lfx) 
Moxifloxacin (Mfx) 
Gatifloxacin (Gfx) 
4 Oral bacteriostatic 
second-line agents 
Ethionamide (Eto) 
Prothionamide (Pto) 
Cycloserine (Cs) 
Terizidone (Trd) 
Para-aminosalicylic acid (PAS) 
Continued on next page 
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Continued from previous page 
5 Agents with unclear 
role in treatment of DR-
TB 
Clofazimine (Cfz) 
Linezolid (Lzd) 
Amoxicillin/Clavulanate (Amx/Clv) 
Imipenem (Ipm) 
Thiocetazone (Thz) 
High-dose Isoniazid (High-dose H) 
Clarithromycin (Clr) 
The WHO (World Health Organization, 2010, 2011) provides principles and guidelines for 
the management and planning of MDR-TB treatments. At least four drugs, to which the 
M.TB isolate is likely to be susceptible and for which effectiveness is certain, should be 
included in a hierarchical order from Groups 1-5, although more than four drugs might 
be necessary (Caminero et al., 2010). In general, one drug from Group 1, 2 and 3 should 
be included if susceptibility is documented or suspected, or the agent is thought to have 
efficacy and drugs from Group 4 are used to complete the regimen, to have at least four 
effective drugs. Group 5 drugs are not recommended due to their unclear influence on 
the efficacy of multidrug regimens and should only be included in cases where the 
design of adequate regimens was impossible. The typical regimen to treat patients with 
MDR-TB, includes the following:  
1. pyrazinamide from Group 1;
2. an injectable parenteral agent from Group 2;
3. a fluoroquinolone from Group 3;
4. ethionamide or prothionamide from Group 4; and
5. cycloserine or PAS (only if cycloserine cannot be used) from Group 4.
From the Group 2 formulations, kanamycin or amikacin is often the first choice for an 
injectable agent since they are inexpensive and have been widely used in the treatment 
of drug- resistant TB. However, kanamycin and amikacin are very similar and therefore 
have a high frequency of cross-resistance. Cross-resistance is when resistant mutations 
(in M.TB bacteria) to one of the anti-TB drugs may cause resistance to some of the other 
members in the drug family (World Health Organization, 2010). If drug resistance 
surveillance data indicates high prevalence of resistance to amikacin and kanamycin, 
capreomycin should be used instead. Avoiding the use of streptomycin is highly 
recommended, even if a DST shows susceptibility, due to the high amount of cases 
reporting resistance with DR-TB strains (World Health Organization, 2011). Ethionamide 
or protionamide (Group 4) is frequently added to the regimen since it is inexpensive. If 
cost is not a limitation, PAS may be added first, because it is relatively well tolerated 
and there is no cross-resistance to other agents. If two formulations are required from 
Group 4, cycloserine should be used instead of PAS, as a combination of ethionamide 
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or protionamide and PAS can cause gastrointestinal side-effects and hypothyroidism. 
PAS, cycloserine and ethionamide or protionamide should only be used together when 
three Group 4 drugs are required (World Health Organization, 2010).  
The chosen formulations should be based on treatment history and drug susceptibility 
testing, although the reliability and clinical value of drug susceptibility testing for drugs 
in Group 4 and 5 have not been entirely documented. Drugs that are commonly used 
in the country and the prevalence of resistance to specific FLDs and SLDs should also 
be taken into consideration (World Medical Association, 2008). Any drug for which there 
is a possibility of cross-resistance or that is not safe to use due to, for example, unknown 
quality, should not be considered (World Health Organization, 2010). The total treatment 
lasts between 18 and 20 months and most regimens are divided into two phases, an 
initial intensive phase, followed by a continuation phase. The intensive phase lasts at 
least 6 months and at least four drugs, including the parental agent, and pyrazinamide 
are included in the treatment. The exact length of the intensive phase is guided by 
smear and culture conversion, since the injectable agent should be continued for at 
least 4 months after the patient becomes and remains smear- or culture-negative. If the 
susceptibility pattern is unknown or the effectiveness of an agent is questionable, the 
injectable agent is continued for a longer period. In the continuation phase, the patient 
takes at least four oral drugs for 12 months or more. During both of the phases the drugs 
are taken daily (Caminero et al., 2010) and it is therefore recommended that each dose 
is given as a directly observed treatment (DOT) (World Health Organization, 2010).  
In May 2016, WHO released a conditional recommendation on the use of a shorter MDR-
TB regimen. The shorter regimen lasts less than 12 months and has been used in clinical 
trials in a number of countries, including Cameroon, DR Congo, Guinea, Niger, 
Uzbekistan and Bangladesh. The new recommendation is anticipated to help MDR-TB 
patients worldwide, but the resistance could be worsened if not used appropriately 
(World Health Organization, 2016b). Figure 2.1 demonstrates the flow chart, adapted from 
WHO’s recommendation, outlining the selection of patients for the shorter regimen.  
Stellenbosch University  https://scholar.sun.ac.za
Page | 18 Chapter 2: Overview of MDR-TB 
Department of Industrial Engineering 
Figure 2.1: Flowchart of the selection of patients for the shorter treatment regimen (Adapted from World 
Health Organization, 2016b).
2.4.1 Directly Observed Therapy Short Course 
DOT is a constituent of the wider WHO strategy called Directly Observed Therapy Short 
Course (DOTS) (Karumbi and Garner, 2015). The DOTS treatment strategy was 
introduced in the 1990s by WHO (Nicholson et al., 2013), and incorporates five 
components (Nicholson et al., 2013; World Health Organization, 2015a): (i) political 
commitment to improve TB programmes with increased financing; (ii) case detection 
through quality-assured bacteriology; (iii) standardised treatment with supervision; (iv) 
an effective drug supply and management system; and (v) impact measurement and a 
monitoring system. The DOT constituent is part of an effort to improve patient adherence 
by actively monitoring and logging the consumption of all drugs by a suitable observer 
(Karumbi and Garner, 2015). 
The DOTS strategy was, however, specifically designed for the treatment of drug-
susceptible TB (Nicholson et al., 2013). While DOTS treatment requires the collection of 
data on patient admission, follow-up and smear results, MDR-TB requires considerably 
more detailed data on the drug regimens, laboratory results, treatment side-effects and 
treatment difficulties (Fraser et al., 2013). To address the rising epidemic of MDR-TB, the 
DOTS-Plus framework was developed to include treatment of MDR-TB with SLDs 
(Nicholson et al., 2013).  
CRITERIA: Do any of the following apply?
• Confirmed resistance or suspected ineffectiveness to a medicine in
the shorter MDR-TB regimen (except isoniazid resistance)
• Exposure to >1 second-line medicines in the shorter MDR-TB
regimen for >1 month
• Intolerance to >1 medicines in the shorter MDR-TB regimen or risk
of toxicity (e.g. drug-drug interactions)
• Pregnancy
• Extrapulmonary disease
• At least one medicine in the shorter MDR-TB regimen not available 
in the programme
Individualised
(“conventional”) 
MDR/RR-TB regimens
Shorter MDR-TB 
Regimen
Failing regimen, drug intolerance, 
return after interruption >2 months, 
emergence of any exclusion 
criterion
Intensive phase
Duration: Up to 8 months
Composition: 4 or more 
second-line drugs
Continuation phase
Duration: 12 months or more
Composition: 3 or more 
second-line drugs
Supported by selected first-
line TB drugs
Intensive phase
Duration: 4-6 months
Composition: 4 second-
line drugs
Continuation phase
Duration: 5 months
Composition: 2 second-
line drugs
Supported by selected 
first-line TB drugs
Choosing The MDR-TB Treatment Regimen in Patients with Confirmed 
Rifampicin-Resistance or MDR-TB
YESNO
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2.5 Other factors fuelling the disease 
TB skin test data suggest that more than two billion individuals are infected with latent 
TB (Field, 2013). Latent tuberculosis infection (LTBI) is a condition that occurs when the 
immune system stabilises M.TB infection inside the macrophages of healthy patients 
(Shi and Sugawara, 2010). This means that almost one third of the global population 
runs the risk of developing the active disease (Field, 2013). The lifetime risk of a person 
with LTBI progressing to active TB is approximately 10% (Horsburgh, 2004).  
In LTBI, treatment is difficult, since the hypoxic intracellular environment inhibits the 
M.TB metabolism (Stover et al., 2000). The diagnoses and treatment of LTBI is vital for 
TB prevention strategies. Once diagnosed, the risk of developing the active disease 
can be reduced with preventative drugs and treatment (Field, 2013). The risk of 
progressing from LTBI to active TB is greater in children younger than 5 years, patients 
previously cured of TB and patients that are underweight, have had a gastrectomy or 
have a history of renal failure or silicosis. The two conditions that increase the risk of 
developing active TB the most are diabetes and HIV (Field, 2013), these are discussed 
in more detail in the subsequent subsections. 
2.5.1 Diabetes 
Diabetes used to be associated with high-income groups as one of the principal causes 
of the disease is diets that are high in fat and sugar. This is, however, not the situation 
today (Senthilingam, 2014). According to the International Diabetes Federation diabetes 
atlas (International Diabetes Federation, 2013), eighty percent of diabetics live in low- 
and middle-income countries (LMICs), as can be concluded from Figure 2.2. 
Figure 2.2: Number of people with diabetes per region in 2013 (Reproduced from Aguiree et al., 2013, p. 
11).
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Diabetes decreases the body’s ability to produce insulin and absorb glucose from the 
bloodstream (Senthilingam, 2014). This triples the risk of developing TB (International 
Diabetes Federation, 2013). As of 2014, approximately 387 million people have 
diabetes, and the International Diabetes Federation predicts that this will increase to 
592 million people by 2035 (International Diabetes Federation, 2013).  
The high percentage of people with latent TB is already a cause for alarm. When 
considering the global increase in diabetes, it is immediately evident that there is a 
serious risk (Senthilingam, 2014). In some areas, such as Kerala in India, almost fifty 
percent of people diagnosed with TB suffer from diabetes as well (International 
Diabetes Federation, 2013). The cost of treating patients with diabetes in countries with 
high TB cases could be significant, especially when taking the unfaltering levels of TB 
drug-resistance into account (Senthilingam, 2014).  
2.5.2 Human Immunodeficiency Virus (HIV) 
A serious constraint in the effective control of the TB epidemic is the lethal co-infection 
of TB and HIV (Zhang and Yew, 2009). In 2013, more than 12% of people infected with 
TB, were also HIV positive (World Health Organization, 2014). In countries with high HIV 
prevalence, the rate of TB infection can increase up to four times, as HIV weakens the 
immune system (Senthilingam, 2014) and results in a patient being 29 times more likely 
to develop TB (World Health Organization, 2014). Additionally, there is also a high 
mortality rate in MDR-TB and HIV co-infected patients, especially in low-income areas 
(Gandhi et al., 2010).  
The association between HIV and drug resistant TB is complex. The HIV infection does 
not cause the drug-resistant mutants to multiply more rapidly, but it potentially 
accelerates the prevalence of drug-resistant TB (Selwyn et al., 1989). More specifically, 
it can cause the number of people that have a high-probability to develop drug 
resistance to increase (Gandhi et al., 2010).  
A recent meta-analysis of observational data in LMICs, led by WHO, found that 
antiretroviral therapy decreases tuberculosis incidence by 65% (Suthar et al., 2012). The 
earlier delivery of antiretroviral therapy and drug resistance treatment to co-infected 
patients, may play a significant  role in improving and controlling the HIV-associated TB 
syndemic (Gandhi et al., 2010; Chang and Yew, 2012).  
2.6 Areas of infection
More than 95% of tuberculosis mortality occurs in LMICs. In 2013, South East Asia and 
the Western Pacific Regions carried the largest number of new TB cases (56% of new 
cases globally). The greatest proportion of new cases per population, also in 2013, 
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occurred in Africa where 280 out of every 100,000 people were diagnosed with TB 
(Smith, 2015).  
Since 1998, twenty-two countries have been prioritised on a global level due to their 
high TB prevalence and mortality (TB Statistics | Global, regional, high burden & MDR, 
2013). These countries are known as high burden countries (HBCs) and account for 
approximately 80% of the global TB burden (Wells et al., 2011). These 22 countries, in 
alphabetical order, are: Afghanistan, Bangladesh, Brazil, Cambodia, China, DR Congo, 
Ethiopia, India, Indonesia, Kenya, Mozambique, Myanmar, Nigeria, Pakistan, Philippines, 
Russian Federation, South Africa, Thailand, Uganda, UR Tanzania, Vietnam and 
Zimbabwe.  
Recently, the WHO defined three new HBC lists for the period 2016 to 2020.  There is 
now a separate list for TB, MDR-TB and for TB/HIV, with 30 countries on each list. 
Twenty of the countries are defined as the top 20 in terms of absolute numbers of cases, 
while the remaining 10 countries are those with the highest burden in terms of incidence 
rates per capita, namely 10 000 cases per year for TB and 1 000 cases per year for 
MDR-TB and TB/HIV. The 30 countries on the list account for 87% to 92% of the global 
burden, almost exclusively accounted for by the top 20 countries (World Health 
Organization, 2016a). The countries in each list are summarised in Table 2.2.  
Table 2.2: List of the HBCs for TB, TB/HIV and MDR-TB (Adapted from World Health Organization, 
2016a). 
TB HBC List TB/HIV HBC List MDR-TB HBC List 
Top 20 Additional 10 Top 20 Additional 10 Top 20 Additional 10 
- Angola 
- Bangladesh 
- Brazil 
- China 
- DPR Korea 
- DR Congo 
- Ethiopia 
- India 
- Indonesia 
- Kenya 
- Mozambique 
- Myanmar 
- Nigeria 
- Pakistan 
- Philippines 
- Russian 
Federation 
- South Africa 
- Thailand 
- UR Tanzania 
- Viet Nam 
- Cambodia 
- Central 
African 
Republic 
- Congo 
- Lesotho 
- Liberia 
- Namibia 
- Papua New 
Guinea 
- Sierra 
Leone 
- Zambia 
- Zimbabwe 
- Angola 
- Brazil 
- Cameroon 
- China 
- DR Congo 
- Ethiopia 
- India 
- Indonesia 
- Kenya 
- Lesotho 
- Malawi 
- Mozambique 
- Myanmar 
- Nigeria 
- South Africa 
- Thailand 
- Uganda 
- UR Tanzania 
- Zambia 
- Zimbabwe 
- Botswana 
- Central 
African 
Republic 
- Chad 
- Congo 
- Ghana 
- Guinea-
Bissau 
- Liberia 
- Namibia 
- Papua New 
Guinea 
- Swaziland 
- Bangladesh 
- China 
- DPR Korea 
- DR Congo 
- Ethiopia 
- India 
- Kazakhstan 
- Kenya 
- Indonesia 
- Mozambique 
- Myanmar 
- Nigeria 
- Pakistan 
- Philippines 
- Russian 
Federation 
- South Africa 
- Thailand 
- Ukraine 
- Uzbekistan 
- Viet Nam 
- Angola 
- Azerbaijan 
- Belarus 
- Kyrgyzstan 
- Papua New 
Guinea 
- Peru 
- Republic of 
- Moldova 
- Somalia 
- Tajikistan 
- Zimbabwe 
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From the table, it is clear that several countries appear on more than one of the lists. 
Figure 2.3 illustrates this overlap among the three lists.  
Figure 2.3: Overlap of HBC lists (Adapted from World Health Organization, 2016a). 
2.7 Funding for TB and MDR-TB 
It is estimated that approximately US$ 8 billion, divided into four spending categories 
as shown in Figure 2.4, is required per year to fund a full response to the TB epidemic in 
LMICs (World Health Organization, 2015a). This amount excludes the US$ 2 billion per 
year necessary for research and development (for new TB vaccines and diagnostics), 
as laid out in the Global Plan (Frick, 2014).  
Figure 2.4: Spending categories for a full TB response (Adapted from World Health Organization, 
2015a).
MDR-TB
Azerbaijan
Belarus
Kazakhstan
Kyrgyzstan
Peru
Republic of Moldova
Somalia
Tajikistan
Ukraine
Uzbekistan
TB/HIV
TB
Botswana
Cameroon
Chad
Ghana
Guinea-Bissau
Malawi
Swaziland
Uganda
Cambodia
Sierra Leone
Bangladesh
DPR Korea
Pakistan
Philippines
Russian Federation
Viet Nam
Brazil
Central African Republic
Congo
Lesotho
Liberia
Namibia
UR Tanzania
Zambia
Angola
China
DR Congo
Ethiopia
India
Indonesia
Kenya
Mozambique
Myanmar
Nigeria
Papua New Guinea
South Africa
Thailand
Zimbabwe
Treatment of MDR-TB
Rapid Diagnostic Tests & 
Associated Laboratroy  Strengthening
Collaborative TB/HIV Activities
20%
6%
8%
Detection & Treatment of 
Drug-Susceptible TB66%
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According to projections made in 2013, the WHO recommends that US$6 billion could 
be obtained from domestic sources, while the remaining US$2 billion would most likely 
need to be obtained through international donors (World Health Organization, 2015a). 
The BRICS countries (Brazil, Russian Federation, India, China and South Africa) 
collectively make up 50% of the global TB cases, yet most of them (India being the 
exception) are able to obtain the majority or all of their necessary funding from domestic 
sources (World Health Organization, 2016a). In 2016, 84% of the available US$6.6 for 
TB care and prevention in LMICs, were domestically sourced. International donors, 
however, remain the main source of funding in most of the low income HBCs. In 
Afghanistan, Bangladesh, the Democratic Republic of the Congo and Mozambique 
more than 90% of the available funding in 2015 was from international donors (World 
Health Organization, 2015a).  
2.8 Conclusion: Overview of MDR-TB 
This chapter provided background information on the TB and MDR-TB epidemic. The 
primary causes of TB and MDR-TB were discussed, as well as the advancement of MDR-
TB over the last 100 years. The steps involved with the diagnosis were summarised, as 
well as the treatment regimens for both TB and MDR-TB. The risk of developing active 
TB due to diabetes or HIV were also discussed. A summary of the HBCs and the funding 
required to respond to the epidemic were provided.  
Chapter 3 will provide further background information for this research, focussing on 
supply chains and their importance in controlling the TB epidemic.  
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"No supply chain exists in isolation. Many supply chains are integrated and a disruption at 
one point could have knock on effects for other entities." 
- Evan Bloom (Founder and managing partner of Root Change) 
The previous chapter provided background information on TB with the focus on MDR-
TB. This chapter includes a description of applicable topics and themes, related to 
supply chains, that would help put the research in context. Topics that will be discussed 
include the levels of supply chains, measuring the performance of the supply chain with 
measures and metrics, demand forecasting, push and pull systems, and inventory 
management policies.   
3.1 Defining supply chains and supply chain management 
Adding to the definition provided in Section 1.1, a supply chain is a collection of facilities, 
materials, clients, products and procedures to manage inventory, procurement, and 
distribution (Sabri and Beamon, 2000). In a supply chain, goods flow through numerous 
echelons as they progress from supplier to customer, where each of these echelons 
may consist of more than one facility (Sabri and Beamon, 2000). In an effective and 
operational supply chain, each unit is treated as a customer by its predecessor, with 
the focus always on providing the best possible service to the end user (Holmstrom, Jr 
and Louhiluoto, 2012). 
Supply chain management (SCM) involves the services associated with the set of 
activities involved in moving products from the supplier to customer (Dowling, 2011). 
APICS (‘APICS Dictionary 10th Edition’, 2002) defines SCM as “the design, planning, 
execution, control, and monitoring of supply chain activities with the objective of 
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creating net value, building a competitive infrastructure, leveraging worldwide logistics, 
synchronising supply with demand, and measuring performance globally.”  
A common theme in defining a supply chain and SCM is that it takes place among a 
connected series of echelons and facilities (Scannell, Vickery and Dröge, 2000) that 
operate at various levels within a country (Dowling, 2011). Furthermore, there can be a 
number of different supply chains that operate vertically within a country. These supply 
chains usually have many points where they overlap and a diverse set of participants. 
It is essential to link all functions and components of the supply chain to ensure that 
supply can meet demand (Dowling, 2011).   
Medical supply chains, such as for MDR-TB SLDs, require agile procurement 
mechanisms that are able to deliver high quality drugs at the lowest possible cost. More 
funds and support are being provided to the various initiatives that aim to aid in the 
development and strengthening of this type of procurement. Such initiatives include the 
Global Fund’s Voluntary Pooled Procurement Mechanism and the Global Drug Facility, 
as will be discussed in Section 5.2.3 (Dowling, 2011).   
3.2 Levels of supply chain management decision making 
Supply chain management includes all of the decisions made in the supply chain 
process and covers various decision areas (Biswas and Narahari, 2004). Over time, a 
certain factor in one decision area can influence a factor in another. To understand the 
relationships and influences of the different decision areas, it is necessary to 
comprehend the three levels of SCM decision making (Thierry, Bel and Thomas, 2010), 
namely the strategic, operational and tactical levels. These levels are best explained 
when represented as a pyramid, refer to Figure 3.1, since it illustrates the hierarchy 
which governs the control over the supply chain as well as the development and 
arrangement of guidelines and policies.  
Figure 3.1: Levels of supply chain management decision making. 
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This hierarchy is based on factors such as the time horizon for activities and the 
relevance of decisions to the different levels of management. When moving down from 
the strategic to operational level, the focus shifts from improving the effectiveness of the 
supply chain to improving its efficiency (Gunasekaran, Patel and McGaughey, 2004).  
3.2.1 Strategic level 
The strategic level involves long-term decisions and is influenced by top-level 
management. At this level, the basis of the entire supply chain process is planned, the 
organisational goals are set and broad based policies are determined (Gunasekaran, 
Patel and McGaughey, 2004). Usually decisions at a strategic level will need revision 
after one or several years, depending on the design of the supply chain network, since 
it involves long-range choices such as the locations and number of warehouses, 
factories, distribution centres, and so forth (Thierry, Bel and Thomas, 2010).  
3.2.2 Tactical level 
The tactical level involves medium-term decisions, usually covering approximately six 
to twelve months. These decisions involve cost control and risk management, logistics 
planning, fleet management and storage management, among others, and are limited 
by the strategic decisions. Although the supply chain processes are planned at the 
strategic level, they are outlined at the tactical level. Performance measurements are 
taken to evaluate whether the goals, set at the strategic level, have been met. This 
provides valuable feedback to mid-level management (Gunasekaran, Patel and 
McGaughey, 2004).  
3.2.3 Operational level 
The operational level involves short-term decisions that take place on a weekly, daily 
or hourly basis. Accurate data is an essential requirement on this level since it entails 
the day-to-day decisions required for the effective functioning of the supply chain 
(Thierry, Bel and Thomas, 2010). Operational level activities include monitoring, 
production processes and communicating with suppliers and customers. Operational 
objectives are set by low-level management in order to achieve the tactical objectives. 
Strong strategic and tactical decisions will contribute to the effectiveness of the 
operational processes (Gunasekaran, Patel and McGaughey, 2004). 
3.3 Importance of supply chains 
Although there are several variables that influence the availability of drugs and access 
to drugs, a principal constraint is the capacity of supply chains to forecast, procure and 
deliver the drugs and health supplies that are crucial in the treatment of TB (Dowling, 
2011). This constraint is strongly related to the quality of information-, product- and 
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financial flow management. Many LMICs do not initially consider the critical role of the 
supply chain in effective management of TB and this can drive the aforementioned 
constraint (Riungu, 2011). 
Inadequate supply chain management and weak procurement systems lead to poor 
drug quality and treatment interruptions (Atun et al., 2010). This can lead to the 
development of drug-resistant TB, as discussed in Section 2.1. More than 10 million lives 
could be saved, per year, through improved access to drugs and treatment (Frick, 2014). 
Furthermore, disruptions in the supply can result in multiple additional problems, such 
as inefficiency, waste, stock-outs, and poor service (Holmstrom, Jr and Louhiluoto, 2012). 
These disruptions can be reduced and prevented by paying the necessary attention to 
the operations and management of the supply chain (Holmstrom, Jr and Louhiluoto, 
2012). By incorporating the supply chain in the overall disease management strategy, 
efforts towards controlling the TB epidemic can be enhanced through the effective 
utilisation of available assets and recourses. This is, however, becoming increasingly 
difficult due to the  participation of an increasing number of organisations and 
stakeholders on both a national and international level (Riungu, 2011). 
The positive effect that SCM can have on a country’s health system is evident in the 
Hashemite Kingdom of Jordan in the Middle East. Two years after a new management 
system for contraceptives was implemented, the number of stock-outs in health centres 
was reduced by 75% (Holmstrom, Jr and Louhiluoto, 2012). Other than reduced stock-
outs, an effective supply chain can also increase response time, flexibility and drug 
utilisation, reduce waste and possibly decrease the chances of medication errors 
(Riungu, 2011). 
3.4 Measuring supply chain performance 
A supply chain analysis involves studying how products move from forecasting and 
procurement to the final delivery to the consumer. It entails assessing the performance 
of all the entities and processes involved during the entire supply chain (Unicef, 2009). 
In this research, the supply chain’s performance will be measured under the different 
circumstances of the modelling scenarios and then compared with one another in order 
to make recommendations for the strengthening of the supply chain. 
3.4.1 Measures and metrics 
Measures and metrics are required to test the feasibility and sustainability of strategies 
and support the development of clear improvement goals (Gunasekaran, Patel and 
Tirtiroglu, 2001). A performance measure can be described as a selection of metrics that 
is used to quantify and subsequently measure the effectiveness and/or efficiency of a 
process, action or entity (Mandal, 2012a). In this sense, effectiveness typically refers to 
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meeting the customer’s requirements and efficiency measures the utilisation of 
resources (Mandal, 2012b). The metric typically includes the measure’s definition, the 
calculation method and the data source (Mandal, 2012a). With this in mind, all metrics 
can ultimately be grouped into either (i) utilisation, (ii) productivity, or (iii) effectiveness 
metrics. Utilisation is a measure of input usage and is typically a ratio of an actual 
amount and a norm value. For example, a ratio of the number of hours a machine was 
used and the number of hours the machine is available. Productivity (or efficiency) 
compares inputs with outputs and is typically a ratio of the actual output and the actual 
inputs that were consumed. For example, a ratio of the amount of orders that were 
processed and the number of hours it took. Lastly, effectiveness measures the quality 
of the output and is typically a ratio of the actual output and a norm output. For example, 
a ratio of the amount of orders fulfilled and the amount of orders received.  
A challenging aspect of performance measurement, is identifying the key performance 
indicators (KPIs) that will add the most value to the supply chain analysis (Mandal, 
2012a, 2012b). Having several metrics measuring all the aspects of the supply chain will 
waste time and is often unnecessary. Therefore, the metrics used in performance 
measurement and improvement should be chosen carefully and only be used if they 
capture a necessary aspect of the supply chain performance (Gunasekaran, Patel and 
McGaughey, 2004). Metrics can be assessed according to several criteria, namely (i) 
robustness, (ii) validity, (iii) usefulness, and (iv) integration (Caplice, 2016b). A robust 
metric is timeless, comparable across locations and organisations and is repeatable. 
Valid metrics accurately represent the processes measured and take outside influences 
into account. Useful metrics are easy to comprehend and deliver a sensible description 
of the measured process. An integrative metric includes all of the significant factors and 
influences of the measured process and encourages coordination across the entire 
supply chain. The metrics will typically have trade-offs between these criteria. For 
example, a metric that is exceptionally integrative, will typically be less useful and valid. 
This is why it is best for a system to have a set of metrics.  
The goals of the measurement system should represent the goals of the organisation 
and, in this case, the goals of the research as well. This is often reflected in the way that 
the metrics and measurement system is grouped. In previous studies, metrics and 
measurement systems have been grouped according to the type of information or data 
they provide, i.e. whether they are quantitative or qualitative (Chan et al., 2003) or 
according to their tactical, operational or strategic focus (Gunasekaran, Patel and 
Tirtiroglu, 2001; Gunasekaran, Patel and McGaughey, 2004). Furthermore, they have 
also been grouped according to the process, activity or tier in the SC that they relate to 
most (Lambert and Pohlen, 2001), or at what link they influence the performance across 
the entire supply chain (Lockamy and McCormack, 2004). Combinations of the above-
mentioned groupings can be used, such as grouping the metrics according to their level 
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of focus and then subgrouping them according to their related SC process. In a global 
supply chain, such as the one being investigated in this study, the metrics that monitor 
the supply chain can be said to be on either a global-, regional-, or country-level (Unicef, 
2009). Regardless of the grouping used, it is best that the metrics comprise of both 
financial and non-financial measures (Biswas and Narahari, 2004; Gunasekaran, Patel 
and McGaughey, 2004).  
3.4.2 Supply Chain Operations Reference (SCOR) 
The Supply Chain Operations Reference (SCOR®) was developed by the Supply Chain 
Council in 1996 and has since become the world’s leading management tool for supply 
chain decision making. The SCOR framework provides a unique supply chain 
framework that links people, practices, processes and performance metrics. For this 
study, the focus will be on performance metrics.  
The performance metrics section of SCOR is divided into two types of elements, namely 
metrics and performance attributes. A metric measures the capability of a supply chain 
to achieve a certain strategy, while a performance attribute is described as a set of 
metrics that represent the strategy. SCOR distinguishes between three levels of metrics. 
The overall wellbeing of the supply chain is described by Level 1 metrics and helps to 
ascertain supply chain targets and goals. These metrics are characterised by Level 2 
metrics, which aim to identify causes of performance gaps in the Level 1 metrics. 
Likewise, Level 2 metrics are characterised by Level 3 metrics. Furthermore, there are 
five core performance attributes identified by SCOR, namely (i) reliability, (ii) 
responsiveness, (iii) agility, (iv) costs and (v) assets. Each of these five attributes are 
described in Table 3.1. 
Table 3.1: Description of SCOR attributes. 
Attribute Description 
Reliability 
• Addresses the capability to execute and complete expected tasks.
• Centred around the predictability of process outcomes.
• Customer-oriented attribute.
• Level 1 metric is Perfect Order Fulfilment.
Responsiveness 
• Describes the rate at which tasks are executed.
• Customer-oriented attribute.
• Level 1 metric is Order Fulfilment Cycle Time.
Agility 
• Describes the capability to respond and adapt to outside influences,
such as unexpected changes in demand, suppliers leaving the market, 
labor issues, etc.  
• Customer-oriented attribute.
• Level 1 metric is Upside Supply Chain Flexibility.
continued on next page 
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continued from previous page 
Costs 
• Describes the costs of the processes.
• Covers all supply chain spend, including labour costs, material costs,
transportation costs, supply chain management cost etc. 
• Internally-oriented attribute.
• Level 1 metric is Supply Chain Management Cost.
Assets 
• Describes the proficiency of asset utilisation.
• Strategies include inventory reduction, outsourcing vs. insourcing, etc.
• Internally-oriented attribute.
• Level 1 metric is Cash-to-Cash Cycle Time.
3.5 Demand Forecasting 
Demand forecasting refers to the prediction of the likely demand for a product or a 
service based on historical events and present trends. There are three levels within the 
demand forecasting component, related to the forecast’s time horizon and purpose. 
These levels are associated with the supply chain levels discussed in Section 3.2, 
namely strategic forecasts, tactical forecasts and operational forecasts.  
There are several forecasting methods, each with their own advantages and limitations. 
The methods can be divided into two groups, namely subjective and objective. 
Subjective methods can be further divided into judgemental methods (such as sales 
force surveys or expert opinions) or experimental methods (such as customer surveys 
or focus groups). Objective methods can also be subdivided into two groups, namely, 
causal methods (such as regression analysis) and time series methods (such as 
exponential smoothing). Subjective methods are mostly applied by marketing and 
sales, while objective methods are mostly applied for production and inventory 
planning). For the purpose of this study, some of the more common objective methods 
will be discussed further. 
3.5.1 Time series 
Time series is essentially used to identify patterns or trends in the data distributed over 
time. To be able to identify and capture the patterns, historical data or records of 
demand for several time periods are required. There are five aspects associated with 
time series, namely (i) level, (ii) trend, (iii) seasonality, (iv) random variabilities and (v) 
cyclical movements. Each of these components are described shortly in Table 3.2. 
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Table 3.2: Five components of time series. 
Aspect Description Graphical Example 
Level 
• The demand remains approximately the
same with small variations. 
• In the absence of other patterns, the
demand remains a constant value. 
Trend 
• The demand either grows or declines over
time; i.e. it moves in one direction. 
• Trends are typically linear, but can be
exponential, quadratic etc. 
Seasonality 
• Demand follows a repeated cycle related to
a known and fixed time period (hourly, 
weekly, monthly, etc.). 
• This can be due to natural (winter vs
summer) or man-made (school holidays, 
sporting events) forces. 
Random 
Variabilities 
• Demand is irregular and unpredictable.
Cyclical 
Movements 
• Similar to seasonality, but the time period is
not fixed. 
• The duration of the cycle can be different
every time. 
The forecasting procedure for time series can be described in four steps: 
1. Select a suitable model of the demand pattern;
2. Estimate and regulate values for the model parameters;
3. Forecast the future demand with the selected model and parameters; and
4. Review the model’s performance and adjust the parameters if necessary.
Three common time series models are the cumulative forecast model, the naive 
forecast model and the moving average forecast model. In a cumulative forecast model, 
all the history matters equally and therefore all of the data is included. These forecasts 
often change very slowly over time and are more constant than responsive. The 
equation for a cumulative forecasting model is 𝑥6,6KG = 𝑥(6(FG𝑡
where: 
(3.1) 
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𝑥6,6KG represents the forecast for period 𝑡 + 1 made during period 𝑡, and𝑥6 represents the actual demand in period 𝑡.
In a naive forecast model, only the latest data point affects the system. These forecasts 
are typically more volatile and can alter rapidly and dramatically making it more 
responsive than stable. The equation for a naive forecasting model is 𝑥6,6KG = 𝑥6.
In a moving average forecast model, the amount of data to use (the last 𝑀 periods) can 
be altered. The equation for a moving average forecasting model is 𝑥6,6KG = STUTVUWXYZ[ . 
All of three of these model examples assume stationary demand. Therefore, if there is 
any trend or seasonality present in the data, the forecast will be lagging. Furthermore, 
the models also apply equal importance to each of the historical data points. A fourth 
model, the exponential smoothing forecasting model, treats data points differently 
depending on their age. The basic principle of exponential smoothing is that the weight 
of a data point decreases over time to ensure that the more recent observations have 
a greater effect on the forecast. The weights that data points carry, decrease 
exponentially as they age. The equation for a simple exponential smoothing forecasting 
model is 𝑥6,6KG = 𝛼 1 − 𝛼 '𝑥6 + 𝛼(1 − 𝛼)G𝑥6MG + 𝛼(1 − 𝛼)^𝑥6M^ + ⋯+ 𝛼(1 − 𝛼)N𝑥6MN
where: 𝑥6,6KG is the forecast for time 𝑡 + 1 made during time 𝑡,𝛼 is the exponential smoothing factor 0 ≤ 𝛼 ≤ 1 , 𝑥6 is the actual demand during time 𝑡, and𝑥6MN is the actual demand during time 𝑡 − 𝑛.
As with the previous three models, this model also assumes stationary demand; 
however, the equation can be altered to assume a level, trend and seasonality. This 
model is also known as the Holt-Winter Method. The equation is given by  𝑥6,6K` = (𝑎6 + 𝜏𝑏6)𝐹6K`M<,
where 𝑎6 and 𝑏6 is the estimated level and trend at time 𝑡, respectively, and 𝐹6 is the
multiplicative seasonal index appropriate for period 𝑡 calculated by 𝑎6 = 	𝛼 SUcUYd + (1 − 𝛼)(𝑎6MG + 𝑏6MG),𝑏6 = 	𝛽& 𝑎6 + 𝑎6MG + (1 − 𝛽&)𝑏6MG, and
(3.2) 
(3.3) 
(3.4) 
(3.5) 
(3.6) 
(3.7) 
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𝐹6 = 𝛾& 𝑥6𝑎6 + (1 − 𝛾&)𝐹6M<
where: 𝛽& represents the exponential smoothing trend factor 0 ≤ 𝛽& ≤ 1 ,𝛾& the seasonality smoothing factor 0 ≤ 𝛾& ≤ 1 , and𝑃 the number of time periods within the seasonality 𝐹( = 𝑃<(FG . 
3.5.2 Causal analysis 
Causal analysis is used when the demand is correlated with some known and 
measurable factors. The demand (𝑌) is the dependent variable, and is given as a 
function of one or several independent variables (𝑥G, 𝑥^, … , 𝑥N). The equation for linear
regression is: 𝑌( = 𝛽' + 𝛽G𝑥G( + 𝛽^𝑥^( + ⋯+ 𝛽(𝑥N(		𝑓𝑜𝑟	𝑖 = 1,2, …𝑛,
where: 𝛽' is the estimate of the intercept, and𝛽(: is the estimate of the slope for variable 𝑖.
3.5.3 Forecasting quality 
Irrespective of the chosen forecasting method, the quality of the forecast remains an 
important consideration. There are two dimensions significant to forecasting quality, 
namely bias and accuracy. Bias is the persistent tendency to over- or under-forecast, 
while accuracy refers to the forecast’s closeness to the actual data. Since no single 
metric can accurately capture both of these dimensions, it is best to use multiple metrics. 
The most common metrics used for accuracy are the mean absolute percent error and 
the root mean squared error, while the most common metric used for bias is the mean 
percent error.  
The root mean squared error (𝑅𝑀𝑆𝐸), mean absolute percent error (𝑀𝐴𝑃𝐸) and mean 
percent error (𝑀𝑃𝐸) is given by: 
𝑅𝑀𝑆𝐸 = 	 lUmnUVXN , 
       𝑀𝐴𝑃𝐸 = 	 oUpUnUVXN  , and 𝑀𝑃𝐸 =	 oUpUnUVXN  , 
where 𝑒6 is the forecast error for time 𝑡 and is calculated as the difference between the
actual demand and forecasted demand for time 𝑡.  
(3.8) 
(3.9) 
(3.11)
(3.10) 
(3.12) 
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3.6 Push and pull systems 
A system where the forecasted demand, instead of the actual demand, is used during 
planning and operations is referred to as a push system. In contrast, a pull system is 
where planning and operations are only initiated in response to an order, when the 
exact demand is known for certain. Push systems are known to have faster response 
times, since stock is already on hand, but can sometimes result in either excess stock 
or a shortage of stock. In contrast, pull systems rarely have any excess stock or stock 
shortages, since the actual demand is used; however, it is accompanied by longer 
response times.  
Although push systems are more common, nearly all supply chains implement a push-
pull hybrid, which is combination of both a push and a pull system. The point in the 
supply chain where it changes from a push system to a pull system is typically referred 
to as the decoupling point or customer order decoupling point. A common strategy is to 
implement a push system in the upstream segment of the supply chain and a pull 
system in the downstream segment. A simple example is illustrated in Figure 3.2. The 
demand is forecasted, orders are placed to manufactures and stock is kept at a central 
warehouse or distribution centre. When a customer places an order it is pulled from the 
warehouse or DC. This strategy combines the benefits of having a product ready on 
demand (push system) and of fast customisable services (pull system).  
 
Figure 3.2: Example of a push-pull hybrid system. 
3.7 Inventory management 
Inventory management involves the administration and monitoring of the order, storage 
and use of the items or products that a company sells. Where applicable, it also involves 
the management of the raw materials used to produce the products or items. Inventory 
is kept to use as a safeguard against uncertainties in the demand, supply, distribution 
or manufacturing. It alleviates the need to manufacture a product from scratch for each 
individual order. Inventory is the result of a push system where the forecast regulates 
the amount of inventory that is required.  
It is important to determine the amount of inventory that will reduce the probability of 
having excess inventory and consequently possible spoilage or obsolescence. To do 
1 Warehouse/ DCManufacturers Customers
Orders Orders
Orders in Transit Orders in Transit
2
Forecast-Driven (Push System) Order-Driven (Pull-System)
Decoupling Point)
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this, inventory decisions are made across all three supply chain levels. Strategic 
inventory decisions cover the implications of the design (of the product and network), 
such as the capacity of warehouses and distributions, implementing a centralised or 
decentralised network, etc. Tactical inventory decisions cover the details of the 
distribution process, such as what products to keep in stock and where. Lastly, 
operational decisions cover the replenishment policies of inventories, such as the safety 
stock level, reorder periods, etc. The operational decisions are critical to establish how 
the supply chain is set up. Some of the inventory policies related to operational 
decisions will be discussed in the remainder of this section.  
3.7.1 Single period inventory models 
A single period inventory model, also known as the newsvendor problem, permits 
variable and stochastic demand and assumes only a single time period. Only a single 
order can be placed at the beginning of the time period and no replenishment orders 
can take place during the period. Any excess inventory at the end of the time period is 
discarded and any unmet demand is lost.  
3.7.2 Base stock policy 
The base stock policy determines a base stock for each item. If an order is placed for 
that item, an order of the same size is placed to replenish the inventory to the base 
stock level. Therefore, the inventory position will always equal the base stock. The 
inventory position is given as the sum of the stock on hand and the orders placed, 
subtracted by backorders (if applicable). The base stock is typically set at a level to 
meet the estimated demand during the lead time. Furthermore, the model assumes that 
any excess inventory can be used at a later time period and it is not discarded.  
3.7.3 Continuous review policies 
A continuous review policy allows inventory replenishment at any time. There are two 
common continuous review policies used, namely: the order-point, order quantity (𝑠, 𝑄); 
and the order-point, order-up-to-level (𝑠, 𝑆) policy. With the (𝑠, 𝑄) policy, 𝑄 units are 
ordered when the inventory position is less than or equal to the replenishment point 𝑠, 
while with the (𝑠, 𝑆) policy, a maximum of 𝑆 units can be ordered. The latter policy is 
especially useful in cases where there is a capacity or budget constraint. The order size 
of the (𝑠, 𝑆) policy is typically the difference between the inventory position and 𝑆. Both 
of these policies are illustrated with an example in Figure 3.3, where a lead time of one 
period is applied. 
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 (a)     (b) 
Figure 3.3: (a) Example of an order-point, order quantity (s,Q) policy, (b) example of an order-point, 
order-up-to-level (s,S) policy. 
In the (𝑠, 𝑄) policy example, the same amount (𝑄) is ordered every time the inventory 
position falls below the replenishment point 𝑠, while in the (𝑠, 𝑆) policy, the amounts 
being ordered differ, since these depend on the inventory position at the time of the 
order placement. 
3.7.4 Periodic review policy 
A periodic review policy allows inventory replenishment only at certain time periods. 
For example, with an order-up-to-level policy (𝑅, 𝑆), a maximum of 𝑆 units are ordered 
every 𝑅 time periods. This is illustrated in Figure 3.4, where an order is placed every 
four periods and there is a lead time of one period. The order size differs depending on 
the inventory position at the time of the order placement. 
Figure 3.4: Example of an order-up-to-level (R,S) policy. 
The different inventory policies can also be combined to form a hybrid policy, for 
example, an (𝑅, 𝑠, 𝑄) policy indicates that every 𝑅 periods, 𝑄 units should be ordered,  
only if the inventory position is less than 𝑠. Another popular hybrid is a (𝑅, 𝑠, 𝑆) policy 
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where every 𝑅  time periods, a maximum of 𝑆  units should be ordered, only if the 
inventory position is less than 𝑠. 
3.8 Conclusion: Supply chains 
This chapter provided a brief introduction to supply chains and a description of the 
applicable topics and themes in more detail. The importance of the MDR-TB supply 
chain for SLDs was also discussed. The following chapter will present typical 
approaches to model supply chains, before identifying and describing the approach 
that will be applied in this study.   
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Supply chain modelling 
"What gets measured gets improved." 
- Peter F. Drucker (described as the “founding father of modern management”) 
The previous two chapters aimed to provide background information on the two main 
themes of the study, namely TB and supply chains. This chapter will continue to put the 
research in context by describing the approaches and techniques that are typically 
applied to model supply chains. A taxonomy of supply chain modelling approaches 
and techniques will be provided and discussed, after which the discussion will move on 
to the selection of an approach that will be applied to this study. The selected approach 
and important concepts related to it, will be described in detail.  
4.1 Supply chain modelling and analysis 
Modelling implies ‘mapping’ the system, in some shape or form, so that it represents the 
real system. The analysis of these models can lead to significant contributions to the 
improvement of organisations and product or service delivery. Supply chains are 
modelled for multiple reasons, such as optimising the supply chain activities and 
processes or to merely gain an understanding of the cause-and-effect relationships in 
the supply chain (Kleijnen and Smits, 2003). 
In this section, the perspective from which a supply chain can be modelled is discussed, 
after which a taxonomy of supply chain modelling approaches and techniques will be 
presented.  
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4.1.1 Supply chain perspectives 
When modelling a supply chain, it is necessary to determine which (of two) potential 
perspectives will be applied. The perspectives are: (i) the supply chain is of a single 
given organisation, or (ii) the supply chain comprises of a network of organisations and 
the focus of the study is on the entire system and not on a specific organisation in the 
network (Thierry, Bel and Thomas, 2010).
In the first perspective, the supply chain can be further divided into the internal and 
external supply chain. The internal supply chain focuses on functional processes, 
material flow and information flow. The external supply chain focuses on the integration 
and cooperation between the organisation, the suppliers, the suppliers’ suppliers, the 
customers and the customers’ customers (Thierry, Bel and Thomas, 2010).  
In the second perspective, the network of supply chains is linked through upstream and 
downstream segments. These segments connect all the organisations and actors that 
are involved in the various processes and activities that contribute to the delivery of the 
product or service to the end consumer. The focus is on the relationship and 
cooperation between the organisations and actors in the supply chain (Thierry, Bel and 
Thomas, 2010). 
4.1.2 Classification of modelling approaches and techniques 
As already mentioned, a supply change involves various stages. To model the multi-
stage supply chain as a whole, there are various modelling techniques to consider. 
These techniques are grouped or categorised into different modelling approaches. 
There has been some discrepancy in the literature as to how the modelling approaches 
should be categorised.  
Beamon (1998) defines four categories of modelling approaches and discusses various 
modelling techniques associated with each. The approach categories are: (i) 
deterministic analytical models, (ii) stochastic analytical models, (iii) economic models, 
and (iv) simulation models. Most of the techniques leads to static models, with average 
performance or steady state conditions used as input variables (Sarimveis et al., 2008). 
When modelling supply chains, it is necessary to take into account aspects such as 
fluctuations in demand, sales forecasting, delays in delivery and procurement, etc., all 
which add to the dynamic complexity of a supply chain. The static models, however, do 
not sufficiently describe and analyse problems in the supply chain (Sarimveis et al., 
2008), since they are ineffective in modelling the complex dynamics of the supply chain 
as a whole (Manzini et al., 2005). Furthermore, the static models do not allow easy 
adjustments and any changes typically require additional computing time (Manzini et 
al., 2005).  
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Riddalls, Bennett and Tipi (2000) propose an alternative categorisation of approaches 
for modelling the dynamics of supply chains: (i) continuous time differential equation 
models, (ii) discrete time difference equation models, (iii) discrete event simulation 
models, and (iv) classical operational research methods.  
Both of the aforementioned groupings are largely based on mathematical techniques. 
For this study, a more general classification is desired. Biswas and Narahari (2003) 
categorised the various modelling techniques into three approaches, namely (i) 
optimisation models, (ii) analytical performance models, and (iii) simulation models. Two 
of the three approaches defined by Thierry, Bel and Thomas (2010), labelled as 
analytical methods, and simulation and emulation, align to Biswas and Narahari’s 
(2003) categories (ii) and (iii). Thierry et al.’s third category, however, is physical 
experimentation and they omit to categorise optimisation models as a separate 
approach.  
The different approaches, as defined in the literature, were compared and combined in 
order to determine a classification of the approaches that would encompass most (if not 
all) of the applicable modelling techniques. The three modelling approaches, used in 
this study’s supply chain modelling taxonomy, are categorised and defined below.  
1. Analytical measures and modelling
Analytical models primarily use mathematical models to define the system. Equations 
and mathematical functions are used to describe the environment of the system and 
the changes made to it. This approach encompasses numerous techniques that are 
subdivided as (i) optimisation models or operations research, (ii) statistical models, and 
(iii) supply chain analytics. These subcategories were determined by comparing the 
different techniques and analytical models described in the literature. 
2. Physical experiments
This approach is used to improve the design of certain processes by changing the 
actual process and evaluating the results. Physical experiments, such as industrial pilot 
implementations, are rarely used in supply chain management today. This is mainly 
due to the technical- and cost-related limitations associated with physical experiments 
(Mandal, 2012b), especially when modelling large-scale improvements. Using this 
approach to evaluate an entire supply chain will be particularly difficult if not 
impossible. 
3. Simulation and emulation
As with the modelling approaches, there is also some discrepancy in the literature as 
to how the simulation and emulation techniques should be categorised. Kleijnen and 
Smits (2003) categorised the different simulation techniques as (i) spreadsheet 
simulation, (ii) system dynamics, (iii) discrete-event dynamic system simulation, and (iv) 
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business game simulation. Kersten and Saeed (2013) defined similar categories, with 
the exceptions that they defined a fifth category, namely agent-based simulation, and 
that the third category (discrete-event dynamic system simulation) is instead merely 
labelled discrete-event simulation. 
The difference between discrete-event dynamic system simulation and discrete-event 
simulation is made clear by Thierry, Bel and Thomas (2010). They define two categories 
of simulation techniques, namely continuous simulation and discrete event simulation.  
The latter is further divided into being either event-driven or time bucket-driven. 
Discrete-event dynamic system simulation is an example of event-driven DES, whereas 
time bucket-driven DES is alternatively referred to as spreadsheet simulation. System 
dynamics, as mentioned in the other sources, is an example of continuous simulation. 
Hybrid simulation is also important to consider as a modelling technique. White and 
Ingalls (2009) acknowledge hybrid models as one of five categories, which is given as 
(i) continuous system simulation, (ii) Monte Carlo simulation, (iii) discrete-event 
simulation, (iv) hybrid simulation, and (iv) agent-based simulation.   
After reviewing the techniques and their categorisation as discussed in the literature, 
the techniques associated with this approach will be classified in the taxonomy as (i) 
discrete-event simulation, (ii) business games, (iii) agent-based simulation, (iv) 
continuous simulation, and (v) hybrid simulation. The taxonomy of supply chain 
modelling approaches and techniques is illustrated in Figure 4.1, with one or more 
examples of selected techniques. Since physical experimentation will be infeasible for 
this study, only the two alternative approaches (‘Analytical Measures & Modelling’ and 
‘Simulation & Emulation’) will be further discussed in more detail.  
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4.1.3 Operations research 
Operations research (OR) is a branch of knowledge concerned with the application of 
analytical methods to aid in decision-making (Mielczarek and Uzialko-Mydlikowska, 
2010). OR is commonly used in industry, even though it is not technically considered a 
modelling technique. Well-known examples of OR include linear programming, game 
theory and nonlinear optimisation. OR is usually associated with a computational 
burden and typically requires the estimation of many of the model’s parameters. When 
using OR, a comprehensive understanding of the model is required and the models are 
often validated through the use of discrete event simulation (Riddalls, Bennett and Tipi, 
2000). In most cases, however, OR techniques fail to explain the dynamics of the system 
(Riddalls, Bennett and Tipi, 2000).  
The technique describes the different processes and corresponding activities of a 
system using mathematical models (Ahmadi, 2012). A systematic problem solving 
approach is followed (Ahmadi, 2012) to reach an optimal or near-optimal solution 
(Mielczarek and Uzialko-Mydlikowska, 2010). Traditionally, an optimisation model 
involves the minimisation or maximisation of a certain function, under constraints. In 
supply chain optimisation models, algorithms and data structures, that are capable of 
achieving large-scale systems integration, are developed (Biswas and Narahari, 2004). 
One of the major focus areas of this type of modelling is to optimise specific aspects of 
the supply chain, such as the optimal amount and location of warehouses or facilities 
(Biswas and Narahari, 2004), the optimal distribution methods, etc.  
4.1.4 Statistical models 
Statistical modelling and analysis embodies families of probability distributions and 
aims to represent the assumptions of the real-world situation. For the modelling to be 
successful, data and patterns that are subject to statistical analysis are required. These 
patterns are not always available in practice; consequently, estimates have to be 
determined and used instead. This often leads to limited success when using this 
technique to model large, complex systems (Luke and Stamatakis, 2012). Nonetheless, 
statistical modelling essentially attempts to reduce complex data to less complex terms, 
focusing primarily on individual aspects (such as parameter estimates, links and 
interactions) in the supply chain (Luke and Stamatakis, 2012).  
4.1.5 Supply chain analytics 
Supply chain analytics involves the application of organisational procedures and tools 
in combination with various techniques from statistical analysis and operations research 
(Trkman et al., 2010). It is used to gain and analyse information that will allow better 
decision-making with regard to the product-, finance-, and information flows (Souza, 
2014) and to predict the results of changes to the supply chain (Trkman et al., 2010). A 
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foremost unique characteristic of this technique is that it is a proactive model used to 
continually sense changes and that it therefore allows immediate response (O’Dwyer 
et al., 2011). It allows proven techniques and algorithms (such as data mining, stochastic 
modelling and regression analysis) to be applied to large, ever-expanding sets of data 
(O’Dwyer et al., 2011). The technique comprises of three types of analytics: (i) descriptive, 
(ii) predictive and (iii) prescriptive , all of which work in parallel for optimal results (Souza, 
2014). 
Descriptive analytics uses modern day data sources, such as global positioning system 
(GPS) data of transportation vehicles containing inventories, and radio frequency 
identification data from tags in pallets, to derive real-time information. With data 
visualisation, this information allows the organisation to see where schedule 
adjustments need to take place, whether emergency orders will be required and so 
forth. The acquired information is also used in the predictive analytics, where demand 
forecasts are derived. In prescriptive analytics, statistical techniques and optimisation 
models are applied to the real-time information and forecasts (from the previous 
categories). Recommendations for improvement are derived from these model 
conclusions (Souza, 2014).	
4.1.6 Analytical measures and modelling: verdict 
For the global upstream supply chain being investigated in this study, the techniques 
associated with the analytical measures and modelling approach will be impractical 
due to the simplifications (of real-world factors) that are required to analyse such 
models (Kersten and Saeed, 2013).  
In order to understand and analyse the behaviour of an entire supply chain, the system 
should be studied as a whole and not as individual parts (Luke and Stamatakis, 2012). 
This implies that for this study, an analytical approach would not suffice as the required 
mathematical models would be too large and complex to solve (Thierry, Bel and 
Thomas, 2010).  
4.2 Computer simulation 
Simulation involves experimenting with a computer model of a real world system 
(Kersten and Saeed, 2013). With simulation, it is easy to investigate the effects of certain 
changes in order to determine the configuration that would benefit the system the most 
(Thierry, Bel and Thomas, 2010). Simulation aims to model the complex and dynamic 
behaviour of a real world system and to increase the understanding and knowledge of 
this system through observations of the effects of model configuration (Mielczarek and 
Uzialko-Mydlikowska, 2010).	Therefore, simulation is used in industry to aid decision 
makers in the design and improvement of supply chain operations since the dynamic 
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behaviours of the supply chain can be studied and better understood (Kersten and 
Saeed, 2013).	
4.2.1 Discrete-event simulation 
These techniques involve the flow of physical entities between resources. For example, 
in the MDR-TB SLD supply chain, the entities will start as raw materials that progresses 
through manufacturing processes (resources), at which point their attributes are 
changed and they emerge as drugs for treatment. As previously mentioned, discrete-
event simulation (DES) techniques are either classified as time bucket-driven or event-
driven. They are classified according to the time advance process of the technique 
(Kasaie, Dowdy and David Kelton, 2013). The time bucket-driven technique is often 
referred to as spreadsheet simulation. In this technique, refer to Figure 4.2, time is divided 
into buckets (periods of a given length) and incremented step by step within a given 
bucket. An activity causes the system to move from one step to the next. After every 
step, an event occurs that changes the state of the system, requiring the calculation of 
the new state using the model equations (Thierry, Bel and Thomas, 2010).  
Figure 4.2: Time bucket-driven discrete-event simulation (Adapted from Thierry, Bel and Thomas, 
2010).
This technique allows the development of a simple time slice model, however, 
attempting to model an entire complex system will prove difficult (Kersten and Saeed, 
2013). 
The event-driven technique works similarly to the time bucket driven technique, except 
that it omits time buckets. Instead, it focuses only on event times, which are the moments 
at which the model’s state undergoes a change. This is illustrated in Figure 4.3.  
Figure 4.3: Event-driven discrete-event simulation (Adapted from Thierry, Bel and Thomas, 2010).
When using this technique to model large and complex supply chains, some difficulties 
might occur due to the size of the supply chain. The flow of each individual actor or 
entity in the supply chain can create an excessively large number of events, which 
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could make the model infeasible. In some cases, however, this risk can be reduced with 
the use of model reduction techniques (Thierry, Bel and Thomas, 2010). 
4.2.2 Business games 
Supply chain modelling provides members of the chain with the opportunity to 
understand and visualise their own network and integration of activities. By using 
corresponding business games with the model, it can serve as a beneficial tool for the 
discussion and validation of possible changes to the real-world supply chain network 
(Holweg and Bicheno, 2002). By letting managers and essential partners operate within 
the simulation of the supply chain, their human behaviour can also be modelled. It is 
difficult to model the human behaviour aspect with other simulation techniques (Kersten 
and Saeed, 2013). Although business games can be accomplished without computers, 
this study only considers business games that rely on computers, classifying them as a 
type of computer simulation.  
Business games are further classified as being either strategic or operational. Strategic 
games consist of several teams, each representing an organisation or partner of the 
supply chain network, competing with each other in the simulation for numerous rounds. 
The game is usually modelled to illustrate a specific cause-effect relationship (Kleijnen, 
2005). In operational games, only a single team interacts with the simulated world, also 
for numerous rounds. The team consists of one or several players (Kersten and Saeed, 
2013). The games are against nature, such as games for training in production 
scheduling (Kleijnen, 2005). Business games take advantage of every individual 
participant’s knowledge of their area of expertise. The participants are more open for 
improvements to the way in which they make decisions as they have personally 
experienced the potential effects of their behaviour in the simulation (Holweg and 
Bicheno, 2002).  
4.2.3 Agent-based simulation 
Agent-based modelling is used to study complex systems by outlining characteristics 
and rules of the different individual elements (agents) of the system. Agents can either 
be a real or virtual entity. For example, agents can represent different supply chain 
activities (virtual entity) and their interactions. Agents are active, independent and 
responsive and therefore interact with one another. The simulation examines the system 
environment and how the agents behave and interact as a function of their 
characteristics and rules. Histories that explain the emergent behaviour and properties 
of the system are generated in order to obtain solutions for the improvement of the 
system. Many agent-based simulations allow the system behaviour to be viewed in 
real-time, which is an important attraction of this technique (Luke and Stamatakis, 2012). 
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4.2.4 Continuous simulation 
Models of this technique often use mathematical equations that fit the assumptions of 
the system under investigation. Similar to the time-bucket driven approach in Section 
4.2.1, time advances in equal periods. After every period, the model equations and 
values are recalculated (Ahmadi, 2012). The state of the system therefore changes 
continuously (Kleijnen, 2005). One of the predominant continuous simulation 
techniques is system dynamics, which focuses on the dynamic behaviour of complete 
systems (Thierry, Bel and Thomas, 2010). In system dynamics, organisations and supply 
chains are seen as complex systems with various distinctive flows. The system also has 
stocks or levels that, over time, integrate with each other according to the flow variations 
(Thierry, Bel and Thomas, 2010).    
4.2.5 Hybrid simulation 
For several systems, the use of a single simulation technique will not be the most 
effective or efficient approach. In these cases, hybrid simulation can be used to improve 
the modelling process. Hybrid simulation involves the combination of a simulation 
technique with another technique from either the same, or a different approach.  
A popular combination is discrete-event simulation and operations research. As 
previously stated, discrete-event simulation is often used to validate operations 
research models. Another reason for this combination is when the input variables for 
the optimisation model are unknown. A discrete-event simulation model is run to provide 
estimates to be used in the optimisation model. The decision rules for the discrete-event 
simulation are restructured based on the solution of the optimisation model. The 
process is repeated until both models provide approximately the same solutions 
(Almeder, Preusser and Hartl, 2009). A hybrid simulation can also consist of two 
computer simulation techniques such as discrete-event simulation and system 
dynamics. In this combination, DES are used to model decisions for selected divisions 
of the network, while system dynamics are used to model the long term effects of the 
decisions on the entire network (Tako and Robinson, 2012). 
4.2.6 Computer simulation: verdict 
Computer simulation is often used in the industry and appears to be the better approach 
when it comes to the modelling and analysis of supply chain performance (Kleijnen, 
2005; Kersten and Saeed, 2013). Simulation is an ideal tool for replicating the behaviour 
of complex systems for decision-making, since the implications of the changes can be 
evaluated before being applied to the real system (Kersten and Saeed, 2013). With 
simulation, problems can be diagnosed, operations can be optimised and cause-effect 
relationships can be studied, all without interrupting or disturbing the real system 
(Mandal, 2012b; Kersten and Saeed, 2013). 
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The best computer simulation technique to be applied depends on the type of problem 
to be solved (Kleijnen, 2005; Thierry, Bel and Thomas, 2010; Kersten and Saeed, 2013). 
Kersten and Saeed (2013) did a study on the use of simulation in SCM. Included in their 
conclusions is a summary of the main simulation techniques that support a certain 
SCOR-based SCM process, as discussed in Section 3.4. The chart in Figure 4.4 illustrates 
the application of simulation techniques when modelling more than one of the SCOR 
processes, as is the case with this study.  
Figure 4.4: Application of simulation techniques for modelling more than one SCOR process (Adapted 
from Kersten and Saeed, 2013).
As can be concluded from the figure, the most widely used techniques when modelling 
more than one process are system dynamics (a type of continuous simulation) and 
discrete event simulation (a type of discrete, event-driven simulation). In order to 
determine which of these two techniques will be the better choice for modelling the 
MDR-TB SLD upstream supply chain, a comparison of the two techniques will be done. 
From this point forward, when referring to discrete-event simulation, it will imply that it is 
event-driven. It is important to note that though this research will employ a computer 
simulation approach, techniques from the analytical measures and modelling approach 
will also be incorporated where appropriate. As mentioned in Section 1.6, this study will 
potentially make use of correlational analysis and statistical analysis, which are all 
techniques that fall under the analytical measures and modelling approach. These 
techniques will not necessarily be used to model the supply chain, but it will aid in the 
analysis process.  
4.3 Selection of modelling approach 
This section will provide a comparison of system dynamics (SD) and discrete-event 
simulation (DES). The origin of SD dates back to 1961, where Jay Wright Forrester 
introduced a methodology for simulating dynamic models in his book Industrial 
Dynamics (Campuzano and Mula, 2011). The key points of DES were first discussed in 
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an article published in 1959 by Richard W. Conway, William L. Maxwell and Louis W. 
Miller, believed by many to be the introduction to DES (Goldsman, Nance and Wilson, 
2010). Even though both these techniques were developed around the late 1950s, 
minimal attention was devoted to comparing the two fields. In recent years, however, 
there has been a significant amount of interest in their comparison (Tako and Robinson, 
2010). The majority of literature on the subject is based on personal opinions of authors 
and often biased towards their field of expertise (Tako and Robinson, 2010).  
In the remainder of this section, an overview of the general principles of each technique 
will be given and compared in order to determine which technique will potentially 
model the upstream MDR-TB SLD supply chain more effectively.  
4.3.1 Structure 
The different elements (entities, resources, activities, etc.) and the relationships between 
these elements are referred to as the structure of the system. In SD, an essential 
concept is that structure regulates performance. A clear understanding of the system 
structure is therefore required to be able to effectively improve the performance. To 
illustrate this concept, the relationships or links between the elements should leave no 
room for confusion (Sweetser, 2009). Feedback loops are used to model these links, 
which causes the variables that are linked to be interdependent. As the entities advance 
through the system the variables will change, consequently causing the behaviour of 
the system to change. It is these changes throughout the system that causes SD models 
to be dynamic (Sweetser, 2009).  
Although structure is also important in DES, it is not as essential as in SD. Less emphasis 
is placed on the structure and instead the focus is placed on ensuring statistical validity. 
To successfully populate the model, accurate historical data or estimates are required. 
Therefore, a considerable amount of time is spent on data analysis and determining the 
distribution that fits the data best in order to ensure statistically valid outputs (Sweetser, 
2009). 
4.3.2 General procedure 
As stated in the previous section, SD is best suited for modelling continuous systems 
and primarily focuses on the study of the entire system. Although SD can be used to 
model discrete changes in systems, it performs best when applied to continuous 
processes where dynamic changes in the system behaviour are observed (Sweetser, 
2009). DES, on the other hand, largely models only specific processes (instead of whole 
systems). DES can model both continuous and discrete processes, yet its focus is on 
discrete processes. This is due to the technique’s capability to model discrete changes 
in the behaviour of the process and to deliver a comprehensive analysis of linear 
processes (Sweetser, 2009). 
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With SD, the modelling process begins with the identification of the basic structure of 
the system and its relationships. The relationships are defined by assigning functions 
and values to them. After the system is entirely described, the model is simulated to 
investigate whether the outputs accurately reflect the initial perception of the system. 
This process is iterative and is only complete once the modeller(s) is satisfied with the 
model’s output. The model can help to increase the modeller’s knowledge and 
comprehension of the system and how its performance is dependent on the system 
structure (Sweetser, 2009).  
DES modelling follows a similar procedure, but with some alterations. As discussed in 
Section 4.2.1, DES represents individual events which cause the state of the system to 
change (Kersten and Saeed, 2013). The events can be scheduled, such as a change of 
a shift, or unscheduled, such as the failure of a resource, and occur at discrete points in 
time (Sweetser, 2009). The model follows individual entities as they partake in 
processes and consume resources (Mielczarek and Uzialko-Mydlikowska, 2010). The 
model can provide an animation of the system in which icons or images represent the 
entities as they move through the system. This graphical representation can improve 
understanding of the process. However, in complex processes with a larger amount of 
entities, the animation is often hard to follow and make sense of (Sweetser, 2009).  
4.3.3 Underlying principles 
Both DES and SD models are developed to improve the understanding of the system 
behaviour and to analyse what effect different conditions will have on its performance. 
There are, however, some differences related to the underlying principles of the 
techniques (Tako and Robinson, 2012). In SD, the system is modelled as a set of stock 
and flows where the state changes continuously over time. The entities are viewed as 
a continuous quantity with a fixed rate by which they move in and out of processes. 
Even though the state changes are continuous, the differential equations in the model, 
transfer time (which is continuous) into a discrete counterpart using a time-slicing 
approach (Brailsford and Hilton, 2001). With DES, on the other hand, the system is 
modelled as a network of queues and activities where the state changes at irregular 
discrete points in time (Tako and Robinson, 2012). The time duration that an individual 
entity spends in a process, is sampled from probability distributions as determined by 
the modeller (Brailsford and Hilton, 2001).  
4.3.4 Mapping of systems 
Often when organisations use SD to model a system, the individuals that contribute to 
a specific process have their own unique interpretation and understanding of the 
system. They each envision a ‘mental model’ in their head. A key step in the SD 
modelling process is to develop an accurate representation of the system in a casual-
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loop diagram (CLD). This mapping process is iterative and participants continue to add 
or modify the diagram until it incorporates everyone’s mental model (Sweetser, 2009).  
DES models are instead often built from an activity diagram, flow chart or process map, 
which allows clarification of the important decisions, relationships and processes in the 
system. In DES models, defining the system with diagrammatic representations tend to 
be easier since the systems being modelled typically have a narrower focus (than those 
modelled using SD). In SD, obtaining a CLD that everyone is satisfied with can prove to 
be a difficult task. This is mainly due to the exceptionally complex networks that are 
typically modelled with SD (Sweetser, 2009). 
4.3.5 Validity 
In SD, models are built from CLD, as discussed in the previous section. Therefore, they 
are considered to be based on a single group’s interpretation of the system at that 
specific point in time. The captured representation could quickly become out-dated due 
to changes caused by the dynamic behaviour of the real system. Furthermore, human 
behaviour, which often plays a vital role in SD, is extremely challenging to quantify 
(Sweetser, 2009).  
As previously mentioned, in DES historical data is analysed and used to populate the 
model. When historical data is absent, estimates are determined and the model’s users 
approve the assumptions before implementation. This gives DES a stronger empirical 
basis compared to SD, especially since the processes modelled with DES are usually 
specific and observable. Unfortunately, the ability of DES models to adapt and predict 
changes of system behaviour decline over time (Sweetser, 2009). 
4.3.6 Application to supply chain levels 
To answer specific questions on an operational or tactical level, DES is typically the 
preferred modelling technique (Tako and Robinson, 2012). SD has a strong focus on 
structure, as discussed in Section 4.3.1, and can model both qualitative and quantitative 
data. Therefore, it is most often used at a more strategic level since it can be used to 
increase the understanding of the different relationships and links between the different 
elements of the system (Brailsford and Hilton, 2001). However, SD has been effectively 
used to model operational systems as well. It can be concluded that each modelling 
technique may have a different outlook of the same problem and therefore emphasise 
different aspects of the problem (Tako and Robinson, 2012).  
4.3.7  Comparison conclusion 
DES is beneficial due to its flexibility and capability to incorporate uncertainty, such as 
customers arriving at different points in time. Apart from being used to design new 
systems, DES permits easy assessment of the system efficiency and the ability to 
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analyse what-if scenarios (Mielczarek and Uzialko-Mydlikowska, 2010). One drawback 
of DES, is that clients can have difficulty understanding certain aspects of the DES 
models, especially the underlying statistics, such as the probability distributions and 
sampling, especially if they do not have a statistical background (Brailsford and Hilton, 
2001). Since SD models can incorporate both quantitative and qualitative variables, 
they can normally enhance the client’s understanding of large and complex systems 
(Mielczarek and Uzialko-Mydlikowska, 2010).  
Although SD can effectively model relationships within the system, the output is 
normally limited to graphs, numerical displays and data outputs that can be analysed. 
The output of DES, in addition to graphs, numerical displays and data outputs, also 
includes an animation of the system (Sweetser, 2009).  
Both approaches clearly have distinctive advantages and limitations. The choice of 
which technique to use, is therefore dependent on the type of system that has to be 
modelled and the type of information that is desired (Sweetser, 2009). To conclude the 
comparison, a summary of the criteria that will be taken into consideration during the 
selection was created and is given in Table 4.1.  
Table 4.1: Criteria for comparing system dynamics and discrete-event simulation. 
System Dynamics Discrete-Event Simulation 
Purpose Policy making: gaining understanding 
Decisions: optimisation, prediction and 
comparison 
Performance 
Dependency 
Structure (Relationships) Statistical (Validity) 
Scope Strategic level Tactical, Operational level 
Control Rates (Stocks and flows) Holding (Queues and activities) 
Relative 
Timescale 
Long Short 
Perspective 
Holistic, emphasis on dynamic 
complexity 
Analytic, emphasis on detail 
complexity 
Resolution 
Homogenised entities, continuous 
policy pressures and emergent 
behaviour 
Individual entities, attributes, decisions 
and events 
Time 
Increments 
Continuous Discrete 
Outputs 
Understanding of structural source of 
behaviour modes 
Point predictions, performance 
measures 
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The MDR-TB SLD supply chain has various elements, both quantitative and qualitative, 
that play an important role in understanding the dynamics of the supply chain as well 
as the effects of decisions. The model will be used to quantify the impacts of strategic 
improvements and to analyse the cause-and-effect relationships in the supply chain. To 
effectively analyse the impact of these improvements, it is necessary to model the 
supply chain over a longer timescale.  
After comparing these requirements with the criteria in Table 4.1, SD was selected as 
the more appropriate modelling technique to use in this study.  
4.4 Overview of system dynamics 
In several cases, the policies and decisions implemented to improve the supply chain 
do not necessarily accomplish the anticipated goals, but instead instigate unforeseen 
and unwanted consequences (Atun, 2012b). In order to prevent this, it is necessary to 
understand the behaviour of the supply chain as well as the nonlinear dynamics and 
feedback enclosed within the chain (Sterman, 2001). 
SD is a computer aided, graphical (Kumar and Kumar, 2014) and analytical modelling 
technique (Brailsford and Hilton, 2001) that can be accredited to Professor Jay Wright 
Forrester and his students at the Massachusetts Institute of Technology (Brailsford and 
Hilton, 2001; Kumar and Kumar, 2014). He presented the first published work on the 
application of SD on Supply chain management in the book Industrial Dynamics: A 
major breakthrough for decision makers (Angerhofer and Angelides, 2000).  
The technique provides a theoretical framework to model, analyse and understand the 
behaviour of complex systems over time (Luke and Stamatakis, 2012). SD models are 
capable of incorporating numerical data as well as descriptive data, making it possible 
to combine qualitative and quantitative aspects in order to enhance the understanding 
of the total system and its environment, elements and variables as well as the 
relationships between them (Brailsford and Hilton, 2001). This contributes to the broader 
boundaries that SD models permit, compared to other types of models (Luke and 
Stamatakis, 2012).   
The aim of SD is not necessarily optimisation or point prediction, but rather to enhance 
the comprehension of the dynamics, behaviour and feedback loops of complex systems 
by providing both quantitative and qualitative output measures (Brailsford and Hilton, 
2001). This section provides an overview of the SD modelling technique by defining 
important concepts.  
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4.4.1 Policy resistance 
Policy resistance stems from the inability to comprehend the full network of functioning 
feedbacks in a system. In order to solve problems, well-intentioned solutions are 
applied and often cause unexpected consequences and reactions. These attempts to 
prevent or alter problems in the system are overcome by the system’s response to the 
attempt (Sterman, 2001).  
When it comes to systems that are dynamic, interrelated and always changing, 
decisions are usually based on the mental models of users. These mental models 
normally fail to capture the full network (Sterman, 2001) and reduce the complexity by 
overlooking the non-linearities, feedback structures and time-delays of the system 
(Atun, 2012b). This is due to the incapability of the human mind to fully comprehend 
complexity and to understand the effects of our choices. Normally the mental models 
only consider actions that will address the short-term and immediate concerns, which 
often causes adverse effects in the future (Sterman, 2001). An example of policy 
resistance, relevant to this study, is the evolution of drug-resistant pathogens. This is 
illustrated in Figure 4.5. 
Figure 4.5: Example of policy resistance - evolution of drug-resistant pathogens (Adapted from U.S. 
Department of Health and Human Services, 2013). 
To comprehend the cause and effects of policy resistance, it is necessary to assume a 
holistic view of the system and all of its complexity (Sterman, 2001). An important 
concept in understanding this is dynamic complexity.  
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4.4.2 Dynamic complexity 
A system can be defined as a set of elements, such as procedures and events, 
functioning in conjunction as parts of an integrated network. When a system contains 
properties that cannot be entirely described through an understanding of the parts, it is 
said to be a complex system. The main differences between complex systems and 
traditional systems is summarised in Table 4.2.  
Table 4.2: Main differences between complex systems and traditional systems (Adapted from Luke and 
Stamatakis, 2012).
Domain Traditional Systems Assume: Complex Systems Assume: 
Functional Form Linearity Non-Linearity 
Common Distributions Normality Non-Normality 
Characteristics of 
Actors 
Homogeneity Heterogeneity 
Level-of-Analysis Single Level Multiple Levels 
Temporality Static, or Discretely 
Longitudinal 
Dynamic, with Feedback 
Fundamental 
Relationship 
Among Variables Interaction of Actors 
Perspective Reductionist Holistic 
Complex systems are characterised by non-linearity and dynamic behaviour while 
traditional analytic techniques typically assume linear relationships where changes in 
dependent variables causes changes in independent variables. Normal distributions 
are commonly used in analytical modelling, which provides an unlikely description of 
reality. Complex systems, on the other hand, typically assume power laws resulting in 
scale-free distributions. Traditional analytical modelling tends to takes a reductionist 
perspective, focusing only on individual parameters, interactions and links. Complex 
systems, in contrast, consider the whole system and its complex behaviour (Luke and 
Stamatakis, 2012). Complex systems incorporate a large number of diverse 
interconnected and interdepended elements that form part of a widespread network of 
feedback loops. The different elements interact with each other, causing a system 
response or ‘effect’ (Atun, 2012b). Over time, the effects will cause the system 
environment to change, which can influence the elements and the way that they interact 
with each another (Luke and Stamatakis, 2012). These effects often behave differently 
than anticipated, which leads to dynamic complexity (Sterman, 2001).  
Dynamic complexity is when: (i) the short term and long term effect, caused by the same 
element or interaction, is noticeably different; (ii) the effect, caused by the same element 
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or interaction, is distinctively different on two different parts of the system; and (iii) clear 
actions lead to different unintended results (Atun, 2012b). Examples of system 
characteristics that can lead to dynamic complexity as discussed by Sterman (2001) are 
provided in Appendix B. 
As mentioned previously, the mental models and tools we use to analyse relationships 
and links omit important elements of dynamic complexity. Therefore, tools and 
approaches that are able to accurately capture the various sources of dynamic 
complexity are required to understand how these sources create the dynamics of a 
system. Among the sources of dynamic complexity are feedback, stocks and flows and 
time delays. The tools that can be used to evaluate these sources include causal-loop 
diagrams and the simulation of these diagrams (Swanson, 2002). These aspects will be 
discussed in the remainder of this section.  
4.4.3 Systems thinking 
Systems thinking is the ability to view a system and its environment as a complex whole 
of interrelated parts instead of separate entities, symptoms and event sequences (Atun, 
2012b; Porsteinsson, 2015). It involves the understanding that every individual element 
in the system is connected to every other element. Identifying the links and relationships 
that results in events is eminent in systems thinking (Porsteinsson, 2015) since it can help 
to predict events and therefore better prepare for unfolding problems and challenges 
(Atun, 2012b). Although it is important to view the system as a whole, systems thinking 
includes the ability to define and communicate boundaries of the system under study 
(Porsteinsson, 2015).  
The systemic perspective implied with systems thinking, supports the decision making 
process by ensuring that the decisions are not only beneficial for the short-term 
requirements, but also for the long-term requirements of the elements and the system 
as a whole (Sterman, 2000). In order to fully comprehend the system as a whole, 
however, it is necessary to deconstruct the system. This is referred to as systems 
analysis and helps to create an understanding of the cause-and-effect relationships, 
structural arrangement and stocks-and-flows of the system (Porsteinsson, 2015). 
Systems analysis allows the user to learn more of the system by questioning certain 
occurrences observed in the model. The results of the system analysis are used to 
reconstruct the system to further expand the knowledge of the system and forms part 
of the SD process.  
4.4.4 Causal-loop diagrams 
A causal-loop diagram (CLD) is a significant tool in SD modelling. The CLD captures the 
causalities, feedback structures (Porsteinsson, 2015) and the factors that influence the 
system behaviour (Sweetser, 2009). The links and relationships between the individual 
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elements of the system, as well as those between the system and its functional 
environment are illustrated in the diagram (Sweetser, 2009). The qualitative analysis of 
constructing CLDs alone can prove to be significantly useful as it provides a better 
understanding of the whole system and its behaviour (Brailsford and Hilton, 2001). 
Additionally, CLDs are used to effectively capture theories about the causes of the 
system’s dynamics and to illustrate the collective mental models of the system 
participants (Porsteinsson, 2015).  
In order to construct a CLD, it is first necessary to determine linkages that associates 
the system elements with each other. These links are represented by a set of directed 
arrows, as shown in Figure 4.6 (Brailsford and Hilton, 2001). The system’s structure is 
explained by the link polarities – it does not explain the variable behaviour, but rather 
the effects that will result from a change in the system (Porsteinsson, 2015). A positive 
link (+ sign) signifies that the effect is positively related to the cause (Sterman, 2003). 
Referring to Figure 4.6 (a), if X increases, then Y increases and if X decreases, Y 
decreases. In contrast, a negative link (- sign) signifies that the effect is negatively 
related to the cause. Thus, as illustrated in Figure 4.6 (B), if X increases, Y decreases 
and if X decreases, Y increases (Porsteinsson, 2015). 
Figure 4.6: (a) Positive link between variables, (b) negative link between variables, (c) time delay 
between variables. 
Another critical aspect in SD is delays. Naturally, time will pass between a decision and 
its effect on the system. These delays cause unpredictability and increase the 
probability of oscillations in the system, which are necessary for a realistic 
representation of the system. Decision makers tend to assume an event-based view of 
causality and continue to interfere with the system in an attempt to correct the 
differences between the desired and actual state of the system. The disregard of time 
delays can lead to over estimation and uncertainty (Sterman, 2001; Swanson, 2002). 
A simple example of a CLD is depicted in Figure 4.7. 
Figure 4.7: Example of a causal-loop diagram (Adapted from Brailsford and Hilton, 2001).
X Y 
+ 
X Y 
- 
X Y 
+ 
  (a)       (b)   (c) 
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4.4.5 Feedback thinking 
As previously mentioned, a cause of policy resistance is the misconception of the 
collection of feedbacks in the system. An event-based view of a system, refer to Figure 
4.8 for an example, omits apparent feedback loops in the real system. Real systems 
react to actions causing additional effects through the feedback loops (Sterman, 2001). 
Figure 4.8: Example of an event-based view of a system (Adapted from Sterman, 2001).
With an event-based perspective of systems, the emerging problems that result as a 
consequence of the feedback processes will be interpreted as confirmation that the 
system is unstable, irregular and unmanageable. The use of feedback loops, as 
depicted in Figure 4.9, will improve the understanding of the feedback processes and 
consequently the perception of the system will be less deceiving (Sterman, 2001).  
Figure 4.9: Example of a system with feedback (Adapted from Sterman, 2001).
Problem Decision Results
Situation
Goals
Environment
Decisions
Goals
Environment
Decisions
Goals Side Effects
Actions of 
Others
Goals of Other 
Agents
Any decision made will have a 
changing effect on the 
environment, which leads to 
new decisions.
These decisions, will trigger 
side effects, delayed reactions 
changes in goals. The 
environment will also be 
affected by the goals and 
actions of other agents. All of 
these feedbacks and their 
effects, can lead to 
unanticipated results and 
ineffective policies
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Feedback loops involve the flow of information generated by an action through several 
variables until it returns back to its origin, affecting the functioning of the entire system 
in the process. The relationships between the variables and constants determine the 
nature of the information. A feedback loop, similar to the directed arrows that illustrate 
linkages, either has a positive or negative polarity that can be determined by 
multiplying the polarity of all the arrows in the loop (Kumar and Kumar, 2014).  
Positive feedback loops are self-stimulating and generate their own growth or decline, 
which is why they are often termed reinforcing loops and denoted by an R symbol, as 
illustrated in Figure 4.10 (Sterman, 2000). These loops pursue exponential growth, but 
since no quantity can increase indefinitely, the growth must be limited (Porsteinsson, 
2015). Negative feedback loops are described as self-limiting and cause balance and 
stability. They are therefore often referred to as balancing loop and denoted by a B 
symbol, also depicted in Figure 4.10. Where positive feedback loops reinforce and 
amplify (Sterman, 2001; Swanson, 2002), the negative feedback loops attempt to 
achieve balance by counteracting and opposing in order to achieve a specified goal 
(Kumar and Kumar, 2014). 
Figure 4.10: Reinforcing (R) and balancing (B) loop. 
A complex system typically contains numerous feedback loops of both types that are 
connected through delays, nonlinearities and accumulations. The interactions of these 
feedbacks are the foundation of the dynamics of systems. Although it is possible to 
explain the dynamics of isolated loops, it is nearly impossible to do so when multiple 
loops interact. This is why the CLDs have to be modelled with computer simulation 
(Sterman, 2000). 
4.4.6 Stocks and flows 
To model the CLD with computer simulation it is beneficial to first clarify the important 
stocks and flows. Stocks and flows are fundamental in the dynamics of complex 
systems (Sterman, 2001). A simple example of a stocks and flow system is a bathtub, as 
illustrated in Figure 4.11. In this case the stock would be the water in the tub, which is 
filled by the inflow of water from the tap and drained by the outflow of water through 
the drain (Sterman, 2003).  
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Figure 4.11: Example of a stocks and flows system (Adapted from Sterman, 2001).
Normally state variables and stocks are represented by rectangles; pipe-like arrows 
represents the flows and flow rates (Sterman, 2001); curved arrows represents the 
linkages/connectors (Kumar and Kumar, 2014); and the remaining elements are the 
auxiliary variables and constants. This is illustrated in Figure 4.12, which is the flow 
diagram of the CLD in Figure 4.7. In this example, the stock is food that is increased by 
eating (inflow) and decreased due to digestion (outflow). The amount of food in the 
stomach affects the hunger variable, which influences the eating rate (Brailsford and 
Hilton, 2001).   
Figure 4.12: Example of a stock and flow diagram (Adapted from Brailsford and Hilton, 2001).
4.4.7 Modelling procedure 
The procedure followed when building a model with system dynamics can be described 
in five steps. The five steps that will be followed in this study are summarised in Figure 
4.13, with a more comprehensive description provided in Appendix C. These steps and 
sub steps were determined by comparing the modelling processes laid out by Sterman 
(2003); Campuzano and Mula (2011); and  Maani and Cavana (2012) with one another.  
Since modelling is an iterative process and will go through constant testing and 
modification, the steps are not necessarily sequential, but rather an iterative cycle. As 
illustrated in Figure 4.13, the output of one step can change the current understanding 
of the system and therefore require revision of an earlier step.  
Source
Control
Valve
Inflow
Stock
Control
Valve
Outflow
Sink
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Figure 4.13: System dynamics modelling procedure. 
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Simulation models are built from mental models and are based on information of the 
real world system. When the aspects of the real world are captured and tested in the 
model, the mental models and interpretation of the system can change, leading to the 
redesign or adaption of the current model. Therefore, modelling is said to be a 
continuing process of switching between the model and the real world.  
4.4.8 Conclusion: System dynamics 
In SD, simulations are constructed as a series of equations that monitor the 
accumulations of stocks that are established by the flows, feedback loops and time 
delays in the system (Luke and Stamatakis, 2012). With SD modelling, the behaviour of 
systems with a high level of unpredictability, fluctuation, structural complexity and 
different types of delays, can be easily described and analysed (Peng, Chen and Zhou, 
2014). SD improves the understanding of complex systems by allowing the adjustment 
of parameters and variables, rearrangement of system elements and adding of new 
links and feedback loops. This also enhances the decision-maker’s ability to model 
different scenarios and analyse how the scenarios will impact the system (Sweetser, 
2009). Furthermore, a SD model provides a visualisation of the system that increases 
the understanding of the structure and the interaction between the different elements 
(Piewthongngam et al., 2014).  
4.5 Conclusion: Supply chain modelling 
This chapter provided an introduction to the different techniques and approaches used 
to model supply chains. The characteristics of two widely applied techniques, namely 
system dynamics and discrete event simulation, were compared and system dynamics 
was chosen as the more suitable approach for this study.  
The next chapter will aim to provide an accurate and valid description of the MDR-TB 
supply chain for SLDs. 
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Chapter 5:
Mapping the upstream 
MDR-TB SLD supply 
chain 
"We have known how to cure TB for many years. What we have lacked is the will and the 
resources to quickly diagnose people and get them the treatment they need" 
- July 2004, Nelson Mandela 
The previous chapter was the last to provide background information to the research, 
by introducing different supply chain modelling approaches, comparing the 
characteristics of two widely applied techniques, and selecting and discussing the 
chosen approach for this study.  
This chapter aims to present an accurate and valid representation of the supply chain 
for SLDs for MDR-TB, by providing a description of: (i) unique characteristics of the 
supply chain; (ii) the initiatives developed to address TB and MDR-TB; (iii) the flow of 
information, finances and products in the supply chain; (iv) other important concepts and 
entities related to the upstream supply chain. The described concepts will be combined 
to map and describe the supply chain through a theoretical model, followed by a 
summary of the difficulties and challenges in the supply chain as well as 
recommendations to improve the supply chain. 
5.1 Unique characteristics of the supply chain 
The MDR-TB SLD supply chain is donor-funded. Donor-funded supply chains have a 
number of characteristics that distinguish them from commercial supply chains and that 
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should be taken into consideration when studying the dynamics of these supply chains. 
During the course of this study, a paper on the distinguishing features of donor-funded 
supply chains was written and published as a conference proceeding. Table 5.1 
summarises the most prominent distinguishing features. 
Table 5.1: Summary of characteristics for commercial and donor funded supply chains (Reproduced 
from: Lingervelder, Bam and Bam, 2016).
Characteristics Commercial SC DFSC (general) 
Structure & Components 
Upstream (global) segment and 
downstream (domestic) segment 
primarily managed as two 
coupled segments by primary 
stakeholders 
Upstream (global) segment and 
downstream (domestic) segment 
are ordinarily decoupled from 
one another 
Stakeholders 
Primary 
Stakeholders 
Shareholders (that guide the 
organisation’s policies, goals and 
decisions) 
Host Government and some 
NGOs 
Other 
Stakeholders 
Several stakeholders with 
different needs – rarely conflicts 
with shareholders’ interests 
Stakeholders have different, 
often conflicting, goals, missions, 
interests, capacity and 
constraints with different 
perspectives and approaches 
Trust 
Spend time and resources to 
build lasting relationships with 
their partners 
There is often not enough time or 
resources to enable the building 
of trust 
Goals & 
Objectives 
Main Goal 
To make profits and provide 
financial returns to shareholders 
To produce value for money, be 
efficient and effective, ensure fair 
competition between suppliers, 
ensure accountability, and 
ensure procedures are done 
ethically 
Objectives 
‘Owners’ of the supply chain 
share the organisations policies, 
goals and decisions 
Each organisation involved in the 
supply chain strives to achieve its 
own purpose and mission 
Finances 
As an 
objective 
Strategic objectives are based 
on the financial returns paid out 
to the shareholders and the 
value created through delivering 
high quality goods and services 
to the consumers 
Finances are seen as a 
constraint rather than an 
objective 
Revenue 
Income earned from the sale of 
goods and services 
Government funding and 
donations from individuals and 
organisations  
Financial 
Supply Chain 
Manages payment transactions 
and orders collectively 
Often has a separate chain for 
international flows and domestic 
flows 
Customer 
Service & 
Marketing 
Customer 
characteristics 
Any individual or organisation 
that buys and receives the 
product or service 
Often seen as the end-
consumers that receive the 
intended aid, but some view the 
donors as the customers 
Choice of 
product 
End-consumer can analyse the 
market and choose which 
product, out of several options, to 
buy 
End-consumers often do not 
have a choice of product 
continued on next page 
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continued from previous page 
Customer 
Service & 
Marketing 
Target 
Market their product to the 
customer 
Targets donors and convince 
them to provide some 
contribution 
Market 
segmentation 
Large amounts of time and 
money is allocated towards 
market segmentation – in most 
cases dedicated departments 
are assigned to segment the 
consumers and market the 
product/service according to the 
segments.   
Doesn’t spend time and money 
to market product differently to 
market segments – since the 
consumers are in need of the 
product, the goal is to provide 
supplies and services to 
populations in need. 
Research & Development 
(R&D) 
Financial resources are typically 
allocated to both strategic and 
operational activities with large 
amounts of time and money 
allocated for R&D 
Typically, funding is provided 
specifically for operational 
activities and not R&D. Instead, 
they have to rely on global 
initiatives for their R&D. 
Demand & 
Forecasting 
Stability 
Relatively stable and predictable 
demand 
Irregular amounts at irregular 
intervals 
Demand 
Pattern 
Occurs from recognised 
locations in fixed quantities at 
consistent time intervals  
Often unpredictable and occurs 
in irregular amounts and time 
intervals 
Procurement 
Often build a lasting relationship 
with their partners and set up 
long-term agreements and 
contracts 
Often use a competitive bidding 
process and short-term contracts 
or agreements are set up 
Manufacturing 
Processes 
Processes can be forecast-driven 
due to the relatively stable 
demand patterns 
Processes are mostly order-
driven due to the unpredictable 
demand 
Volume 
Typically uses economic batch 
sizes and order quantities. One 
manufacturer often has several 
customers and can produce 
larger volumes. 
Supplies are manufactured in 
smaller batch sizes that are not 
cost effective, since the limited 
actual demand and lack of 
accurate forecasting weakens 
the manufacturers’ confidence to 
produce large volumes of 
supplies.  
Market & 
competition 
Manufacturers rarely have a 
monopoly in the market 
The difficult nature of products 
and lack of incentives leads to a 
restricted market structure and 
lack of competition.  
Logistics 
Definition 
Process of managing flows from 
source to the final customers
Process of managing flows from 
the donors to the affected 
populations 
Collaboration 
Often implements horizontal 
collaboration, to create a 
distribution pool 
Unpredictable demand patterns 
makes collaboration difficult 
Agility 
A key strategy that allows them 
to compete in the global market 
by improving delivery rates 
Used in managing different 
relationships between donors 
and actors, evaluating impacts of 
distributed supplies and 
monitoring various ongoing 
activities 
In the remainder of this section, the following four of these distinguishing characteristics 
are discussed in the context of the supply chain for SLDs for MDR-TB: (i) structure and 
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components, (ii) price and demand elasticity, (iii) demand and forecasting, and (iv) 
market constraints.  
5.1.1 Structure and components 
As mentioned in the previous section, a supply chain comprises of various functions. 
Figure 5.1 summarises the basic steps in a drug supply chain. It involves the continuous 
flow of products from supplier to consumer. Typically the flow of materials is forward 
and the flow of information backward (Sarimveis et al., 2008).  
Figure 5.1: Basic steps in a drug supply chain. 
All of the various steps and activities involved with the different processes in Figure 5.1, 
cooperate with one another to form an integrated supply chain (Beamon, 1998). As can 
be seen from Figure 5.1, financing is a key component of the supply chain, as it is 
associated with every process. The procurement and distribution of supplies are 
dependent on the availability of funds (Dowling, 2011). However, even with enough 
domestic and donor funding, and a selection of new treatments, problems and flaws in 
the supply chain will continue to restrict access to the required drugs (Riungu, 2011). 
The manufacturing process includes sub-processes such as scheduling for the 
acquisition of raw materials, the design and scheduling of manufacturing processes and 
the control of materials (Beamon, 1998). The storage and delivery (global) process 
determines how the drugs and health supplies are transported from storage to the in-
country suppliers. Similarly, the storage and distribution (domestic) process determines 
how it is transported from storage to the organisation(s) and facilities that treat the 
patients (Beamon, 1998). At a domestic level, drugs for treatment are primarily 
distributed through three organisation types, namely (i) public or government-run 
systems, (ii) private not-for-profit systems, and (iii) private commercial systems (Dowling, 
2011). This is especially the case in LMICs. A vital sub-process of both of the storage and 
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delivery/distribution processes is inventory management, as illustrated in Figure 5.1. 
Inventory management and control encompasses the design and management of 
policies and procedures for any type of inventory (Beamon, 1998). 
Furthermore, the MDR-TB SLD supply chain is divided into two components, namely the 
‘upstream’ component and the ‘downstream’ component, also known as the global- and 
domestic segments. This is the case for most donor-funded supply chains. A key 
characteristic of these types of supply chains is that the two components are decoupled 
from one another (Nicholson et al., 2013). This is illustrated in Figure 5.2. 
Figure 5.2: Upstream and downstream components (Adapted from Yadav, 2012).
The structure of the upstream component of the supply chain entails the (i) 
manufacturing, (ii) procurement, (iii) financing, (iv) forecasting, and (v) storage 
(warehousing) of the drugs. The manufacturing includes the manufacture of the starting 
material, the active pharmaceutical ingredient (API), and the finished pharmaceutical 
product (FPP). The warehousing of the upstream component only involves the storage 
of drugs prior to its shipment to other countries (Nicholson et al., 2013). The downstream 
component includes the (i) in-country warehousing, (ii) distribution of drugs, and (iii) the 
treatment of patients (Nicholson et al., 2013). It is important to note that a single upstream 
component can be connected to more than one downstream component, i.e. a global 
manufacturer can distribute the drugs and medication to more than one country.  
5.1.2 Price and demand elasticity 
The MDR-TB SLDs supply chain has two separate financial supply chains, an 
international chain financed by one or more global funds and a domestically financed 
chain within a given country (Nicholson et al., 2013). This corresponds with the 
previously mentioned upstream and downstream segments of the supply chain that are 
decoupled from one another. The decoupled financial supply chain results in a unique 
situation with regard to price and demand elasticity. Demand in the internationally 
financed supply chain is ordinarily inelastic to small changes in price, when compared 
to the domestically financed portion. The demand starts out flat and unresponsive to 
large changes in volume or small changes in price (international), but the volume 
drastically increases when the price falls below a certain threshold (domestic) 
(Nicholson et al., 2013).  
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5.1.3 Demand and forecasting 
A principle difference between the MDR-TB SLDs supply chain and a commercial supply 
chain is the demand. For most commercial supply chains, demand is steady and can 
be predicted (Afshar, 2009), due to the fact that the demand typically occurs from 
known locations and the orders are placed for the same quantities, in constant time 
intervals and from fixed suppliers (Beamon and Balcik, 2008; Afshar, 2009). In the MDR-
TB SLDs supply chain, however, the demand is unpredictable and occurs in irregular 
amounts and time intervals (Giffin and Robinson, 2009; Nicholson et al., 2013).  
The irregular demand makes accurate forecasting very difficult, which weakens 
manufacturers’ confidence to work with large volumes. Instead, they make use of small 
batch sizes that are not cost effective. Consequently, several manufacturers choose to 
instead start the production process only once an order has been received, causing 
long delivery lead times. Countries are often pressured to place orders months or even 
years in advance. In many cases, the inaccurate forecasting leads to either shortages, 
when needs are forecasted too low, or destruction of expired goods, when needs are 
forecasted too high (Nicholson et al., 2013). 
5.1.4 Market constraints 
The MDR-TB SLDs supply chain is faced with some unique market constraints. The 
poorest and most susceptible populations are often in areas that are difficult to 
distribute to, which causes distribution costs to rise even more (Nwuneli et al., 2014). 
Another market constraint for the supply chain is the weak visibility into the market due 
to inconsistent demand and lack of data, as discussed previously. The weak market 
visibility is one of several reasons for a third market constraint, namely, a lack of 
manufacturers. The lack of competition in the manufacturing of some the drugs, results 
in a monopoly – with only a single supplier of the drug (Nicholson et al., 2013).  
5.2 Initiatives to address TB and MDR-TB 
This section provides short descriptions of initiatives, relevant to this study, that have 
been developed to address TB and MDR-TB.  
5.2.1 The Green Light Committee 
The Green Light Committee (GLC) was founded between 1998 and 2000, as a multi-
institutional partnership, composed of global stakeholders, to respond to the emerging 
threat of MDR-TB. The GLC was designed with the intention that it would act as a pilot 
project mechanism for DOTS-Plus projects, by providing affordable SLDs exclusively to 
DOTS-Plus pilot projects and to gather data about these projects in order to determine 
recommended MDR-TB treatment policies (Nicholson et al., 2013).  During its 
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development, the GLC’s multi-institutional partnership was hosted by WHO’s TB 
department, but was transferred to the Stop TB partnership when it was founded in 2001. 
Since 2007, following the increasing number of approved projects, the GLC merged with 
the GDF (see Section 5.2.3) to share responsibility.  
5.2.2 The Global Partnership to Stop TB 
On 24 March 2000, the first World TB Day, ministerial representatives from 20 HBCs 
came together at The Ministerial Conference on Tuberculosis and Sustainable 
Development to develop the ‘Amsterdam Declaration to Stop TB’ (Amsterdam 
Declaration to Stop TB, 2000). The declaration urged the necessity for drastic action in 
HBCs and called for the development of the Global Partnership to Stop TB to organise 
and manage these exertions, together with WHO. This global partnership, ultimately 
founded in 2001, aims to (i) identify and fund innovative diagnostic and treatment 
approaches; (ii) aid in the procurement of drugs and diagnostics; (iii) help with 
forecasting and preventing stock-outs; and (iv) assist the Global Fund to Fight Aids, 
Malaria and TB (The Stop TB Partnership: Leading the Fight Against TB, 2015).  
5.2.3 The Global Drug Facility 
On 24 March 2001, a year after the Amsterdam Declaration to Stop TB was developed, 
the Global Drug Facility (GDF) was launched as an initiative of the Global Partnership 
(Kumaresan et al., 2004). The main donors of the GDF includes the World Bank, the 
Government of the Netherlands (Kumaresan et al., 2004), the Canadian International 
Development Agency and the United States Agency for International Development 
(USAID) (Kumaresan et al., 2004; De Lucia, 2014). It also has projects supported by 
UNITAID and the Kuwait Fund (De Lucia, 2014). The reason for establishing the GDF, 
was to support the Global Partnership by contributing to the development and 
improvement of (i) procurement management by operating a direct procurement system 
to attain quality-assured drugs at low prices; and (ii) supply chain management of 
countries in need by offering in-country assistance on SCM (Atun et al., 2010; De Lucia, 
2014). The GDF mainly provides two services, one being a grant service and the other 
a direct procurement service. Through the grant service, the GDF serves countries in 
need of resources for the procurement of quality assured adult and paediatric FLDs and 
supports the expansion and sustainability of DOTS. The direct procurement service 
permits countries or agencies to procure quality-assured drugs and equipment at 
reduced prices. Countries usually place orders with donor funding, typically from the 
Global Fund or from their national government budgets. 
5.2.4 The Global Fund to Fight Aids, Malaria and TB 
The Global Fund to Fight Aids, Malaria and TB (Global Fund), founded in 2002, is the 
largest international donor for TB and provides more than 80% of TB funding worldwide 
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(Stop TB Partnership, 2015). It is described as a “partnership between governments, civil 
society, the private sector and people affected by the disease”. Almost US$4 billion is 
raised and invested every year to support programs to fight TB, Malaria and HIV in 
countries in need (The Global Fund, 2016) 
5.2.5 UNITAID 
UNITAID was launched in September 2006 through a partnership of countries (Brazil, 
Chile, France, Norway and the United Kingdom) as an international drug purchase 
facility to provide funding for SLDs against MDR-TB. What makes UNITAID unique, is 
their innovative financing – the ‘air ticket levy’ that is used to fund the programme. The 
ten participating countries (Cameroon, Chile, Congo, France, Guinea, Madagascar, Mali, 
Mauritius, Niger and the Republic of Korea) decides on an amount to add to an existing 
airport tax, usually ranging from US$ 1 for economy-class tickets to approximately 
US$ 40 for business and first class tickets (UNITAID, 2016a). 
5.2.6 Relationship between the different initiatives 
Today, the above-mentioned organisations and foundations can be seen as an inter-
connected system that has collectively taken responsibility for the execution of MDR-
TB projects in countries. The GLC is responsible for approving MDR-TB projects in 
countries, which permits the Global Fund or UNITAID to release funds to a project. The 
Stop TB Partnership provides technical assistance by facilitating effective management 
of the projects, planning and, if necessary, site visits.  
A country can procure SLDs through the open market and/or state procurement 
mechanisms, with the drugs often being of unknown quality. Another option is to procure 
quality-assured drugs, often at reduced prices, from the GDF under supervision of 
WHO’s GLC. If a country is funded by the Global Fund or UNITAID they are required to 
procure through GDF. A country can apply to the GLC through their website, the GLC 
then reviews the application form and approves a number of patients for treatment. The 
country/project will be monitored and regularly evaluated by GLC consultants to assess 
whether and when scale-up is required. The only responsibility of the GLC is to ensure 
that the approved projects deliver quality-assured drugs under the program conditions 
described in WHO’s Guidelines for the programmatic management of drug-resistant 
tuberculosis. The procurement of these drugs falls under the responsibility of the GDF 
and their contracted procurement agent (PA). Furthermore, the GDF tracks orders and 
monitors the performance of the PA, while the PA oversees SLD purchases and solicits 
agreements with manufacturers at reduced prices for approved projects.  
Stellenbosch University  https://scholar.sun.ac.za
MDR-TB SLD supply chain flows  Page | 73 
Stellenbosch University 
5.3 MDR-TB SLD supply chain flows 
This section aims to provide a description of the application process for grants from the 
GF, financing, application for procurement from the GDF, the ordering process of the 
GDF and the physical flow of the SLDs by investigating the flows in the supply chain. 
5.3.1 Information flow 
Information flow plays a particularly important role in the MDR-TB SLDs supply chain, 
since it warrants more effective use of drugs and treatments, which are often in short 
supply (Ballou-Aares et al., 2008). Information flow can have a powerful effect on the 
efficiency and effectiveness of the activities in a supply chain, since it helps to maintain 
a balance between supply and demand and provides a basis for good planning (Unicef, 
2009). Stakeholders can greatly benefit from an established information flow that can 
enable them to adjust their activities in order to improve their performance, but only if it 
is timely, reliable and provides actionable data. 
The basic information flow diagram of the supply chain for MDR-TB for SLDs is depicted 
in Figure 5.3. Initially, a country has to apply to the GLC to approve one or more projects. 
On approval, the GLC Secretariat will send a letter to notify the country of the approval. 
Additionally, GLC sends a letter of agreement (LoA) to countries whose projects are in 
accordance with WHO’s Guidelines for the programmatic management of drug-resistant 
tuberculosis. The country has to accept the conditions of the letter of agreement by 
returning a countersigned original of the letter – no SLDs can be ordered until the letter 
is received by the GLC (World Health Organization, 2008). 
Figure 5.3: Information flow diagram of the supply chain. 
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All GLC-approved projects submit an estimation of their SLD needs for a full 2 year 
course of treatment for their patient regimens. The GLC has to review and approve these 
quantities before they share it with the GDF. Once the GDF receives the approved 
quantities they forward a letter of authorization with the drug needs to the PA. Only then 
is the PA allowed to sell the required drugs, up to the approved quantity, to the project 
(Nicholson et al., 2013). For a project to place an order, they have to complete a 
procurement form and send it to the GDF who has to verify the information regarding 
regimens, quantities, consignee details, documents needed for importation or status of 
drugs registration in the country (World Health Organization, 2008). Once reviewed and 
validated the PA is requested to initiate the procurement process for the project. After 
the PA has received (i) a letter of authorisation with the total approved quantity, (ii) the 
quotation request from a project site, and (iii) an official request to initiate the 
procurement process from the GDF, will they respond to the project with a quotation 
containing pricing information and expected delivery dates. After a quotation is 
received, reviewed and accepted by the project, they confirm by sending a purchase 
order and transferring payment, if applicable. Once the order is confirmed and paid for, 
the PA communicates with the manufacturer to begin production and deliver the drugs 
to its facility. The PA will allocate the drugs to the project sites and contact them when 
delivery is arranged (World Health Organization, 2008; Giffin and Robinson, 2009).  
5.3.2 Financial flow 
The lifeblood of the supply chain is its finances, since regular and effective financial 
flows are essential for the accurate functioning of the supply chain. An apparent 
difference in a donor funded supply chain such as this one, is the source of revenue. 
Where commercial supply chains rely on customers that purchase goods and services 
for their own benefit (Moore, 2000), the MDR-TB supply chain relies on government 
funding (Menzies et al., 2012) and charitable donations from individuals and 
organisations (Beamon and Balcik, 2008). Well-timed financial flows between the 
different stages of the supply chain will assist in ensuring a maintainable system with a 
continuous product flow (Ballou-Aares et al., 2008). The timing and reliability of 
available funding has a strong impact on the production and distribution schedule of 
the SLDs. A delay in funding could lead to a delay in treatment, which can cause 
resistance to some of the SLDs.  
Figure 5.4 illustrates the basic financial flow diagram of the supply chain for MDR-TB for 
SLDs. The diagram also includes the information flows directly associated with finances, 
such as grant application process. The process begins when the GF issues an “open 
call for proposals”. The country coordinating mechanism (CCM) prepares and submits 
a proposal on behalf of the country. If accepted, the CCM is also responsible for 
identifying the principle recipients in the country and to oversee implementation. 
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Typically, representatives from both the public and private sectors can serve on the 
CCM, such as the government, NGOs, private businesses, academic institutions, etc. 
The Global Fund Secretariat assesses whether the proposal meets the eligibility 
criteria, after which the Technical Review Panel assesses the technical merit of the 
proposal. Finally, it is up to the board to decide whether the proposal is approved or 
declined. 
Figure 5.4: Financial flow diagram of the supply chain. 
To ensure that procurement is done in accordance with the Global Fund, WHO 
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recipient by local funding agents. Once the PSM is approved by the local funding 
agents, the funds can be disbursed. The agents also monitor the principal recipients on 
an annual basis and serves as advisor to the Global Fund. 
5.3.3 Product flow 
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linear and forward-moving process that forms the backbone of the supply chain. The 
product flow process relies on the integrated activities of the different entities and has 
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the longest and more variable steps in in a supply chain is transportation. Various 
factors can cause long transportation time and high variability. On a local level, causes 
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shipments of multiple supplies (not just SLDs for MDR-TB) to be prepared. On a global 
level, delays and variability often take place at the port of departure, point of 
transhipment and port of arrival due to congestion, regulatory paperwork and loading 
and unloading of containers. 
The basic product flow diagram of the supply chain for MDR-TB for SLDs is depicted in 
Figure 5.5. The process is initiated once the PA places an order at the manufacturer. 
The production of SLDs involves several steps as illustrated in the Figure. A starting 
material has to be manufactured from raw materials before the active pharmaceutical 
ingredient can be manufactured. These first two steps can be complicated, dangerous 
and expensive due to the often toxic nature of the chemicals and the crystallisation 
steps required (Nicholson et al., 2013).  
Figure 5.5: Product flow diagram of the supply chain. 
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5.4 Other important concepts and entities in the MDR-TB SLD 
supply chain 
This section provides a description of some concepts and entities, in addition to those 
introduced in the previous sections, that are important for understanding the global 
MDR-TB SLD supply chain.  
5.4.1 The price and quality reporting tool 
Principal recipients of grants from the Global Fund are required to report all purchases 
of key pharmaceutical and health products that were procured with funds from the 
grant, by entering procurement information in the online Price and Quality Reporting 
(PQR) Tool. The recipients enter the data only when receiving the goods in the country, 
based on the best available documentation at that time. The recipient also has to select 
whether goods were purchased directly from the manufacturer or via a third-party 
intermediary such as the GDF (The Global Fund, 2014).  
To properly fill out the PQR form, a recipient will need: 
• The invoice(s) from the manufacturer;
• The invoice(s) or cost estimate(s) of the third party intermediary (where applicable);
• The scheduled and actual delivery dates; and
• The purchase order date and number. This specifies the first date on which a price
was secured from a manufacturer or third party intermediary.
5.4.2 Manufacturers 
For a manufacturer to be eligible to supply SLDs to the GDF, their product and 
manufacturing site must comply with the GDF quality assurance criteria. The criteria 
require all of the products to be authorized by the relevant national medicines 
regulatory authority in the country of use as well as either one of the following (Global 
Drug Facility, 2016): 
i. The product is pre-qualified by WHO under the WHO Prequalification of
Medicines Program; or
ii. The product is approved by the relevant Stringent National Medicines
Regulatory Authority; or
iii. The product is found acceptable through an assessment process involving an
independent expert review panel.
Newly approved manufacturers can qualify for long-term agreements (LTAs) through a 
competitive bidding process managed by the GDF’s PA. Up to 4 LTAs are rewarded per 
product, with an established market share of the potential orders based on the
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manufacturers’ ranking following the bidding process. The ranking is done according to 
the manufacturers’ score (with a maximum score of 100) from the evaluation criteria. The 
evaluation criteria and the corresponding maximum points are provided in Table 5.2 (IDA 
Foundation, 2016). 
Table 5.2: Evaluation criteria for manufacturers (Adapted from IDA Foundation, 2016).
Criteria Max Points 
Price (lowest) 50 
Supplier performance on delivery lead time (highest) 15 
Shelf life (longest) 20 
Production lead time (shortest) 5 
MOQ (lowest) 5 
Product registration in HBCs and LMICs 5 
A primary, secondary, tertiary and auxiliary status is awarded to the manufacturers 
according to their rank following the bid. The market share allocation is executed per 
product formulation and the estimated total orders for that formulation as follows (IDA 
Foundation, 2016): 
• For 1 LTA – 100% for the sole manufacturer;
• For 2 LTAs – 55% for the primary and 45% for the secondary manufacturer; and
• For 3 LTAs – 50% for the primary, 30% for the secondary and 20% for the tertiary
manufacturer.
When more manufacturers enter the market, the total production capacities increase, 
creating more competition within the market. This can have a positive impact on the 
prices of drugs, since manufacturers can reduce prices to compete in the market (Lunte, 
2012). 
5.4.3 The strategic rotating stockpile 
The TB market remains small and divided with more than 40 different regimens being 
offered by various different suppliers/agents. Manufacturers have few incentives to 
invest and innovate for new medicines, demand is difficult to pool in order to negotiate 
price reductions, and forecasting to plan production and avoid product shortages is 
difficult (UNITAID, 2014). 
UNITAID’s solution for the prevention of stock-outs is the Strategic Rotating Stockpile 
(SRS), implemented by the STOP TB Partnership through its GDF. The stockpile consists 
of SLDs for MDR-TB which is accessible by countries in emergencies, i.e. when they 
require drugs at short notice to prevent a stock-out and possible treatment interruptions 
Stellenbosch University  https://scholar.sun.ac.za
Map of the MDR-TB SLD supply chain  Page | 79 
Stellenbosch University 
(UNITAID, 2016b). The procurement of the SLDs for the SRS began in November 2007 
with the aim of having enough drugs for up to 800 patients or treatments (Giffin and 
Robinson, 2009). Currently, the SRS has enough SLDs for 5,800 MDR-TB treatments 
(UNITAID, 2016b).  
5.4.4 Projects outside the GLC initiative 
Most countries require MDR-TB treatment as part of their TB-program and need access 
to an expanded supply of SLDs. For most SLDs available through the GLC mechanism, 
there is only one eligible manufacturer that is quality assured. The insufficient drug 
supply and logistical problems result in long delays for countries procuring through the 
GLC initiatives. A procurement mechanism with inadequate supplies and long lead 
times will provide little incentive to countries to seek endorsement from the mechanism. 
Therefore, several countries with a large MDR-TB burden that are not obliged to procure 
through the GLC, avoid procuring through the GLC and GDF (Giffin and Robinson, 2009). 
Additionally, some countries, such as Korea and the BRICS representatives, have local 
manufacturers and national markets for SLDs, so they have no reason to procure 
through the GLC or GDF (Giffin and Robinson, 2009). For examples, refer to Coetzee 
(2015) for a study of a section of South Africa’s downstream supply chain or Giffin and 
Robinson (2009) for a country profile of Brazil.  
5.5 Map of the MDR-TB SLD supply chain 
In this section, the complete global supply chain for MDR-TB SLDs will be mapped and 
described by providing a theoretical model that combines the discussed characteristics, 
actors, flows, entities and concepts.  
The complete supply chain, including both the upstream and downstream segments, is 
illustrated in Figure 5.6. The supply chain begins with the extraction of raw materials 
and the manufacturing of the starting material. The active pharmaceutical ingredient(s) 
is then manufactured from the raw materials and starting materials through both 
chemical and physical means. Once a formulation has been manufactured (through 
finished product manufacturing), there are three alternative paths it can take, namely:  
i. to the GDF and its procurement agent or the GDF stockpile, who then distributes
it to the applicable countries;
ii. directly to the country, if the country ordered directly from the manufacturer; or
iii. to a supplier or agent acting on behalf of a country, this is the case for projects
outside the GLC initiative.
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Figure 5.6: Map of the supply chain for SLDs for MDR-TB. 
5.6 Challenges in the supply chain 
In this section, the key difficulties and challenges in the upstream segment of the supply 
chain (up and till drugs reaches the country, as illustrated in Figure 5.6) will be 
discussed, these constitute the primary focus of this study. Table 5.3 provides a 
summary of the predominant difficulties and challenges in the upstream segment of the 
supply chain as given by Giffin and Robinson, (2009); Nicholson et al., (2013); de Lucia, 
(2014); Keravec, (2014); Olson, English and Claiborne, (2014); and Coetzee, (2015). 
Table 5.3: Summary of difficulties and challenges. 
Aspect Related Difficulties and Challenges 
Demand 
and 
Forecasting 
• There is a high degree of uncertainty in the procurement process due to the
limited demand and lack of accurate forecasting, 
• Most of the current demand forecasting techniques do not fully or accurately
capture patients’ needs for SLDs, thus the forecasted demand is most likely lower 
than the actual demand, and 
• The inconsistent and unpredictable demand patterns prevent manufacturers
from implementing optimal production processes, resulting in backlogs, delays, 
and high prices. 
Market • The general SLD market is comparatively small due to the restricted diagnostic
capacity at country level, and 
• Visibility into the SLD markets are limited and doubtful, with high barriers to entry
that often discourage current manufacturers and prevent new manufacturers from 
entering the market.  
continued on next page 
Raw Materials Starting Material Manufacturing API Manufacturing
GDF/PA
Stockpile
Finished Product Manufacturing
Country
Supplier/AgentMedical DepotHospitals, Clinics & PharmaciesPatients
(i)
(ii)
(iii)
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Financial 
Challenges 
• SLDs carry high prices when compared with FLDs,
• Ineffective and inefficient management of funding coming from several sources,
• Financial limitations making access to drugs difficult for patients, and
• Some countries struggle with managing the complex global financing
architecture. 
Lead Times • The arrival of drugs into countries procured directly from manufactures or
through the GLC-mechanism can be delayed for months, during which time 
patients are transmitting DR-TB, and   
• The timely delivery of high-quality SLDs is part of a complex health care
challenge that includes several steps, such as testing, diagnosis, treatment 
protocols, drug manufacturing, delivery and initiation and completion of treatment. 
Other 
Challenges 
• Most SLDs have a short shelf life compared with FLDs,
• Some countries struggle with the procurement processes and mechanisms,
• Strict regulatory processes and quality standards often creates barriers to
suppliers entering the SLD market, and 
• Low volumes of active pharmaceutical ingredients and finished pharmaceutical
products. 
According to Mostaghim, (2012) high prices (listed under “financial challenges” in Table 
5.3) and the limited availability of quality assured SLDs (listed under “market” and “other 
challenges” in Table 5.3), are the two leading challenges faced by the upstream 
segment of the supply chain. These are discussed in more detail in the following 
subsections. The section is concluded with a short discussion of the causes of 
challenges facing the supply chain. 
5.6.1 High prices 
There are four elements that affect the pricing of SLDs, namely (i) monopoly premium, 
(ii) risk premium, (iii) cost of sub-scale manufacturing, and (iv) the true cost of 
manufacturing (Mostaghim, 2012). A monopoly premium refers to the premium that 
manufacturers charge due to the lack of competition among manufacturers. The risk 
premium is driven by the poor market visibility, which causes manufacturers to charge 
a premium based on the risk of investing in the SLD market. Sub-scale manufacturing 
costs are associated with suboptimal batch sizes and production policies that 
manufacturers have to implement due to the limited actual demand and lack of 
accurate demand forecasting. The true cost of manufacturing refers to the actual cost 
of producing the drugs, such as raw material and labour (Nicholson et al., 2013). By 
increasing volumes and creating competition between manufacturers, the non-essential 
price elements (monopoly premium, risk premium and sub-scale manufacturing costs) 
can be drastically decreased or even eliminated (Kimerling, 2012), which would 
contribute to the affordability of SLDs.  
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5.6.2 Limited availability of quality assured SLDs 
For most second-line drugs procured through the GLC mechanism, there are only one 
or a few quality assured manufactures. Inadequate drug supplies, that can be at least 
partially attributed to the small number of suppliers, frequently cause delays. Several 
manufacturers have worthwhile contracts in place with the national TB programs in their 
countries where they are situated, in some cases, this can limit their motivation for 
joining the GLC initiative (Giffin and Robinson, 2009; Lunte, 2012). Some of these 
manufacturers do not have the required quality control and assurance measures in 
place to meet the WHO prequalification. Since the steps for prequalification are 
considered laborious by some manufactures, they require significant financial incentive 
to participate. The high production costs and irregular demand provide little motivation 
for manufacturers to join the GLC initiative (Lunte, 2012). According to industry 
interviews, adapting and using manufacturing facilities for the production of SLDs does 
not maximise profit generation (Nicholson et al., 2013).  
It is worth noting that several of the countries outside the GLC Initiative have 
government-run or other quality assured programs that provide appropriate treatment 
and quality assured drugs. However, approximately 90% of patients with DR-TB are 
receiving their treatment from sources outside of these government-run and quality 
assured programs (Nicholson et al., 2013). In a recent study, Arinaminpathy et al. (2016) 
concluded that the suspected number of TB cases in India is two to three times more 
than was previously estimated. This is due to the fact that several patients in India use 
private medical programs instead of the government-run or quality assured programs. 
The private system comprises of several providers and is essentially unregulated with 
most cases of TB not being reported to public health officials. The patients are given 
drugs, but do not receive the appropriate education and support. Consequently, 
patients stop treatment as soon as they feel better, instead of completing the full 
treatment therapy (Arinaminpathy et al., 2016). Interrupted treatments, as previously 
mentioned, is a primary cause of DR-TB. 
5.6.3 Causes of difficulties and challenges 
The difficulties and challenges are predominantly a result of (i) the unpredictable 
demand patterns, as discussed in Section 5.1.3; (ii) the restricted market structure, as 
introduced in Section 5.1.4; and (iii) the low volumes of active pharmaceutical ingredients 
(APIs) and finished pharmaceutical products (FPPs) (Mostaghim, 2012). The production 
of APIs is restricted to only a few manufacturers. As with the final product manufacturing, 
there are few incentives to invest and innovate for new medicines, the demand is difficult 
to pool, and forecasting to plan production and avoid product shortages is difficult. As 
previously mentioned, the lack of competition (monopoly premium) and the unstable 
demand patterns (risk premium) add to the total cost of the APIs. It is estimated that the 
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costs of APIs are responsible for a 30% to 60% variability in the cost of FPPs (Keravec, 
2014). 
Furthermore, the limited demand and lack of accurate forecasting weakens the 
manufacturers’ confidence to produce large volumes of supplies.  Therefore, they are 
forced to implement suboptimal manufacturing processes and manufacture the 
supplies in smaller batch sizes that are not cost effective. China is the world’s leading 
provider of APIs for TB drugs, both FLDs and SLDs, holding more than 85% of the market 
(Olson, English and Claiborne, 2014). The manufacturers in China, however, have not 
been pre-qualified by WHO to sell the drugs globally, which has a major influence over 
the availability of SLDs (Nicholson et al., 2013; Olson, English and Claiborne, 2014). 
5.7 Improving the MDR-TB SLD supply chain 
Between 2008 and 2013, experts on the prevention, diagnosis, treatment and 
management of drug-resistant TB came together to discuss and investigate ways to 
improve the effectiveness of the MDR-TB SLD supply chain. This discussion took the 
form of a series of workshops, held by the Institute of Medicine’s (IOM) Forum on Drug 
Discovery, Development and Translation, and took place in Washington, Pretoria, 
Moscow, New Delhi and Beijing. A workshop summary, put together by the IOM, 
summarised the conclusions and recommendations from the workshops, which included 
participants from the World Health Organisation, Harvard Medical School, Stop TB 
partnership, the World Bank, the Bill & Melinda Gates Foundation and Médecins sans 
Frontières, among others.  
The suggestions and possible solutions derived from these workshops, were arranged 
in three categories, namely (i) mechanisms of purchase and supply; (ii) logistics, supply 
and demand; and (iii) innovative financing. Table 5.4 summarises some of these 
suggestions that are applicable to the upstream segment of the supply chain.  
Table 5.4: Summary of recommendations to improve the upstream segment of the supply chain. 
Mechanisms of purchase and supply 
- Restructuring of the current organisational and institutional formation to align the interests of all 
the partners in the system in order to possibly improve the current internal politics among key 
partners of the supply chain (Keshavjee, 2012). 
- Provide clearer guidelines to manufacturers on how to enter to SLD market, to potentially 
encourage the entry of new suppliers to the market (Mostaghim, 2012). 
- Applying a tiered pricing strategy according to the country’s ability to pay. However, high income 
groups in poor populations should pay the same prices as high income groups in developed 
countries. Therefore, the tiered pricing strategy should also investigate the possible application 
of market segmentation within the countries to ensure suitable price differences for all lower-
income markets, regardless of the country’s income group (Yadav, 2012; Nicholson et al., 2013). 
continued on next page 
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- Improving the current information systems in the supply chain, for example developing a universal 
bar coding system for the drugs and diagnostics, combined with mobile information technology 
that will allow the tracking of drug supply and stock-outs (Bloom, 2013). The sharing of this data 
between countries and projects could improve forecasting for manufacturers (Giffin and Robinson, 
2009) 
Logistics, supply and demand 
- Providing incentives for manufacturers of SLDs that would encourage them to manufacture the 
drugs according to a set of quality standards. This could potentially include the support of local 
manufacturers as well. International donors should not allow the procurement of drugs that are 
not quality assured with their funds (Nicholson et al., 2013). 
- Reducing procurement barriers of the GDF to allow countries to procure drugs from local quality 
assured suppliers (Giffin and Robinson, 2009) 
- Developing and implementing smooth, reliable and accurate forecasting methods to reduce the 
large differences between actual and forecasted needs. It is important to improve communication 
with and between manufacturers in order to share the knowledge of the whole supply chain, i.e. 
to forecast the donor-driven and non-donor-driven markets together and not in isolation (Yadav, 
2012; Nicholson et al., 2013). 
- Developing public-private partnerships (Bloom, 2013). 
- The development of a buffer inventory to fulfil orders of countries, while smoothing orders placed 
to the manufactures. This could possibly improve batch sizes and reduce costs associated with 
set-up and changeovers (Yadav, 2012). 
Innovative financing 
- Implementing a pooled financing system from which countries could withdraw funding at the 
appropriate time to pay for procurement, instead of providing funds to countries in advance, when 
their needs might still be uncertain due to inaccurate forecasting. WHO could then incorporate 
their data to monitor the pooled finances to ensure that drugs are procured and used at the 
appropriate times and countries (Bloom, 2013). 
- Implementing push and pull financing strategies. Push strategies will be used to create incentives 
to new manufacturers to enter the market, such as providing research and development credits 
or fast-tracking regulatory approval. Pull strategies will be used to create demand, by expanding 
health insurances or risk insurance to cover MDR-TB, and encourage current manufacturers to 
stay in the market, by providing long-term partnerships and providing funds for the development 
of new SLDs (Atun, 2012a). 
- Implementing new long-term contract structures to manufactures that allows quantities to be 
flexible (if the actual demand is slightly different than what was forecasted) and/or volume-price 
arrangements that would, for example, guarantee the manufacturer a certain percentage 
increase in orders every year, in return for a mutual percentage decrease in price over the same 
period (Yadav, 2012; Nicholson et al., 2013).  
One of the recommendations included in the table is the development of a buffer 
inventory. By smoothing the orders placed to manufactures, this buffer inventory could 
possibly resolve several problems associated with the erratic and inconsistent demand 
for SLDs, such as batch sizing and costs. Yadav (2012) suggested that this buffer
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inventory could aid in implementing a push-pull boundary, as depicted in Figure 5.7. Refer 
to Section 3.6 for a description of this type of push-pull hybrid system. In the current 
supply chain, processes such as substance manufacturing, formulating and packaging, 
pre-delivery inspection and transport are predominantly order-driven due to the erratic 
demand. Manufacturers apply suboptimal batch sizes and production policies which 
results in longer lead times and higher costs. With the buffer inventory, a lean 
manufacturing approach could be applied upstream, while simultaneously ensuring 
that the stockpile is agile and capable of delivering drugs to the unpredictable 
marketplace, as illustrated in Figure 5.7. This would enable manufacturers to forecast 
more accurately and plan ahead, which would allow improved inventory management 
and batch sizes to be implemented. Furthermore, the implementation of such a buffer 
inventory could, in time, also address problems associated with lead times, demand 
and forecasting; consequently making the SLD market more attractive to potential 
manufacturers (Nicholson et al., 2013).  
 
Figure 5.7: Implementation of a buffer inventory (Adapted from Yadav, 2012). 
To evaluate the impact of such a buffer inventory, a model will be designed where the 
current SRS, with an increased capacity, is used to fulfil all orders placed through the 
GDF, as opposed to it being used only for emergency orders. This will be explored in 
more detail in the next chapter.  
5.8 Conclusion: Mapping the upstream MDR-TB SLD supply 
chain 
This chapter provided a description of the supply chain for SLDs for MDR-TB by 
providing background on the characteristics, flows and entities of the supply chain. A 
map of the supply chain was provided, followed by a summary of problems and 
difficulties experienced in the chain. Some of the recommendations to improve the 
supply chain were summarised and the idea of implementing a buffer inventory was 
discussed in more detail.  
The following chapter will provide a description of the modelling process that was 
followed. 
 
1 Buffer InventoryManufacturers Countries
Order for drugs Order for drugs
Drugs in transit Drugs in transit
2
De-coupling Point
Forecast-Driven (Push System) Order-Driven (Pull-System)
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Dynamic model 
development 
 "The good thing about computers is that they do what you tell them to do. The bad news is 
that they do what you tell them to do." 
- Ted Nelson (American pioneer of information technology) 
The previous chapter provided background information, as well as a map (conceptual 
model) of the supply chain for SLDs for MDR-TB. This chapter will focus on the modelling 
process used to simulate the applicable segment of the supply chain as well as the 
scenarios to be implemented.  
The chapter is divided into five sections, each related to the five main steps in the 
modelling process provided in Appendix C, namely (i) defining the problem and its 
boundaries, (ii) understanding the model, (iii) simulating the model, (iv) testing and 
validating the model, and (v) identifying and implementing scenarios.  
6.1 Defining the problem and its boundaries 
This section aims to clearly define the purpose of the model and discuss the boundaries 
and limitations associated with the data and information. It is divided into three 
subsections, namely (i) problem area, (ii) data and information, and (iii) time horizon. 
6.1.1 Problem area 
The problem area will be clarified by providing the reason for developing the model, 
summarising the stakeholders and considering the objectives of both the SRS and the 
model. 
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6.1.1.1 Reasons for developing a dynamic model 
Many parts of the world experience serious and frequent drug shortages. In most cases, 
this can lead to treatment failures and cause the patient to become drug-resistant. 
Patients with MDR-TB who fail to adhere to treatment due to drug shortages, are at risk 
to develop XDR-TB. The cost of curing a single XDR-TB patient is equal to the cost of 
curing 200 non-resistant TB patients (Nugent, 2010).  
Although several recommendations towards improving the global SLD supply chain has 
been documented, there are almost no evidence of quantitative models of the supply 
chain that can be used to accurately predict the expected impact of these 
recommendations on the supply chain performance.  
6.1.1.2 Stakeholders 
The majority of the stakeholders that are involved in the supply chain were described 
in Sections 5.2 and 5.4. The central entity in the model is the GDF, who is responsible 
for ordering the drugs from the suppliers and manufacturers on behalf of countries and 
delivering these drugs to countries. They also govern the SRS on behalf of the Stop TB 
Partnership and UNITAID. Funding for the SRS and other activities is received from 
several donors, though UNITAID and the Global Fund are the main funders. 
6.1.1.3 Model objectives 
To comprehend the main objectives of the model, it is useful to consider the motives for 
having a SRS. The SRS was mainly developed to be used as a safety stock for 
emergency orders in order to prevent stock-outs. Other than preventing treatment 
interruptions, it was also intended to combine and time orders – permitting current 
manufacturers to produce medicines more efficiently and increases market 
attractiveness to draw in new manufacturers (UNITAID, 2016b). However, a retrospective 
analysis done by Yadav (2015) for the GDF, concluded that although the SRS was 
successfully used as a buffer inventory for emergency orders, it was not effectively used 
to consolidate and time orders to optimize production for manufacturers. 
With the right data scenarios can be modelled in an attempt to identify changes to the 
operation of the SRS that would allow it to satisfy both of these goals. The model can 
also simulate design changes that can support consistent access and reduced lead 
times whilst making the market more attractive for manufacturers. With this in mind, the 
main goal of the simulation model is to measure: 
1. the impact of certain changes to operational policies on the variability of the
demand to the suppliers and the availability of stock for clients; and
2. the combination of changes to operational policies that achieve the best
outcome in terms of the variability of the demand to the suppliers and the
availability of stock for clients.
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In addition to two aforementioned metrics (variability of demand to suppliers and 
availability of stock for clients), the impact of operational changes on the cost of 
operating the supply chain, must of course also be taken into consideration. The extent 
to which these questions can be answered or discussed will depend on the boundaries, 
limitations and level of detail of the model. 
6.1.2 Data and information 
To substantiate and clarify the scope of the problem statement, the boundaries and 
limitations will be discussed and a conceptual model provided to illustrate the fragment 
of the supply chain that falls within these boundaries. Furthermore, the available data 
and accompanying limitations will be examined.  
6.1.2.1 Boundaries, limitations and conceptual model 
As initially mentioned in Section 1.4, two boundaries of the project are that (i) only the 
upstream segment of the supply chain will be considered, i.e. only up and till the point 
that the drugs are dispatched and delivered to the country; and (ii) it will only include 
the flow of SLDs for MDR-TB and not any FLDs. Since there is a lack of reliable data for 
the processes and activities that precedes the finished product manufacturing (i.e. API 
manufacturing, starting material manufacturing and raw materials), these steps will not 
be included in the simulation model. Furthermore, since the procurement data for 
projects outside of the GLC and GDF are not included in the main source of data for this 
report, the PQR database, their associated activities will be omitted from the model. By 
way of explanation, the map of the supply chain presented in the previous chapter in 
Figure 5.6 is repeated in Figure 6.1, with emphasis on the fragment of the supply chain 
that falls within the abovementioned boundaries and limitations. 
Figure 6.1: Fragment of the supply chain that falls within boundaries and limitations. 
GDF/PA
Stockpile
Finished Product Manufacturing
Country
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A conceptual model was developed to clarify the steps and pathways in the fragment 
of the supply chain that will be modelled. The conceptual model, depicted in Figure 6.2, 
is centred around the GDF and its PA who manages the warehouse, DC and SRS. As 
shown in Figure 6.2, there are currently four main ‘pathways’, namely (i) normal, 
‘everyday’ orders; (ii) emergency orders; (iii) orders to replenish the stockpile; and (iv) 
orders from countries directly to the manufacturer. Each of these pathways will be 
discussed shortly.  
Figure 6.2: Conceptual model of the fragment of the supply chain to be modelled. 
Pathways i and ii: Normal, ‘everyday’ orders and Emergency orders 
It is important to note that the steps in the information flow, described in Section 5.3.1, 
still applies to pathways i and ii, even if some steps are not explicitly mentioned in the 
descriptions that follow. In this research, a normal, everyday order is understood to be 
those orders placed by a country in accordance with the expected drug needs that they 
submitted to the GLC and GDF. Emergency orders, on the other hand, are orders that 
are urgently required, at reduced lead times, to prevent a stock-out and treatment 
interruptions. 
The process for normal, everyday orders is: 
1. A country puts in a requisition of a certain size, required by a certain date.
Normal “Everyday” Orders Stockpile Replenishment Direct from ManufacturerEmergency Orders
Manufacturing GDF/PA
Stockpile
GDF/PA DC
Country
Order From 
Country 
To GDF/PA
Order From 
GDF/PA
To Manufacturer
Order From  Country To Manufacturer
Delivery From Manufacturer To Country - Order Directly
Delivery From SRS 
To Country
Delivery From 
Manufacturer To SRS
Delivery From Manufacturer To Country -
On Behalf of GDF/PA
Delivery From Manufacturer To Country -
On Behalf of GDF/PA
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2. The GDF considers the country’s laboratory capacity, clinics, patients registered
for treatment etc. and enters into negotiation with the country. Ultimately the GDF
has the final say on the size of the order; however, there is usually no or only a
small difference from the original requisition amount. The GDF confirms the order
and forwards it to the PA.
3. The PA creates a firm purchase order based on the country requisition and
places this to the various manufacturers. Drugs can also be dispatched from the
SRS instead of the manufacturer to assist with stock rotation in the SRS.
4. The manufacturer(s) produces the order and dispatches it to the DC. In some
cases, the GDF/PA can request that the manufacturer dispatch the drugs directly
to the country, instead of the DC.
5. The PA does inspection at the DC and dispatches the drugs to the countries.
The process for emergency orders is: 
1. A country places an emergency order through the GDF.
2. The GDF considers the country’s laboratory capacity, clinics, patients registered
for treatment etc. and enters into negotiation with the country.
3. The GDF creates a firm purchase order based on the country requisition and
places this to the PA who makes necessary arrangements with the SRS.
4. The drugs are dispatched from the SRS to the country, typically within 30 to 55
days.
Pathway iii: Orders to Replenish the Stockpile 
There are two flows of drugs out of the stockpile, namely (i) drugs dispatched for 
emergency orders, and (ii) drugs of a certain age that are dispatched as a part of stock 
rotation to ensure drugs do not become obsolete. The stockpile, however, is set to 
always have a certain number of drugs on hand for emergency orders. The exact 
process for stockpile replenishment is unknown due to the lack of data or information 
available on the inventory and ordering policies currently applied by the PA for the SRS. 
For the purpose of this research, the process for stockpile replenishment is assumed to 
be as follows:  
1. The PA places an order to manufacturers; and
2. The manufacturer(s) produces the order and dispatches it to the SRS.
Pathway iv: Orders from Countries Directly to the Manufacturer 
In some cases, a country decides to rather order directly from a manufacturer instead 
of ordering through the GDF. There are three typical reasons for this decision, namely 
(i) a country doesn’t want to create a dependency on the GDF; (ii) countries that order 
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large volumes are often able to negotiate better prices themselves when ordering 
directly from the manufacturer; and (iii) some countries (this is debatable and there is no 
data to prove this) believe there are unnecessary steps when ordering from the GDF. 
This was confirmed by a Subject Matter Expert (SME) who has made several notable 
contributions to the development and research of the MDR-TB SLD supply chain, (SDL 
supply chain SME, Personal communication, 16 February 2016). The process for these 
orders is rather simple: 
1. A country places an order directly to the manufacturer; and
2. The manufacturer dispatches the drugs to the country after production is
completed.
Since there is no authority or control over a country’s decision to order directly from the 
manufacturers, this path will be omitted from the model as no operational policy will 
directly affect their decision.  
6.1.2.2 Available Data 
As previously mentioned, the main source of data for the model is the PQR database, 
discussed in Section 5.4.1. The data from this database, however, comes with some 
constraints and limitations, as summarised in Table 6.1.  
Table 6.1: Limitations and constraints of the database (Adapted from The Global Fund, 2005). 
Constraint Description 
Misreporting There is a large number of principal recipients that enter data into the database, 
increasing the chances for data entry errors to occur. The most frequent entry to 
be misreported is the order quantity or size and the currency. 
Costs As preferred by the PQR, some principal recipients report the unit costs without 
the freight, insurance, in-country distribution and handling fees. However, since it 
is not standard practice in the industry to report costs separately, many invoices 
and tender documents do not have the separate unit cost. Therefore, some 
principal recipients are unable to report the unit costs and includes other costs in 
their data entry.  
Currency A principal recipient has to specify the date on which the order was placed and 
report data in the currency specified on the invoice. The PQR then converts the 
amount into USD based on what the exchange rate was on the date that the 
order was placed. If a recipient misreports the order date, the converted cost will 
not accurately represent the manufacturer’s price. The fluctuating exchange 
rates can also lead to variability in the converted prices. 
Data integrity Other errors and issues, such as the duplication of orders, have been reported in 
the past.  
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The purchase order information included in the PQR database is: 
• the country/territory and their grant number;
• the supplier/agent;
• the manufacturer;
• the formulation and description of thereof;
• the product pack, pack quantity and pack cost (in USD);
• the purchase order date;
• the scheduled delivery date; and
• the actual delivery date.
The limited available data provides several additional limitations. The database doesn’t 
provide any lead times, however, the time between the ‘purchase order date’ and 
‘actual delivery date’ can be derived from the data. The ‘actual delivery date’ is the 
date that the drugs arrives in the country. There are, however, several separate steps 
in the ordering and manufacturing processes that constitutes this lead time. Thus none 
of these steps (described in Section 5.3) can be modelled separately. Furthermore, the 
entries made in the database do not state whether the order is normal or urgent. It could 
be argued that the emergency order classification can be derived from the data by 
looking at orders with a shorter lead time; however, the orders that are dispatched from 
the SRS as a part of stock rotation will also have a shorter lead time. Therefore, there is 
no way to confidently distinguish between normal orders, emergency orders and orders 
fulfilled due to stock rotation. Additionally, no information or data regarding the 
replenishment process of the SRS are available. Since the time between when the drugs 
are manufactured and delivered to the SRS is not specified, it would be difficult to 
determine the age of the drugs. Consequently, determining the number of drugs 
available for stock rotation or the number of drugs that exceeds their shelf life (and 
becomes obsolete) becomes problematic. The data regarding the manufacturers’ batch 
sizes, minimum order quantity, lead times etc. is not publically available, making it 
impossible to model the manufacturers and their processes in detail.  
6.1.2.3 Formulations to include in the model 
An analysis of the GDF’s expenditure on SLDs in 2012 and 2013 (Stop TB Partnership, 
2013) indicated that 10 formulations are accountable for 92% of the total cost for SLDs. 
Figure 6.3 illustrates the 10 formulations and their procurement value in $US millions. 
These values are the total unit costs, and excludes costs associated with freight, 
insurance, procurement administration, handling, quality control or inspections.  
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Figure 6.3: Top 10 SLDs based on procurement values from 2012 and 2013 (Adapted from Stop TB 
Partnership, 2013).
To ensure that the recommendations based on this research are robust, three different 
formulations will be included in the model. After an initial analysis of the formulations in 
Figure 6.3, it was decided to include (i) capreomycin, (ii) kanamycin, and (iii) cycloserine. 
These three formulations account for approximately 58% of the total procurement costs. 
Both kanamycin and capreomycin are from Group 2, the second-line parenteral agent 
(injectable anti-tuberculosis drugs). As mentioned in Section 2.4, kanamycin or amikacin 
is often the first choice from the Group 2 formulations; however, if drug resistance 
surveillance data indicates high prevalence of resistance to amikacin and kanamycin, 
capreomycin should be used instead. Cycloserine is from Group 4, the oral 
bacteriostatic second-line agents, and is a preferred choice from the group (World 
Health Organization, 2010) 
Although PAS (acid) and PAS (sodium) account for a large percentage of the total cost, 
it will not be included in the model. PAS (acid) cannot be included since there is no 
recorded data entries in the PQR database, while PAS (sodium) will not be included due 
to a drastic decrease in the amount of orders placed from 2010 to 2014. For example, 
in 2014 only 19 orders for PAS (sodium) were placed throughout the entire year. The 
reasons behind the decline in PAS (sodium) could possibly be ascribed to the recent 
increase in the use of PAS (acid), although this cannot be proven by the available 
historical data from the PQR database. While the first PAS compound to be used was 
acid salt, PAS sodium became increasingly common during the 1950s and 1960s. It was 
the compound used in most countries from the 1970s until 2000 (Caminero et al., 2010). 
The demand for PAS sodium continued to increase from 2000 to 2010, due to its 
effectiveness in the treatment of MDR-TB. To manage this high demand, PAS acid was 
reintroduced in the form of enteric-coated aminosalicylic acid granules (Peloquin et al., 
1994). Since then, the acid formulation has steadily replaced PAS sodium, while some 
countries still use it due its proven effectiveness (Caminero et al., 2010).  
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It should also be noted that cycloserine, accountable for almost a third (32%) of the 
procurement costs, is available in both a 250mg tablet and 250mg capsule. It is unclear 
whether the percentage in Figure 6.3 covers tablets, capsules or both. From an 
examination of the data, orders for cycloserine capsules increased significantly from 
2010 to 2014 whilst there was a corresponding decrease in orders placed for 
cycloserine tablets, see Figure 6.4. As reported on the Stop TB partnership’s list of 
available products, only cycloserine capsules are currently available for purchase from 
the GDF. This could explain the drastic decrease in orders placed for the tablets, as it 
has progressively been replaced by capsules.  
Figure 6.4: Annual order percentages of cycloserine tablets and capsules. 
For practical purposes, the orders for both capsules and tablets from 2010 to 2014 can 
be used in the model to represent the demand for cycloserine. To ensure that this option 
is valid, a Mann-Whitney U test was performed to compare differences between the 
tablet and capsule samples. The Mann-Whitney U-test is a non-paracontinuous-level 
test, that does not assume any properties regarding the distribution of the variables. 
The data was arranged to meet the assumptions of the test, with the order size (of both 
dosage forms) as the dependent variable at a continuous level and dosage form as the 
independent variable represented by two categorical, independent groups, namely 
tablets and capsules. The test was performed on the SPSS software and returned a 
p=value of 0.159. As the computed p-value is greater than the significance level 𝛼	 =0.05, there is no compelling evidence that the two samples differ. Therefore, the total 
demand for cycloserine in the model developed in this research will comprise of orders 
for both capsules and tablets.   
6.1.3 Time horizon 
The PQR database contains the purchase order information for MDR-TB SLDs from 
2007; however, only data from 2010 to 2014 will be used to ensure that the data relates 
only to steady state operation of the supply chain, and therefore excludes the initial 
build-up and growth phases from 2007 to 2009.  
2010 2011 2012 2013 2014
Orders for Capsules 4.50% 7.20% 35.40% 80.40% 90.90%
Orders for Tablets 95.50% 92.80% 64.60% 19.60% 9.10%
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When deciding which time step (hours, days, weeks, etc.) to use in the simulation model, 
it is important to consider how it will affect both the level of detail and the practicality of 
the model. For this model, using a daily time step will provide a high level of detail, but 
the orders placed per day are too irregular and will result in an unnecessarily high 
amount of ‘empty’ outputs. For example, in 2010 orders were placed on only 92 days 
of the year, i.e. there were 268 ‘empty’ days. This is illustrated in Figure 6.5. A weekly 
time step combines an acceptable level of detail with significantly fewer empty entries 
(refer to Figure 6.5). Although a monthly time step has no empty entries, the level of 
detail it provides is not as high as a weekly time step. Therefore, a weekly time step will 
be used in the model.  
Figure 6.5: Comparison of data entries for different time steps. 
For the validation and verification, the model will be run for a time horizon of 5 years in 
order to compare the results with the historical data (from the PQR database) from 2010 
to 2014. When experimenting with the operational policies, the time horizon will be much 
longer to ensure that the effects and changes in system behaviour can be identified 
and analysed.  
As suggested by Law (2004), a warm-up period will be implemented. The warm-up time 
is a specified number of time cycles that the simulation runs for before collecting data. 
The purpose of a warm-up period is to allow the parameters and queues to stabilise 
before measurements commence. From a graphical evaluation, it was concluded that 
the parameters and queues stabilise after approximately 40-45 weeks. Therefore, data 
will only be collected after a warm-up period of 52 weeks (one year). The impact of the 
various scenarios will therefore effectively be evaluated over a period of four years. 
6.2 Understanding the model 
This section aims to illustrate the system and its environment by identifying and 
describing the elements relevant to the system and by providing a CLD that reveals the 
links, relationships and feedbacks between the elements. The three subsections are (i) 
key variables and concepts, (ii) historical and possible future behaviour of variables and 
concepts, and (iii) the CLD.  
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6.2.1 Key variables and concepts 
The key variables and concepts can be derived from the sections discussed in Chapter 
5. The chief variables to be included in the model are centred around the conceptual
model in Figure 6.2. There are also several associated variables that, as discussed in 
the previous section, will be consciously excluded from the model. All of the possible 
variables associated with the conceptual model, regardless of whether data for the 
variable is available, are listed in Table E.1, in Appendix E, classified as either: 
endogenous variables (determined by other variables), exogenous variables 
(independent of the other variables), or omitted variables.   
It is important to note that these variables and concepts can still be modified during the 
remainder of the modelling process. Some of the variables might be removed or 
replaced and additional variables can be added.  
6.2.2 Historical and possible future behaviour 
This section will investigate the current behaviour by evaluating the descriptive statistics 
of the data and attempting to identify patterns through correlation analyses and 
inspection of graphs. 
6.2.2.1 Demand and order size 
The main input of the model is the country demand. Probability distribution functions 
will be used to feed random values to the model. Each week will comprise of up to four 
separate orders to enable more detailed modelling thereby replicating the behaviour 
of the real-world supply chain more closely. The size of these orders will be acquired 
from the distribution. For each of the three formulations, a frequency chart was 
generated to visualise the data. The charts for capreomycin, kanamycin and 
cycloserine are given in Figure 6.6 – 6.8. Each of the charts also include a polynomial 
trendline to indicate the general tendency of the data. 
Figure 6.6: Frequency diagram of capreomycin. 
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Figure 6.7: Frequency diagram of kanamycin. 
Figure 6.8: Frequency diagram of cycloserine. 
Since the main objectives of the model is to evaluate the impact of changes to 
operational policies, it is expected that the exact value of the order sizes will not 
negatively affect the system. For example, even though an order of 91.34 tablets is 
unrealistic, it would not influence the outcomes of modelling scenarios concerning 
changes to the operational policies. Furthermore, if continuous variables do cause 
difficulties, the model can be coded to round the generated values to integers. For this 
reason, both discrete and continuous distributions will be considered, expanding the list 
of available distributions to fit to the data. A graphical evaluation of the demand for 
each formulation makes it clear that the data is asymmetric and has mostly positive 
outliers. From Figure 6.9 it was therefore concluded that the distribution that will best 
represent the data is either a Negative Binominal distribution (discrete) or a Gamma, 
Weibull or Lognormal distribution (continuous). 
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Figure 6.9: Distributional choices (Adapted from Damodaran, 2016). 
Because Vensim does not support the Lognormal distribution, only the Negative 
Binominal, Gamma and Weibull distributions will be considered for further analysis. 
Distribution fitting tests were performed using the CrystalBall, EasyFit and ModelRisk 
software. All three tests established that, for all three formulations, the Weibull 
distribution is more suitable than the Gamma and Negative Binominal distributions.  
A Weibull distribution can be classified as being a one-parameter (1P) Weibull, a two-
parameter (2P) Weibull or a three-parameter (3P) Weibull. The three obtainable 
parameters are (i) the location parameter or failure-free life, symbolised by 𝛾; (ii) the 
shape parameter or slope, symbolised by 𝛽 ; and (iii) the scale parameter or 
characteristic life, symbolised by 𝜂.  
The 1P Weibull probability distribution function assumes 𝛾 = 0 and 𝛽 = 𝑘, where 𝑘 is 
some assumed constant value. The scale parameter (𝜂) is the only known parameter. 
The probability distribution function for the 1P Weibull is therefore given by 
𝑓 𝑡 = uv 6v uMG 𝑒M Uw x , 
where: 𝑓 𝑡 ≥ 0, 𝑡 ≥ 0, and 𝜂 > 0. 
(6.1) 
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For the 2P Weibull pdf, 𝛾 = 0  and the scale and shape parameter is known. The 
probability distribution function is similar to (6.1) with the constant 𝑘 being replaced by 𝛽: 
𝑓 𝑡 = {v 6v {MG 𝑒M Uw | , 
where:  𝑓 𝑡 ≥ 0, 𝑡 ≥ 0, 𝜂 > 0, and 𝛽 > 0. 
With all parameters known, the 3P Weibull pdf is given by 
𝑓 𝑡 = {v 6M}v {MG 𝑒M UY~w | , 
where: 𝑓 𝑡 ≥ 0, 𝑡 ≥ 0	𝑜𝑟	𝛾,𝜂 > 0, 𝛽 > 0, and −∞ < 𝛾 < +∞. 
The Weibull distribution recommended by the software is either: (i) a two-parameter (2P) 
Weibull distribution, as computed by the ModelRisk software; (ii) a three-parameter (3P) 
Weibull distribution, as computed by the CrystalBall software; or (iii) both a 2P and 3P 
Weibull distribution, as computed by the EasyFit software. A summary of the results can 
be seen in Table 6.2. A Kolmogorov-Smirnov goodness of fit test (K-S test) was 
performed to assess how well all the proposed Weibull distribution functions fit the data. 
The K-S test statistic (𝐷N) for each set of parameters is also provided in Table 6.2.
Since the location, scale, and shape parameters were estimated from the data, the 
critical region of the Kolmogorov-Smirnov test might be invalid. Therefore, the selection 
of a single ‘best’ parameter set, based solely on the best 𝐷N value, will be avoided.
Instead, each of the suggested set of parameters in Table 6.2, will be experimented 
with to determine a new set that generates a more accurate representation of the 
historical data. This is discussed in more detail in Section 6.3.3.2. 
(6.2) 
(6.3) 
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Table 6.2: Weibull parameters determined by distribution fitting software. 
Software 
Weibull Parameters K-S Test 
Location Shape Scale 𝑫𝒏
C
a
p
re
o
m
y
ci
n
 
CrystalBall 78 0.7571 21 477.19 0.0743 
EasyFit 
78 0.6183 21 462.00 0.0494 
0 0.7081 20 557.00 0.0792 
ModelRisk 0 0.6224 21 999.67 0.0542 
K
a
n
a
m
y
ci
n
 CrystalBall 450 0.5100 28 840.68 0.0813 
EasyFit 
450 0.5879 23 752.00 0.0918 
0 0.7859 27 186.00 0.0855 
ModelRisk 0 0.6525 29 773.15 0.0893 
C
y
cl
o
se
ri
n
e
 CrystalBall 1500 0.6832 278 210.51 0.0730 
EasyFit 
1500 0.6755 280 090 0.0628 
0 0.8161 262 280 0.0830 
ModelRisk 0 0.7236 284 342.11 0.0799 
It is important to note that all of the calculations in this section only considered the 
weeks in which at least one order was placed and ignored the weeks where there were 
zero orders. When weeks where no orders were placed were included in the data, the 
software used for distribution fitting concluded that there are no valid distributions that 
represents the data. To compensate for this in the model, the input variable for demand 
will either generate a 0 value, with 𝑥 probability, or a value from the appropriate Weibull 
distribution with 1	– 	𝑥 probability. To determine these probabilities, the proportion of 
weeks where orders were placed and where no orders were placed, for each year, was 
calculated from the data. Similarly, the probabilities that more than one, two and three 
orders are placed were also calculated. The calculations for probabilities from 2010 to 
2014 are summarised in Appendix E, Section E.2.2.2. It could be argued that the 
probabilities could be determined in more detail to have, for example, a different 
probability for every week of the year; however, the unpredictability of the demand 
makes such an approach unsuitable. The appropriateness of this approach to 
generating the demand data for the model was validated through consultation with a 
SME from the Centre for Statistical Consultation at Stellenbosch University. Furthermore, 
if there are any difficulties or anomalies, these will be identified during the validation 
and verification phase. 
6.2.2.2 Descriptive Statistics 
The descriptive statistics of the order size will be used to provide background on the 
behaviour of the orders placed. The descriptive statistics are summarised in Table 6.3 
for each of the three formulations. 
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Table 6.3: Descriptive statistics of order size. 
Statistic Capreomycin Kanamycin Cycloserine 
Mean 33 323 43 808 381 362 
Standard Error 4 146 8 124 43 073 
Median 12 150 13 900 129 600 
Mode 3 600 (5) 1 800 (5) 54 000 (9) 
Q1 2 400 5 200 52 925 
Q3 30 346 40 787.5 381 900 
Standard Deviation 63 012 96 813 803 512 
Minimum 78 450 1 500 
Maximum 448 000 882 000 9 449 100 
Sum 7 697 603 6 220 780 132 714 100 
Count 231 142 348 
A noticeable difference between the different formulations is the much higher values for 
cycloserine. This can be ascribed to the use of the formulations in treatments. 
Capreomycin or kanamycin is used only during the intensive phase of treatment and 
approximately 210 units (for both formulations) is required on average per patient 
course. Cycloserine, on the other hand, is used during both the intensive and 
continuation phase of treatment and requires about 1560 units on average per patient 
course (Lunte, 2012).  
The standard deviations for all of the formulations are exceptionally high, 
approximately double the size of the mean. A high standard deviation is expected since 
the order sizes will vary from country to country. For example, a high-burden country 
with a large population will most likely place a significantly larger order than a low-
burden country with a small population. This, combined with the inconsistent and 
unpredictable demand patterns, leads to the high standard deviations depicted in the 
table. Further proof of the inconsistent demand is found when comparing the mean and 
the median. The median is roughly three times smaller than the mean, which indicates 
that half of the orders placed are smaller than the average order size.  
The next section will investigate possible correlations between the variables in the data 
that could be linked to the order size (demand) and lead times. 
6.2.2.3 Correlation analysis 
For each of the three formulations, both the demand (order size) and lead time were 
tested for correlations with the (i) day of the week, (ii) day of the month, (iii) month of the 
year, (iv) week of the year, and (v) region. Additionally, an analysis was conducted to 
determine whether the two variables were correlated with each other and whether the 
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lead time had any correlation with the manufacturer. Table 6.4 provides a summary of 
the correlation results and provides both the value of the correlation coefficient (CC) 
and the p-value.  
All of the correlations were determined using a Spearman Rank Correlation Test. The 
Spearman Correlation was selected as it is a paracontinuous-level test which does not 
make the assumption that the variables follow a multivariate normal distribution. The 
choice of correlation test was validated as appropriate by an SME from the Centre for 
Statistical Consultation at Stellenbosch University. As revealed in Table 6.4, there are 
only five significant correlations (with a p-value < 0.005), however, for three of these the 
correlation coefficients are small enough (<0.2) to be considered negligible (CC < 0.2) 
and for the remaining two, the correlations are very weak (CC < 0.3). For this reason, 
these correlations will not be considered during the modelling process.  
Table 6.4: Correlation tests results. 
Capreomycin Kanamycin Cycloserine 
CC P-value CC P-value CC P-value 
Demand and Lead 
Time 
0.215 0.000 0.128 0.002 0.084 0.048 
Demand and Day 
of the Week 
-0.027 0.642 -0.015 0.839 0.053 0.216 
Demand and Day 
of the Month 
-0.050 0.392 -0.009 0.877 0.064 0.133 
Demand and Month 
of the Year 
0.013 0.824 0.099 0.179 0.029 0.490 
Demand and Week 
of the Year 
0.011 0.856 0.095 0.198 0.031 0.461 
Demand and 
Region 
0.019 0.743 0.219 0.003 0.024 0.580 
Lead Time and Day 
of the Week 
-0.082 0.161 -0.011 0.881 -0.180 0.000 
Lead Time and Day 
of the Month 
-0.109 0.060 -0.001 0.988 -0.176 0.000 
Lead Time and 
Month of the Year 
-0.006 0.914 0.047 0.520 0.055 0.199 
Lead Time and 
Week of the Year 
-0.014 0.806 0.047 0.527 0.042 0.324 
Lead Time and 
Region 
0.094 0.108 0.023 0.756 0.066 0.119 
Lead Time and 
Manufacturer 
-0.073 0.209 N/A 0.058 0.176 
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6.2.2.4 Visual assessments of the data 
This section will provide visual assessments of the available data following a similar 
approach as applied by Yadav (2015) in his analysis of the SRS for the GDF. Only the 
analysis for capreomycin is provided in this section, while the graphs and analysis for 
kanamycin and cycloserine are provided in Appendix D. Figure 6.10 depicts the weekly 
purchase order quantity as a percentage of the annual order quantity, plotted by week 
for each of the five years. This provides a visual assessment of any possible trends in 
the order timing from one year to the next. The figure clearly illustrates the dynamic 
nature of the data and that there is no trend in the time of year when orders are placed. 
Figure 6.10: Visual assessment of trends in order timing for capreomycin. 
Figure 6.11 illustrates the average weekly order size as well as the average lead time 
for the orders placed in that week over the last five years. This is to enable a visual 
assessment of how the lead time and demand fluctuates and whether any correlation 
between order size and lead time possibly exists. The figure clearly demonstrates the 
inconsistency of both the demand and lead time. The intuitive conclusion from the figure 
also corresponds with the results from the correlation analysis presented in Section 
6.2.2.3 - there is no correlation between the order size and lead time.  
Figure 6.11: Visual assessment of the average lead times and order sizes for capreomycin. 
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Figure 6.12 provides a plot of the weekly lead time against the purchase order dates 
over the five-year period. The lead time is calculated as the difference (in weeks) 
between the purchase order date and the order delivery date. This is to enable a visual 
assessment of whether any changes in the lead time occurred over the last five years. 
A linear regression analysis of the lead time was performed and no statistically 
significant relationships were observed, this is consistent with the graphic 
representation in the figure, which illustrates a relatively stable trend. 
Figure 6.12: Visual assessment of changes in lead time for capreomycin. 
6.2.3 Causal-loop diagram 
This section will capture the theories about the causes of the supply chain’s dynamics 
in order to provide a better understanding of the whole system and its behaviour. To do 
this a CLD will be developed to illustrate the causalities, feedback structures and the 
factors that influence the system behaviour.  
6.2.3.1 Links and relationships 
Figure 6.13 depicts the CLD of the upstream MDR-TB supply chain. As described in 
Section 4.4.4, a positive link (+ sign) signifies that the elements are positively related, 
while a negative link (- sign) signifies that the elements are negatively related. This CLD 
includes (i) variables that influence or have some effect on the upstream segment of the 
supply chain, as well as (ii) some variables that are influenced or affected by the supply 
chain.  
There are loops in the CLD, denoted by either a ‘B’ or an ‘R’, that illustrate the balancing 
and reinforcing processes in the supply chain. The remainder of this section will provide 
a description for each of the balancing and reinforcing loops in order to illustrate the 
relationships between the associated variables.  
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Figure 6.13: Causal-loop diagram of the upstream supply chain. 
6.2.3.2 Feedback loops 
The balancing loops illustrated in Figure 6.14, involves the counteracting and opposing 
effects that the ‘SRS stock on hand’ will have on some of the variables. An increase of 
the ‘GDF/PA orders placed’, will increase the ‘production’ consequently increasing the 
‘drugs available for SRS’, after a delay (production and dispatch lead time). This will 
lead to an increase in the ‘orders fulfilled for SRS’, which causes the amount of ‘drugs 
received by SRS’ to increase, after a delay (distribution lead time). This results in an 
increase of the ‘SRS stock on hand’. As depicted in Figure 6.14 (a), this decreases the 
‘stock shortfall’ and, in turn, decreases the ‘SRS demand’, causing the ‘GDF/PA orders 
placed’ to decrease. In Figure 6.14 (b), an increased ‘SRS stock on hand’ will increase 
the amount of ‘drugs available for stock rotation’, consequently decreasing the ‘normal 
orders from countries’. This leads to a decrease in the ‘GDF/PA orders placed’.  
     (a)                 (b) 
Figure 6.14: Two balancing loops of the SRS stock on hand. 
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Figure 6.15 depicts both a balancing and reinforcing loop related to the ‘SRS Demand’ 
and the ‘SRS Supply Line’. In the balancing loop, an increase in the ‘SRS Demand’ will 
cause the ‘GDF/PA Orders Placed’ to increase, consequently increasing the ‘SRS 
Supply Line’. This increase of the ‘SRS Supply Line’, however, will cause a decrease in 
the ‘SRS Demand’. In the reinforcing loop, the increase in the ‘SRS Demand’ and 
‘GDF/PA Orders Placed’, will cause an increase of ‘Production’, the ‘Drugs Available for 
SRS’, ‘Orders Fulfilled for SRS’ and ‘Drugs Received by SRS’, similar to the balancing 
loop in Figure 6.14. The increase in ‘Drugs Received by SRS’, however, will cause the 
‘SRS Supply Line’ to decrease, which results in an increase of the ‘SRS Demand’.  
Figure 6.15: Balancing and reinforcing loop of SRS demand and supply line. 
A balancing loop associated with the normal orders, is depicted in Figure 6.16. An 
increase in the ‘Country Demand’, will result in more ‘Normal Orders from Countries’ 
causing more ‘GDF/PA Orders Placed’, after a delay (order processing). As with the 
previous balancing loops, this causes an increase in the ‘Production’, ‘Drugs Available 
for GDF/PA’ and ‘Drugs Available for Normal Orders’. With more drugs available, the 
‘Normal Orders Fulfilled for Countries’ will increase, which will increase the ‘Normal 
Order Drugs Received by Countries’, after a delay (distribution lead time). When the 
countries receive drugs, their ‘Country Demand’ will decrease.  
Figure 6.16: Balancing loop of normal orders. 
Stellenbosch University  https://scholar.sun.ac.za
Page | 108 Chapter 6: Dynamic model development 
Department of Industrial Engineering 
The last two balancing loops, depicted in Figure 6.17, involves the emergency orders. 
As illustrated in Figure 6.17 (a), if the ‘Country Demand’ increases, the ‘Emergency 
Orders from Countries’ will increase as well, resulting in more ‘Emergency Orders 
Fulfilled for Countries’. This causes the number of ‘Emergency Order Drugs Received 
by Countries’ to increase, reducing the ‘Country Demand’. As illustrated in Figure 6.17 
(b), on the other hand, an increase of the ‘Emergency Orders Fulfilled for Countries’ will 
cause the ‘SRS Stock on Hand’ to decrease, resulting in a decrease of the ‘Drugs 
Available for Emergency Orders’.  
          (a)              (b) 
Figure 6.17: Balancing loops of emergency orders. 
6.3 Simulating the model 
In this section, the CLD will be expanded to develop the more detailed stock and flow 
diagram to clearly define the physical structure of the model. The process of building 
the stock and flow diagram and simulating the model using the chosen software will 
also be described. The process includes several steps and the subsections of this 
section are divided to follow these steps chronologically. The first subsections are (i) 
selecting the modelling software, (ii) level of detail, and (iii) variable types. This will be 
followed by sections dedicated to describing the different models that were built. For 
each model, the following will be discussed: (i) stock and flow diagram, (ii) characteristics 
and equations of the elements, and (iii) assumptions of the model. 
6.3.1 Modelling software 
The majority of SD software, such as Stella, Vensim, Powersim etc. have a great deal in 
common. A number of factors influence the choice of software for this model, namely 
price of the software, the available support, and whether it has the required tools and 
features. For this model, Vensim (from Ventana Systems incorporated) will be used as it 
is the less expensive software and the preferred SD software by many other students 
at the Industrial Engineering Department, meaning support is readily available. The 
Vensim software is also expected to be sufficient for the model in terms of capacity, 
performance, functionality, speed and optimization capabilities. As stated by Ventana 
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Systems, the sensitivity analysis is fast and powerful and has no limits on the size of the 
model.  
6.3.2 Level of detail 
This subsection includes a discussion of the level of detail for certain variables in the 
model. These detailing decisions corresponds with the limitations and boundaries that 
were discussed in Section 1.4 as well as the limitations associated with the available 
data, as discussed in Sections 6.1.2.1 and 6.1.2.2. 
6.3.2.1 Countries 
More than 70 countries are included in the data set, each placing between one and five 
orders a year for each of the formulations. To ensure that the recommendations based 
on the output of the data is robust, stochastic input data is required. However, with the 
available data, it will be impossible to generate stochastic input data based on only the 
few orders placed per country per year. Instead, the countries will be treated as a single 
entity representing the total demand of all the countries. This approach is sufficiently 
detailed to evaluate the impact of changes to various operational policies on the 
performance of the supply chain, thus it is sufficiently detailed to achieve the objective 
of the modelling exercise. 
6.3.2.2 Formulations 
A ‘formulation’ subscript will be used to include each of the three formulations, namely 
capreomycin, kanamycin and cycloserine. Although a weekly time step will be used in 
the model, each week will contain up to four orders to enable more detailed modelling 
of orders. To achieve this, an additional ‘order’ subscript will be used to represent the 
four possible orders per week. 
6.3.2.3 Manufacturers 
As with countries, there are two options regarding the level of detail in which to model 
manufacturers. The first option is to treat manufacturers as unique entities, where each 
manufacturing company has their own batch sizes and ordering policies and will only 
be able to produce one or more of the formulation types. The GDF/PA places orders at 
different manufacturers according to the formulation. In order to effectively model 
manufacturers in this amount of detail, additional data is required, such as the batch 
sizes and policies regarding batches and production, production rates etc. of each 
manufacturing organisation. Since this data is not publically available, the second 
modelling option will be applied instead. This (second) modelling option entails treating 
the manufacturers as a single entity, where all the orders from the GDF/PA (for each 
formulation) are placed to the same manufacturing entity. This entity will have the same 
ordering policy for all orders and be able to produce all formulations. This level of detail 
is sufficient to achieve the objective of the modelling exercise. 
Stellenbosch University  https://scholar.sun.ac.za
Page | 110 Chapter 6: Dynamic model development 
Department of Industrial Engineering 
6.3.3 Model A 
To evaluate the impact of different scenarios, it would be beneficial to compare the 
performance of the scenarios with the current system. It is, therefore, necessary to 
develop a ‘base case’ model that illustrates the current system. The variables and 
concepts identified in Section 6.2.1, were examined to determine a potential model that 
can be supported by the available historical data obtained from the PQR database. This 
model will be referred to as Model A. Model A is an initial model that is intended to 
define a physical structure of the aspects of the supply chain segment to be modelled, 
that can be supported and validated by the available data. It is intended to serve as a 
valid and reliable starting point from which to expand and add more elements and 
detail necessary to evaluate alternative modes of operating the supply chain.  
6.3.3.1 Model A: Stock and flow diagram 
The complete stock and flow diagram for Model A consists of two parts, namely (i) the 
main model, and (ii) the costs section. These are illustrated in Figures 6.18 and 6.19 
respectively. The cost section is an expansion of the main model, and is necessary to 
assess the effects of different operational policies on cost.  
Figure 6.18: Stock and flow diagram of the main section of Model A. 
Figure 6.19: Stock and flow diagram of the cost section of Model A. 
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6.3.3.2 Model A: Characteristics and equations of elements 
The complete modelling details for Model A, including the list of variables that were 
used and the details and equations of each element, are provided in Appendix E. This 
section will highlight some of the aspects that proved challenging during the 
development of Model A.   
As discussed in Section 6.2.2.1, the input demand will follow a Weibull distribution with 
a location, shape and scale parameter. Each of the suggested set of parameters 
provided in Section 6.2.2.1 were experimented with in the model and the output 
analysed. Through a process of trial and error, the set of parameters that generate the 
most accurate representation of the historical data for each formulation was identified. 
The parameters are summarised in Table 6.5.  
Table 6.5: Final parameters for the demand input. 
Location Shape Scale 
Capreomycin 78 0.6161 32 500 
Kanamycin 450 0.4525 50 000 
Cycloserine 1 500 0.4755 420 000 
As mentioned in Section 6.3.2.2, each week will comprise of up to four orders to provide 
more detail. With this in mind, it is important to note the following prerequisites:  
• a second order can only be placed if a first order has been placed;
• a third order can only be placed if a second order has been placed; and
• a fourth order can only be placed if a third order has been placed.
Therefore, during the time steps that no (first) order is placed, there cannot be any 
second, third, or fourth orders. The probability of a second, third and fourth order being 
placed each week had to be calculated from the data. Refer to Appendix E, Section E.2 
for details on the calculations and results. To incorporate this in the model, a uniform 
variable was added, as suggested by a Vensim ‘super administrator’. The uniform 
variable generates a value between 0 and 1 at every time step and if it is smaller than 
the probability (of an order being placed) the model generates an order value; 
otherwise it returns zero, indicating that no orders are placed that week. This is 
described in more detail in the appendix. 
6.3.3.3 Model A: Assumptions 
The assumptions made with regard to the entities in Model A are discussed in this 
subsection. 
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Assumptions about Manufacturers: 
It is assumed that: 
• the manufacturers have no additional orders other than that of the GDF and their
PA. In reality, they might have orders waiting from other companies (that are not
reported in the PQR database used for this research) which would potentially cause
additional delays in the supply chain.
• second-line anti-TB drugs are not kept in stock by any of the drug manufacturers.
Thus it is assumed that once production is completed, drugs are immediately
dispatched to the GDF and their PA’s DC.
Assumptions about Countries: 
It is assumed that: 
• no delays or other problems related to patent registrations or restrictions can delay
an order. This is assumption is viewed as reasonable since countries requesting
drugs are responsible for ensuring that the drugs comply with the country's
legislation on patent registration or restrictions.
• countries place an order to cover drug needs and include a buffer stock in their
procurement order (to cover drug consumption for the whole expected delivery
time).
Assumptions about the GDF, Distribution Centre and Stockpile: 
It is assumed that: 
• drugs are dispatched from the stockpile based on a first-in-first-out basis.
• the distribution centre is only used as a buffer area, intended to dispatch all
incoming stock to the countries as soon as possible. Thus it is assumed that there is
no permanent stock in the distribution centre.
6.3.4 Stabilising Model A 
As can be derived from the different supply chain flows discussed in Section 5.3, there 
are several separate steps in the ordering and manufacturing processes that constitute 
the lead time. All of these steps can be summarised in three major steps, namely (i) the 
ordering process of the GDF and their PA, (ii) the production of the drugs and its dispatch 
from manufacturers to the GDF and their PA’s distribution centre, and (iii) the quality 
checks (QC’s) at the distribution centre and the dispatch of the drugs from the 
distribution centre to the countries.  
The diagram in Figure 6.20 demonstrates the three major steps, their associated 
activities and an approximation of their lead times, as obtained from WHO (2008); Giffin 
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and Robinson (2009); Lunte (2012); Nicholson et al.  (2013); Keravec (2014); and 
Muzafarova (2015). These lead times were derived either from country case studies, 
averages or estimates that were provided in the sources mentioned above. 
Figure 6.20: The three major steps that summarises the ordering and manufacturing processes. 
The abovementioned steps can be incorporated into Model A with ‘orders ready for 
production’ and ‘orders available for dispatch’ as the stock variables and ‘order 
processing’, ‘production and dispatch to GDF/PA’ and ‘QC’s and dispatch to countries’ 
as the flow variables. If used in the model, the time between when the drugs are 
manufactured and delivered to the GDF/PA can be assumed, consequently making it 
possible to determine the age of the drugs. This will enable the number of drugs 
available for stock rotation and the number of drugs that exceed their shelf life (and 
become obsolete) to be calculated, although more assumptions about the stock 
rotation policies will have to be made.  
6.3.5 Model B 
Model A was developed to serve as a dependable model that could be entirely 
validated with historical data; therefore, several elements had to be omitted from the 
model due to the lack of available data to validate these elements. As previously 
mentioned, it would be beneficial to compare the performance of possible scenarios 
with the current system; however, Model A alone does not accurately represent the 
current system in its entirety and does not provide enough elements to allow the 
effective evaluation of the performance. A second model (Model B) was built, by 
expanding Model A, to incorporate aspects that would allow the current system to be 
evaluated and compared with potential scenarios. These aspects include separate 
lead times, stock rotation, obsolete stock, and emergency orders. Where accurate 
historical data were unavailable, certain assumptions were made to implement the new 
aspects in the model.  
6.3.5.1 Model B: Stock and flow diagram 
The complete stock and flow diagram for Model B consists of two parts, namely (i) the 
main model, and (ii) the costs section. Both of these are illustrated in Figure 6.21 and 
Figure 6.22, respectively. As depicted in Figure 6.21, the main model is larger and more 
complex than Model A. As discussed, this additional complexity is required to enable a 
comparison of the performance of the stock pile in its current mode of operation with 
that of the stockpile under various alternative supply chain management approaches. 
Orders Ready for 
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Stellenbosch University  https://scholar.sun.ac.za
Page | 114 Chapter 6: Dynamic model development 
Department of Industrial Engineering 
Large sections of this model are based on assumptions due to the lack of historical 
data.  
Figure 6.21: Stock and flow diagram of the main section of Model B. 
Figure 6.22: Stock and flow diagram of the cost section of Model B. 
6.3.5.2 Model B: Characteristics and equations of elements 
This section will summarise some of the challenging aspects of the modelling process 
of Model B. The complete modelling details for Model B, such as the list of variables 
that were used and the details and equations of each element, are provided in 
Appendix E, Section E.3.  
The only information on the lead times that could be derived from the sources 
mentioned in Section 6.3.4 is the minimum, maximum and average waiting time for the 
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processes. Therefore, a triangular distribution was used to generate input values for the 
lead time. Additional minimum and maximum constraints were added to control the 
range of the output. Through a process of trial and error, these maximum and minimum 
values, as well as the parameters of the triangular distribution were adjusted until the 
summation of the separate lead times accurately represented the lead times in the 
historical data. More details are provided in the validation in Section 6.4 as well as in 
Appendix E, Section E.3.2.1. 
Since the age of every individual unit cannot be tracked with system dynamics, the shelf 
life of the drugs is when they reach the stockpile from manufacturers is unknown in the 
model. However, with the use of a discrete queue function, the age of the drugs can be 
tracked once they are in the stockpile. The function also ensures that the stockpile 
functions on a first in, first out basis, meaning that the ‘oldest’ drugs are utilised first. This 
function is used to determine when drugs are considered obsolete and when drugs 
become eligible for rotation. It is assumed that when the drugs arrive at the stockpile 
they have a remaining shelf life of 22 months for capreomycin and cyclosorine and 34 
months for kanamycin. Equations were applied to variables to ensure the following 
stockpile ‘rules’ with regard to emergency orders and stock rotation orders are 
implemented in the model: 
• For capreomycin and cyloserine – if a drug has been in the stockpile for 4 months,
it becomes eligible for stock rotation. However, to ensure that drugs have at least
10 months of shelf life remaining when reaching a country (as part of stock rotation),
any drugs that have been in the stockpile for 9 months or longer, are no longer
eligible for stock rotation. All of the drugs in the stockpile are eligible for emergency
orders at all times, but a drug is considered obsolete after it has been in the stockpile
for 13 months or longer. This is to ensure that the drugs dispatched as an emergency
order, will have at least 6 months of shelf life remaining when it reaches the country.
• For kanamycin – if a drug has been in the stockpile for 10 months, it becomes eligible
for stock rotation. However, to ensure that drugs have at least 10 months of shelf life
remaining when reaching a country (as part of stock rotation), any drugs that have
been in the stockpile for 21 months or longer, are no longer eligible for stock rotation.
All of the drugs in the stockpile are eligible for emergency orders at all times, but a
drug is considered obsolete after it has been in the stockpile for 25 months or longer.
This is to ensure that the drugs dispatched as an emergency order, will have at least
6 months of shelf life remaining when it reaches the country.
To calculate the initial stock on hand, it was assumed that there are enough drugs for 
5800 treatments and that the treatments entail several regimens (UNITAID, 2016b). The 
data from the PQR database was used to analyse each of the different SLD groups 
(refer to Table 2.1) in order to determine what proportion the formulations included in 
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the model represent in each group. It was found that 18.32% and 15.33% of all the Group 
2 drugs, were for capreomycin and kanamycin, respectively, while 34% of the Group 4 
drugs were for cycloserine. This would mean that of the 5800 available treatment 
courses for group 2, there are 1063 (18.32%) courses using capreomycin and 889 
(15.33%) courses using kanamycin. Similarly, of the 5800 available treatment courses 
for Group 4, there are 1972 (34%) courses that includes the use of cycloserine. The 
average number of units that a patient will use for each of the formulations during a 
treatment course is 208 for capreomycin and kanamycin and 1560 for cycloserine 
(Lunte, 2012). Thus, it can be assumed that the stock on hand (in units) for the 
formulations is: 
• 221 018 units of capreomycin (1063 x 208)
• 184 984 units of kanamycin (889 x 208)
• 3 076 643 units of cycloserine (1972 x 1560)
6.3.5.3 Model B: Assumptions 
All of the assumptions for Model A, also apply to Model B. This subsection provides a 
summary of the new assumptions that were made with regard to the entities in Model 
B.  
Assumptions about Manufacturers: 
It is assumed that 
• the manufacturer is one entity that fulfils both orders to replenish the stockpile and
orders placed on behalf of countries. To enable the separate analysis of the orders
placed on behalf of countries and the orders placed to replenish the stockpile, these
are modelled as two separate processes.
Assumptions about Orders: 
It is assumed that: 
• emergency orders receive preference over orders for stock rotation.
• if an emergency order cannot be delivered in full, the stockpile will dispatch all of
the available stock to the country, but the ‘outstanding’ drugs will not be put on
backorder. Instead, it is assumed that the country will make other arrangements and
the order is considered lost.
• for stock rotation, normal orders will only be dispatched via the SRS if the entire
order can be fulfilled with the available stock.
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Assumptions about the GDF and Stockpile: 
It is assumed that: 
• a base stock policy is currently applied at the SRS. An assumption is necessary as
no information on the current operational policies of the SRS is available. Based on
a base stock policy, it is assumed that if drugs are dispatched or removed from the
stockpile (due to emergency orders, stock rotation or obsolescence), an order of
identical size is placed to the manufacturers.
Assumptions about Costs 
It is assumed that: 
• the obsolescence costs are equal to the procurement cost (Li, Lim and Rodrigues,
2009). 
Assumptions about Lead Times 
It is assumed that: 
• the lead time components, namely (i) order processing lead time, (ii) production and
dispatch lead time, and (iii) country dispatch lead time, are the same for all three
formulations.
6.3.6 Model C 
Model B has been developed to represent the current system at a sufficient level of 
detail to allow for the evaluation of its performance. However, to quantify the impact of 
a buffer inventory as described in Section 5.7 the model will have to be adapted. 
Therefore, a new model (Model C) was developed by making adjustments to Model B 
to simulate the potential performance of a larger stockpile that is used to fulfil all of the 
demand from countries, instead of being used solely to fulfil emergency orders. 
Different inventory management policies can be applied to the model in order to 
determine which policy or policies are more effectively able to satisfy the demand and 
consolidate and time the orders for stockpile replenishment to smooth the demand to 
manufactures.  
6.3.6.1 Model C: Stock and flow diagram 
The complete stock and flow diagram for Model C also consists of two parts, namely (i) 
the main model, and (ii) the costs section. Both of these are illustrated in Figure 6.23 
and Figure 6.24, respectively.  
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Figure 6.23: Stock and flow diagram of the main section of Model C. 
Figure 6.24: Stock and flow diagram of the cost section of Model C. 
6.3.6.2 Model C: Characteristics and equations of elements 
The complete modelling details for Model C, such as the list of variables that were used 
and the details and equations of each element, are provided in Appendix E, Section E.4. 
This section will highlight some of the aspects that proved challenging during the 
building process of Model C.  
The biggest differences between Models B and C are: 
• In Model C, all of the orders are fulfilled by the stockpile,
• emergency orders and stock rotation have been removed in Model C,
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• backorders have been added in Model C, and
• in Model C, the SRS no longer follows a base stock policy. Instead, different
inventory policies are experimented with.
Since all of the orders are fulfilled by the stockpile, it is assumed that there will no longer 
be emergency orders and stock rotation orders will longer be necessary. In Model B, 
when a country places a normal order, the GDF places an order of the exact size to 
manufacturers on behalf of the countries. Since all of the normal demand is always 
completely fulfilled, there are no backorders. Emergency orders, on the other hand, are 
fulfilled through the stockpile. If the order cannot be fulfilled by the stock-on-hand, it is 
not put on backorder, since an emergency situation requires that the drugs be delivered 
as soon as possible. It is assumed that if an emergency order cannot be fulfilled 
immediately through the stockpile, the country will make other arrangements and the 
order is considered lost (SDL supply chain SME, Personal communication, 16 February 
2016). In Model C, on the other hand, all of the orders go through the stockpile and 
backlogs are now included for orders that cannot be fulfilled immediately.  
System dynamics cannot track the individual orders that are added to the backlog 
separately, but instead pools these together. However, to overcome this modelling 
limitation, the backlogs are implemented as follows:  
• The discrete queue function is used to track the age of incoming orders,
• a variable, ‘backlog range one’, is added to track the oldest backlogged units in the
queue, and
• a second variable, ‘backlog range two’, is added to track the group of backlogged.
units that are half the age of the oldest backlogged units,
This enables the model to keep track of two groups of units that have been backlogged 
the longest and second longest, respectively. This method was confirmed by a Vensim 
super administrator to be a suitable representation of backlogs for a system dynamics 
model. For a more accurate implementation of backlogged order tracking, a discrete-
event simulation should be used instead. 
6.3.6.3 Model C: Assumptions 
Not all of the assumptions for Model A and B apply to Model C. Therefore, for the sake 
of completeness, the applicable assumptions of previous models and the new 
assumptions that were made with regard to the entities in Model C will be summarised 
below.  
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Assumptions about Manufacturers: 
It is assumed that: 
• the manufacturers have no additional orders other than that of the GDF and their
PA. In reality, they may have orders waiting from other companies (that are not
reported in the PQR database used for this research) which would cause additional
delays in the supply chain.
• second-line anti-TB drugs are not kept in stock by any of the drug manufacturers.
Thus it is assumed that once production is completed, manufacturers immediately
dispatch the drugs to the GDF and their PA’s DC.
Assumptions about Orders: 
It is assumed that 
• there will be no emergency orders, since the lead time between placing an order
and receiving an order is reduced. The time that a country will have to wait now
consists only of the order processing time and the dispatch time from the stockpile.
• all of the country demand is being fulfilled by the stockpile. Thus it is assumed that
stock rotation will no longer be implemented to fulfil some of the normal orders.
• backlogged orders will receive preference over new incoming orders.
• if there is not sufficient stock to fulfil the backlogged order(s), but there is sufficient
stock for the incoming order, the incoming order will be fulfilled.
Assumptions about Countries: 
It is assumed that: 
• no delays or other problems related to patent registrations or restrictions can delay
an order. This is assumption is viewed as reasonable since countries requesting
drugs are responsible for ensuring that the drugs comply with the country's
legislation on patent registration or restrictions.
• countries place an order to cover drug needs and include a buffer stock in their
procurement order (to cover drug consumption for the whole expected delivery
time).
Assumptions about the GDF, Distribution Centre and Stockpile: 
It is assumed that: 
• drugs are dispatched from the stockpile based on a first-in-first-out basis.
• Since the stockpile does not currently function like depicted in Model C, different
operational policies will be experimented with.
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Assumptions about Costs 
It is assumed that: 
• the obsolescence costs are equal to the procurement cost (Li, Lim and Rodrigues,
2009). 
Assumptions about Lead Times 
It is assumed that: 
• the lead time components, namely (i) order processing lead time, (ii) production and
dispatch lead time, and (iii) country dispatch lead time, are the same for all three
formulations.
6.4 Testing and validating the models 
The aim of testing and validating the model, is to ensure that the model is accurate with 
regard to the purpose of the model. To assess the accuracy of the model, some of the 
most significant validation tests, as summarised by Sterman (2003), are applied. The 
eight tests that are applied are: (i) CLD Validity, (ii) parameter assessment, (iii) 
dimensional consistency, (iv) boundary adequacy, (v) structure assessment, (vi) 
behavioural reproduction, (vii) extreme conditions, and (viii) sensitivity analysis.  
Additionally, a System Dynamics Modelling (SDM) document is provided, for each of the 
three models, in Appendix I. The SDM document provides a summary of each variable 
and equation and can therefore be used to understand the models, as well as to 
reproduce and expand the models.   
6.4.1 CLD validity 
The first validity test entails evaluating the CLD, since it is the first diagram to be 
constructed and is used as a baseline to construct the stock and flow diagrams. The 
constructed CLD is considered valid if it accurately represents the real-life system and 
can be used to support the execution of the aim and objectives. As previously 
mentioned, the key aim of this study is to evaluate the performance of the upstream 
segment of the supply chain and to measure the impact of certain changes to 
operational policies on this performance. The CLDs includes all the necessary 
parameters of the supply chain as well as the links and relationships between them, 
required to carry out the aim and objectives. 
6.4.2 Parameter assessment 
Parameter assessment refers to whether the values that are assigned to the 
parameters, both constants and variables, are consistent with the applicable data and 
information of the system. To ensure better results, there are two recommended 
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approaches to estimate the parameter values Sterman (2003), namely (i) statistical 
methods using numerical data; or, in cases where no data is available, (ii) judgment 
gained from literature, experience, interviews, etc. Both of these approaches can be 
used collectively by initially estimating a credible range based on knowledge of the 
system (judgemental) followed by statistical estimation to confirm the estimated range. 
As illustrated throughout the modelling details of Model A, B and C in Appendix E, 
statistical methods were applied to the available historical data to assign values to 
constants, such as the shelf life, and estimate values for variables, such as the demand. 
Due to the lack of data, not all of the values could be determined through statistical 
estimation. The majority of the parameter values in Models B and C were estimated 
from what was gleaned from literature or derived from the available data. Possible 
correlations between different parameters were investigated and it was concluded that 
no correlations exist (Section 6.2.2.3). Despite these tests, however, it is possible that 
there are other unknown parameters (for example, the weather) that have an influence 
on the correlations, but that have been inadvertently omitted from the model. This is a 
typical limitation of a correlation analysis.  
6.4.3 Dimensional consistency 
Dimensional consistency entails the investigation of the links and relationships between 
the variables in the model by identifying their primary dimensions (for example, time) 
and their units of measure (for example, days or weeks) and tracing these dimensions 
as equations are constructed throughout the model.  
To ensure dimensional consistency, each of the variables and equations in the models 
are subjected to Vensim’s ‘unit-check’ function, that confirms whether the units on the 
equation’s right-hand side are consistent with the units on the left-hand side. Vensim 
indicated no errors regarding the dimensions and units of both Model A and B. 
Furthermore, each equation was analysed separately to identify any factors that could 
discredit the dimensional consistency. 
6.4.4 Boundary adequacy 
Boundary adequacy involves the assessment of the model boundaries and whether 
these are suitable for the purpose of the study. The model boundaries were discussed 
in Section 6.1.2.1 and illustrated in Figure 6.2. To assess the adequacy of the boundaries, 
some of the feedbacks that were omitted from the models were investigated to assess 
the potential impact these could have on the model. Since there are several omitted 
feedbacks, only those that could be significant to the aim of the model were 
investigated.  
Some of the upstream stages such as raw material sourcing, starting material 
manufacturing and API manufacturing were omitted due to a lack of data. Including 
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these stages in the models could perhaps alter the dynamics of the models. For 
example, since the finished product manufacturers for SLDs are typically order-driven, 
they only order the APIs once an order for drugs has been received. The API 
manufacturers therefore have a direct impact on how long a country has to wait for an 
order to be fulfilled. Therefore, if the omitted upstream stages were represented 
separately in the model, the different lead times of each stage could provide a more 
dynamic and realistic model. Nonetheless, the lead times used in the models, represent 
the total time between placing an order and receiving an order, and include the delay 
caused by API manufacturers. Therefore, although the individual stages are not 
represented in the models through stocks, flows and variables, they are incorporated 
to some extent through the lead time of the finished product manufacturers.   
Furthermore, there are various concepts related to the manufacturers and 
manufacturing process that were omitted, such as batch sizes, manufacturing capacity, 
economic order size, etc. Feedback loops associated with these concepts could impact 
the dynamics of the models. However, as discussed in Section 6.1.2.2, the lack of data 
on manufacturers prevents the inclusion of these details in the model.   
6.4.5 Structure assessment 
Structure assessment refers to whether the model corresponds with the knowledge of 
the real-world system, relevant to the aim of the model. This includes aspects such as 
the model conformance to physical realities such as the conservation of flows, the 
accumulation and decrease of stocks, and the practicality of decision rules.  
A thorough investigation of the stocks and flows confirms that all of the model inputs 
are balanced with outputs. All of the demand from countries integrated into the models 
are accounted for by being fulfilled by manufacturers or the stockpile. Applicable 
variables, for example stock and costs, were monitored to ensure that they remain 
positive throughout the simulation, and that the outflows from all stocks approach zero 
as the stock approaches zero. The number of drugs received by countries is no more 
than the amount ordered. The number of drugs produced by the manufacturers is no 
more than what was ordered and the number of drugs dispatched from the stockpile is 
no more than what was required.  
6.4.6 Behaviour reproduction 
The goal of behaviour reproduction is to identify errors and flaws in the model and to 
determine whether they will affect the aim of the model. It is important to note that all 
models are simplified representations of the real-world system and therefore differ from 
the real-world system in several ways. Since the SLD supply chain is exceptionally 
dynamic, the models will not be able to reproduce the behaviour of the real system with 
100% accuracy. To determine whether the models behave similarly to the real-world 
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system, the following aspects were analysed: (i) Demand; (ii) Number of orders placed 
per week; (iii) Lead time; and (iv) Costs 
6.4.6.1 Demand 
Sterman (2003) and Robinson (1997) state that the most common methods to assess the 
behaviour reproduction are to compare the descriptive statistics of historical data and 
the model data, as well as to visually compare the distribution of the data sets. The 
comparisons for each formulation are provided in Appendix F, Section F.1. In addition to 
the comparisons, a Mann-Whitney U test was performed, for each of the formulations, 
to determine whether there are statistically significant differences between the historical 
and modelled data sets. From the test results it can be concluded that all differences 
are too small to be statistically significant and that the modelled data accurately 
represents the historical data.  
6.4.6.2 Number of orders placed per week 
The number of orders placed per week (for the weeks where an order was in fact 
placed) during the five-year simulation was compared to the historical data. The results 
are summarised in Table 6.6.  
The results show that the number of orders placed per week in the simulation, are very 
similar to the historical data.   
Table 6.6: Number of orders placed per week for model output and historical data. 
Number of 
Orders placed 
Probability from 
Data 
Probability from 
Model Output 
C
a
p
re
o
m
y
ci
n
 1 order 0.5736 0.5736 
2 orders 0.2226 0.2151 
3 orders 0.0566 0.0943 
4 orders 0.0151 0.0377 
K
a
n
a
m
y
ci
n
 
1 order 0.4189 0.4491 
2 orders 0.0792 0.0792 
3 orders 0.0226 0.0264 
4 orders 0.0113 0.0075 
C
y
cl
o
se
ri
n
e
 1 order 0.7210 0.7472 
2 orders 0.3360 0.3962 
3 orders 0.1510 0.1358 
4 orders 0.0450 0.0528 
6.4.6.3 Lead time 
As previously mentioned, there are several limitations associated with the modelling of 
the lead time. Since the lead time in Model B and C is separated into three parts, there 
is no historical data available to compare the modelled data with. Therefore, there is 
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no accurate way to assess whether it replicates the behaviour of the real system. 
Although the separate lead times cannot be analysed, the summation of the separate 
lead times could be compared with the historical data to demonstrate whether the total 
lead time replicates the real-world behaviour.  
Another limitation of the lead time is that there are several outliers in the historical data 
that are not present in the models. This is evident in the comparison of the descriptive 
statistics for the historical data and modelled data, as summarised in Table 6.7. As can 
be derived from the table, the outliers lead to a large difference between the maximum 
and minimum values. When disregarding the outliers, the modelled data represents the 
historical data more accurately, as depicted in the last columns of the table. This is also 
visually illustrated in Figure 6.25. 
Table 6.7: Total lead time for model output and historical data. 
Statistic 
Model 
Output 
Hist. 
Data 
% Diff 
Hist. Data 
(No outliers) 
% Diff 
Mean  40.21  36.24 10.97% 39.93 -0.69% 
Standard Error  0.56  0.69 -18.36% 0.57 2.14% 
Median  36.43  32.29 12.84% 36.14 -0.79% 
Standard Deviation  14.89  21.19 -29.73% 15.21 2.14% 
Minimum  12.85  8.14 57.82% 13.43 4.51% 
Maximum  81.22  159.00 -48.92% 82.14 1.13% 
Sum  28 149.44  34 245.29 -17.80% 27954.43 -0.69% 
Figure 6.25: Graph comparing the lead time of model output and historical data. 
6.4.6.4 Costs 
Cycloserine has the highest costs with 57% of the total expenses, while kanamycin has 
the least with 14% of the total expenses. The ratio of the costs for the formulations is 
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illustrated in Figure 6.26. This is similar to that of the real-world procurement values in 
2012 and 2013, as discussed in Section 6.1.2.3. 
Figure 6.26: Comparison of the distribution of real-wold costs and base case costs. 
6.4.6.5 Plausibility 
The models behave as they expected to and exhibit the same difficult behaviour as the 
real-world system, including long lead times and demand that occurs in irregular 
amounts and at unpredictable time intervals.  
6.4.7 Extreme conditions 
To assess whether the models and their equations respond as expected, extreme 
values were assigned to some of the parameters. A sudden increase and sudden 
decrease of both the demand and lead times were implemented both separately and 
in combination, while monitoring the behaviour of the models. The models behaved as 
expected, for example a sudden decrease in the emergency order demand caused the 
stockpile to deplete faster while a decrease in overall demand caused high levels of 
obsolete stock. Furthermore, the test confirms that the reinforcing and balancing loops 
works as they should, since the model returned to base conditions after the shock of 
sudden increases or decreases in parameters.  
6.4.8 Sensitivity analysis 
A sensitivity analysis is conducted to identify the most sensitive parameters. If a 
parameter is found to be particularly sensitive, the maximum feasible effort is put into 
ensuring its accurate estimation. Additionally, parameters to which they are particularly 
sensitive should be highlighted during the reporting of results. Only the most important 
parameters, namely the demand and the lead time will be assessed. The parameters 
will be adjusted by approximately 10% to measure the impact that such small changes 
will have on the system. The results of the sensitivity analysis for Model B, capreomycin 
are summarised in Table 6.8, while the full set of results for all models and formulations 
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can be found in Appendix F, Section F.2. For each of the adjusted cases (increase or 
decrease in demand and lead time), the following values over the five-year simulation 
are compared with the base case values: 
i. the total obsolete stock,
ii. the total number of drugs received from manufacturers for normal orders,
iii. the total number of drugs delivered stock rotation orders received,
iv. the total number of drugs delivered for emergency orders, and
v. the stock on hand at the end of the simulation period.
For the base case, a base stock policy is assumed. (I.e. it is assumed that if drugs are 
removed from the SRS due to obsolescence, stock rotation or emergency orders, an 
order of the same size is placed to the manufacturers to replenish the inventory to the 
desired level.) The percentage that the value differ from the base case is given in 
brackets below each value. 
Table 6.8: Sensitivity analysis results for Model B, capreomycin. 
Capreomycin 
(Model B) 
Total 
obsolete 
stock 
Total drugs 
received from 
manufacturers 
Total drugs 
received 
from SRS 
Total emergency 
order drugs 
delivered 
Total 
stock on 
hand 
Base Case 0 6 603 560 1 295 330 406 100 88 510 
Increase 
demand 
0 (0%) 7 032 000 (6%) 
1 222 000 
(-6%) 
432 800 
(7%) 
95 200 
(8%) 
Decrease 
demand 
0 (0%) 6 781 000 (3%) 
1 304 000 
(1%) 
395 000 
(-3%) 
96 300 
(9%) 
Increase 
lead times 
0 (0%) 6 734 000 (2%) 
1 213 000 
(-6%) 
388 600 
(-4%) 
97 400 
(10%) 
Decrease 
lead times 
0 (0%) 6 665 000 (1%) 
1 306 000 
(1%) 
401 300 
(-1%) 
87 880 
(-1%) 
As depicted in table, an increase in the demand and lead time has the most significant 
effect on the variables. Furthermore, the variable that is affected the most by the 
changes, is the stock on hand. These findings apply to all three formulations and all the 
models.  
6.5 Identifying and implementing scenarios 
Model B will be evaluated to quantify the performance of the current system, while 
scenario modelling will be applied to Model C. The goal of the scenario modelling is to 
determine what policies should be implemented to allow the prevention of stock-outs 
at countries and to combine and time orders to decrease order variability to 
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manufactures. The scenarios will consist of various inventory policies that will be 
applied to the model  
The identified scenarios, as well as the implementation and results will be described in 
more detail in Chapter 7.  
6.6 Conclusion: Dynamic model development 
The chapter provided a description of the modelling process that was followed to build 
three models. The problem and its boundaries were defined, followed by an analysis 
of the data to provide a better understanding of the system. After CLDs were developed, 
the stock and flow diagrams, assumptions and important characteristics of each of the 
three models were presented. The models were validated by performing various 
validation tests. Finally, the reasoning behind the scenario testing to be implemented 
using Model C was briefly discussed.  
The next chapter will provide a more detailed description of the scenarios that will be 
implemented and the measures and metrics that will be used to evaluate the 
performance. The analysis methodology and results are also presented, followed by a 
discussion of the general research findings.  
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Analysis and results 
"We call things we don’t understand complex, but that means we haven’t found a good way of 
thinking about them." 
- Tsutomu Shimomura (Scientist and computer security expert) 
The previous chapter included a discussion of the modelling process that was followed 
to build the system dynamics simulation models. This chapter will present the analysis 
and results of the current system (the base case) as well as several alternative stockpile 
scenarios. The evaluation criteria that will be used to measure performance is 
described, followed by the evaluation of the base case. After a summary of the 
scenarios to be analysed, the results of the scenario modelling are discussed and 
general findings concluded from the results are provided.  
7.1 Evaluation criteria 
Evaluation criteria are used to determine to what extent alternative scenarios or 
solutions meet the required standards or objectives by comparing their trade-offs, 
strengths and weaknesses (Maani and Cavana, 2012). The evaluation criteria comprise 
of a set of performance measures and metrics that will be used to communicate the 
results of the scenario modelling and the insights that stem from this. 
As discussed in Section 6.1.1, one of the main objectives of the modelling is to assess 
the impact that changes to the operational policies will have on the availability of stock 
for countries and the variability of the demand to the manufacturers. Therefore, the first 
two performance measures are stock performance and order variability performance. 
Furthermore, since cost is an important aspect in any supply chain, a third performance 
measure is also added to measure the impact on costs. 
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7.1.1 Stock performance 
A significant aspect of stock performance, applicable to this study, is how well the stock 
is being used to satisfy customer demand. To evaluate this, the fraction of the total 
demand that was not fulfilled immediately will be measured. The metrics for stock 
performance will therefore include: 
i. the fraction of orders that were backlogged;
ii. the total volume of orders that were backlogged; and
iii. the average and maximum time duration that an order is backlogged for.
7.1.2 Order variability performance 
The order variability performance metrics will be used to evaluate whether the 
scenarios will benefit the manufacturers in terms of decreasing order variability. Two 
metrics will be utilised: 
i. the standard deviation of the order size for each individual order (σ); and
ii. the standard deviation of the volume of orders placed per month (𝜎23).
It is beneficial to manufacturers if both these deviations are low. For example, individual 
order sizes that are the same size, will not benefit the manufacturer if they are placed 
at irregular time intervals.  
7.1.3 Cost performance 
The MDR-TB SLD supply chain is predominantly a donor-funded supply chain where 
funding is used to benefit populations and patients in need. The more funds that are 
available, the more people can benefit from treatment. Therefore, cost performance is 
an important part of the evaluation criteria. There are several aspects contributing to 
costs, including holding costs, logistical costs, shortage costs, procurement costs and 
obsolescence costs. These are discussed in the following subsections. 
7.1.3.1 Holding costs 
In the base case, the stockpile receives funding to be kept at the same level, which 
causes the holding costs (𝐶:) to remain constant. Therefore, the holding costs are seen
as a fixed cost and typically does not play an important role when measuring the cost 
performance of the current stockpile (SDL supply chain SME, Personal communication, 
16 February 2016).  
For the implementation of a large buffer inventory, however, holding costs will be taken 
into consideration. The holding costs will be calculated on a monthly basis and will be 
assumed to be 25% of the value of the average inventory on hand in that month (Hou, 
2013; Vermorel, 2013). 
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7.1.3.2 Logistical costs 
Although logistical costs are an important factor, these cannot be included in the model 
since the countries are grouped into a single entity, as discussed in Section 6.3.2. The 
individual locations of the countries and their distance from the stockpile are not taken 
into account, making the inclusion of logistical costs infeasible. This restriction is not 
considered to pose a significant limitation on the usefulness of the modelling results as 
it is unlikely that the various inventory management policies that are being evaluated 
will have a significant impact on these logistical costs. 
7.1.3.3 Shortage costs 
Although stock-outs can occur at the stockpile, the GDF assumes that the country 
should prepare for this probability and therefore have their own safety stock. Therefore, 
there are no shortage costs or backorder costs (SDL supply chain SME, Personal 
communication, 16 February 2016). 
7.1.3.4 Procurement costs 
The procurement costs (𝐶) are, as the name implies, the costs related to the purchasing
of the drugs from manufacturers. In Model B, the procurement costs will comprise of the 
costs of drugs purchased for normal orders placed by the GDF on behalf of countries 
and for orders placed to replenish the stockpile. In Model C, all orders go through the 
SRS and the only procurement cost will be for the orders made to replenish the 
stockpile. 
7.1.3.5 Obsolescence costs 
Obsolescence costs (𝐶;), are the cost of stock that is ‘lost’ due to the shelf life being
exceeded. An excessively large stockpile will be able to fulfil all orders at any time, but 
is likely to lead to high levels of excess stock that will become obsolete. It is therefore 
important to consider obsolescence costs.  
7.1.3.6 Total costs 
In summary, the only costs to be included are the procurement costs, holding costs and 
obsolescence costs. The total cost is therefore given by:  𝐶0 = 𝐶< + 𝐶: + 𝐶;
7.2 Performance of base case 
Before any scenarios can be implemented and analysed, the performance of the base 
case (Model B) will be analysed. The stock performance, order variability performance 
and cost performance will be discussed separately. For ease of reference, the results 
of the base case will be repeated in each of the tables that summarise the results of 
different scenarios.  
(7.1) 
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7.2.1 Stock performance 
As previously mentioned, there are no backorders in Model B; therefore, the fraction of 
orders that were backlogged as well as the average and maximum time that an order 
is backlogged cannot be measured. Instead, the amount of emergency orders that were 
not fulfilled in full will be considered. During the five-year simulation, all of the 
emergency orders for kanamycin and cycloserine were 100% fulfilled. For capreomycin 
there was only one emergency order which could not be fulfilled completely, however, 
51% of that order quantity was dispatched.  
7.2.2 Order variability performance 
In the base case model, there are two types of orders that are placed to manufacturers, 
namely normal orders placed by the GDF on behalf of countries and orders placed to 
replenish the stockpile. The order variability performance metrics for both order types, 
as well as for the total orders placed to manufacturers are provided in Table 7.1.  
Table 7.1: Order variability performance of base case. 
Capreomycin Kanamycin Cycloserine 
𝜎34 Normal Orders 58 647 87 424 958 925 Stockpile Orders 11 916 7 412 173 176 
All Orders 59 466 88 219 976 715 
𝜎23 Normal Orders 129 050 172 988 1 780 729 Stockpile Orders 23 389 13 287 362 617 
All Orders 132 118 173 929 1 865 129 
Both the standard deviation of the order size for each individual order (𝜎34) and the
standard deviation of the volume of orders placed per month (𝜎23) are exceptionally
high. The reason for the high variation in order sizes, is ascribed to the fact that orders 
are placed from different countries, each with different demand. For example, a high-
burden country with a large population will undoubtedly place a larger order than a 
low-burden country with a small population. The high value of the standard deviation 
of the volume of orders placed per month (𝜎23 ) indicates that, regardless of the
separate order types, the total order quantities per month vary considerably. This is 
also clear from the graphical illustration, in Figure 7.1 to Figure 7.3, of the total quantity 
of each drug ordered per month.  
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Figure 7.1: Base case order variability of capreomycin. 
Figure 7.2: Base case order variability of kanamycin. 
Figure 7.3: Base case order variability of cycloserine. 
7.2.3 Cost performance 
For the base case, the procurement costs consist of the cost to manufacture drugs for 
normal orders, which are not fulfilled through stock rotation, as well as the cost to 
replenish the stockpile due to the outgoing orders for emergencies and stock rotation. 
In order to compare the total cost of the scenarios with the total cost of the base case, 
a holding cost for the base case will be calculated based on the assumption that the 
holding cost remain constant, as discussed in Section 7.1.3.1. All of the costs are provided 
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in Table 7.2. As shown in the table, there are no obsolescence costs with the base case, 
as all of the stock were rotated well before they reached their expiration date.  
Table 7.2: Cost performance of base case during a five-year simulation. 
Capreomycin Kanamycin Cycloserine 
Emergency Order Costs $2 332 182 $389 984 $4 277 763 
Stockpile Rotation Costs $5 782 832 $1 349 844 $7 273 228 
Normal Order Costs $35 026 266 $19 266 897 $73 649 431 
Obsolescence Costs $0.00 $0.00 $0.00 
Holding Costs $18 764 428 $7 186 628 $25 382 280 
Total Costs $61 905 708 $28 193 353 $110 582 702 
7.3 Scenario planning and modelling 
Scenario planning can be seen as the process of visualising what future conditions are 
possible and what the consequences of these conditions will be. This section provides 
a description of the scenarios that are formulated and evaluated. The scenarios will 
consist of various inventory policies that will be applied to Model C, in order to 
determine the likely impact of each policy on the variability of the demand to the 
suppliers and the availability of stock for countries. 
7.3.1 Inventory policies 
In a typical commercial supply chain, an organisation wants to satisfy customer demand 
in the shortest possible time. When an order is placed by the organisation to the 
manufacturers, there is a time delay (lead time) between placing the order and receiving 
the goods that were ordered. For an organisation to be able to satisfy incoming demand 
during this lead time, on-hand inventory is required.  
An inventory policy is a set of boundaries and guidelines that serve as a framework 
when making decisions regarding inventory and inventory management, such as when 
to order, how regularly to order, how much to order, the level of safety stock, etc. Two 
factors that have a large influence on the amount of inventory that is required, are lead 
time variability and demand variability. The greater the variability, the greater the 
amount of inventory required.  
As previously mentioned, the MDR-TB SLD supply chain experiences high variability in 
terms of both demand and lead time. Therefore, different inventory policies will be 
applied and evaluated to determine how they perform based on the evaluation criteria 
discussed in Section 7.1. The remainder of this section will discuss the concepts 
associated with inventory policies, namely (i) the reorder point, 𝑠; (ii) the order-up-to-
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level, 𝑆; (iii) the reorder frequency, 𝑅; and (iv) the reorder quantity, 𝑄. A summary of the 
alternative values for each concept will be provided at the end of the section. The 
inventory policy scenarios will be applied to Model C, where the SRS is used to fulfil all 
of the orders for SLDs. Each of the policies’ performance will evaluated individually, 
compared with each other and compared with the base case. The scenarios will consist 
of the following inventory policies: 
• (𝑠, 𝑆) policy;
• (𝑅, 𝑆) policy;
• (𝑅, 𝑠, 𝑆) policy;
• (𝑠, 𝑄) policy; and
• (𝑅, 𝑠, 𝑄) policy.
7.3.1.1 Reorder point 
The reorder point is the stock level at which a new order should be placed to the 
manufacturer to replenish the stock. The equation for calculating the reorder point (𝑠) is 
(Jacobs and Chase, 2014):  𝑠 = 	 𝜇.	×	𝜇/0 + 𝑆𝑆	,
where 𝜇. is the average demand, 𝜇/0 the average lead time, and 𝑆𝑆 the safety stock.
Safety stock is a level of extra stock that is held to mitigate the risk of stock-outs caused 
by factors such as unpredictable demand, inaccurate forecasting and inconsistent lead 
times. There are several methods to determine the required level of safety stock, each 
with its own benefits and drawbacks. It can be determined from time-based calculations 
(such as the percentage growth in demand over a time period) or from statistical and 
mathematical calculations using the theory of probability. It can also be set at a fixed 
level based purely on managerial judgment, usually informed by forecasted stock 
levels.  
For the purpose of this study, four alternatives for safety stock will be evaluated. The 
first three alternatives will be a fixed value based on the very basic safety stock 
equation shown in (7.3) (Jacobs and Chase, 2014). In this method, a safety factor (𝑆𝐹) is 
added to the average demand to cope with the variations of the manufacturer lead time 
and country demand. A typical safety factor is 1.5; however, with the high variations in 
this study, a larger safety factor is required. Consequently, a safety factor of 3, 4.5 and 
6 will be evaluated.   𝑆𝑆 = 𝜇.	×	𝑆𝐹
The fourth alternative will be based on a desired service level and the fact that the 
consumption and lead time pattern both have large fluctuations. The equation is given 
as (King, 2011):  
(7.2) 
(7.3) 
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𝑆𝑆 = 𝑧 𝜇. +	𝜎/ ^ + 𝜇/0 +	𝜎.^  ,
where 𝑧  is the safety stock coverage factor based on the service level, 𝜎/	 is the
standard deviation of the lead time and 𝜎. the standard deviation of the demand. Since
the stockpile aims to never have a stock-out, a service level of 100% is desired. The 
value of 𝑧 for a service level of 99.99% is 3.72. 
7.3.1.2 Order-up-to-level (reorder maximum) 
The order-up-to-level (𝑆) is the maximum inventory position that is allowed and can be 
seen as the target level of stock to have on hand. The inventory position is dependent 
on the inventory on hand, backlogs and the inventory on order, which is defined as the 
total drugs that have been ordered from manufacturers, but not yet received. The 
formula for inventory position (𝐼𝑃) is given as (Caplice, 2016a):  𝐼𝑃 = 𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦	𝑂𝑛	𝑂𝑟𝑑𝑒𝑟 + 𝐼𝑛𝑣𝑒𝑛𝑡𝑜𝑟𝑦	𝑂𝑛	𝐻𝑎𝑛𝑑 − 𝐵𝑎𝑐𝑘𝑙𝑜𝑔𝑠 
The order-up-to-level and inventory position determines how much should be ordered 
from the manufacturer. The formula for the order quantity is (Caplice, 2016a):  𝑂𝑟𝑑𝑒𝑟	𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦 = 	𝑆 − 	𝐼𝑃 
The order-up-to-level is typically calculated by multiplying the average demand and 
average lead time and adding some safety amount. For the purpose of this study, two 
alternatives for the order-up-to-level will be evaluated. The first alternative is based on 
a basic formula for the order-up-to-level, given by (Jacobs and Chase, 2014):  𝑆 = 𝜇.	×	𝜇/0 	×	𝑆𝐹
In this formula the product of the average demand and average lead time is multiplied 
with a safety factor. For this study, a safety factor of 2.5 is chosen, based on the high 
variability of the demand and lead time. The second alternative to calculate the order-
up-to-level, is based on a desired service level, similar to (7.4) for safety stock. The 
formula is (Jacobs and Chase, 2014):  𝑆 = 𝜇.	×	𝜇/0 + 𝑧	×	𝜎.×	 𝜇/0
Here the safety amount is based on the desired service level and the deviation of the 
demand over the average lead time. As with the safety stock equation, a 𝑧 value of 3.72 
will be used, corresponding to a service level of 99.99%.  
7.3.1.3 Reorder frequency 
Reorder frequency refers to the regularity of review periods to determine whether or 
not to place an order to manufacturers. There are two groups of inventory control 
policies based on the reorder frequency, namely continuous review policies and 
periodic review policies. With continuous review policies, an order can be placed at any 
(7.4) 
(7.5) 
(7.6) 
(7.7) 
(7.8) 
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time, usually when the inventory level reaches some threshold. In contrast, periodic 
review policies are time-based and orders are only placed every 𝑅 time periods. 
Four alternative reorder frequencies will be evaluated in the scenarios, including every 
week, two weeks, three weeks and four weeks. It should be noted, that since the model 
follows a weekly time step, an 𝑅  value of one week will function the same as a 
continuous review policy. For example, in the model, a continuous (𝑠, 𝑆) policy will 
generate the same results as an (𝑅, 𝑠, 𝑆) policy if 𝑅	 = 	1. 
7.3.1.4 Reorder quantity 
In this model, the SRS demand is analogous to the reorder quantity (𝑄). A common 
method for calculating the reorder quantity is by determining the economic order 
quantity (𝐸𝑂𝑄):  
𝐸𝑂𝑄 = 	 2×𝐷×𝐶;𝐶: 		 , 
where 𝐷 is the demand, 𝐶;  the ordering costs and 𝐶:  the holding costs. The 𝐸𝑂𝑄 is
used to calculate the order quantity that will minimise the total holding and ordering 
costs. It is based on the assumption that the ordering cost is constant, the demand rate 
is evenly dispersed and known, and the lead time is known and fixed. These 
assumptions do not hold for the supply chain being analysed in this study and will 
therefore not be considered as a valid value for the reorder quantity.  
Another method to calculate the reorder quantity, is to base the amount to be ordered 
on a forecast of the demand. Since no trend or seasonality is present in the model, the 
best method of forecasting to use is simple exponential smoothing, as discussed in 
Section 3.5. Exponential smoothing is calculated as:  𝑄 = 𝛼 1 − 𝛼 '𝑥6 + 𝛼(1 − 𝛼)G𝑥6MG + 𝛼(1 − 𝛼)^𝑥6M^ + ⋯+ 𝛼(1 − 𝛼)N𝑥6MN
where 𝛼 is the smoothing factor, which determines the weight that is assigned to the 
latest data. As 𝛼 → 1, the latest data has a greater impact and the forecast becomes 
more volatile. In contrast, as 𝛼 → 0 , the latest data has less of an impact and the 
forecast is more cumulative and smooth. Therefore, three alternative smoothing factors 
will be evaluated during the scenario modelling, namely 0.1, 0.5 and 0.9, as suggested 
by Coetzee (2015) and Caplice (2016a).  
In the (𝑠, 𝑆), (𝑅, 𝑆) and (𝑅, 𝑠, 𝑆) policies, the reorder quantity will be calculated with 
(7.6), as stated in the previous section. 
7.3.2 Summary of inventory policy scenarios 
Table 7.3 provides a summary of the alternative equations that will be used for the 
reorder point, order-up-to-level, reorder frequency and reorder quantity.  
(7.9) 
(7.10) 
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Table 7.3: Summary of equations for inventory policy variables. 
Reorder Point (𝒔) 𝑠G = 𝜇.	×	𝜇/0 + 𝜇.	×	3𝑠^ = 𝜇.	×	𝜇/0 + 𝜇.	×	4.5𝑠 = 𝜇.	×	𝜇/0 + 𝜇.	×	6𝑠 = 𝜇.	×	𝜇/0 + 3.72 𝜇. +	𝜎/ ^ + 𝜇/0 + 	𝜎.^
Order-Up-To-Level (𝑺) 𝑆G = 𝜇.	×	𝜇/0 + 3.72	×	𝜎.×	 𝜇/0𝑆^ = 𝜇.	×	𝜇/0 	×	2.5
Reorder Frequency (𝑹) 𝑅G = 1𝑅^ = 2𝑅 = 3𝑅 = 4
Reorder Quantity (𝑸) 𝑄G =		Exponential smoothing, with 𝛼 = 0.1𝑄^ =		Exponential smoothing, with 𝛼 = 0.5𝑄 =		Exponential smoothing, with 𝛼 = 0.9
Each of the alternative values in Table 7.3 will be applied to each of the five inventory 
policies, where applicable. This results in: 
• 8 possible combinations of 𝑠 and 𝑆 for the (𝑠, 𝑆) policy;
• 8 possible combinations of 𝑅 and 𝑆 for the (𝑅, 𝑆) policy;
• 32 possible combinations of 𝑅, 𝑠 and 𝑆 for the (𝑅, 𝑠, 𝑆) policy;
• 12 possible combinations of 𝑠 and 𝑄 for the (𝑠, 𝑄) policy; and
• 48 possible combinations of 𝑅, 𝑠 and 𝑄 for the (𝑅, 𝑠, 𝑄) policy.
As mentioned in Section 7.3.1.3, an 𝑅 value of one week will function in an identical 
manner to a continuous review policy, since the model follows a weekly time step. 
Therefore, any combination with 𝑅G in the (𝑅, 𝑠, 𝑆) and (𝑅, 𝑠, 𝑄) policy can be omitted
since it will yield the same results as the (𝑠, 𝑆) and 𝑠, 𝑄  policy where the same values 
of 𝑠 and 𝑆 and 𝑠 and 𝑄 are used, respectively. This reduces the number of scenarios to 
be modelled to 88, all of which are summarised in Appendix G. 
It should also be noted that the reorder point 𝑠, is larger than both order-up-to-levels.
Therefore, in scenarios where 𝑠 is applied to a (𝑠, 𝑆) or (𝑅, 𝑠, 𝑆) policy, the inventory
position will always be below the order-up-to-level and an order will be placed to 
manufacturers at every opportunity.  
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7.4 Scenario results 
The impact that the various proposed inventory management policies have on the 
performance of Model C will be discussed in this section. As previously mentioned, this 
will be communicated through the performance measures and metrics that were 
identified and discussed in Section 7.1. The performance of each policy and its 
alternatives will be compared to the performance of the base case, where applicable. 
The full set of results for capreomycin, kanamycin and cycloserine are provided in 
Appendix H. However, to illustrate how these results should be interpreted, the 
scenarios that exhibited the best and the worst performance, in the case of 
capreomycin, will be discussed. This will be done separately for each performance 
measure.  
7.4.1 Stock performance 
The following tables provides a summary of the stock performance metrics that 
measures how well the stock is being used to satisfy demand. The results include the 
fraction of orders that were backlogged, the volume of the backlog as well as the 
average and maximum length of time that an order is backlogged. The policies that 
resulted in the least number of backlogs and where these backlogs were fulfilled in the 
shortest amount of time, are summarised in Table 7.4. These policies also resulted in 
the lowest total volume of the backlog. The majority of the policies in the table are (𝑅, 𝑆) 
policies, with 7 of the 8 (𝑅, 𝑆) scenarios included in the table. It is interesting to note, 
that of all of the policies that were modelled, the (𝑅, 𝑆) policy is the only one that does 
not implement a reorder point 𝑠. The (𝑅, 𝑆) policy attempts to replenish the stockpile to 
its full capacity, every 𝑅 periods, while the other policies dictate that an order is only 
placed when the stockpile is below the reorder point 𝑠.  
Table 7.4: Scenario results – Capreomycin high stock performance policies. 
Policy # R s S Q %BLs 𝝁𝑩𝑳_𝑨𝒈𝒆 𝑴𝒂𝒙𝑩𝑳_𝑨𝒈𝒆 Total Vol.
(s,S) 5 s3 S1 2.63% 2.44 6 1 859 470 
(R,S) 1 R1 S1 2.63% 2.44 6  722 871 
(R,S) 2 R1 S2 2.11% 5.68 14  651 444 
(R,S) 3 R2 S1 2.26% 3.89 11  1 006 581 
(R,S) 5 R3 S1 1.58% 2.31 5  159 302 
(R,S) 6 R3 S2 5.79% 4.41 13  1 000 613 
(R,S) 7 R4 S1 1.58% 2.57 5  252 229 
(s,Q) 11 s4 Q2 5.26% 3.14 8  1 023 422 
(R,s,Q) 24 R3 s4 Q3 4.74% 4.00 11  876 604 
(R,s,Q) 36 R4 s4 Q3 4.70% 3.00 9  1 003 628 
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The policies that resulted in the most backlogs are summarised in Table 7.5. These 
policies also have the highest average and maximum waiting time until a backlogged 
order is fulfilled. All of the policies listed in Table 7.5, are (𝑅, 𝑠, 𝑄) policies. The order 
quantity, in (𝑅, 𝑠, 𝑄) policies, is based on an exponential smoothing forecast of previous 
demand. However, the high variability of the demand could lead to inefficient forecasts, 
resulting in inadequate levels of stock and more backlogs. The majority of the (𝑅, 𝑠, 𝑄) 
policies resulted in high backlogs, although there are exceptions. The exceptions, two 
of which were included in Table 7.4, are the (𝑅, 𝑠, 𝑄) policies where the reorder point 
was set to the highest alternative, namely 𝑠, and a smoothing factor of 0.5 (𝑄^) or 0.9
(𝑄) was applied. This is expected since forecasts with higher smoothing factors place
more emphasis on the latest data, which would cause the reorder quantities to be a 
more accurate reflection of recent trends, although more dynamic. 
Table 7.5: Scenario results – Capreomycin poor stock performance policies. 
Policy # R s S Q %BLs 𝛍𝐁𝐋_𝐀𝐠𝐞 𝐌𝐚𝐱𝐁𝐋_𝐀𝐠𝐞
(R,s,Q) 13 R3 s1 Q1 35.26% 17 58 
(R,s,Q) 16 R3 s2 Q1 34.74% 16 58 
(R,s,Q) 19 R3 s3 Q1 34.74% 16 58 
(R,s,Q) 22 R3 s4 Q1 35.79% 14 54 
(R,s,Q) 25 R4 s1 Q1 41.10% 29 75 
(R,s,Q) 28 R4 s2 Q1 30.00% 28 71 
(R,s,Q) 31 R4 s3 Q1 34.70% 28 71 
(R,s,Q) 34 R4 s4 Q1 32.60% 23 73 
7.4.2 Order variability performance 
The policies with the best order variability performance are summarised in 
Table 7.6. In the scenarios listed in the table, the orders were placed to manufacturers 
on regular intervals and the order sizes varied less than in the base case. It should be 
noted that several of the policies that exhibited poor stock performance, had the best 
order variability performance. Again, the policies in  
Table 7.6 implement a reorder quantity that is based on an exponential smoothing 
forecast of previous demand. The standard deviations are primarily affected by the 
smoothing factor. A lower smoothing factor results in more uniform forecasts, while the 
opposite is true for higher smoothing factors. In general, the 𝑅, 𝑠, 𝑄  and (𝑠, 𝑄) 
scenarios exhibit lower standard deviations than other policies. The standard deviation 
is lowest with a reorder quantity of 𝑄G which has the lowest smoothing factor (0.1); while
the higher standard deviations are associated with 𝑄, which has the highest smoothing
factor (0.9). 
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Table 7.6: Scenario results – Capreomycin high order variability performance policies. 
Policy # R s S Q 𝝈𝒐𝒔 𝝈𝒎𝒐
Base NA NA NA NA 59 466 132 118 
(s,Q) 1 s1 Q1 11 575 46 945 
(s,Q) 4 s2 Q1 11 634 47 068 
(s,Q) 7 s3 Q1 11 620 47 124 
(s,Q) 10 s4 Q1 11 623 45 102 
(R,s,Q) 13 R3 s1 Q1 20 178 46 992 
(R,s,Q) 16 R3 s2 Q1 20 325 46 751 
(R,s,Q) 19 R3 s3 Q1 20 325 46 751 
(R,s,Q) 22 R3 s4 Q1 20 325 46 751 
The policies that generate the highest order variability are summarised in Table 7.7. The 
orders in these policies are placed at irregular times and are of inconsistent size. In 
general, the majority of the (𝑅, 𝑠, 𝑆) policies resulted in high standard deviations, except 
for those that implemented the highest reorder point, namely 𝑠. A study by De Kok and
Inderfurth (1997), concluded that (𝑠, 𝑆)  type policies generally exhibit the worst 
performance with regards to “nervousness and stability” among a number of policies 
considered. This is evident in the scenario results, since the policies with the highest 
order variability are the (𝑠, 𝑆) and (𝑅, 𝑠, 𝑆) policies.  
Table 7.7: Scenario results – Capreomycin poor order variability performance policies. 
Policy # R s S Q 𝝈𝒐𝒔 𝝈𝒎𝒐
Base NA NA NA NA 59 466 132 118 
(R,s,S) 2 R2 s1 S2 277 018 233 650 
(R,s,S) 4 R2 s2 S2 275 298 211 417 
(R,s,S) 6 R2 s3 S2 214 604 195 895 
(R,s,S) 10 R3 s1 S2 271 853 230 097 
(R,s,S) 12 R3 s2 S2 273 173 209 015 
(R,s,S) 14 R3 s3 S2 263 082 193 342 
(R,s,S) 18 R4 s1 S2 274 002 224 721 
(R,s,S) 20 R4 s2 S2 274 998 214 604 
(R,s,S) 22 R4 s3 S2 268 781 193 069 
7.4.3 Cost performance 
The scenarios which resulted in the lowest total costs are depicted in Table 7.8. As with 
the order variability, the policies that generally resulted in lower total costs than the 
other policies, are those that implement a reorder quantity that is based on an 
exponential smoothing forecast of previous demand. This is predominantly due to the 
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lower holding costs, which can be ascribed to the lower stock levels associated with 
these policies.  
Table 7.8: Scenario results – Capreomycin high cost performance policies. 
Policy # R s S Q 𝑪𝑶 𝑪𝑷 𝑪𝑯 𝑪𝑻
Base NA NA NA NA - 43 141 280 18 764 428 61 905 708 
(s,Q) 3 s1 Q3  -   39 046 015 8 047 223 47 093 238 
(R,s,Q) 13 R3 s1 Q1  -   39 653 475 7 804 489 47 457 964 
(R,s,Q) 22 R3 s4 Q1  -   39 936 146 7 675 583 47 611 729 
(R,s,Q) 25 R4 s1 Q1  -   39 482 690 7 717 470 47 200 160 
(R,s,Q) 26 R4 s1 Q2  -   38 590 165 6 318 457 44 908 622 
(R,s,Q) 28 R4 s2 Q1  -   39 482 690 8 020 257 47 502 947 
(R,s,Q) 31 R4 s3 Q1  -   39 482 690 8 020 257 47 502 947 
(R,s,Q) 34 R4 s4 Q1  -   39 482 690 7 416 403 46 899 093 
The policies associated with the highest costs are summarised in Table 7.9. The total 
cost for these policies is elevated by their high holding costs. This is ascribed to the high 
inventory levels of these policies, possibly caused by the high order-up-to-level 𝑆G
and/or reorder point 𝑠.
Table 7.9: Scenario results – Capreomycin poor cost performance policies. 
Policy # R s S Q 𝑪𝑶 𝑪𝑷 𝑪𝑯 𝑪𝑻
Base NA NA NA NA - 43 141 280 18 764 428 61 905 708 
(s,S) 7 s4 S1 - 39 632 701 59 832 891 99 465 592 
(R,S) 1 R1 S1 - 39 632 701 59 832 891 99 465 592 
(R,S) 3 R2 S1 - 39 733 608 52 517 777 92 251 385 
(R,S) 5 R3 S1 - 39 337 908 59 290 396 98 628 304 
(R,S) 7 R4 S1 - 39 733 612 56 526 390 96 260 002 
(R,s,S) 7 R2 s4 S1 - 39 733 608 52 517 777 92 251 385 
(R,s,S) 15 R3 s4 S1 - 39 337 908 59 290 396 98 628 304 
(R,s,S) 23 R4 s4 S1 - 38 733 612 56 526 390 95 260 002 
7.4.4 Summary of scenario results 
As made clear by the results, the best and worst alternatives that are concluded from 
a separate analysis of the performance measures, are often contradicting; policies that 
generated good results in terms of order variability or cost performance, resulted in 
poor stock performance. Therefore, it would be infeasible to make any conclusions 
based on the results of the separate performance measures.  
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7.5 Analysis of scenario results 
This section will discuss the analysis of the results, obtained from Model C, for each of 
the three formulations. Only the optimal policies, as obtained through the methodology 
presented in the following section, will be described while general findings and 
conclusions will be discussed in Section 7.6.  
7.5.1 Analysis methodology 
As previously mentioned, the goal of the stockpile in Model C is to ensure the 
availability of stock for countries and reduce the variability of the demand to the 
manufacturers. Therefore, the primary focus of the analysis will be on the backlogs and 
the standard deviation of the volume of orders placed per month (order variability). 
Considering the importance of costs to the supply chain, the total cost will be added as 
a third objective.  
To compare the performance of the scenarios in terms of the backorders, a single 
backlog metric is required. This metric should provide an indication of:  
i. the percentage of the total orders that were backlogged;
ii. the volume of the backlog; and
iii. the average length of time for which orders were backlogged.
Various potential metrics were considered (and tested through application to the 
scenario modelling results) before selecting the product of the three stock performance 
metrics, namely the percentage of backlogs, the average age of a backorder and the 
total volume of backorders. Though this metric does not have a unit that makes intuitive 
sense, this is considered acceptable as the only purpose of the metric is to provide a 
relative indication of the performance of each scenario in terms of backlog.  
To illustrate the performance of the scenarios, the order variability, backlog metric and 
total costs will be plotted against one another for each of the scenarios and be grouped 
according to the type of inventory policy. Determining which scenario performed better, 
depends on both the backlogs, order variability and costs, making it a multi-objective 
minimisation decision, since all of these factors should be as low as possible. Multi-
objective optimisation involves the optimisation of several objectives simultaneously, 
where the objectives are often opposing each other. To determine the optimal points, a 
Pareto optimal set will be generated. A Pareto optimal set comprises of a complete set 
of Pareto optimal solutions. A Pareto optimal solution is defined as a solution for which 
the improvement of one objective function will cause another objective value to 
deteriorate. In other words, a solution is a Pareto optimal if there is no other solution 
that dominates it. A solution 𝑥1  is said to dominate another solution 𝑥2  if both the 
following are true: 
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1. The solution 𝑥1 is no worse than 𝑥2 in all of the three objectives; and
2. The solution 𝑥1 is strictly better than 𝑥2 in at least one objective.
In effect, each Pareto optimal solution reaches a trade-off between the objectives. In 
this study, the Pareto optimal set of outcomes are the policies for which: 
i. the variability of the demand to the suppliers cannot be reduced without
decreasing the availability of stock and/or increasing the total costs;
ii. the availability of stock cannot be guaranteed without increasing the variability
of the demand to the supplier and/or increasing the total costs; or
iii. the total costs cannot be reduced without increasing the variability of the
demand to the supplier and/or decreasing the availability of stock.
Furthermore, for each formulation, a summary will be provided of the scenarios in the 
Pareto optimal set as well as the impact each of these scenarios have on: 
• the percentage of backlogs;
• the average age of a backorder;
• the total volume of backorders;
• the standard deviation of the volume of orders placed per month; and
• the total cost.
7.5.2 Capreomycin 
Figure 7.4 provides a 3-dimensional scatter plot of the backlog measurement, order 
variability and total cost of all 88 scenarios for capreomycin. The figure also illustrates 
three 2-dimensional scatter plots that compare two of the objectives, namely (i) order 
variability and backlog performance, (ii) order variability and total costs, and (iii) backlog 
performance and total costs. The Pareto optimal solutions as well as those that are 
close to the Pareto frontier are circled in the plots in the figure, while more detailed 
results for these scenarios are given in Table 7.10.  
As depicted in Table 7.10, there are 31 solutions included in the Pareto optimal policies 
for capreomycin. Two thirds of the policies in the Pareto frontier implement a reorder 
quantity that is based on an exponential smoothing forecast of previous demand, 
specifically the (𝑅, 𝑠, 𝑄) and (𝑠, 𝑄) policies. In general, these policies, have both a lower 
order variability and lower total cost than the other policies. Furthermore, the lower 
order variability is typically associated with the policies that implement a smoothing 
factor of 0.1 for the exponential smoothing forecast. Although the (𝑠, 𝑄) and (𝑅, 𝑠, 𝑄) 
policies are generally associated with more backlogs, there are a few exceptions; most 
of which implement the highest reorder point, namely 𝑠 . In contrast, the Pareto set
policies with the most backlogs generally implement the lowest reorder point, namely 𝑠G.
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Table 7.10: Summary of Pareto optimal solutions for capreomycin. 
Variables 
Scenario   
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% 
Backlogs 
Average 
Age 
Total 
Volume 
Std Dev 
(Monthly) Total Cost 
Base NA NA NA 132 118   61 905 708 
(s,S) 2 s1  S2 17.37%  7  2 728 524 205 729 58 868 469 
(s,S) 5 s3  S1 2.63%  2  1 859 470  94 309  76 702 211 
(s,S) 6 s3  S2 2.11%  6  2 541 754  94 309  69 735 512 
(R,S) 1 R1 S1 2.63%  2  722 871  94 309 99 465 592 
(R,S) 2 R1 S2 2.11%  6  651 444  94 309 78 428 309 
(R,S) 3 R2 S1 2.26%  4  1 006 581  89 510  92 251 385 
(R,S) 5 R3 S1 1.58%  2  159 302  94 524 98 628 304 
(R,S) 8 R4 S2 6.32%  3  1 249 302  102 599  75 049 318 
(R,s,S) 15 R3 s4  S1 1.58%  2  159 302  94 524 98 628 304 
(R,s,S) 23 R4 s4  S1 1.58%  3  252 229  102 599 95 260 002 
(s,Q) 1 s1 Q1 27.37%  14  4 135 590  46 945 48 243 738 
(s,Q) 3 s1  Q3 35.26%  6  4 105 420  100 498 47 093 238 
(s,Q) 4 s2 Q1 21.58%  15  3 451 015  47 068  49 130 166 
(s,Q) 7 s3 Q1 21.58%  15  3 059 089  47 124  49 469 712 
(s,Q) 8 s3 Q2 25.26%  8  3 929 361  86 469  48 182 180 
(s,Q) 10 s4 Q1 10.53%  6  2 374 224  45 102  61 565 939 
(R,s,Q) 10 R2 s4 Q1 7.37%  4  1 555 461  65 895  72 267 341 
(R,s,Q) 11 R2 s4 Q2 7.37%  4  1 555 461  65 895  72 267 341 
(R,s,Q) 13 R3 s1 Q1 35.26%  17  4 677 504  46 992  47 457 964 
(R,s,Q) 14 R3 s1 Q2 30.53%  8  4 160 316  68 506  47 300 611 
(R,s,Q) 16 R3 s2 Q1 34.74%  16  4 637 472  46 751 47 520 342 
(R,s,Q) 17 R3 s2 Q2 28.42%  7  3 556 032  67 176  48 283 681 
(R,s,Q) 19 R3 s3 Q1 34.74%  16  4 637 472  46 751 47 520 342 
(R,s,Q) 20 R3 s3 Q2 19.47%  7  3 078 278  67 176  50 553 123 
(R,s,Q) 22 R3 s4 Q1 35.79%  14  4 559 710  46 751  47 611 729 
(R,s,Q) 23 R3 s4 Q2 5.79%  4  1 258 965  67 612  74 928 108 
(R,s,Q) 26 R4 s1  Q2 41.60%  8 5 026 680  56 552 44 908 622 
(R,s,Q) 32 R4 s3 Q2 30.00%  6  4 770 356  56 373 47 927 979 
(R,s,Q) 34 R4 s4 Q1 32.60%  23  4 585 716  21 733 46 899 093 
(R,s,Q) 35 R4 s4 Q2 7.40%  4  1 603 273  53 757  68 811 742 
(R,s,Q) 36 R4 s4 Q3 4.70%  3  1 003 628  75 241  76 138 223 
7.5.3 Kanamycin 
A 3-dimensional scatter plot of the backlog measurement, order variability and total 
cost of all 88 scenarios for kanamycin, is depicted in Figure 7.5. The 2-dimensional 
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scatter plots of the (i) order variability and backlog performance, (ii) order variability and 
total costs, and (iii) backlog performance and total costs, are also illustrated in the figure. 
The Pareto optimal solutions as well as those that are close to the Pareto frontier are 
circled in the figure. The detailed results for these scenarios are provided in Table 7.11.  
F
ig
u
re
 7
.5
: S
ca
tt
e
r 
p
lo
ts
 o
f 
th
e
 s
ce
n
a
ri
o
 r
e
su
lt
s 
fo
r 
ka
n
a
m
y
ci
n
. 
Stellenbosch University  https://scholar.sun.ac.za
Page | 148 Chapter 7: Analysis and results 
Department of Industrial Engineering 
Table 7.11: Summary of Pareto optimal solutions for kanamycin. 
Variables 
Scenario   
R
e
o
rd
e
r 
F
re
q
u
e
n
cy
  
R
e
o
rd
e
r 
P
o
in
t 
  
O
rd
e
r-
u
p
-t
o
-l
e
ve
l 
  
O
rd
e
r 
Q
u
a
n
tit
y
 
% 
Backlogs 
Average 
Age 
Total 
Volume 
Std Dev 
(Monthly) Total Cost 
Base NA NA NA 132 118 28 193 353 
(s,Q) 1 s1 Q1 9.60%  16  2 683 523  59 321  24 681 673 
(s,Q) 4 s2 Q1 7.20%  13  2 592 497  59 228  26 434 033 
(s,Q) 10 s4 Q1 1.60%  3  432 487  58 707  41 509 888 
(s,Q) 12 s4 Q3 5.60%  9  1 813 642  146 092  32 950 187 
(R,s,Q) 2 R2  s1 Q2 11.20%  10  2 859 217  96 437  26 089 148 
(R,s,Q) 4 R2  s2 Q1 13.60%  12  3 434 096  40 472 24 940 842 
(R,s,Q) 9 R2  s3 Q3 6.40%  7  2 161 586  117 518  31 642 430 
(R,s,Q) 10 R2  s4 Q1 4.80%  8  1 450 940  38 393  35 683 918 
(R,s,Q) 13 R3  s1 Q1 16.80%  17  3 752 626  45 321  22 603 511 
(R,s,Q) 14 R3  s1 Q2 15.20%  11  3 297 102  93 415 23 928 385 
(R,s,Q) 22 R3  s4 Q1 7.20%  12  2 253 633  44 240  27 321 994 
(R,s,Q) 23 R3  s4 Q2 0.00%  -    -    93 389  43 721 039 
(R,s,Q) 25 R4  s1 Q1 16.80%  19  3 649 091  23 194  22 110 732 
(R,s,Q) 26 R4  s1 Q2 8.00%  10  2 430 360  78 604  27 315 424 
(R,s,Q) 27 R4  s1 Q3 6.40%  10  2 309 863  113 583  29 074 195 
(R,s,Q) 28 R4  s2 Q1 14.40%  14  2 922 409  23 194  23 215 047 
(R,s,Q) 30 R4  s2 Q3 8.80%  16  2 559 163  73 035 24 836 969 
(R,s,Q) 32 R4  s3 Q2 8.80%  8  2 318 406  79 038  29 917 411 
(R,s,Q) 33 R4  s3 Q3 8.80%  6  2 635 818  113 583  31 936 723 
(R,s,Q) 34 R4  s4 Q1 11.20%  10  3 137 629  23 194  25 521 066 
For kanamycin, 20 policies are included in the Pareto optimal set, as depicted in Table 
7.11. All of the 20 policies in the Pareto frontier set are either (𝑅, 𝑠, 𝑄) or (𝑠, 𝑄). These 
policies implement a reorder quantity that is based on an exponential smoothing 
forecast of previous demand. As with capreomycin, these policies have (on average) 
both a lower order variability and lower total cost when compared with the other 
policies. As illustrated in the table, the policies that implement a smoothing factor of 0.1, 
typically results in a lower standard deviation of order variability. Although the (𝑠, 𝑄) 
and (𝑅, 𝑠, 𝑄) policies are generally associated with more backlogs, there are a few 
exceptions; most of which implement a higher reorder point, such as 𝑠. In contrast, the
majority of Pareto optimal policies in the table with more backlogs implement a lower 
reorder point, such as 𝑠G or 𝑠^.
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7.5.4 Cycloserine 
Figure 7.6 provides a 3-dimensional scatter plot of the backlog measurement, order 
variability and total cost of all 88 scenarios for cycloserine. Also included in the figure, 
are the 2-dimensional plots for (i) order variability and backlog performance, (ii) order 
variability and total costs, and (iii) backlog performance and total costs. The Pareto 
optimal solutions as well as those that are close to the Pareto frontier are circled in the 
figure, while more detailed results for these scenarios are given in Table 7.12.  
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Table 7.12: Summary of Pareto optimal solutions for cycloserine. 
Variables 
Scenario   
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% 
Backlogs 
Average 
Age 
Total 
Volume 
Std Dev 
(Monthly) Total Cost 
Base NA NA NA 1 865 129 110 582 702 
(R,S) 1 R1  S1 8.63%  6  38 540 211  1 881 802  117 726 448 
(R,S) 5 R3  S1 5.88%  11  36 812 271  1 963 972  113 374 365 
(s,Q) 1 s1 Q1 20.78%  5 74 677 760  821 523  83 295 165 
(s,Q) 4 s2 Q1 26.27%  12 74 753 861  823 317  83 070 774 
(s,Q) 5 s2 Q2 18.82%  15 86 246 305  1 682 445 82 369 294 
(s,Q) 7 s3 Q1 20.39%  10  73 167 130  818 010  84 070 779 
(s,Q) 10 s4 Q1 7.45%  6  65 101 767  807 828  88 861 987 
(R,s,Q) 1 R2  s1 Q1 24.71%  24 80 040 441  581 001  80 721 402 
(R,s,Q) 2 R2  s1 Q2 27.84%  15 87 589 007  1 347 708  81 012 251 
(R,s,Q) 4 R2  s2 Q1 22.75%  21 80 234 787  593 517 82 020 833 
(R,s,Q) 8 R2  s3 Q2 25.10%  13  80 042 713  1 347 708  82 847 315 
(R,s,Q) 10 R2  s4 Q1 18.43%  20  74 513 354  568 449  82 351 128 
(R,s,Q) 13 R3  s1 Q1 27.06%  31 82 928 799  802 391  77 670 211 
(R,s,Q) 16 R3  s2 Q1 25.10%  31  80 180 710  802 391  77 942 924 
(R,s,Q) 22 R3  s4 Q1 24.31%  30 78 593 482  802 391  78 212 188 
(R,s,Q) 25 R4  s1 Q1 30.98%  35 87 737 520  476 603  76 186 321 
(R,s,Q) 26 R4  s1 Q2 27.45%  16  83 661 572  1 058 420  81 030 528 
(R,s,Q) 27 R4  s1 Q3 30.59%  13 91 479 764  1 489 485  81 177 472 
(R,s,Q) 31 R4  s3 Q1 24.24%  36  85 136 813  476 603 76 688 962 
(R,s,Q) 33 R4  s3 Q3 33.73%  11  91 726 106  1 489 485 82 259 349 
(R,s,Q) 34 R4  s4  Q1 34.90%  32 88 781 954  476 603 74 599 586 
Table 7.12 summarises the 21 policies included in the Pareto optimal set for cycloserine. 
Nineteen of the 21 policies in the Pareto frontier are either (𝑅, 𝑠, 𝑄) or (𝑠, 𝑄) policies that 
implements a reorder quantity that is based on an exponential smoothing forecast of 
previous demand. As with capreomycin and kanamycin, these policies typically results 
in both a lower order variability and lower total cost when compared with the other 
policies. As illustrated in the table, a smoothing factor of 0.1, typically results in a lower 
standard deviation of order variability. Although the (𝑠, 𝑄) and (𝑅, 𝑠, 𝑄) policies are 
generally associated with more backlogs, there are a few exceptions; most of which 
implement a higher reorder point, such as 𝑠  or 𝑠 . In contrast, most of the Pareto
optimal policies in the table with more backlogs implements a lower reorder point, such 
as 𝑠G.
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7.6 Research findings 
This section will provide a discussion of the research findings that were derived from 
the majority of the 264 scenarios (88 for each formulation) that were implemented and 
evaluated.  
The (𝑠, 𝑆) and (𝑅, 𝑠, 𝑆) policies generally resulted in the highest order variability, with 
several scenarios where it was higher than the base case. This supports the study by 
De Kok and Inderfurth (1997), that concluded that (𝑠, 𝑆) type policies generally exhibit 
poor performance with regards to “nervousness and stability”. However, the scenarios 
which resulted in the lowest backlogs were either (𝑠, 𝑆) or (𝑅, 𝑠, 𝑆) policies. Although 
the (𝑠, 𝑄) and (𝑅, 𝑠, 𝑄) policies did result in more backlogs than the other policies (on 
average), they performed better in terms of cost and variability. There are, however, 
some exceptions to the (𝑠, 𝑄) and (𝑅, 𝑠, 𝑄) policies, where certain combinations of a 
large reorder point and a smoothing factor of either 0.1 or 0.5 resulted in low order 
variability, low backlogs and low costs.   
The order variability for the (𝑠, 𝑄) and (𝑅, 𝑠, 𝑄) policies tend to rise with the smoothing 
factor. For the majority of these policies, a smoothing factor of 0.1 resulted in the lowest 
order variability, while a 0.9 smoothing factor caused high variability. As mentioned in 
Section 7.3.1.4, a lower smoothing factor results in more uniform forecasts, while the 
opposite is true for higher smoothing factors.  
The procurement cost of all scenarios, for each formulation, is less than in the base 
case. With the holding cost, however, there are several scenarios that resulted in a 
much higher holding cost, while other resulted in holding cost lower than the base case. 
This is depicted in Table 7.13, where the procurement cost is fairly similar for all of the 
scenarios, with small variations, while the holding cost has a much larger range. 
Therefore, the disparity in the total cost of the different scenarios can be ascribed to the 
holding costs. A higher holding cost is associated with policies that attempt to keep the 
stockpile as full as possible, typically resulting in fewer backlogs. 
Table 7.13: Comparison of the procurement cost and holding cost range. 
Procurement cost Holding cost 
Capreomycin $37.2m - $41.8m $6.3m - $59.8m 
Kanamycin $14.1m - $18.3m $7.1m - $56.5m 
Cycloserine $63.5m - $70.8m $11.1m - $46.5m 
A typical concern with keeping such a large stockpile, is the potentially high levels of 
obsolete stock and obsolescence costs. However, as illustrated in the results, 
obsolescence did not prove to be a problem in the scenarios. For example: 
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• from the 88 scenarios for capreomycin, there were 16 scenarios that resulted in low
levels of obsolete stock with the highest obsolescence cost accounting for 0.9% of
the total costs;
• from the 88 scenarios for kanamycin, none resulted in obsolete stock; and
• from the 88 scenarios for cycloserine, there were 21 scenarios that resulted in low
levels of obsolete stock with the highest obsolescence cost accounting for 0.7% of
the total cost.
Currently, when a country places an order, they have to wait for (i) the order to be 
processed, (ii) the drugs to be manufactured, and (iii) for the order to be dispatched and 
delivered. With the larger buffer inventory introduced in Model C, orders are fulfilled 
directly from the stockpile. Therefore, countries no longer need to wait for the 
manufacturing of the drugs, subsequently reducing the total lead time that a country 
has to wait for a delivery. The reduced lead times, if kept relatively stable, would 
potentially allow countries to plan and forecast more accurately and would potentially 
either significantly reduce or eliminate the existence for emergency orders. When 
comparing the performance of the current system with the scenarios in the Pareto 
frontier, it is clear that a larger stockpile, implemented with the appropriate inventory 
policies, has the potential to: (i) aid current manufacturers to produce medicines more 
efficiently and increase market attractiveness to draw in new manufacturers, and (ii) 
reduce stock-outs at countries by decreasing the current lead time for order delivery. 
7.7 Conclusion: Analysis and results 
This chapter presented the analysis of the current system (the base case) as well as 
several alternative stockpile scenarios. The scenarios that were analysed, as well as 
the results obtained for these, were presented. The general findings that can be 
concluded from the results were also discussed.  
The following chapter will conclude the research by providing an overall summary and 
by discussing the contributions and limitations of the research. The recommendations 
to stakeholders will be presented and opportunities for further research will be 
identified. 
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"In high school, I won a prize for an essay on tuberculosis. When I got through writing the 
essay, I was sure I had the disease." 
- Constance Baker Motley (African-American state senator and Borough President of Manhattan) 
The previous chapter presented the analysis results of the base case and the scenarios 
that were modelled. It also provided the general findings that can be concluded from 
the results. This chapter will provide an overall summary of the research and discuss 
some recommendations to stakeholders of the global MDR-TB SLD supply chain. Both 
the contributions and limitations of the research are provided, followed by suggested 
opportunities for further research. 
8.1 Project summary 
The background, problem statement, objectives and scope of the research were 
defined in Chapter 1. Chapter 2 provided contextual information on TB and MDR-TB. 
This included information on the causes of the disease, advances in the management 
of the disease, treatment regimens and risks associated with diabetes and HIV. The 
chapter concluded with an estimate of the financial commitment required to respond to 
the epidemic. Chapter 3 consisted of an introduction to supply chains and concepts that 
are relevant to their management. Chapter 4 introduced several methods for modelling 
supply chains and the characteristics of system dynamics and discrete event simulation 
were compared. System dynamics was selected to be applied for the purpose of this 
study, and an outline on this approach was provided.
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In Chapter 5 a description of the supply chain for SLDs for MDR-TB was provided. The 
challenges and difficulties experienced in the supply chain were summarised together 
with some recommendations towards improving the supply chain. The notion of 
implementing a large buffer inventory to improve supply chain performance was also 
detailed in this chapter. Chapter 6 provided background information and a conceptual 
model of the segment of the MDR-TB supply chain for SLDs that will be modelled. The 
modelling process used to simulate this segment of the supply chain was discussed 
and the scenarios that would bet evaluated were introduced. Analyses of the current 
system and several alternative stockpile scenarios were presented in Chapter 7. A 
summary of the results obtained from the scenario modelling and overall conclusions 
that can be drawn from results were also discussed.  
8.2 Recommendations to stakeholders 
A key problem in the SLD supply chain is the dynamic and irregular demand patterns, 
since these makes forecasting and effective planning impossible, consequently 
reducing the manufacturers’ confidence to enter the market and their ability to produce 
economical batch sizes. This causes higher drug prices and longer, inconsistent lead 
times. A possible solution to address this problem, is the implementation of a large 
buffer inventory that could be used to fulfil the erratic demand from countries while 
consolidating and timing the orders to replenish the stockpile, in an attempt to smooth 
the demand to manufactures. This research investigated the implementation of such a 
stockpile and evaluated various scenarios to identify a set of inventory policies that 
would achieve the goals of the stockpile. From the results, it can be concluded that the (𝑠, 𝑄) and (𝑅, 𝑠, 𝑄) inventory policies are present in the Pareto set of solutions for all of 
the formulations and would seem to be the best policies to implement. There is also an 
indication that a lower smoothing factor (0.1 or 0.5), combined with a higher reorder point 
(either 𝑠4  or 𝑠3 ) is has the most positive impact on the supply chain performance. 
Furthermore, none of the reorder frequencies consistently resulted in better or poorer 
results. Therefore, it is recommended that the implemented reorder frequency should 
be based on whichever frequency benefits both the operations of the SRS and the 
manufacturers. 
As mentioned in Chapter 1, Section 1.5, this research forms part of a larger project that 
incorporates both the upstream and downstream components of the MDR-TB SLD 
supply chain. In the study of the downstream segment, Coetzee (2015) concluded that 
placing orders based on an exponential smoothing forecast was not recommended, 
since it led to high stock-outs. In this research, however, several of these type of policies, 
namely (𝑠, 𝑄)  and (𝑅, 𝑠, 𝑄)  policies, are present in the Pareto set of solutions. The 
reason behind the contradictory recommendations is the different objectives associated 
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with the supply chain segments. For the downstream segment of the supply chain, as 
in Coetzee's (2015) study, the main objectives are to minimise the total cost and reduce 
stock-outs. For the upstream segment, however, an added main objective is to reduce 
the order variability to manufacturers. The addition of this third objective, consequently 
led to different policies being recommended. This decoupling of the supply chain 
segments and their associated objectives is illustrated in Figure 8.1. 
Figure 8.1: Illustration of the different objectives associated with the supply chain segments. 
To implement the larger stockpile, it is recommended that a rollout plan is designed 
that would allow the stockpile to gradually increase in size, while allowing more 
countries to receive their drugs directly from the stockpile. The plan would have to 
specify the intended time horizon and how it will grow during this time horizon. Since 
not all countries will be able to receive drugs directly from the stockpile immediately, 
further investigation should be done to decide how the stockpile will manage the higher 
levels of stock during its growth. For example, it should be determined whether the 
current stock rotation policies can be continued or whether some countries should 
initially receive their drugs directly from the stockpile with more countries being added 
as it grows. The required level of stock for the larger buffer stockpile will depend on the 
policy that is implemented. To provide some indication of how much the current 
stockpile will potentially have to grow, the size of the stockpile implemented in the base 
case as well the required size or capacity associated with the policies are summarised 
in Table 8.1. The level of stock for the policies that implement an order-up-to-level, will 
never be more than the value of 𝑆1 or 𝑆2, as provided in the table. For the (𝑠, 𝑄) and (𝑅, 𝑠, 𝑄) policies, there is not a fixed inventory level and it will vary for each policy. 
Therefore, to illustrate the potential size of the stockpile for these policies, the maximum 
inventory levels of the policies in the Pareto set were used to generate a range in which 
the capacity of the stockpile will fall, depending on the exact policy that is implemented. 
Table 8.1: Summary of stock levels. 
Current S1 S2 Range for Q-policies 
Capreomycin 221 018 1 211 877 999 690 376 492 - 864 044 
Kanamycin 184 984 1 773 273 1 314 240 706 656 -  1 301 290 
Cycloserine 3 076 643 14 930 768 11 440 860 6 894 090 - 13 895 700 
Upstream Downstream
Manufacturers Buffer Stockpile Country and/or
Medical Depot
Hospitals, Clinics 
and Pharmacies 
Objectives
Reduce order variability (smooth
demand to manufacturers).
Prevent stock-outs at country 
and/or medical depots.
Minimise costs.
Objectives
Reduce stock-outs at hospitals,
clinics and pharmacies
Minimise costs.
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8.3 Research contributions 
This research contributes to the current academic literature in several ways: 
• It adds to the system dynamic modelling literature, specifically the modelling of drug
supply chains. Although several studies have been done on various supply chains,
there is limited literature on the modelling of drug supply chains.
• It provides valuable insights on the SLD supply chain through the quantitative
modelling to accurately predict the expected impact of proposed changes to the
operation of the supply chain on the availability and delivery of SLDs.
• It adds to the knowledge and understanding of the SLD supply chain by being (one
of) the first research studies to provide modelling insights of the supply chain on a
global level.
• It adds to the field of donor funded supply chains. As mentioned in Section 5.1,  an
article was written during the course of this research and was presented at the 2016
SAIIE conference in October. The article mainly served as an exploratory high-level
literature study, intended to outline the field of donor funded supply chains and
summarise how it differs from commercial supply chains in terms of the main drivers
and characteristics.
8.4 Research limitations 
The assumptions regarding Model A, Model B and Model C, were discussed in detail in 
Sections 6.3.3.3, 6.3.5.3, and 6.3.6.3, respectively. This section will summarise all of the 
known limitations that have been revealed throughout the project. In Section 6.1.2, the 
limitations associated with the data and the availability of the data were discussed, 
namely: 
• the database does not include procurement data for projects outside of the GLC and
GDF, therefore these projects were omitted from the model;
• only the total lead time (between the ‘purchase order date’ and ‘actual delivery
date’) can be derived from the data, while data about the various separate lead time
components are unavailable;
• database entries do not specify the order type making it impossible to confidently
distinguish between normal orders, emergency orders and orders fulfilled due to
stock rotation;
• no available information or data regarding the stockpile’s current replenishment
process is available; and
• data regarding the batch sizes, minimum order quantity and lead times of
manufacturers are not publically available, making it impossible to accurately
model the manufacturers and their processes in detail.
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Furthermore, there are some aspects which could not be modelled accurately due to 
the limitations of systems dynamics. Since system dynamics applies continuous state 
changes, individual units cannot be tracked and modelled. To overcome this limitation, 
a discrete function was applied to the stockpile variable to track the age of a unit from 
when it enters the stockpile; enabling the model to identify when a unit was near a 
specified age. This feature was used to determine when drugs in the stockpile were 
eligible for rotation or when the drugs was considered obsolete. However, the model is 
unable to track the age outside of the stockpile and the age of the units when it reaches 
the stockpile cannot be determined. The age of the drugs when it reaches the stockpile 
was assumed to be two months, therefore possibly overcompensating the age of the 
drugs during most periods and undercompensating during others. This also limited the 
management of backorders in the model, since the individual units that are added to 
the backlog cannot be tracked separately, but is instead pooled together. With system 
dynamics there is no way to track each individual drug through these stages.  
From the sensitivity analysis, discussed in Section 6.4.8, it was concluded that the stock 
on hand is the most sensitive variables, especially when the demand or lead time is 
increased.  
8.5 Opportunity for further work 
It is recommended that the following opportunities for further research be explored, 
since it is believed that each of these proposed studies would contribute to the 
significant research gap related to the modelling of the SLD supply chain: 
i. Evaluate the agility and responsiveness of the different inventory policies. This
would prove beneficial as a way to test the impact on the supply chain and its
performance if more countries were to order through GDF and the stockpile.
ii. Experiment with different forecasting methods, other than exponential smoothing
and evaluate the impact of non-stationary inventory policies on the stockpile.
iii. Attempt to model individual countries, or individual regions, by identifying some
relationship or pattern between the prevalence of TB in the country and the
orders that the country places. This would allow the inclusion of logistical costs
and delivery lead times that vary according to the distance of the delivery.
(However, this should only be done if a significant correlation between distance
and lead time can be established).
iv. Eventually, an attempt should be made to develop a complete model of the
supply chain, incorporating both the upstream and downstream segments, to
investigate the possible ripple-effects that decisions in one of the supply chain
segments has on the other.
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v. With more data, the manufacturers can be modelled as individual entities, where
each manufacturer only produces a certain formulation(s). This would enable
consideration of each manufacturer’s batch size, economic order quantity, etc.
in the modelling process. Whilst it is immediately apparent that this would benefit
the manufacturer, it is likely that it will also indirectly benefit the entire supply
chain. With this in mind, the impact of the order variability on manufacturers can
also be evaluated to determine to what extent the demand patterns affect the
manufacturers and what effect orders that align more closely to economic order
quantities would have on the prices of drugs.
vi. Develop a discrete-event simulation of the models to analyse the impact on
individual units and orders.
vii. Evaluate the possibility of having more than one stockpile. For example, having
a stockpile in some or each of the WHO regions. With this in mind, local
manufacturing in the region of the stockpile could be encouraged, potentially
reducing manufacturing and logistical costs.
8.6 Closing summary 
The SLD supply chain faces a number of significant challenges highlighting the 
importance of optimal supply chain management. A large number of MDR-TB cases (as 
many as 75% according to the World Health Organization (2015) remain undiagnosed. 
Consequently, there will be an ongoing increase in demand for SLDs. The 
implementation of new diagnostic technologies is gradually increasing worldwide, with 
a noteworthy example stemming from South Africa. Since 2011, South Africa 
implemented GeneXpert MTB/RIF testing technology, which significantly increased the 
number of MDR-TB diagnoses.  
As the number of MDR-TB diagnoses increase worldwide, a substantial burden will be 
placed on the supply chain as the demand for SLDs increases due to more patients 
being introduced to MDR-TB treatments. The spread of MDR-TB is worsened by poor 
adherence to rigorous treatments and the dearth of transmission control (World Health 
Organization, 2016a). Contrastingly, improved diagnosis and accuracy of surveillance 
data of MDR-TB will improve forecasts of demand for SLDs. This could potentially 
relieve some of the main challenges faced in the supply chain, which may positively 
impact the MDR-TB drug market as it becomes more lucrative to suppliers; thereby 
increasing competition which in turn improves supplier performance (Keshavjee and 
Seung, 2008). 
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Appendix A Checklist 
This appendix provides a checklist that is used to analyse each source throughout the 
literature review process. This is mainly to strengthen the validity of the study by 
performing a critical analysis on each source before making assertions and conclusions 
based thereon. The checklist is provided in Table A.1 and is based on the evaluation 
method as laid out by Jonathan Paulo in the Madison Research Essentials Toolkit 
(Paulo, 2014) as well as the Critical Appraisal and Analysis technique from the Cornell 
University Library (Engle, 2015).  
Table A.1: Checklist for literature analysis. 
Criteria Checklist 
Credibility of Author
       ⧠ The author seems reputable⧠ The author provides citations⧠ Information of the author’s background is available
Accuracy
⧠ No grammatical or spelling errors⧠ Information was reviewed before publication⧠ Information seems accurate based on my knowledge⧠ Information can be verified by another source
Relevance
⧠ The source covers at least one relevant topic ⧠ The content and language is used at an appropriate 
    level ⧠ The source has been cited
Currency / Date
⧠ The source was written and published at least within the 
     last 10 years⧠ The currency of the source is pertinent to the study
Objectivity / Bias / 
Reliability
⧠ The motive of the source is relevant⧠ The information is objective
Style / Functionality
⧠ The source is well-written and organised⧠ The links are working (if a website)⧠ The page is easy to navigate (If a website)
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Appendix B Characteristics of Dynamic 
Complexity 
There are various characteristics of systems that can cause dynamic complexity. Table 
B.1 lists the majority of these characteristics and a short description of each. Many of 
the characteristics mentioned in the table are discussed in more detail in Section 4.4.2. 
Table B.1: Summary of dynamic complexity characteristics. 
Characteristic Description 
Dynamic Changes in systems take place over numerous time scales that 
sometimes interact. Systems might seem stable and constant, but often 
when considering the system over a long time period, fluctuations are 
observed. 
Tightly Coupled Every individual element in a system is connected and interacts with one 
another and their environment. Therefore, a single action can have a 
rippling effect. 
Governed by 
Feedback 
Due to the tight couplings between elements, decisions cause the system 
environment to change in some way that triggers other elements to act. 
This results in a new system state, which influences the next decisions. 
Nonlinear Nonlinearity is often a result of the system’s basic physics or due to the 
interaction of multiple factors in decision-making. Effect is rarely relational 
to cause – what happens near the current operational point in the system 
does not necessarily apply in other states of the system. 
History-Dependent Certain choices that are made at one point in time will dismiss the 
availability of certain options at a later point in time. 
Self-Organising The internal structure of the systems causes its dynamic complexity. 
Minor complications in the system are often amplified due to feedback 
loops creating patterns and path dependence. 
Adaptive The decision rules and capabilities of the system elements will adapt and 
change over time causing some elements to multiply and the extinction 
of others. 
Counterintuitive In complex systems, the participants often look for causes near the 
problem area, while in many cases the causes originate from a different 
event at another time instance. When analysing complex systems, 
attention is often drawn to the observable consequences of problems 
instead of the inconspicuous main cause. 
Policy Resistant The human mind is incapable to fully comprehend the complexity of 
systems, which is why many solutions fail or worsen the problem. 
Characterised by 
Trade-Offs 
Feedback loops often contain time delays that cause the short-term and 
long-term response of the system to differ. 
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Appendix C The SD Modelling Procedure 
This appendix discusses the different steps and substeps in the modelling procedure of 
System Dynamics, as summarised in Section 4.4.7. 
1. Defining the Problem and its Boundaries
The most important part of the modelling process is to clearly define the purpose of the 
model. Any model represents a system, but for it to be beneficial and valuable, it must 
capture a specific problem. The purpose should help define the scope and boundaries 
of the model. 
Formulate the Problem Area 
The problem area comprises of, among others, a problem statement, which is similar to 
those provided in Section 1.2. It is also necessary to identify the main stakeholders and 
their interests. The problem area should clearly communicate the objectives of the 
model, taking into consideration the different perspectives and goals of the various 
stakeholders.   
Collect data and information 
Data and information is important to substantiate and clarify the scope and extent of 
the identified problem statement and strategic questions. The data and information can 
be collected from any relevant and reliable sources, such as reports, previous studies, 
journal articles, interviews, databases etc. 
Decide on the time horizon 
The time horizon should not only capture the present situation and its future 
performance, but also include historical events that led to the emergence of the 
problem and its symptoms. As previously stated, the effects of system changes are 
often witnessed in the distant future. Therefore, it is important that the time horizon 
extends far enough into the future that the effects and changes in system behaviour can 
be identified and analysed.  
2. Understanding the Model
After the problem statement and the model boundaries are defined, the system and its 
environment are illustrated through a CLD. This involves identifying the elements 
relevant to the system and the strategic questions. Usually the strategic questions will 
be refined as the understanding of the system and its stakeholders are improved.  
Identify key variables and concepts 
Once the problem is known, it is best to identify the different variables and concepts of 
the system, although it is not necessary to assign values to them at this stage. In further 
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steps of the modelling procedure, these variables and concepts are often adjusted or 
more are added. 
Identify historical and possible future behaviour of variables and concepts 
This step involves the identification of patterns that were revealed over time as well as 
predictions of how it might change and develop in the future. These patterns, 
represented by graphs and figures, are often referred to as the reference models. The 
reference models are important to avoid looking at the system from an event-driven 
view and are referred to throughout the modelling process.  
Define links and relationships 
The linkages and relationships between different elements are indicated with an arrow. 
The polarity of the link or relationship should also be stated.  
Define feedback loops 
The feedback loops and their polarity should be defined as well as any relations where 
there are information lags or backlogged materials.  
Map and Refine the CLD 
After creating the CLD it should be refined and simplified to ensure the final format 
remain as small as possible.  
3. Simulating the Model
Once the CLD is completed, the more detailed stock and flow diagram can be built to 
clearly define the physical structure of the model. This step involves the process of 
building the stock and flow diagram and simulating the model on the chosen software. 
Define variable types 
The basic variable types and concepts are described in Table D.1. 
Table D.1: Definitions of variable types. 
Variable/Concept Name Description 
Stock or State Variables Accumulations within the system. Determines the decisions that 
control the flow variables (Campuzano and Mula, 2011; 
Piewthongngam et al., 2014). 
Flow Variables The elements that determine the variation of stock as quantities are 
transferred in or out, either immediately or over time (Campuzano and 
Mula, 2011; Piewthongngam et al., 2014). 
Auxiliary Variables The rest of the elements not included in the abovementioned 
variables (Campuzano and Mula, 2011). 
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Construct stock and flow diagram 
The stock and flow diagram is usually constructed from the CLD, although in some 
cases the system is easier visualised by directly constructing the stock and flow 
diagram.  
Characterise the elements 
Values are assigned to the variables and concepts that were identified in the first step 
of the procedure. These values can either be known values or estimates.  
Write the equations 
Equations are generally used to describe the relationships between elements. The 
equations can include arithmetic formulae, software functions and rate tables among 
others. 
Stabilise the Stock and Flow Diagram 
The first functioning version of the model will often be altered and improved until it runs 
smoothly. It will still, however, constantly undergo adjustments throughout the 
modelling process.  
Identify the elements that are significant to model improvements and scenarios 
When analysing the system not all variables will be evaluated. Instead, only a few 
significant elements will be monitored throughout the simulation and used as a basis 
for conclusions. 
4. Testing and Validating the Model
Before modelling and analysing different scenarios, it is necessary to ensure that the 
model performs as expected. This is done through model validation.  
Compare the model to reference modes 
The first step taken after completing the model is often to compare the system’s 
behaviour with the actual behaviour. The simplest way to do this is to refer back to the 
reference models. If built correctly, the historical patterns and future predictions in the 
reference models should more or less match those in the simulation. 
Perform validation tests 
The aim of model validation is to determine whether the model can be accepted or 
whether it should be rejected. Some of the most significant validation tests, as 
summarised by Sterman (2003), are: 
i. Boundary Adequacy Tests: Assesses the relevance of the boundary and whether the
significant concepts were considered. 
ii. Dimensional Consistency Test: Examines the consistency of measurement units.
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iii. Behaviour Reproduction Tests: Discovers errors and faults in the structure or
parameters and determines whether it will affect the purpose of the model.   
iv. Extreme Conditions Test: Assesses whether the model performs realistically
regardless of the extremity of the conditions. For example, products cannot be 
manufactured without materials and inventories cannot be below zero. 
v. Sensitivity Analysis: Analyses the system’s robustness in terms of changes made to
the parameters. 
5. Identifying and Implementing Scenarios
After validating the model, scenarios can be designed and modelled to aid in the 
analysis and improvement of the system.  
Identify scenarios to be modelled 
The different scenarios to be modelled should be clearly defined as well as the 
reasoning behind it and the expected outcomes. To enhance the analysis, it is 
suggested that the expected results be discussed and added to the reference model.  
Specify the new decision rules and structures for the scenarios 
Each scenario will require the structure and decision rules of the model to be adjusted. 
It will possibly also demand the adaption of feedback loops, stock and flow structure, 
time delays and variables. The changes to be made must be clearly defined together 
with the reasoning behind the changes. 
Model the scenarios 
Implement the changes and simulate. 
Evaluate the system’s response to the scenarios 
A what if analysis can be done to determine what effects the scenario has on the 
system. The robustness of the scenario recommendations can be assessed using a 
sensitivity analysis. Different scenarios can possibly interact with one another. These 
interactions should be evaluated since it is often not as is expected due to the 
nonlinearity of complex systems.  
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This appendix provides the visual assessments of the available data for kanamycin and 
cycloserine. The assessment for capreomycin was provided in Section 6.2.2.4. 
D.1 Kanamycin 
Figure D.1 depicts the weekly purchase order quantity, for kanamycin, as a percentage 
of the annual order quantity, plotted by week for each of the five years. This provides a 
visual assessment of any possible trends in the order timing from one year to the next. 
The figure clearly illustrates the dynamic nature of the data and that there is no trend 
in the time of year when orders are placed.  
Figure D.1: Visual assessment of trends in order timing for kanamycin. 
Figure D.2 illustrates the average weekly order size as well as the average lead time 
for the orders placed in that week over the last five years. This is to provide a visual 
assessment of how the lead time and demand fluctuates and whether any correlation 
possibly exists. The figure clearly demonstrates the inconsistency of both the demand 
and lead time. It also corresponds with the correlation analysis in Section 6.2.2.3, that 
there is no correlation between the order size and lead time. 
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Figure D.2: Visual assessment of the average lead times and order sizes for kanamycin. 
Figure D.3 provides a plot of the weekly lead time against the purchase order dates 
over the five-year period. The lead time is calculated as the difference (in weeks) 
between the purchase order date and the order delivery date. This is to provide a visual 
assessment of whether any changes in the lead time is presents over the last five years. 
A lead time linear regression analysis was performed and no statistically significant 
relationships were observed, this is consistent with the graphic representation in the 
figure, which illustrates a relatively stable trend. 
Figure D.3: Visual assessment of changes in lead time for kanamycin. 
D.2 Cycloserine 
Figure D.4 depicts the weekly purchase order quantity, for cycloserine, as a percentage 
of the annual order quantity, plotted by week for each of the five years. This provides a 
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visual assessment of any possible trends in the order timing from one year to the next. 
The figure clearly illustrates the dynamic nature of the data and that there is no trend 
in the time of year when orders are placed.  
Figure D.4: Visual assessment of trends in order timing for cycloserine. 
Figure D.5 illustrates the average weekly order size as well as the average lead time 
for the orders placed in that week over the last five years. This is to provide a visual 
assessment of how the lead time and demand fluctuates and whether any correlation 
possibly exists. The figure clearly demonstrates the inconsistency of both the demand 
and lead time. It also corresponds with the correlation analysis in Section 6.2.2.3, that 
there is no correlation between the order size and lead time.  
Figure D.5: Visual assessment of the average lead times and order sizes for cycloserine. 
Figure D.6 provides a plot of the weekly lead time against the purchase order dates 
over the five-year period. The lead time is calculated as the difference (in weeks) 
0%
3%
6%
9%
12%
15%
18%
21%
24%
27%
30%
33%
36%
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52
PE
RC
EN
TA
G
E
WEEK
WEEKLY ORDER QUANTITY AS % OF  ANNUAL ORDER 
QUANTITY 
2010 2011 2012 2013 2014
Q1 Q2 Q3 Q4
Stellenbosch University  https://scholar.sun.ac.za
Page | 182 Appendix D: Historical behaviour 
Department of Industrial Engineering 
between the purchase order date and the order delivery date. This is to provide a visual 
assessment of whether any changes in the lead time is presents over the last five years. 
A lead time linear regression analysis was performed and no statistically significant 
relationships were observed, although the graphic representation if Figure D.6 
illustrates an upward trend. 
Figure D.6: Visual assessment of changes in lead time for cycloserine. 
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This Appendix provides details of each of the three models. The main purpose of the 
appendix is to ensure reproducibility of the models by providing all of the equations 
used for the variables. 
E.1 Variable definitions 
As mentioned in Section 6.2.1, the key variables and concepts can be derived from the 
sections discussed in Chapter 5 and the variables to be included in the model are 
centred around the conceptual model in Figure 6.2. The variables are summarised in 
Table E.1 and are classified as either: endogenous variables (determined by other 
variables), exogenous variables (independent of the other variables), or omitted 
variables.  These variables are preliminary and will be modified during the remainder 
of the Appendix as the modelling process progresses.  
Table E.1: Definition of variables. 
Variable Name Description 
Endogenous variables: 
Drugs available for 
emergency orders 
The number of drugs ready to be dispatched to countries by the SRS. 
Drugs available for 
GDF/PA 
The number of drugs that has been manufactured and is ready to be 
dispatched to the GDF and their PAs for quality assessment. 
Drugs available for SRS The number of drugs that has been manufactured and is ready to be 
dispatched to the SRS. 
Drugs available for stock 
rotation 
The amount stock, from what the SRS has on hand, that is eligible for 
stock rotation based on the remaining shelf life.  
Drugs received by SRS The number of drugs that have been received by the SRS from 
manufacturers. 
Emergency order drugs 
received by countries 
The number of drugs that have been received by the countries from the 
SRS. 
Emergency orders from 
countries 
Orders received from countries that are considered an emergency, since 
treatment interruptions will occur if not received as soon as possible.  
GDF/PA orders placed The number of drugs that the GDF and their PA decides to order from the 
manufacturers, includes the SRS demand and the orders from countries. 
Normal order drugs 
awaiting dispatch 
The number of drugs that have undergone quality assessment by the 
GDF/PA and is ready to be dispatched to countries. 
Normal order drugs 
received by countries 
The number of drugs that have been received by the countries from the 
GDF/PA. 
Normal orders from 
countries 
Orders received from countries. 
Normal orders supply 
line 
The orders that have been placed by countries, but not yet fulfilled. 
Obsolete stock Stock that has reached their shelf life and can no longer be used for the 
treatment of patients. 
Production & dispatch to 
GDF/PA 
The production and dispatch of the orders placed by the GDF and their 
procurement agent. 
continued on next page 
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SRS demand The number of drugs that the GDF/PA has to order from manufacturers to 
satisfy both emergency orders and the drugs required for the SRS. 
SRS stock on hand The stock available at the SRS to be dispatched to countries. 
SRS supply line The amount of stock that has been ordered from manufacturers, but not 
yet delivered. 
Stock shortfall The amount of stock that the SRS requires to have the desired level of 
stock on hand. 
Exogenous variables: 
Desired level of stock for 
SRS 
The level of inventory that the SRS prefers to have on hand at all times, 
i.e. the full capacity of the stockpile. 
Expiration Value The shelf life value of the drugs when it is considered obsolete and no 
longer eligible to be delivered to countries. 
Manufacturer lead time The time it takes for the manufacturer to produce and deliver the drugs. 
Obsolescence Cost The total cost of obsolete drugs; i.e. the per unit cost multiplied by the 
number of obsolete units. 
Per Unit Cost The (average) cost per unit; i.e. per pill, vial, kit etc. 
Rotation Value The shelf life value of a drug that makes it eligible to be used for stock 
rotation.  
Shelf life The amount of time that the drugs can be stored, after production, before 
it becomes obsolete. 
Total Cost The total cost of both unit costs and obsolete costs. 
Total Unit Cost The total cost for an order; i.e. the per unit cost multiplied by the number 
of units in the order. 
Omitted variables: 
API’s delivered to 
manufacturer 
The amount of API’s delivered to the drug manufacturers. 
API’s ordered The amount of API’s ordered by the drug manufacturers. 
Drugs provided to 
patients 
The drugs provided to the patients by their clinic/doctor/pharmacy. 
Logistical Cost The cost associated with the dispatch and delivery of drugs from one 
point to another. 
Manufacturer Capacity The maximum number of drugs that the manufacturer can produce due to 
facility and production line restrictions. 
Manufacturer reliability The ability of manufacturers to consistently deliver orders on time and in 
full. 
Manufacturers’ demand 
of APIs 
The amount of API’s required by the manufacturers to produce the drugs. 
Number of 
manufacturers 
The number of manufacturers/suppliers that are currently manufacturing 
drugs. 
Patient demand The number of drugs that patients require from their 
clinic/doctor/pharmacy.  
Patient drop-out The number of patients that has to stop their treatment due to a 
treatment interruption, such as a stock-out.  
SRS Capacity The maximum amount of inventory that the SRS can store due to space 
restriction. 
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E.2 Modelling details of Model A 
This section will discuss the modelling details associated with Model A, as defined and 
discussed in Section 6.3.3. The variables that are included in Model A will be identified 
and the characteristics and equations for each of these variables will be provided.  
E.2.1 Model A: Variable types 
All of the variables and concepts identified in Section E.1 were examined to determine 
a potential model that can be supported by the available historical data. This model 
will be referred to as Model A. The applicable variables and concepts were identified 
as either a stock variable (accumulations within the system), flow variable (determines 
the variation of stock) or auxiliary variable (constants or estimates), refer to Table D.1 in 
0 for more detail. A list of the applicable variables, their variable type and their units is 
given in Table E.2. The table includes several variables, in addition to those initially 
identified in Section 6.2.1, that were added during the development of the model.  
Table E.2: Variable types for Model A. 
Variable Name Units Variable Type 
Country Demand Input   Drugs/Week Auxiliary 
Cumulative Total Unit Cost   Dollar Stock 
Normal Lead Time Lookup   Week Auxiliary 
Normal Order Drugs Awaiting Dispatch   Drugs Stock 
Normal Order Drugs Received By Countries  Drugs/Week Flow 
Normal Orders From Countries   Drugs/Week Flow 
Normal Orders Fulfilled For Countries   Drugs/Week Flow 
Normal Orders Supply Line   Drugs Stock 
Per Unit Cost   Dollar/Drugs Auxilary 
Production   Drugs/Week Flow 
Proportion Of Orders Placed   Dmnl Auxiliary 
Total Costs   Dollar Auxilary 
Total Drugs Received By Countries   Drugs Stock 
Total Unit Cost   Dollar/Week Flow 
Uniform   Dmnl Auxiliary 
Weibull Distribution   Drugs/Week Auxiliary 
E.2.2: Model A: Characteristics and equations of elements 
This subsection provides the equations and values that were assigned to the previously 
identified variables and concepts of Model A. 
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E.2.2.1 Subscripts 
As previously mentioned, two subscripts will be included in the model. The first subscript 
is named ‘Formulations’ with three available elements, namely (i) capreomycin, (ii) 
kanamycin, and (iii) cycloserine. The second subscript is ‘Order Number’ and has four 
elements, namely (i) order 1, (ii) order 2, (iii) order 3 and (iv) order 4. Subscripts are 
enclosed in square brackets [ ] directly following the variable name. Any variable with 
the subscript range [Formulation, Order Number] will therefore represent the following 
12 individual variable ranges: Capreomycin, Order 1; Capreomycin, Order 2; 
Capreomycin, Order 3; Capreomycin, Order 4; Kanamycin, Order 1; Kanamycin, Order 
2; Kanamycin, Order 3; Kanamycin, Order 4; Cycloserine, Order 1; Cycloserine, Order 2; 
Cycloserine, Order 3; and Cycloserine, Order 4. 
A variable can also be followed by a subscript range that specifies which of the 12 
variables it represents. For example, the subscript range [Capreomycin, Order Number] 
will represent all four variables associated with capreomycin (Capreomycin, Order 1; 
Capreomycin, Order 2; Capreomycin, Order 3; and Capreomycin, Order 4), while the 
range [Formulation, Order 1] will represent the three variables associated with Order 1 
(Capreomycin, Order 1; Kanamycin, Order 1; Cycloserine, Order 1).  
E.2.2.2 Demand related variables 
The demand section of the model is repeated in Figure E.1 for convenience. As seen in 
the figure, the variables related to the demand are, (i) Weibull Distribution, (ii) Proportion 
of Orders Placed, (iii) Uniform, (iv) Country Demand Input, and (v) Normal Orders From 
Countries. 
Figure E.1: Demand section of Model A. 
• Weibull Distribution
The Weibull Distribution variable generates random values (for the order size) from the 
chosen Weibull distribution. As previously mentioned, all of the parameter sets in Table 
6.2 will be experimented with and used as basis to develop a set of parameters that 
provide an accurate representation of the data. The equation in Vensim for Weibull 
Distribution is: 
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RANDOM WEIBULL(m,x,S,h,r,s)
where m represents the minimum, x the maximum, S the shape parameter, h the
location parameter, r the scale stretch, and s the stream ID. Only values below the
minimum and above the maximum will be returned. There are three equations for the 
Weibull Distribution variable:  
Weibull Distribution[Capreomycin,Order Number] =  
RANDOM WEIBULL(78 , 448000 , 0.6161, 78, 32 500,1) 
Weibull Distribution[Kanamycin,Order Number] =  
RANDOM WEIBULL(450 , 882000 , 0.4525, 450, 50 000,1) 
Weibull Distribution[Cycloserine,Order Number] =  
RANDOM WEIBULL(2000 , 9.4491e+06 , 0.4755, 1 500, 420 000,1) 
• Proportion of Orders Placed
It is important to note the following prerequisites: 
• a second order can only be placed if a first order has been placed;
• a third order can only be placed if a second order has been placed; and
• a fourth order can only be placed if a third order has been placed.
Therefore, during the time steps that no (first) order is placed, there cannot be any 
second, third, or fourth orders. From the available data, the number of orders placed 
every week can be derived and used to calculate the average probability of a second, 
third and fourth order being placed on any day of the year can be calculated. Using the 
multiplication rule these probabilities are used to calculate the probabilities to be used 
in the model.  
These values are provided in Table E.3. For example, if there is 52 weeks in the year, 
there will be an order placed for capreomycin in 30 (0.574 x 52) of those weeks. Out of 
that 30 weeks, there will be second order placed in 12 (0.389 x 30) of those weeks, etc. 
The average probability for 2 orders of capreomycin placed is 0.223, which also gives 
12 weeks (0.223 x 52). 
Table E.3: Summary of probabilities of more than one order being placed. 
Number of 
Orders Placed 
Probability to 
use in Model 
Average Probability 
C
a
p
re
o
m
y
ci
n
 1 order 0.574 0.574 
2 orders 0.389 0.223 (0.574 x 0.389) 
3 orders 0.255 0.057 (0.574 x 0.389 x 0.255) 
4 orders 0.263 0.015 (0.574 x 0.389 x 0.255 x 0.263) 
continued on next page 
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K
a
n
a
m
y
ci
n
 1 order 0.419 0.419 
2 orders 0.191 0.080 (0.419 x 0.191) 
3 orders 0.287 0.023 (0.419 x 0.191 x 0.287) 
4 orders 0.479 0.011 (0.419 x 0.191 x 0.287 x 0.479) 
C
y
cl
o
se
ri
n
e
 1 order 0.721 0.721 
2 orders 0.508 0.366 (0.721 x 0.508) 
3 orders 0.412 0.151 (0.721 x 0.508 x 0.412) 
4 orders 0.298 0.045 (0.721 x 0.508 x 0.412 x 0.298) 
Since every order for each formulation will have its own proportion, there will be 12 
unique variables. Instead of adding 12 equations to 12 subscript ranges, a comma can 
be used to separate the values for the four elements (Order1, Order2, Order3, and 
Order4) of the Order Number subscript. The equations for the variable are: 
Proportion Of Orders Placed[Capreomycin,Order Number]= 
0.574, 0.389, 0.255, 0.263 
Proportion Of Orders Placed[Kanamycin,Order Number]=
0.419, 0.191, 0.287, 0.479 
Proportion Of Orders Placed[Cycloserine,Order Number]=
0.721, 0.508, 0.412, 0.298 
• Uniform
This variable is used together with the Proportion of Orders Placed variable as 
suggested by a Vensim Super Administrator. It will be explained in more detail when 
discussing the Country Demand Input equations. The equation is similar for all variables: 
RANDOM 0 1() 
This will generate a random value between 0 and 1 with equal probability. 
• Country Demand Input
The Country Demand Input variable specifies the size of the order. As previously 
mentioned, the question of whether or not an order is placed, is dependent on (i) the 
proportions of orders placed, and (ii) the prerequisites mentioned in the proportion of 
orders placed section. To take these two factors into account, the equation will make 
use of the following function, 
IF THEN ELSE( a, b , c ), 
where a is the condition, b is the value that will be returned if the condition a is met, and
c is the value that will be returned if the condition a is not met.
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The equation for the Order1 element of all formulations is: 
Country Demand Input[Formulations,Order1]= IF THEN ELSE( 
Uniform[Formulations,Order1] < Proportion Of Orders 
Placed[Formulations,Order1] , Weibull Distribution[Formulations,Order1] 
, 0 ) 
Since Order1 has no prerequisite, the only factor taken into consideration is the 
proportion of orders placed. The condition is whether the random value (between 0 and 
1) returned by the Uniform variable is smaller than the Proportion of Orders Placed
variable. If this is true, an order is placed that week and the value generated by the 
Weibull Distribution variable will be returned. If it is not true, however, a value of 0 is 
returned, indicating that no orders are placed that week. 
The equations for the Order2, Order3 and Order4 elements are: 
Country Demand Input[Formulations,Order2]= IF THEN ELSE( Country Demand 
Input[Formulations,Order1] > 0 , IF THEN ELSE( 
Uniform[Formulations,Order2] < Proportion Of Orders 
Placed[Formulations,Order2] , Weibull Distribution[Formulations,Order2] 
, 0 ) , 0 ) 
Country Demand Input[Formulations,Order3]= IF THEN ELSE( Country Demand 
Input[Formulations,Order2]>0, IF THEN ELSE( 
Uniform[Formulations,Order3] < Proportion Of Orders 
Placed[Formulations,Order3] , Weibull Distribution[Formulations,Order3] 
, 0 ) , 0 ) 
Country Demand Input[Formulations,Order4]=IF THEN ELSE( Country Demand 
Input[Formulations,Order3]>0, IF THEN ELSE( 
Uniform[Formulations,Order4] < Proportion Of Orders 
Placed[Formulations,Order4] , Weibull Distribution[Formulations,Order4] 
, 0 ) , 0 ) 
As shown in the equation, the first condition tests whether the prerequisite is met. Only 
if the preceding Order Number element is larger than 0 (i.e. an order was placed) will it 
continue to consider the Proportion of Orders Placed. The second condition in the 
equation is the same as the one discussed in the equation for Order1.  
• Normal Orders From Countries
The Normal Orders From Countries variable is merely equal to the value generated by 
Country Demand Input. Its equation is: 
Normal Orders From Countries[Formulations,Order Number]=
Country Demand Input[Formulations,Order Number] 
Stellenbosch University  https://scholar.sun.ac.za
Page | 190 Appendix E: Modelling details 
Department of Industrial Engineering 
E.2.2.3 Manufacturing related variables 
The section of the model related to manufacturing and dispatch of the drugs is repeated 
in Figure E.2 for convenience. As seen in the figure, the variables related to 
manufacturing are, (i) Normal Lead Time Lookup, (ii) Production, (iii) Normal Order Drugs 
Available for Dispatch, and (iv) Normal Orders Fulfilled for Countries. 
Figure E.2: Manufacturing section of Model A. 
• Normal Lead Time Lookup
Since no distributions could be fitter to the normal lead time lookup is merely a lookup 
value of the average lead time recorded during each time period. The equation is given 
as: 
Normal Lead Time Lookup[Formulations, Order Number] = [(0,0)-(10,10)],(1,154), 
(2,154),(3,260),(4,267),(5,155),(6,322),(7,322),(8,274),(9,274),(10,180),(11,180),(
12,610),(13,364),(14,95),(15,137),(16,186),(17,224),(18,29),(19,273),(20,142),(21,3
4),(22,74),(23,115),(24,317),(25,61),(26,152),(27,128),(28,14),(29,225),(30,105),(3
1,166),(32,183),(33,313),(34,143),(35,143),(36,285),(37,226),(38,226),(39,285),(40,
194),(41,17),(42,8),(43,16),(44,21),(45,21),(46,21),(47,27),(48,27),(49,30),(50,88)
,(51,171),(52,55),(53,137),(54,32),(55,57),(56,481),(57,481),(58,165),(59,295),(60,
44),(61,44),(62,534),(63,534),(64,194),(65,204),(66,292),(67,193),(68,352),(69,301)
,(70,195),(71,172),(72,109),(73,109),(74,450),(75,450),(76,708),(77,188),(78,118),(
79,126),(80,108),(81,108),(82,146),(83,94),(84,55),(85,143),(86,100),(87,100),(88,8
2),(89,82),(90,75),(91,207),(92,236),(93,234),(94,34),(95,199),(96,285),(97,316),(9
8,271),(99,132),(100,54),(101,35),(102,35),(103,89),(104,146),(105,178),(106,197),(
107,245),(108,55),(109,61),(110,61),(111,61),(112,61),(113,155),(114,263),(115,128)
,(116,370),(117,291),(118,291),(119,152),(120,87),(121,87),(122,155),(123,155),(124
,502),(125,502),(126,363),(127,117),(128,59),(129,102),(130,413),(131,27),(132,419)
,(133,45),(134,45),(135,239),(136,107),(137,65),(138,19),(139,19),(140,123),(141,12
3),(142,123),(143,305),(144,86),(145,251),(146,251),(147,187),(148,200),(149,187),(
150,339),(151,136),(152,348),(153,105),(154,107),(155,312),(156,312),(157,198),(158
,128),(159,127),(160,158),(161,164),(162,367),(163,205),(164,129),(165,165),(166,26
4),(167,371),(168,168),(169,301),(170,205),(171,160),(172,278),(173,360),(174,34),(
175,89),(176,92),(177,225),(178,318),(179,366),(180,21),(181,196),(182,397),(183,85
),(184,85),(185,250),(186,266),(187,57),(188,305),(189,305),(190,305),(191,305),(19
2,305),(193,73),(194,154),(195,154),(196,261),(197,258),(198,232),(199,152),(200,36
3),(201,363),(202,108),(203,174),(204,324),(205,324),(206,379),(207,302),(208,156),
(209,251),(210,216),(211,255),(212,304),(213,304),(214,267),(215,267),(216,267),(21
7,108),(218,39),(219,249),(220,126),(221,183),(222,18),(223,146),(224,223),(225,420
),(226,38),(227,232),(228,232),(229,232),(230,253),(231,94),(232,204),(233,208),(23
4,248),(235,76),(236,204),(237,248),(238,406),(239,134),(240,86),(241,221),(242,264
),(243,69),(244,69),(245,253),(246,166),(247,190),(248,190),(249,145),(250,207),(25
1,145),(252,207),(253,396),(254,278),(255,278),(256,255),(257,255),(258,72),(259,51
3),(260,394),(261,471),(262,505),(263,505),(264,505) 
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• Production
The Production variable takes the value of Normal Orders From Countries and delays 
it for the amount of time given by Normal Lead Time Lookup before pushing it back into 
the model. To achieve this, a delay function will be used. From the available delays in 
Vensim, the Delay Material function is most applicable since it preserves quantities and 
the delay time can be a variable instead of being a fixed value. The function for delay 
material is: 
DELAY MATERIAL( a , b , c , d ) 
where a is the input, b is the delay time, c is the starting value and d is the value to be
used if no delayed inputs are available. The equation for production is therefore: 
Production[Formulations,Order Number]=
DELAY MATERIAL(Normal Orders From Countries[Formulations,Order Number], 
Normal Lead Time Lookup[Formulations,Order Number](time) , 0 , 0) 
• Normal Order Drugs Awaiting Dispatch
Normal Order Drugs Awaiting Dispatch is calculated as the integral of the difference 
between the inflow and the outflow, in this case the production and normal orders 
fulfilled for countries, respectively. In Vensim, this equation is: 
Normal Order Drugs Awaiting Dispatch[Formulations,Order Number]= 
INTEG(Production[Formulations,Order Number]-Normal Orders Fulfilled For 
Countries[Formulations,Order Number],0) 
As previously mentioned, the model assumes that the manufacturer entity does not 
keep any stock and that the SLDs are immediately dispatched once the production is 
completed. Therefore, the value this variable takes represent the drugs that have 
been received but not yet dispatched and delivered to countries. 
• Normal Orders Fulfilled For Countries
Since drugs are immediately dispatched after production, the Normal Orders Fulfilled 
For Countries variable will take on the same value as the Production variable, as soon 
as the delay period is over and a value is generated. The equation for the variable is 
therefore: 
Normal Orders Fulfilled For Countries[Formulations,Order Number]=   
IF THEN ELSE(Production[Formulations,Order Number] > 0 , 
Production[Formulations,Order Number], 0 ) 
E.2.2.4 Country related variables 
The section of the model related to the countries is repeated in Figure E.3 for 
convenience. As seen in the figure, the variables related to the cost are (i) Normal Order 
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Drugs Received By Countries, (ii) Normal Orders Supply Line, and (iii) Total Drugs 
Received By Countries.  
Figure E.3: Country section of Model A. 
• Normal Order Drugs Received By Countries
The Normal Order Drugs Received By Countries variable is merely equal to the value 
generated by Normal Orders Fulfilled For Countries. Its equation is: 
Normal Order Drugs Received By Countries[Formulations,Order Number]= 
Normal Orders Fulfilled For Countries[Formulations,Order Number] 
• Normal Orders Supply Line
The number of drugs that have been ordered by countries, but not yet received is 
represented by the Normal Orders Supply Line variable. This variable can be used at 
the end of the simulation run to identify the number of drugs that have not yet been 
delivered. The equation for this variable is as follows: 
Normal Orders Supply Line[Formulations,Order Number]=
INTEG(Normal Orders From Countries[Formulations,Order Number]-    
Normal Order Drugs Received By Countries[Formulations,Order Number], 0) 
• Total Drugs Received By Countries
The Total Drugs Received By Countries variables returns the total number of drugs (for 
all order numbers) that have been delivered to the countries, for each formulation. This 
variable is useful to compare with the total demand values from the historical data.  
Total Drugs Received By Countries[Formulations]=  
INTEG(Normal Order Drugs Received By Countries[Formulations,Order 
Number!],0) 
E.2.2.5 Cost related variables 
The cost section of the model is repeated in Figure E.4 for convenience. As seen in the 
figure, the variables related to the cost are, (i) Per Unit Cost, (ii) Total Unit Cost, (iii) 
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Cumulative Total Unit Cost, and (iv) Total Costs. The Normal Orders From Countries 
variable is a shadow variable from the main model.  
Figure E.4: Cost section of Model A. 
• Per Unit Cost
The average unit cost, from 2010 to 2015, for the 3 formulations, as well as the average 
cost over the six years, is summarised in Table E.4.   
Since the per unit cost will be the same for all order numbers, but different for each 
formulation, the equations for the variable are: 
Per Unit Cost [Capreomycin,Order Number] = 5.54, 5.54, 5.54, 5.54 
Per Unit Cost [Kanamycin,Order Number] = 2.59, 2.59, 2.59, 2.59 
Per Unit Cost [Cycloserine,Order Number] = 0.53, 0.53, 0.53, 0.53 
Table E.4: Summary of costs from 2010 – 2014. 
Formulation Description 
Average Unit Cost ($US) 
2010 2011 2012 2013 2014 Avg 
Capreomycin 
1g powder for 
injection 
4.00 7.01 6.66 5.53 5.13 5.66 
Kanamycin 
1g solution for 
injections (4ml) 
2.79 2.61 2.58 2.49 2.50 2.59 
Cycloserine 
250mg hard 
capsules 
0.67 0.60 0.59 0.49 0.42 0.55 
• Total Unit Cost
The total unit cost is calculated separately for each order by multiplying the per unit 
cost by the number of drugs ordered. The equation in Vensim is: 
Total Unit Cost[Formulations,Order Number]=   
Normal Orders From Countries[Formulations,Order Number] * 
Per Unit Cost[Formulations ,Order Number] 
• Cumulative Total Unit Cost
The cumulative total unit cost is added so that the total costs for each order at any given 
time step can be viewed. The equation is: 
Cumulative Total Unit Cost[Formulations,Order Number]= 
INTEG (Total Unit Cost[Formulations,Order Number], 0) 
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• Total Costs
The Total Costs variable is intended to include all of the costs; however, since only unit 
costs are used in this model, it is the only cost included. The equation is: 
Total Costs[Formulations]=   
SUM(Cumulative Total Unit Cost[Formulations,Order Number!]) 
This variable can be used to compare the total costs associated with different policies 
during the scenario implementation phase.  
E.3 Modelling details of Model B 
This section provides the modelling details associated with Model B, as defined and 
discussed in Section 6.3.5. The variables that are included in the model will be identified 
and their equations and characteristics will be described.  
E.3.1 Model B: Variable types 
As before, the applicable variables and concepts were identified as either a stock 
variable (accumulations within the system), flow variable (determines the variation of 
stock) or auxiliary variable (constants or estimates). The list of the applicable variables, 
their variable type and their units can be seen in Table E.5. The table includes several 
variables, in addition to those initially identified in Section E.1, that were added during 
the development of the model.  
Table E.5: Variable types for Model B. 
Variable Name Unit Variable Type 
Country Dispatch Lead Time  Week Auxiliary 
Cumulative Obsolete Stock  Drugs Stock 
Cumulative Purchase Unit Cost  Dollar Stock 
Cumulative Stockpile Replenishment Cost Dollar Stock 
Cumulative Total Obsolescence Cost  Dollar Stock 
Demand Input  Drugs/Week Auxiliary 
Dispatch Emergency Drugs To Countries  Drugs/Week Flow 
Drugs Available For Emergency Orders Drugs/Week Flow 
Drugs Available For Stock Rotation  Drugs/Week Auxiliary 
Drugs Dispatched As Stock Rotation Drugs/Week Flow 
Drugs Received From Manufacturer  Drugs/Week Flow 
Drugs To Be Dispatched For Stock Rotation Drugs/Week Auxiliary 
Emergency Input  Drugs/Week Auxiliary 
Emergency Order Cost  Dollar/Week Flow 
Emergency Order Drugs Received By 
Countries  
Drugs/Week Flow 
Emergency Orders From Countries  Drugs/Week Flow 
Emergency Orders Supply Line  Drugs Stock 
continued on next page 
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continued from previous page 
Emergency Proportion Of Orders Placed  Dmnl Auxiliary 
Emergency Weibull Distribution  Drugs/Week Auxiliary 
Expiration Value  Week Auxiliary 
Initial Stock On Hand  Drugs Auxiliary 
Normal Order Drugs Awaiting Dispatch  Drugs Stock 
Normal Order Drugs Received By Countries Drugs/Week Flow 
Normal Order Purchase Cost Dollar/Week Flow 
Normal Orders From Countries  Drugs/Week Flow 
Normal Orders Supply Line  Drugs Stock 
Obsolete Stock  Drugs/Week Flow 
Order Processing  Drugs/Week Flow 
Order Processing Lead Time  Week Auxiliary 
Orders Placed To Manufacturer  Drugs/Week Flow 
Per Unit Cost  Dollar/Drugs Auxiliary 
Processed Orders  Drugs/Week Auxiliary 
Processing Drugs For Stock Rotation  Drugs/Week Flow 
Production & Dispatch Lead Time  Week Auxiliary 
Production & Dispatch To GDF/PA  Drugs/Week Flow 
Production & Dispatch To SRS  Drugs/Week Flow 
Proportion Of Orders Placed  Dmnl Auxiliary 
QC's & Dispatch To Countries  Drugs/Week Flow 
Rotation Value Start Week Auxiliary 
Rotation Value Stop Week Auxiliary 
SRS Demand  Drugs/Week Auxiliary 
SRS Stock On Hand  Drugs Stock 
SRS Supply Line  Drugs Stock 
Stockpile Rotation Cost Dollar/Week Flow 
TIME STEP  Week Built-in 
Total Costs  Dollar Auxiliary 
Total Emergency Order Drugs Received  Drugs Stock 
Total Normal Order Drugs Received  Drugs Stock 
Total Obsolescence Cost  Dollar/Week Flow 
Uniform  Dmnl Auxiliary 
Weibull Distribution  Drugs/Week Auxiliary 
E.3.2 Model B: Characteristics and equations of elements 
This subsection provides the equations and values that were assigned to the previously 
identified variables and concepts of Model B. 
E.3.2.1 Lead times 
The main difference in Model B is the implementation of three separate lead times. As 
discussed in Section 6.3.5.2, the lead times was implemented in the model through 
triangular distributions. The triangular distribution is based on three values, a minimum, 
maximum and peak value. Vensim also allows the application of a ‘range constraint’ of 
sorts, which limits the output generated by the triangular distribution to fall within the 
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range. The initial parameters and range values were based on country case studies, 
averages or estimates obtained from WHO (2008); Giffin and Robinson (2009); Lunte 
(2012); Nicholson et al.  (2013); Keravec (2014); Muzafarova (2015). These values were 
experimented with and adjusted until the total lead time (sum of the three lead times) 
from the model, represented the lead time in the data.  
The equation used for triangular distributions in Vensim is: 
RANDOM TRIANGULAR( _min_ , _max_ , _start_ , _peak_ , _stop_ , _seed_ ) 
Where min and max is the range of the output values, and start, peak, and stop is the 
start, average and stop value of the triangle. The equation for the order processing lead 
time is: 
Order Processing Lead Time[Formulations,Order Number]= 
RANDOM TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) 
This is illustrated in Figure E.5. The output values will all fall within the shaded area. 
Figure E.5: Illustration of triangular distribution for order processing lead time. 
The equation for the production and dispatch lead time is: 
"Production & Dispatch Lead Time”[Formulations,Order Number]=
RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) 
This is illustrated in Figure E.6. The output values will all fall within the shaded area. 
Figure E.6: Illustration of triangular distribution for production and dispatch lead time. 
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The equation for the country dispatch lead time is: 
Country Dispatch Lead Time [Formulations,Order Number] =
RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) 
This is illustrated in Figure E.7. The output values will all fall within the shaded area. 
Figure E.7: Illustration of triangular distribution for country dispatch lead time. 
E.3.2.2 Normal order related variables 
The normal orders section of the model is repeated in Figure E.8 for convenience. As 
seen in the figure, the variables related to the normal orders are, (i) Weibull Distribution, 
(ii) Proportion of Orders Placed, (iii) Uniform, (iv) Demand Input, (v) Normal Orders From 
Countries, (vi) Normal Orders Supply Line, (vii) Normal Order Drugs Received By 
Countries, (viii) Total Normal Order Drugs Received, (ix) Order Processing, and (x) 
Processed Orders. 
Figure E.8: Normal orders section of Model B. 
As with Model A, there can be up to four normal orders placed in any time step. 
Variables that remained and has the same equations as Model A: 
i. Demand Input (Called country demand input in Model A),
ii. Normal Orders From Countries,
iii. Normal Orders Supply Line,
iv. Proportion Of Orders Placed,
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v. Total Normal Order Drugs Received (called Total Drugs Received By Countries
in Model A),
vi. Uniform, and
vii. Weibull Distribution.
The remaining three variables of the normal orders section are described below. 
• Order Processing
Order Processing is a flow variable that was added to represent the ordering process 
of the normal orders that were placed by countries. A delay function is used to take the 
value of Normal Orders From Countries and delay it for the amount of time given by 
Order Processing Lead Time before pushing it back into the model. The equation for 
this variable is: 
Order Processing[Formulations,Order Number]=   
DELAY MATERIAL (Normal Orders From Countries[Formulations,Order 
Number], Order Processing Lead Time[Formulations,Order Number], 0, 0) 
• Processed Orders
The Processed Orders variable is merely equal to the value generated by Order 
Processing. Its equation is: 
Processed Orders[Formulations,Order Number]= 
Order Processing[Formulations,Order Number] 
• Normal Order Drugs Received By Countries
Normal order drugs are fulfilled by the GDF/PA either through stock rotation or by 
ordering the drugs from manufacturers on behalf of countries. Therefore, the Normal 
Order Drugs Received By Countries variable equals the sum of both QC's & Dispatch 
To Countries and Drugs Dispatched As Stock Rotation, as illustrated in the equation: 
Normal Order Drugs Received By Countries[Formulations,Order Number]=  
"QC's & Dispatch To Countries"[Formulations,Order Number] +  
Drugs Dispatched As Stock Rotation[Formulations,Order Number] 
E.3.2.3 Production of normal order drugs 
The production of normal order drugs section of the model is repeated in Figure E.9 for 
convenience. As seen in the figure, the unique variables related to this section are, (i) 
Production & Dispatch TO GDF/PA, (ii) QC’s & Dispatch To Countries, and (iii) Normal 
Order Drugs Awaiting Dispatch. 
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Figure E.9: Production of normal order drugs section of Model B. 
• Production & Dispatch To GDF/PA
The Production & Dispatch to GDF/PA variable represents the orders that have been 
processed and has to be produced by manufacturers and dispatched to the GDF/PA; 
therefore, it only considers the orders that have completed the order process and that 
will not be fulfilled through stock rotation. This calculated amount of orders that has to 
produced are delayed for the amount of time given by Production & Dispatch Lead 
Time. The equation for the variable is:  
"Production & Dispatch To GDF/PA"[Formulations,Order Number]=     
DELAY MATERIAL(( Processed Orders[Formulations,Order Number] -  
Drugs To Be Dispatched For Stock Rotation[Formulations,Order Number] 
),"Production & Dispatch Lead Time"[Formulations,Order Number],0, 0) 
• QC's & Dispatch To Countries
After production, the drugs are dispatched to the GDF/PA for quality checks (QC). This 
variable takes the value of the Production & Dispatch To GDF/PA variable and delays 
it for the amount of time given by Country Dispatch Lead Time before pushing it back 
into the model. The equation is: 
"QC's & Dispatch To Countries"[Formulations,Order Number]=
DELAY MATERIAL( IF THEN ELSE("Production & Dispatch To 
GDF/PA"[Formulations,Order Number] > 0 , "Production & Dispatch To 
GDF/PA"[Formulations,Order Number] , 0 ) , Country Dispatch Lead 
Time[Formulations,Order Number] , 0 , 0) 
As illustrated in the equation, an IF THEN ELSE function is used to ensure that the value 
of the variable is zero if the Production & Dispatch To GDF/PA variable is zero. 
• Normal Order Drugs Awaiting Dispatch
The Normal Order Drugs Awaiting Dispatch variable can be seen as a ‘buffer’ area 
where drugs that have been produced and dispatched are waiting to be sent to the 
countries. This variable will mostly have a value of zero, or swiftly return to a value of 
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zero, since the drugs will immediately go from production to QC and dispatch. The 
equation is: 
Normal Order Drugs Awaiting Dispatch[Formulations,Order Number]= INTEG ( 
"Production & Dispatch To GDF/PA"[Formulations,Order Number]-"QC's & 
Dispatch To Countries"[Formulations,Order Number],0) 
E.3.2.4 Stockpile related variables 
This section will describe the four variables specifically related to the stockpile section 
of Model B. The four variables are (i) Initial Stock On Hand, (ii) SRS Stock On Hand, and 
(iii) SRS Demand. Although there can be up to four normal orders placed, processed, 
manufactured and delivered; the stockpile only recognises one order. However, since 
the subscripts are coded in the model, a value of 0 is assigned to order2, order3 and 
order4 for the variables related to the stockpile.  
• Initial Stock On Hand
The calculations for the initial stock on hand were provided in Section 6.3.5.2. The 
equations in Vensim are: 
Initial Stock On Hand[Capreomycin,Order Number] = 221018, 0, 0, 0 
Initial Stock On Hand[Kanamycin,Order Number] = 184984, 0, 0, 0 
Initial Stock On Hand[Cycloserine,Order Number] = 3.07664e+06, 0, 0, 0 
• SRS Stock On Hand
The following function was used for the stockpile: 
QUEUE FIFO (inflow, outflow, profile, initial, age range) 
This will assume that the stockpile handles drugs on a first-in-first-out basis, to 
potentially minimise the obsolete stock. Another advantage of the QUEUE function, is 
that the model now tracks the age of the drugs in the stockpile, which is used to 
determine when drugs are eligible for rotation and when they become obsolete.  
It is assumed initially the stockpile is full and that the drugs still have their full shelf life 
remaining. The profile variable is a probability distribution function that runs from 0 to 
age range and has an area of 1. The inflow of the stockpile are drugs delivered from 
manufacturers based on orders placed by the SRS while the outflow comprises of 
emergency orders, stock rotation and obsolete stock. This is illustrated in the equation: 
SRS Stock On Hand[Formulations,Order Number]= QUEUE FIFO( "Production & 
Dispatch To SRS"[Formulations,Order Number] , Processing Drugs For 
Stock Rotation[Formulations,Order Number] + Obsolete 
Stock[Formulations,Order Number] + Drugs Available For Emergency 
Orders[Formulations,Order Number]  , Profile , Initial Stock On 
Hand[Formulations,Order Number] , 0 ) 
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• SRS Demand
Since it is assumed that the SRS currently follows a base stock policy, they will place 
an order to manufacturers of the exact size of what was removed from the stockpile. 
The equation for the SRS demand is therefore: 
SRS Demand[Formulations,Order Number]= Drugs Available For Emergency 
Orders[Formulations,Order Number] + Obsolete Stock[Formulations,Order 
Number] + Processing Drugs For Stock Rotation [Formulations,Order 
Number] 
E.3.2.5 Stockpile supply line related variables 
The stockpile supply line section is illustrated in Figure E.10. The three unique variables 
associated with this section, are (i) Orders Placed To Manufacturer, (ii) SRS Supply line, 
(iii) Drugs Received From Manufacturer, and (iv) Production & Dispatch To SRS. 
Figure E.10: Stockpile supply line section of Model B. 
• Production and dispatch to SRS
The Production & Dispatch To SRS variable takes the value of SRS Demand and delays 
it for the amount of time given by Production & Dispath Lead Time before pushing it 
back into the model. The equation is: 
"Production & Dispatch To SRS"[Formulations,Order Number]= DELAY 
MATERIAL (SRS Demand[Formulations,Order Number] , "Production & 
Dispatch Lead Time"[Formulations,Order Number] , 0 , 0) 
• Orders placed to manufacturer
The Orders Placed To Manufacturer variable is merely equal to the value generated by 
SRS Demand. Its equation is: 
Orders Placed To Manufacturer[Formulations,Order Number]=       
SRS Demand[Formulations,Order Number] 
• Drugs received from manufacturer
The Drugs Received From Manufacturer variable is merely equal to the value 
generated by Production & Dispatch To SRS. Its equation is: 
Drugs Received From Manufacturer[Formulations,Order Number]= 
"Production & Dispatch To SRS"[Formulations,Order Number] 
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• SRS supply line
The SRS supply line represents the drugs that have been ordered from manufactures, 
but not yet delivered. The equation is given as: 
SRS Supply Line[Formulations,Order Number]= INTEG   
(Orders Placed To Manufacturer[Formulations,Order Number]- 
Drugs Received From Manufacturer [Formulations,Order Number],0) 
 
E.3.2.6 Stock rotation related variables 
The stock rotation section of Model B is presented in Figure E.11 for convenience. The 
related variables that will be discussed are, (i) Rotation Value Start, (ii) Rotation Value 
Stop, (iii) Drugs Available For Stock Rotation, (iv) Drugs To Be Dispatched For Stock 
Rotation, and (v) Drugs Dispatched As Stock Rotation. 
Figure E.11: Stock rotation section of Model B. 
• Rotation values
The details of the rotation values was discussed in Section 6.3.5.2. The values were 
determined based on the shelf life of each formulation, as provided in Table E.6.  
Table E.6: Shelf lives of the dormulations. 
Formulation Description Shelf Life 
Capreomycin 1g powder for injection 24 Months 
Kanamycin 1g solution for injections (4ml) 36 Months 
Cycloserine 250mg hard capsules 24 Months 
The rotation value start and rotation value stop are given as: 
Rotation Value Start[Capreomycin,Order Number]= 16,16,16,16 
Rotation Value Start[Kanamycin,Order Number]= 40, 40, 40, 40 
Rotation Value Start[Cycloserine,Order Number]= 16,16,16,16 
Rotation Value Stop[Capreomycin,Order Number]= 36,36,36,36 
Rotation Value Stop[Kanamycin,Order Number]= 84,84,84,84 
Rotation Value Stop[Cycloserine,Order Number]= 36,36,36,36 
• Drugs available for stock rotation
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Since all of the orders can be fulfilled through stock rotation, the drugs available for 
each of the four orders (order1, order2, order3 and order4) are: 
Drugs Available For Stock Rotation[Formulations,Order Number]= 
MAX(0,(QUEUE AGE IN RANGE( SRS Stock On Hand[Formulations,Order1] , 
Rotation Value Start[Formulations,Order1] , Rotation Value 
Stop[Formulations,Order1] )/TIME STEP) - Obsolete 
Stock[Formulations,Order1]) 
This equation (Queue age in range) ensures that only the drugs that have been in the 
stockpile between the Rotation Value Start and Rotation Value Stop will be dispatched. 
• Drugs to be dispatched for stock rotation
The most orders that can be fulfilled at any time is four (order1, order2, order3 and 
order4). It is possible that all four of these orders can be fulfilled through means of stock 
rotation as long as the number of drugs that are eligible for stock rotation is enough for 
all four of these orders. To implement this in the model, however, it is assumed that 
order1 will receive preference over order2, which receives preference over order 2, 
which receives preference over order4. The equation for the drugs to be dispatched for 
stock rotation for order1 is: 
Drugs To Be Dispatched For Stock Rotation[Formulations,Order1]= IF THEN 
ELSE(Drugs Available For Stock Rotation[Formulations,Order1] > Processed 
Orders[Formulations,Order1], Processed Orders[Formulations,Order1] , 0 ) 
As depicted in the equation, all of the drugs required for order1 is dispatched if enough 
is available, otherwise no drugs are dispatched. For order2, the equation is different. 
The model first assesses whether drugs were dispatched for order1 from the stockpile. 
If no drugs for order1 were dispatched through stock rotation, but there are enough 
drugs available to fulfil order2, the drugs are dispatched for order2; otherwise, zero 
drugs are dispatched. However, if order1 was fulfilled through stock rotation, the drugs 
available for stock rotation has to be adjusted by subtracting the number of drugs that 
was dispatched for order1. This is illustrated in the equation for order2: 
Drugs To Be Dispatched For Stock Rotation[Formulations,Order2]= IF THEN 
ELSE(Drugs To Be Dispatched For Stock Rotation[Formulations,Order1]>0 , 
IF THEN ELSE(Drugs Available For Stock Rotation[Formulations,Order2] - 
Drugs To Be Dispatched For Stock Rotation [Formulations,Order1] > 
Processed Orders[Formulations,Order2],  
Processed Orders [Formulations,Order2] , 0 ) ,  
IF THEN ELSE( Drugs Available For Stock Rotation[Formulations,Order2] > 
Processed Orders [Formulations,Order2] , Processed 
Orders[Formulations,Order2] , 0 ) ) 
The same principle is followed for the remaining two equations, however, for order3 the 
drugs dispatched for order1 and order2 is taken into consideration, while for order4 the 
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drugs the dispatched for order1, order2 and order3 is taken into consideration. The 
remaining two equations are: 
Drugs To Be Dispatched For Stock Rotation[Formulations,Order3]= IF THEN 
ELSE( Drugs To Be Dispatched For Stock Rotation[Formulations,Order1] + 
Drugs To Be Dispatched For Stock Rotation[Formulations,Order2] > 0 ,     
IF THEN ELSE( Drugs Available For Stock Rotation[Formulations,Order3] - 
Drugs To Be Dispatched For Stock Rotation [Formulations,Order2] -     
Drugs To Be Dispatched For Stock Rotation[Formulations,Order1] > 
Processed Orders[Formulations,Order3] ,  
Processed Orders[Formulations,Order3] , 0 ) ,  
IF THEN ELSE( Drugs Available For Stock Rotation[Formulations,Order3] > 
Processed Orders [Formulations,Order3] ,   
Processed Orders[Formulations,Order3] , 0 ) ) 
Drugs To Be Dispatched For Stock Rotation[Formulations,Order4]= IF THEN 
ELSE( Drugs To Be Dispatched For Stock Rotation[Formulations,Order1] + 
Drugs To Be Dispatched For Stock Rotation[Formulations,Order2] + Drugs 
Available For Stock Rotation [Formulations,Order3] > 0 ,   
IF THEN ELSE( Drugs Available For Stock Rotation[Formulations,Order4] - 
Drugs To Be Dispatched For Stock Rotation [Formulations,Order3] - Drugs 
To Be Dispatched For Stock Rotation[Formulations,Order2] - Drugs To Be 
Dispatched For Stock Rotation[Formulations,Order1] > Processed 
Orders[Formulations,Order4] , Processed Orders[Formulations,Order4],0 ) 
, IF THEN ELSE( Drugs Available For Stock Rotation[Formulations,Order4] 
> Processed Orders [Formulations,Order4] , Processed 
Orders[Formulations,Order4] , 0 ) ) 
• Processing drugs for stock rotation
Although order1, order2, order3 and order4 can be fulfilled through stock rotation from 
the stockpile, the stockpile only acknowledges order1. To ensure that the stockpile 
recognises outgoing stock of all four orders, the equation for order1 is given as: 
Processing Drugs For Stock Rotation[Formulations,Order1]= (  
Drugs To Be Dispatched For Stock Rotation[Formulations,Order1]) +     
Drugs To Be Dispatched For Stock Rotation[Formulations,Order2] +       
Drugs To Be Dispatched For Stock Rotation[Formulations,Order3] +       
Drugs To Be Dispatched For Stock Rotation[Formulations,Order4] 
This ensures that the sum of the drugs that are dispatched for all four orders are 
removed from the stockpile. The value for order2, order3 and order3 are set to zero: 
Processing Drugs For Stock Rotation[Formulations,Order2] = 0 
Processing Drugs For Stock Rotation[Formulations,Order3] = 0 
Processing Drugs For Stock Rotation[Formulations,Order4] = 0 
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• Drugs dispatched as stock rotation
This variable takes the output of processing drugs for stock rotation and delays it by 
the amount of time specified by country dispatch lead time, before returning it to the 
model. The equation is given as: 
Drugs Dispatched As Stock Rotation[Formulations,Order Number]= DELAY 
MATERIAL(Processing Drugs For Stock Rotation[Formulations,Order Number], 
Country Dispatch Lead Time[Formulations,Order Number], 0, 0) 
E.3.2.7 Obsolete stock related variables 
The variables related the obsolete stock are (i) expiration value, (ii) obsolete stock, and 
(iii) cumulative obsolete stock.  
• Expiration value
The expiration value is the age of a drug when it is considered obsolete. These values 
are less than the shelf life, since it takes into account the average time that it takes a 
drug to be delivered to a country and that a drug typically needs several months of 
shelf life left when delivered. The equations are: 
Expiration Value[Capreomycin,Order Number] = 52, 0, 0, 0 
Expiration Value[Kanamycin,Order Number] = 100, 0, 0, 0 
Expiration Value[Cycloserine,Order Number] = 52, 0, 0, 0 
• Obsolete stock
All of the drugs that have been in the stockpile longer than the expiration value, are 
considered obsolete and removed from the stock. Since the stockpile only keeps one 
stock for all orders, the value for order2, order3, and order4 is automatically zero. The 
equations are: 
Obsolete Stock[Formulations,Order1]= QUEUE AGE IN RANGE( SRS Stock On 
Hand[Formulations,Order1] , Expiration Value[Formulations,Order1] , 
:NA: )/TIME STEP 
Obsolete Stock[Formulations,Order2]= 0 
Obsolete Stock[Formulations,Order3]= 0 
Obsolete Stock[Formulations,Order4]= 0 
• Cumulative obsolete stock
The cumulative obsolete stock, is a stock variable that adds up all of the obsolete stock 
to provide the total number of units that was ‘lost’. The equation is: 
Cumulative Obsolete Stock[Formulations,Order Number]= 
INTEG (Obsolete Stock[Formulations,Order Number],0) 
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E.3.2.8 Emergency order related variables 
The emergency order section is illustrated in Figure E.12 for convenience. In generela, 
this section functions the same as the normal orders section, except that drugs are 
dispatched from the stockpile instead of being manufactured first. The variables 
associated with the emergency orders are, (i) Emergency Weibull distribution, (ii) 
Emergency proportion of orders placed, (iii) Emergency input,  (iv) Emergency orders 
from countries, (v) Drugs available for emergency orders, (vi) Dispatch emergency drugs 
to countries, (vii) Emergency order drugs received by countries, (viii) Emergency orders 
supply line, and (ix) Total emergency order drugs received.  
Figure E.12: Emergency order section of Model B. 
• Emergency Weibull distribution
The Weibull distributions for emergency orders are assumed to be the same as for 
normal orders (Weibull Distribution Variable) but the maximum value has been reduced 
since only small orders are allowed for emergency. It is assumed that the maximum 
size an emergency order may be is 25% of the stockpile capacity. The equations are: 
Emergency Weibull Distribution[Capreomycin,Order Number]=
RANDOM WEIBULL( 78 , 55255 , 0.6161 , 78 , 32500 , 0 ) 
Emergency Weibull Distribution[Kanamycin,Order Number]=
RANDOM WEIBULL( 450 , 46246 ,0.4525 , 450 , 50000 , 1 ) 
Emergency Weibull Distribution[Cycloserine,Order Number]= RANDOM 
WEIBULL( 1500 , 769160 , 0.4755 , 1500 , 420000 , 1 ) 
• Emergency proportion of orders placed
Since it is not stipulated in the data which orders are emergency orders, an assumption 
on the proportion of orders had to made.  From all the SLDs in the data with a total lead 
time of less than 90 days, roughly 16,9% of the orders from 2010 to 2014 were for 
cycloserine, while 10,6% was for capreomycin and 11,2% was for kanamycin. This is the 
values that will be used in the model. The equations are therefore: 
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Emergency Proportion Of Orders Placed[Capreomycin,Order Number]=  
0.106, 0, 0, 0 
Emergency Proportion Of Orders Placed[Kanamycin,Order Number]=
0.086, 0, 0, 0 
Emergency Proportion Of Orders Placed[Cycloserine,Order Number]=   
0.168, 0, 0, 0 
• Emergency input
The emergency input is the same as for normal orders. The equation is given as: 
Emergency Input[Formulations,Order Number]=    
IF THEN ELSE( Uniform[Formulations,Order Number] <   
Emergency Proportion Of Orders Placed[Formulations,Order Number] , 
Emergency Weibull Distribution[Formulations,Order Number] , 0 ) 
• Emergency orders from countries
This variable has the same value of the emergency input. The equation therefore is: 
Emergency Orders From Countries[Formulations,Order Number]=
Emergency Input[Formulations,Order Number] 
• Drugs available for emergency orders
If the stockpile has enough stock on hand to fulfil an emergency order, it dispatches the 
number of drugs required by countries. However, if not enough stock is on hand to fulfil 
the entire order, the stockpile will dispatch all the available drugs. This is illustrated in 
the equation: 
Drugs Available For Emergency Orders[Formulations,Order Number]=  
MAX(IF THEN ELSE( SRS Stock On Hand[Formulations,Order Number]>= 
Emergency Orders From Countries[Formulations,Order Number], Emergency 
Orders From Countries[Formulations,Order Number] - Obsolete Stock 
[Formulations,Order Number] , SRS Stock On Hand[Formulations,Order 
Number] - Obsolete Stock[Formulations,Order Number] ),0) 
• Dispatch emergency drugs to countries
The dispatch emergency drugs to countries variable, takes the value of drugs available 
for emergency orders and delays it for the amount of time specified by country dispatch 
lead time. The equation is: 
Dispatch Emergency Drugs To Countries[Formulations,Order Number]= DELAY 
MATERIAL(Drugs Available For Emergency Orders[Formulations,Order 
Number], Country Dispatch Lead Time[Formulations,Order Number], 0, 0) 
• Emergency order drugs received by countries
The emergency order drugs received by countries are equal to the number of drugs 
that have been dispatched to countries. The equation is: 
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Emergency Order Drugs Received By Countries[Formulations,Order Number]= 
Dispatch Emergency Drugs To Countries[Formulations,Order Number] 
• Emergency orders supply line
This supply line, represents the emergency orders that have been placed, but not yet 
fulfilled. The equation is: 
Emergency Orders Supply Line[Formulations,Order Number]= INTEG (Emergency 
Orders From Countries[Formulations,Order Number] - Emergency Order Drugs 
Received By Countries[Formulations,Order Number], 0) 
• Total emergency order drugs received
The total emergency order drugs received is the sum of all the drugs that have been 
received by countries as part of an emergency order. The equation is: 
Total Emergency Order Drugs Received[Formulations,Order Number]= INTEG ( 
Emergency Order Drugs Received By Countries[Formulations,Order Number], 
0) 
E.3.2.9 Cost related variables 
The cost section of Model B is repeated in Figure E.13 for convenience. The Per Unit 
Cost variable is the same as in Model A. The variables that will be discussed in this 
section include (i) Cumulative Purchase Unit Cost, (ii) Cumulative Stockpile 
Replenishment Cost, (iii) Emergency Order Cost, (iv) Normal Order Purchase Cost, (v) 
Stockpile Rotation Cost, (vi) Total Obsolescence Cost, (vii) Cumulative Total 
Obsolescence Cost, and (viii) Total Costs. 
Figure E.13: Cost section of Model B. 
• Normal order purchase cost
The normal order purchase cost entails the cost of procuring drugs from manufacturers 
to send to countries. It is calculated as the product of the per unit cost and the drugs 
that was manufactured for countries. As depicted in the equation, the drugs that was 
manufactured for countries is calculated as the difference between the processed 
orders and the drugs dispatched for stock rotation. The equation is:  
Stellenbosch University  https://scholar.sun.ac.za
E.3 Modelling details of Model B Page | 209 
Stellenbosch University 
Normal Order Purchase Cost[Formulations]= (   
SUM(Processed Orders[Formulations,Order Number!])-
SUM(Drugs To Be Dispatched For Stock Rotation[Formulations,Order 
Number!])) * Per Unit Cost[Formulations] 
• Cumulative purchase unit cost
The cumulative purchase unit cost is the sum of the normal order purchase cost. It gives 
the total cost associated with the procurement of drugs for countries from manufacturers 
over the entire simulation period. The equation is: 
Cumulative Purchase Unit Cost[Formulations]= INTEG (Normal Order Purchase 
Cost[Formulations], 0) 
• Emergency order cost
The drugs that are dispatched from the stockpile to fulfil emergency orders has to 
replace in order to keep the stockpile full. The emergency order costs, therefore, 
represent the total cost of drugs that was dispatched to fulfil the emergency orders. The 
equation is given as: 
Emergency Order Cost[Formulations]= SUM(Drugs Available For Emergency 
Orders[Formulations,Order Number!])*Per Unit Cost[Formulations] 
• Stockpile rotation cost
The drugs that are dispatched from the stockpile as part of stock rotation, has to be 
replaced in order to keep the stockpile full. The stockpile rotation cost, therefore, 
represent the total cost of drugs that was dispatched at stock rotation. The equation is 
given as: 
Stockpile Rotation Cost[Formulations]= SUM(Processing Drugs For Stock 
Rotation[Formulations,Order Number!])*Per Unit Cost[Formulations] 
• Cumulative stockpile replenishment cost
The cumulative stockpile replenishment cost is the sum of the stockpile rotations cost 
and emergency order cost. It gives the total cost associated with the procurement of 
drugs from manufacturers to replenish the stockpile, over the entire simulation period. 
The equation is: 
Cumulative Stockpile Replenishment Cost[Formulations]= INTEG (Emergency 
Order Cost[Formulations]+Stockpile Rotation Cost[Formulations], 0) 
• Total obsolescence cost
The total obsolescence cost is calculated as the product of the per unit cost and the 
number of units that has become obsolete. The equation is: 
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Total Obsolescence Cost[Formulations]= Per Unit Cost[Formulations]     
* SUM(Obsolete Stock[Formulations,Order Number!])
• Cumulative total obsolescence cost
The cumulative total obsolescence cost is the sum of the obsolescence cost. It gives 
the total cost associated obsolescence. The equation is: 
Cumulative Total Obsolescence Cost[Formulations]= 
INTEG (Total Obsolescence Cost[Formulations], 0) 
• Total costs
The total costs are simply the sum of all the cumulative costs. The equation is: 
Total Costs[Formulations]=Cumulative Purchase Unit Cost[Formulations] + 
Cumulative Stockpile Replenishment Cost[Formulations] + Cumulative Total 
Obsolescence Cost[Formulations] 
E.4 Modelling details of Model C 
This section will discuss the modelling details associated with Model C, as defined and 
discussed in Section 6.3.6. The variables that are included in the model will be identified 
and the equations and characteristics for each of these variables will be discussed.  
E.4.1 Model C: Variable types 
As in the previous sections, the applicable variables and concepts of Model C were 
identified as either a stock variable (accumulations within the system), flow variable 
(determines the variation of stock) or auxiliary variable (constants or estimates). The list 
of the applicable variables, their variable type and their units can be seen in Table E.7. 
The table includes several variables, in addition to those initially identified in Section 
E.1, that were added during the development of the model.  
Table E.7: Variable types for Model C. 
Variable Name Unit Variable Type 
Backlog Range One  Drugs/Week Auxiliary 
Backlog Range Two  Drugs/Week Auxiliary 
Backlog Reduction  Drugs/Week Flow 
Country Dispatch Lead Time  Week Auxiliary 
Cumulative Obsolete Stock  Drugs Stock 
Cumulative Total Obsolescence Cost Dollar Auxiliary 
Cumulative Total Unit Cost  Dollar Auxiliary 
Demand Input  Drugs/Week Auxiliary 
Dispatch  Drugs/Week Flow 
Backlog Range One  Drugs/Week Auxiliary 
continued on next page 
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continued from previous page 
Dispatch Drugs To Countries  Drugs/Week Flow 
Drugs Available For Dispatch  Drugs/Week Auxiliary 
Drugs Received From Manufacturer  Drugs/Week Flow 
Drugs To Be Dispatched  Drugs/Week Auxiliary 
Expiration Value  Week Auxiliary 
Incoming  Drugs/Week Flow 
Initial Stock On Hand  Drugs Auxiliary 
Inventory Position  Drugs Auxiliary 
Normal Order Drugs Received By 
Countries  
Drugs/Week Flow 
Normal Orders From Countries  Drugs/Week Flow 
Normal Orders Supply Line  Drugs Stock 
Obsolete Stock  Drugs/Week Flow 
Order Backlogs  Drugs Stock 
Order Processing  Drugs/Week Flow 
Order Processing Lead Time  Week Auxiliary 
Orders Placed To Manufacturer  Drugs/Week Flow 
Per Unit Cost  Dollar/Drugs Auxiliary 
Processed Orders  Drugs/Week Auxiliary 
Production & Dispatch Lead Time  Week Auxiliary 
Production & Dispatch To SRS  Drugs/Week Flow 
Proportion Of Orders Placed  Dmnl Auxiliary 
SRS Demand  Drugs/Week Auxiliary 
SRS Stock On Hand  Drugs Stock 
SRS Supply Line  Drugs Stock 
Total Costs  Dollar Auxiliary 
Total Normal Order Drugs Received Drugs Stock 
Total Obsolescence Cost  Dollar/Week Auxiliary 
Total Unit Cost  Dollar/Week Auxiliary 
Uniform  Dmnl Auxiliary 
Weibull Distribution  Drugs/Week Auxiliary 
E.4.2 Model C: Characteristics and equations of elements 
This subsection provides the equations and values that were assigned to the previously 
identified variables and concepts of Model C.  
E.4.2.1 Lead times 
Model C also implements three separate lead times. The equations of the three lead 
time variables, namely (i) Order Processing Lead Time, (ii) Production & Dispatch Lead 
Time, and (iii) Country Dispatch Lead Time are equal to those in Model B, as discussed 
in Section E.3.2.1. 
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E.4.2.2 Normal order related variables 
The normal orders section of the model is repeated in Figure E.14 for convenience. The 
following variables related to normal orders are identical to those in Model B: (i) Weibull 
Distribution, (ii) Uniform, (iii) Proportion Of Orders Placed, (iv) Demand Input, (v) Normal 
Orders From Countries, (vi) Normal Orders Supply Line, (vii) Total Normal Order Drugs 
Received, (viii) Order Processing, and (ix) Processed Orders. These variables were 
discussed in Section E.3.2.2. 
Figure E.14: Normal order section of Model C. 
There is only one variable that has a slightly different equation, namely Normal Order 
Drugs Received By Countries. The new equation is: 
Normal Order Drugs Received By Countries[Formulations,Order Number]= 
Dispatch[Formulations,Order Number] 
E.4.2.3 Stockpile supply line related variables 
The section depicting the stockpile supply line is repeated in Figure E.15 for 
convenience. The variables that remained the same as in Model B are (i) Orders Placed 
To Manufacturer, (ii) SRS Supply line, (iii) Drugs Received From Manufacturer, and (iv) 
Production & Dispatch To SRS. Details on the equations for these variables are provided 
in Section E.3.2.4. 
Figure E.15: Stockpile supply line section of Model C. 
The equation for the SRS Demand variable will change according to the inventory 
policy that applies to the scenario being modelled. The inventory position is calculated 
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with the equation provided in Section 7.3.1. The equations for the inventory position are 
given as: 
Inventory Position[Formulations,Order1]= 
SRS Stock On Hand[Formulations,Order1] + 
SRS Supply Line[Formulations,Order1] -   
Order Backlogs[Formulations,Order1] -  
Order Backlogs[Formulations,Order2] - 
Order Backlogs[Formulations,Order3] - 
Order Backlogs[Formulations,Order4] 
Inventory Position[Formulations,Order2]= 0 
Inventory Position[Formulations,Order3]= 0 
Inventory Position[Formulations,Order4]= 0 
As with Model B, the stockpile only recognises one order, which is why the inventory 
position of order2, order3 and order4 is always zero. 
E.4.2.4 Obsolete stock related variables 
All three variables associated with the obsolete stock namely (i) Expiration Values, (ii) 
Obsolete Stock, and (iii) Cumulative Obsolete Stock are identical to those in Model B, 
as described in Section E.3.2.7. 
E.4.2.5 Cost related variables 
The cost section of Model C is repeated in Figure E.16 for convenience. The Per Unit 
Cost variable is the same as in Model A and Model B. The Total Obsolescence Cost 
and Cumulative Total Obsolescence Cost variables have the same equation as in 
Model B and is discussed in Section E.3.2.9.  
Figure E.16: Cost section of Model C. 
The variables to be described are (i) Total Unit Cost, (ii) Cumulative Total Unit Cots, and 
(iii) Total Costs.  
• Total unit cost
The total unit cost represents the cost associated with the procurement of drugs to 
replenish the stockpile. Other than with the other models, this is the only procurement 
cost since all of the orders go through the stockpile and is not differentiated in any way. 
The equation is:  
Total Unit Cost[Formulations,Order Number]= 
SRS Demand[Formulations,Order Number]*Per Unit Cost[Formulations,Order 
Number] 
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• Cumulative total unit cost
The cumulative total unit cost is the sum of the total unit cost. It gives the total cost 
associated with the procurement of drugs from manufacturers over the entire simulation 
period. The equation is: 
Cumulative Total Unit Cost[Formulations,Order Number]= INTEG ( 
Total Unit Cost[Formulations,Order Number],0) 
• Total costs
The total costs are simply the sum of all the cumulative costs. The equation is: 
Total Costs[Formulations]= 
SUM(Cumulative Total Unit Cost[Formulations,Order Number!]) + 
SUM(Cumulative Total Obsolescence Cost[Formulations,Order Number!]) 
E.4.2.6 Stockpile related variables 
This section will describe the variables specifically related to the stockpile section of 
Model C, repeated in Figure E.17 for convenience. The variables are (i) Initial Stock On 
Hand, (ii) SRS Stock On Hand, (iii) Dispatch Drugs To Countries, (iv) Drugs Available For 
Dispatch, (v) Drugs To Be Dispatched and (vi) Dispatch.   
Figure E.17: Stockpile section of Model C. 
• Initial stock on hand
The equation for the initial stock on hand will be similar to the one provided in Section 
E.3.2.4. The values, however, will be dependent on the type of inventory policy applied 
in the scenario. The values will be equal to the value of the order-up-to-level.  
• SRS stock on hand
The same QUEUE FIFO equation and assumptions are applied here as in Section E.3.2.4. 
The only difference is the outflow. The inflow is identical to that of Model B, namely the 
production and dispatch to the SRS, but for Model C, the outflow is only the obsolete 
stock and dispatch drugs to countries. The equation is given as: 
SRS Stock On Hand[Formulations,Order Number]= 
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QUEUE FIFO("Production & Dispatch To SRS"[Formulations,Order Number], 
Obsolete Stock[Formulations,Order Number] + Dispatch Drugs To 
Countries[Formulations,Order Number]  , Profile , Initial Stock On Hand 
[Formulations,Order Number] , 0 ) 
• Drugs available for dispatch
As previously mentioned, the stockpile only recognises order1; however, all of the 
orders (order1, order2, order3 and order4) can be fulfilled from the stockpile. The drugs 
available for dispatch variable is therefore used to indicate that all of the “order1” drugs 
in the stockpile is available for all of the order numbers. The equations are given as: 
Drugs Available For Dispatch[Formulations,Order1]=   
MAX(0, SRS Stock On Hand[Formulations,Order1]/TIME STEP - 
Obsolete Stock[Formulations,Order1]) 
Drugs Available For Dispatch[Formulations,Order2]=   
MAX(0, SRS Stock On Hand[Formulations,Order1]/TIME STEP - 
Obsolete Stock[Formulations,Order1]) 
Drugs Available For Dispatch[Formulations,Order3]=    
MAX(0, SRS Stock On Hand[Formulations,Order1]/TIME STEP - 
Obsolete Stock[Formulations,Order1]) 
Drugs Available For Dispatch[Formulations,Order4]=   
MAX(0, SRS Stock On Hand[Formulations,Order1]/TIME STEP - 
Obsolete Stock[Formulations,Order1]) 
• Dispatch drugs to countries
The dispatch drugs to countries variable represents the outflow of drugs from the 
stockpile. Since the stockpile only recognises order1, the drugs that are dispatched for 
all other orders are also counted towards the order1 subscript of this variable in order 
to account for their removal from the stockpile. This is made clear in the equations: 
Dispatch Drugs To Countries[Formulations,Order1]= 
Drugs To Be Dispatched[Formulations,Order1] + 
Drugs To Be Dispatched[Formulations,Order2] + 
Drugs To Be Dispatched[Formulations,Order3] + 
Drugs To Be Dispatched[Formulations,Order4] 
Dispatch Drugs To Countries[Formulations,Order2]= 0 
Dispatch Drugs To Countries[Formulations,Order3]= 0 
Dispatch Drugs To Countries[Formulations,Order4]= 0 
• Dispatch
The dispatch variable is used to delay the drugs that are dispatched to countries by the 
amount of time specified by country dispatch lead time. The equation is: 
Dispatch[Formulations,Order Number]= DELAY MATERIAL ( 
Drugs To Be Dispatched[Formulations,Order Number], Country Dispatch 
Lead Time[Formulations,Order Number], 0, 0) 
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• Drugs to be dispatched
This variable follows the same principals discussed in Section E.3.2.4 with some 
alterations. The drugs to be dispatched equations each has seven IF THEN ELSE 
statements that prioritises the orders to be dispatched. The priorities that the equations 
implement is as follows:  
1. Firstly, the model evaluates whether enough drugs are available to fulfil both new
processed orders, and all of the backorders; if not
2. The model evaluates whether enough drugs are available to fulfil all of the
backorders; if not
3. The model evaluates whether enough drugs are available to fulfil the new
processed orders as well as the two oldest ‘groups’ of backlogs if not
4. The model evaluates whether enough drugs are available to fulfil the two oldest
groups of backlogs; if not
5. The model evaluates whether enough drugs are available to fulfil the new
processed orders as well as the oldest group of backlogs; if not
6. The model evaluates whether enough drugs are available to fulfil the oldest group
of backlogs; if not
7. The model evaluates whether enough drugs are available to fulfil the new
processed orders; if not
8. No drugs are dispatched.
To ensure that the maximum number of drugs are dispatched, order4 will received 
priority over order3, order3 will receive priority over order2 and order2 will receive 
priority over order1. This is due to the chances being less likely that an order4 is 
backlogged or incoming, while the chances of an order1 being backlogged or incoming 
is high. The equations are given as: 
Drugs To Be Dispatched[Formulations,Order1]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs 
To Be Dispatched 
[Formulations,Order2] - Drugs To Be Dispatched [Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Processed 
Orders[Formulations,Order1] + Order Backlogs[Formulations,Order1]/TIME 
STEP , Processed Orders[Formulations,Order1] +  
Order Backlogs[Formulations,Order1]/TIME STEP ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs 
To Be Dispatched 
[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Order 
Backlogs[Formulations,Order1]/TIME STEP , Order 
Backlogs[Formulations,Order1]/TIME STEP ,  
IF THEN ELSE( Backlog Range One[Formulations,Order1] >0 :AND: Backlog 
Range Two 
[Formulations,Order1] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be 
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Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] + Backlog Range Two[Formulations,Order1] + 
Processed Orders[Formulations,Order1], Backlog Range 
Two[Formulations,Order1] + Backlog Range One[Formulations,Order1] + 
Processed Orders[Formulations,Order1],  
IF THEN ELSE( Backlog Range One[Formulations,Order1] >0 :AND: Backlog 
Range Two 
[Formulations,Order1] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] + Backlog Range Two[Formulations,Order1]  , 
Backlog Range Two[Formulations,Order1] + Backlog Range 
One[Formulations,Order1] ,  
IF THEN ELSE( Processed Orders[Formulations,Order1] > 0 :AND: Backlog 
Range One 
[Formulations,Order1] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] + Processed Orders[Formulations,Order1] , 
Backlog Range One[Formulations,Order1] + Processed 
Orders[Formulations,Order1] , 
IF THEN ELSE( Backlog Range One[Formulations,Order1] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] , Backlog Range One[Formulations,Order1] ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs 
To Be Dispatched 
[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4]> Processed 
Orders[Formulations,Order1] , Processed Orders[Formulations,Order1] , 0 
) ) ) ) ) ) ) 
Drugs To Be Dispatched[Formulations,Order2]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs 
To Be Dispatched 
[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Processed Orders[Formulations,Order2] + Order 
Backlogs[Formulations,Order2]/TIME STEP , Processed 
Orders[Formulations,Order2] + Order Backlogs[Formulations,Order2]/TIME 
STEP ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs 
To Be Dispatched 
[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Order Backlogs[Formulations,Order2]/TIME STEP , Order 
Backlogs[Formulations,Order2]/TIME STEP ,  
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IF THEN ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog 
Range Two 
[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2] + 
Processed Orders[Formulations,Order2], Backlog Range 
Two[Formulations,Order2] + Backlog Range One[Formulations,Order2] + 
Processed Orders[Formulations,Order2],  
IF THEN ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog 
Range Two 
[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2]  , 
Backlog Range Two[Formulations,Order2] + Backlog Range 
One[Formulations,Order2] ,  
IF THEN ELSE( Processed Orders[Formulations,Order2] > 0 :AND: Backlog 
Range One [Formulations,Order2] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Processed Orders[Formulations,Order2] , 
Backlog Range One[Formulations,Order2] + Processed 
Orders[Formulations,Order2] , 
IF THEN ELSE( Backlog Range One[Formulations,Order2] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] , Backlog Range One[Formulations,Order2] ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs 
To Be Dispatched [Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Processed Orders[Formulations,Order2] 
, Processed Orders[Formulations,Order2] , 0 ) 
 ) ) ) ) ) ) 
Drugs To Be Dispatched[Formulations,Order3]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs 
To Be Dispatched [Formulations,Order4] > Processed 
Orders[Formulations,Order3] + Order Backlogs[Formulations,Order3]/TIME 
STEP , Processed Orders[Formulations,Order3] + Order 
Backlogs[Formulations,Order3]/TIME STEP ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs 
To Be Dispatched [Formulations,Order4] > Order 
Backlogs[Formulations,Order3]/TIME STEP , Order 
Backlogs[Formulations,Order3]/TIME STEP ,  
IF THEN ELSE( Backlog Range One[Formulations,Order3] >0 :AND: Backlog 
Range Two 
[Formulations,Order3] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] + Backlog Range Two[Formulations,Order3] + 
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Processed Orders[Formulations,Order3], Backlog Range 
Two[Formulations,Order3] + Backlog Range One[Formulations,Order3] + 
Processed Orders[Formulations,Order3],  
IF THEN ELSE( Backlog Range One[Formulations,Order3] >0 :AND: Backlog 
Range Two 
[Formulations,Order3] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] + Backlog Range Two[Formulations,Order3]  , 
Backlog Range Two[Formulations,Order3] + Backlog Range 
One[Formulations,Order3] ,  
IF THEN ELSE( Processed Orders[Formulations,Order3] > 0 :AND: Backlog 
Range One[Formulations,Order3] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] + Processed Orders[Formulations,Order3] , 
Backlog Range One[Formulations,Order3] + Processed 
Orders[Formulations,Order3] , 
IF THEN ELSE( Backlog Range One[Formulations,Order3] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] , Backlog Range One[Formulations,Order3] ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs 
To Be Dispatched[Formulations,Order4] > Processed 
Orders[Formulations,Order3] , Processed Orders[Formulations,Order3] , 0 
) ) ) ) ) ) ) 
Drugs To Be Dispatched[Formulations,Order4]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > 
Processed Orders[Formulations,Order4] + Order 
Backlogs[Formulations,Order4]/TIME STEP , Processed 
Orders[Formulations,Order4] +Order Backlogs[Formulations,Order4]/TIME 
STEP ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > Order 
Backlogs[Formulations,Order4]/TIME STEP , Order 
Backlogs[Formulations,Order4]/TIME STEP ,  
IF THEN ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog 
Range Two[Formulations,Order4] >0 :AND: Drugs Available For Dispatch 
[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Backlog Range Two[Formulations,Order4] + Processed 
Orders[Formulations,Order4], Backlog Range Two[Formulations,Order4] + 
Backlog Range One[Formulations,Order4] + Processed 
Orders[Formulations,Order4],  
IF THEN ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog 
Range Two[Formulations,Order4] >0 :AND: Drugs Available For Dispatch 
[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Backlog Range Two[Formulations,Order4]  , Backlog Range 
Two[Formulations,Order4] + Backlog Range One[Formulations,Order4] ,  
IF THEN ELSE( Processed Orders[Formulations,Order4] > 0 :AND: Backlog 
Range One[Formulations,Order4] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] 
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+ Processed Orders[Formulations,Order4] , Backlog Range 
One[Formulations,Order4] + Processed Orders[Formulations,Order4] , 
IF THEN ELSE( Backlog Range One[Formulations,Order4] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order4] > Backlog Range 
One[Formulations,Order4] , Backlog Range One[Formulations,Order4] ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > 
Processed Orders[Formulations,Order4] , Processed 
Orders[Formulations,Order4] , 0 ) 
) ) ) ) ) )  
E.4.2.7 Backlog related variables 
The backlog section of Model C is repeated in Figure E.18 for convenience. The 
variables that will be discussed include: (i) Backlog Range One, (ii) Backlog Range Two, 
(iii) Order Backlogs, (iv) Incoming, and (v) Backlog Reduction. The concept behind these 
variables were described in Section 6.3.6.2.  
Figure E.18: Backlog section of Model C. 
• Order backlogs
The backlogged orders are represented as a queue in order to track the age of the 
units. The equation is given as: 
Order Backlogs[Formulations,Order Number]=  
QUEUE FIFO(Incoming[Formulations,Order Number],  
Backlog Reduction[Formulations,Order Number]  , Profile , 0 , 0 ) 
• Backlog range one
This variable is implemented to track the oldest backlogged units in the queue. The 
equation returns all of the units in the queue (the order backlogs) that are of equal age 
or older than the oldest units in the queue. The equation is: 
Backlog Range One[Formulations,Order Number]= 
QUEUE AGE IN RANGE( Order Backlogs[Formulations,Order Number] , QUEUE 
AGE OLDEST( Order Backlogs[Formulations,Order Number] ) , :NA: )/TIME 
STEP 
• Backlog range two
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This variable is added to track the group of backlogged units that are at least half the 
age of the oldest backlogged units but not older than the oldest backlogged units. The 
equation is: 
Backlog Range Two[Formulations,Order Number]= 
QUEUE AGE IN RANGE( Order Backlogs[Formulations,Order Number] , 0.5* 
QUEUE AGE OLDEST( Order Backlogs[Formulations,Order Number] ) , QUEUE 
AGE OLDEST (Order Backlogs[Formulations,Order Number] ) - 1 )/TIME STEP 
• Incoming
The incoming variable represents the processed orders that are not fulfilled 
immediately. The equation is very similar to the drugs to be dispatched variable, in the 
sense that whenever the newly processed orders are a part of the drugs that are 
dispatched, then the incoming variable will be equal to zero, and be represented by: 
MAX(0,Processed Orders[Formulations,Order Number] - Drugs To Be 
Dispatched[Formulations,Order Number]) 
If the newly incoming orders are not part of the drugs that are dispatched, the incoming 
variable will equal Processed Orders[Formulations,Order Number]. 
The equations are given as: 
Incoming[Formulations,Order1]=  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs 
To Be Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Processed Orders[Formulations,Order1] 
+ Order Backlogs[Formulations,Order1]/TIME STEP , MAX(0,Processed 
Orders[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order1]) ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs 
To Be Dispatched 
[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Order 
Backlogs[Formulations,Order1]/TIME STEP , Processed 
Orders[Formulations,Order1] ,  
IF THEN ELSE( Backlog Range One[Formulations,Order1] >0 :AND: Backlog 
Range Two 
[Formulations,Order1] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched 
[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Backlog Range One[Formulations,Order1] + Backlog Range Two 
[Formulations,Order1] + Processed Orders[Formulations,Order1], 
MAX(0,Processed Orders[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order1]),  
IF THEN ELSE( Backlog Range One[Formulations,Order1] >0 :AND: Backlog 
Range Two 
[Formulations,Order1] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched 
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[Formulations,Order3]- Drugs To Be Dispatched[Formulations,Order4] > 
Backlog Range One[Formulations,Order1] + Backlog Range 
Two[Formulations,Order1]  , Processed Orders 
[Formulations,Order1] ,  
IF THEN ELSE( Processed Orders[Formulations,Order1] > 0 :AND: Backlog 
Range One 
[Formulations,Order1] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] + Processed Orders[Formulations,Order1] , 
MAX(0,Processed Orders[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order1]) , 
IF THEN ELSE( Backlog Range One[Formulations,Order1] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] , Processed Orders[Formulations,Order1] ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs 
To Be Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4]> Processed Orders[Formulations,Order1] 
, MAX(0,Processed Orders[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order1]) , Processed 
Orders[Formulations,Order1] ) 
) ) ) ) ) ) 
Incoming[Formulations,Order2]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs 
To Be Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Processed Orders[Formulations,Order2] 
+ Order Backlogs[Formulations,Order2]/TIME STEP , MAX(0,Processed 
Orders[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order2]) ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs 
To Be Dispatched 
[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Order Backlogs[Formulations,Order2]/TIME STEP , Processed 
Orders[Formulations,Order2] ,  
IF THEN ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog 
Range Two[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2] + 
Processed Orders[Formulations,Order2], MAX(0,Processed 
Orders[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order2]),  
IF THEN ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog 
Range Two[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
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Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2]  , 
Processed Orders[Formulations,Order2] ,  
IF THEN ELSE( Processed Orders[Formulations,Order2] > 0 :AND: Backlog 
Range One[Formulations,Order2] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Processed Orders[Formulations,Order2] , 
MAX(0,Processed Orders[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order2]) , 
IF THEN ELSE( Backlog Range One[Formulations,Order2] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order2] - Drugs To Be Dispatched 
[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Backlog Range One[Formulations,Order2] , Processed 
Orders[Formulations,Order2] ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs 
To Be Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Processed Orders[Formulations,Order2] 
, MAX(0,Processed Orders[Formulations,Order2] - Drugs To Be Dispatched 
[Formulations,Order2]) , Processed Orders[Formulations,Order2] ) 
) ) ) ) ) ) 
Incoming[Formulations,Order3]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs 
To Be Dispatched[Formulations,Order4] > Processed 
Orders[Formulations,Order3] + Order Backlogs[Formulations,Order3]/TIME 
STEP , MAX(0,Processed Orders[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order3]) ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs 
To Be Dispatched[Formulations,Order4] > Order 
Backlogs[Formulations,Order3]/TIME STEP , Processed 
Orders[Formulations,Order3] , 
IF THEN ELSE( Backlog Range One[Formulations,Order3] >0 :AND: Backlog 
Range Two[Formulations,Order3] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] + Backlog Range Two[Formulations,Order3] + 
Processed Orders[Formulations,Order3], MAX(0,Processed 
Orders[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order3]),  
IF THEN ELSE( Backlog Range One[Formulations,Order3] >0 :AND: Backlog 
Range Two[Formulations,Order3] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] + Backlog Range Two[Formulations,Order3]  , 
Processed Orders[Formulations,Order3] ,  
IF THEN ELSE( Processed Orders[Formulations,Order3] > 0 :AND: Backlog 
Range One[Formulations,Order3] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One 
[Formulations,Order3] + Processed Orders[Formulations,Order3] , 
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MAX(0,Processed Orders[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order3]) , 
IF THEN ELSE( Backlog Range One[Formulations,Order3] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] , Processed Orders[Formulations,Order3],  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs 
To Be Dispatched[Formulations,Order4] > Processed 
Orders[Formulations,Order3] , MAX(0,Processed 
Orders[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order3]) , Processed 
Orders[Formulations,Order3] ) 
) ) ) ) ) ) 
Incoming[Formulations,Order4]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > 
Processed Orders[Formulations,Order4] + Order Backlogs 
[Formulations,Order4]/TIME STEP , MAX(0,Processed 
Orders[Formulations,Order4] - Drugs To Be 
Dispatched[Formulations,Order4]) ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > Order 
Backlogs[Formulations,Order4]/TIME STEP , Processed 
Orders[Formulations,Order4] ,  
IF THEN ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog 
Range Two[Formulations,Order4] >0 :AND: Drugs Available For Dispatch 
[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Backlog Range Two[Formulations,Order4] + Processed 
Orders[Formulations,Order4], MAX(0,Processed 
Orders[Formulations,Order4] - Drugs To Be 
Dispatched[Formulations,Order4]),  
IF THEN ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog 
Range Two[Formulations,Order4] >0 :AND: Drugs Available For Dispatch 
[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Backlog Range Two[Formulations,Order4]  , Processed 
Orders[Formulations,Order4] ,  
IF THEN ELSE( Processed Orders[Formulations,Order4] > 0 :AND: Backlog 
Range One 
[Formulations,Order4] > 0 :AND: Drugs Available For Dispatch 
[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Processed Orders[Formulations,Order4] , MAX(0,Processed 
Orders[Formulations,Order4] - Drugs To Be 
Dispatched[Formulations,Order4]) , 
IF THEN ELSE( Backlog Range One[Formulations,Order4] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order4] > Backlog Range 
One[Formulations,Order4] , Processed Orders[Formulations,Order4] ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > 
Processed Orders[Formulations,Order4] , MAX(0,Processed 
Orders[Formulations,Order4] - Drugs To Be 
Dispatched[Formulations,Order4]) , Processed 
Orders[Formulations,Order4] ) 
) ) ) ) ) ) 
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• Backlog reduction
The backlog reduction works in the same way as the incoming variable. The equation 
is very similar to the drugs to be dispatched variable, in the sense that whenever the 
newly processed orders are a part of the drugs that are dispatched, then the backlog 
reduction variable will be equal to zero, and be represented by: 
MAX(0,Drugs To Be Dispatched[Formulations 
,Order1] - Processed Orders[Formulations,Order1]) 
If the newly incoming orders are not part of the drugs that are dispatched, the backlog 
reduction variable will equal Drugs To Be Dispatched[Formulations,Order1]. 
The equations are given as: 
Backlog Reduction[Formulations,Order1]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs 
To Be Dispatched 
[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Processed 
Orders[Formulations,Order1] + Order Backlogs[Formulations,Order1]/TIME 
STEP , MAX(0,Drugs To Be Dispatched[Formulations 
,Order1] - Processed Orders[Formulations,Order1]) ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs 
To Be Dispatched 
[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Order 
Backlogs[Formulations,Order1]/TIME STEP , Drugs To Be 
Dispatched[Formulations,Order1] ,  
IF THEN ELSE( Backlog Range One[Formulations,Order1] >0 :AND: Backlog 
Range Two 
[Formulations,Order1] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] + Backlog Range Two[Formulations,Order1] + 
Processed Orders[Formulations,Order1], MAX(0,Drugs To Be 
Dispatched[Formulations,Order1] - Processed 
Orders[Formulations,Order1]), IF THEN ELSE( Backlog Range 
One[Formulations,Order1] >0 :AND: Backlog Range 
Two[Formulations,Order1] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched 
[Formulations,Order3]- Drugs To Be Dispatched[Formulations,Order4] > 
Backlog Range One[Formulations,Order1] + Backlog Range 
Two[Formulations,Order1]  , Drugs To Be Dispatched[Formulations,Order1] 
,  
IF THEN ELSE( Processed Orders[Formulations,Order1] > 0 :AND: Backlog 
Range One 
[Formulations,Order1] > 0 :AND:Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
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One[Formulations,Order1] + Processed Orders[Formulations,Order1] , 
MAX(0, Drugs To Be Dispatched[Formulations,Order1] - Processed 
Orders[Formulations,Order1]) , 
IF THEN ELSE( Backlog Range One[Formulations,Order1] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] , Drugs To Be Dispatched[Formulations,Order1] 
,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs 
To Be Dispatched 
[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4]> Processed 
Orders[Formulations,Order1] , MAX(0,Drugs To Be 
Dispatched[Formulations,Order1] - Processed 
Orders[Formulations,Order1]) , Drugs To Be 
Dispatched[Formulations,Order1] ) 
 ) ) ) ) ) ) 
Backlog Reduction[Formulations,Order2]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs 
To Be Dispatched 
[Formulations,Order3] - Drugs To Be Dispatched [Formulations,Order4] > 
Processed Orders[Formulations,Order2] + Order Backlogs 
[Formulations,Order2]/TIME STEP , MAX(0,Drugs To Be Dispatched 
[Formulations,Order2] - Processed Orders[Formulations,Order2]) ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs 
To Be Dispatched 
[Formulations,Order3] - Drugs To Be Dispatched 
[Formulations,Order4] > Order Backlogs[Formulations,Order2]/TIME STEP , 
Drugs To Be Dispatched[Formulations,Order2] ,  
IF THEN ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog 
Range Two 
[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2] + 
Processed Orders[Formulations,Order2], MAX(0,Drugs To Be 
Dispatched[Formulations,Order2] - Processed 
Orders[Formulations,Order2]),  
IF THEN ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog 
Range Two[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2]  , 
Drugs To Be Dispatched[Formulations,Order2] ,  
IF THEN ELSE( Processed Orders[Formulations,Order2] > 0 :AND: Backlog 
Range One[Formulations,Order2] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be Dispatched 
[Formulations,Order4] > Backlog Range One[Formulations,Order2] + 
Processed Orders[Formulations,Order2] , MAX(0,Drugs To Be 
Stellenbosch University  https://scholar.sun.ac.za
E.4 Modelling details of Model C Page | 227 
Stellenbosch University 
Dispatched[Formulations,Order2] - Processed 
Orders[Formulations,Order2]) , 
IF THEN ELSE( Backlog Range One[Formulations,Order2] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] , Drugs To Be Dispatched[Formulations,Order2] 
,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs 
To Be Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Processed Orders[Formulations,Order2] 
, MAX(0,Drugs To Be Dispatched[Formulations,Order2] - Processed 
Orders[Formulations,Order2]) , Drugs To Be 
Dispatched[Formulations,Order2] ) 
) ) ) ) ) ) 
Backlog Reduction[Formulations,Order3]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs 
To Be Dispatched[Formulations,Order4] > Processed 
Orders[Formulations,Order3] + Order Backlogs[Formulations,Order3]/TIME 
STEP , MAX(0,Drugs To Be Dispatched[Formulations,Order3] - Processed 
Orders[Formulations,Order3]) ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs 
To Be Dispatched[Formulations,Order4] > Order 
Backlogs[Formulations,Order3]/TIME STEP , Drugs To Be 
Dispatched[Formulations,Order3] ,  
IF THEN ELSE( Backlog Range One[Formulations,Order3] >0 :AND: Backlog 
Range Two[Formulations,Order3] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] + Backlog Range Two[Formulations,Order3] + 
Processed Orders[Formulations,Order3], MAX(0,Drugs To Be 
Dispatched[Formulations,Order3] - Processed 
Orders[Formulations,Order3]),  
IF THEN ELSE( Backlog Range One[Formulations,Order3] >0 :AND: Backlog 
Range Two[Formulations,Order3] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] + Backlog Range Two[Formulations,Order3]  , 
Drugs To Be Dispatched[Formulations,Order3] ,  
IF THEN ELSE( Processed Orders[Formulations,Order3] > 0 :AND: Backlog 
Range One[Formulations,Order3] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] + Processed Orders[Formulations,Order3] , 
MAX(0,Drugs To Be Dispatched[Formulations,Order3] - Processed 
Orders[Formulations,Order3]) , 
IF THEN ELSE( Backlog Range One[Formulations,Order3] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order3] , Drugs To Be Dispatched[Formulations,Order3], 
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IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs 
To Be Dispatched 
[Formulations,Order4] > Processed Orders [Formulations,Order3] , 
MAX(0,Drugs To Be Dispatched[Formulations,Order3] - Processed 
Orders[Formulations,Order3]) , Drugs To Be 
Dispatched[Formulations,Order3] ) 
 ) ) ) ) ) ) 
Backlog Reduction[Formulations,Order4]= 
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > 
Processed Orders [Formulations,Order4] + Order 
Backlogs[Formulations,Order4]/TIME STEP , MAX(0,Drugs To Be 
Dispatched[Formulations,Order4] - Processed 
Orders[Formulations,Order4]) ,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > Order 
Backlogs [Formulations,Order4]/TIME STEP , Drugs To Be 
Dispatched[Formulations,Order4] ,  
IF THEN ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog 
Range Two 
[Formulations,Order4] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] 
+ Backlog Range Two[Formulations,Order4] + Processed 
Orders[Formulations,Order4], MAX(0,Drugs To Be 
Dispatched[Formulations,Order4] - Processed 
Orders[Formulations,Order4]),  
IF THEN ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog 
Range Two 
[Formulations,Order4] >0 :AND: Drugs Available For Dispatch 
[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Backlog Range Two[Formulations,Order4]  , Drugs To Be 
Dispatched[Formulations,Order4] ,  
IF THEN ELSE( Processed Orders[Formulations,Order4] > 0 :AND: Backlog 
Range One 
[Formulations,Order4] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] 
+ Processed Orders[Formulations,Order4] , MAX(0,Drugs To Be 
Dispatched[Formulations,Order4] - Processed 
Orders[Formulations,Order4]) , 
IF THEN ELSE( Backlog Range One[Formulations,Order4] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order4] > Backlog Range 
One[Formulations,Order4] , Drugs To Be Dispatched[Formulations,Order4] 
,  
IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > 
Processed Orders[Formulations,Order4] , MAX(0,Drugs To Be 
Dispatched[Formulations,Order4] - Processed Orders[Formulations,Order4]) 
, Drugs To Be Dispatched[Formulations,Order4] ) ) ) ) ) ) ) 
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Appendix F Validation results 
This appendix provides results from some of the validation tests, namely the behaviour 
reproduction test for the demand (order size), and the sensitivity analysis. The full 
description of these tests are provided in Section 6.4 while this appendix merely 
provides the results on which the conclusions were based.  
F.1 Descriptive statistics of demand 
This section provides a comparison of the descriptive statistics for the historical data 
and the data from the model. The percentage that the model output differs from the 
historical data are also provided in the tables. Additionally, a graph is also provided to 
illustrate how well the order sizes of the model represents the historical data. The 
summary of the results for capreomycin is depicted in Table F.1 and the graph is 
provided in Figure F.1. 
Table F.1: Descriptive statistics of capreomycin order size for model output and historical data. 
Hist. Data Model Output % Diff 
Mean  33 322.96  32 775.91 -1.64% 
Standard Error  4 145.87  3 744.82 -9.67% 
Median  12 150.00  11 030.00 -9.22% 
Standard Deviation  63 011.70  58 495.90 -7.17% 
Range  447 922.00  411 721.61 -8.08% 
Minimum  78.00  78.39 0.50% 
Maximum  448 000.00  411 800.00 -8.08% 
Sum  7 697 603.00  7 997 321.70 3.89% 
Figure F.1: Capreomycin order size comparison of model output and historical data. 
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The results for kanamycin are provided in Table F.2 and illustrated in Figure F.2. 
Table F.2: Descriptive statistics of kanamycin order size for model output and historical data. 
Hist. Data Model Output % Diff 
Mean  43 808.31  42 967.96 -1.92% 
Standard Error  8 124.35  8 258.60 1.65% 
Median  13 900.00  12 170.00 -12.45% 
Standard Deviation  96 812.77  100 809.05 4.13% 
Range  881 550.00  759 650.00 -13.83% 
Minimum  450.00  450.00 0.00% 
Maximum  882 000.00  760 100.00 -13.82% 
Sum  6 220 780.00  6 402 226.00 2.92% 
Figure F.2: Kanamycin order size comparison of model output and historical data. 
The results for cycloserine are summarised in Table F.3 and Figure F.3. 
Table F.3: Descriptive statistics of cycloserine order size for model output and historical data. 
Hist. Data Model Output % Diff 
Mean  381 362.36  350 169.41 -8.18% 
Standard Error  43 072.77  41 728.11 -3.12% 
Median  129 600.00  117 790.00 -9.11% 
Standard Deviation  803 512.19  783 999.94 -2.43% 
Range  9 447 600.00  9 313 500.00 -1.42% 
Minimum  1 500.00  1 500.00 0.00% 
Maximum  9 449 100.00  9 315 000.00 -1.42% 
Sum 132 714 100.00  123 609 803.00 -6.86% 
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Figure F.3: Cycloserine order size comparison of model output and historical data. 
F.2 Sensitivity analysis results 
This section provides the results of the sensitivity analysis for Model A, Model B and 
Model C for all the formulations. The sensitivity analysis is discussed in more detail in 
Section 6.4.8.  
F.2.1 Model A 
The sensitivity analysis results of Model A for capreomycin, kanamycin and cycloserine 
are provided in Tables F.4, Table F.5 and Table F.6, respectively. 
Table F.4: Sensitivity analysis results for Model A, capreomycin. 
Capreomycin 
(Model A) 
Total drugs 
received 
Drugs awaiting 
dispatch 
Base Case 4 648 000 0 
Increase 
demand 
5 112 000 0 
Decrease 
demand 
4 183 000 0 
Increase lead 
times 
4 431 000 0 
Decrease lead 
times 
5 472 601 0 
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Table F.5: Sensitivity analysis results for Model A, kanamycin. 
Kanamycin 
(Model A) 
Total drugs 
received 
Drugs awaiting 
dispatch 
Base Case 3 249 000 0 
Increase 
demand 
3 574 000 0 
Decrease 
demand 
2 924 000 0 
Increase lead 
times 
3 161 000 0 
Decrease lead 
times 
3 601 000 0 
Table F.6: Sensitivity analysis results for Model A, cycloserine. 
Cycloserine 
(Model A) 
Total drugs 
received 
Drugs awaiting 
dispatch 
Base Case 45 430 000 0 
Increase 
demand 
49 970 000 0 
Decrease 
demand 
40 880 000 0 
Increase 
lead times 
41 820 000 0 
Decrease 
lead times 
59 040 000 0 
F.2.2 Model B 
The results for capreomycin were provided in Section 6.4.8. The results for kanamycin 
and cycloserine are provided in Tables F.7 and Table F.8, respectively. 
Table F.7: Sensitivity analysis results for Model B, kanamycin. 
Kanamycin 
(Model B) 
Obsolete 
Stock 
Received 
through Mfg 
Received 
through SRS 
Emergency 
Orders 
Stock on 
hand 
Base Case 0 7 757 300 618 782 194 000 106 800 
Increase 
demand 
0 
(0%) 
7 993 000 
(3%) 
572 100 
(-8%) 
203 300 
(5%) 
117 700 
(10%) 
Decrease 
demand 
0 
(0%) 
7 636 000 
(-2%) 
611 200 
(-1%) 
184 600 
(-5%) 
116 300 
(9%) 
Increase lead 
times 
0 
(0%) 
7 772 000 
(0%) 
611 400 
(-1%) 
194 000 
(0%) 
115 200 
(8%) 
Decrease lead 
times 
0 
(0%) 
7 632 000 
(-2%) 
586 800 
(-5%) 
194 000 
(0%) 
114 700 
(7%) 
Stellenbosch University  https://scholar.sun.ac.za
F.2 Sensitivity analysis results Page | 233 
Stellenbosch University 
Table F.8: Sensitivity analysis results for Model B, cycloserine. 
Cycloserine 
(Model B) 
Obsolete 
Stock 
Received 
through Mfg 
Received 
through SRS 
Emergency 
Orders 
Stock on 
hand 
Base Case 0 121 373 000 16 526 400 8 893 000 1 625 000 
Increase 
demand 
0 
(0%) 
126 810 000 
(4%) 
15 130 000 
(-8%) 
9 083 000 
(2%) 
1 756 000 
(8%) 
Decrease 
demand 
0 
(0%) 
116 500 000 
(-4%) 
16 620 000 
(1%) 
8 504 000 
(-4%) 
1 484 000 
(-9%) 
Increase lead 
times 
0 
(0%) 
117 300 000 
(-3%) 
15 480 000 
(-6%) 
8 893000 
(0%) 
1 537 000 
(-5%) 
Decrease lead 
times 
0 
(0%) 
120 700 000 
(-1%) 
15 921 000 
(-4%) 
8 295 000 
(-7%) 
1 752 000 
(8%) 
F.2.3 Model C 
The sensitivity analysis results of Model C for capreomycin, kanamycin and cycloserine 
are provided in Tables F.9, Table F.10 and Table F.11, respectively. 
Table F.9: Sensitivity analysis results for Model C, capreomycin. 
Capreomycin 
(Model C) 
Obsolete 
Stock 
Received 
through Mfg 
Received 
through SRS 
Stock on 
hand 
Backlogged 
units 
Base Case 0  6 393 000  6 903 000  270 500  1 678 000 
Increase 
demand 
0 
(0%) 
5 953 000 
(3%) 
7 190 000 
(4%) 
289 300 
(-5%) 
1 648 000 
(6%) 
Decrease 
demand 
0 
(0%) 
6 612 000 
(-7%) 
6 588 000 
(-5%) 
257 200 
(7%) 
1 779 000 
(-8%) 
Increase lead 
times 
0 
(0%) 
6 393 000 
(0%) 
6 903 000 
(0%) 
270 500 
(0%) 
 1 653 000 
(-1%) 
Decrease lead 
times 
0 
(0%) 
5 998 000 
(-6%) 
6 902 000 
(0%) 
273 000 
(1%) 
1 688 000 
(1%) 
Table F.10: Sensitivity analysis results for Model C, kanamycin. 
Kanamycin 
(Model C) 
Obsolete 
Stock 
Received 
through Mfg 
Received 
through SRS 
Stock on 
hand 
Backlogged 
units 
Base Case 0  4 773 000  6 093 000  155 400  265 300 
Increase 
demand 
0 
(0%) 
4 428 000 
(5%) 
6 379 000 
(5%) 
146 560 
(-6%) 
261 800 
(3%) 
Decrease 
demand 
0 
(0%) 
4 988 000 
(-7%) 
5 784 000 
(-5%) 
159 630 
(3%) 
272 600 
(-1%) 
Increase lead 
times 
0 
(0%) 
4 843 000 
(1%) 
5 903 000 
(-3%) 
160 500 
(3%) 
279 100 
(5%) 
Decrease lead 
times 
0 
(0%) 
4 927 000 
(3%) 
6 092 000 
(0%) 
163 200 
(5%) 
266 400 
(0%) 
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Table F.11: Sensitivity analysis results for Model C, cycloserine. 
Cycloserine 
(Model C) 
Obsolete 
Stock 
Received 
through Mfg 
Received 
through SRS 
Stock on 
hand 
Backlogged 
units 
Base Case 413 100  93 570 000  101 500 000  17 840  68 500 000 
Increase 
demand 
391 100 
(2%) 
95 830 000 
(2%) 
92 960 000 
(4%) 
16 960 
(-5%) 
69 270 000 
(1%) 
Decrease 
demand 
419 820 
(-5%) 
89 970 000 
(-4%) 
105 900 000 
 (-8%) 
18 798 
(5%) 
63 210 000 
(-8%) 
Increase lead 
times 
403 450 
(-2%) 
93 530 000 
(0%) 
102 200 000 
(1%) 
17 300 
(-3%) 
69 640 000 
(2%) 
Decrease lead 
times 
398 200 
(-4%) 
93 180 000 
(0%) 
102 300 000 
(1%) 
17 000 
(5%) 
69 060 000 
(1%) 
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This appendix provides a detailed summary of each scenario that was modelled. The 
alternative values for the reorder point, order-up-to-level, reorder frequency and 
reorder quantity are provided in the tables below. Where different values are assigned 
to each of the three formulations, it is given as:   𝐶𝑎𝑝𝑟𝑒𝑜𝑚𝑦𝑐𝑖𝑛	 	𝐾𝑎𝑛𝑎𝑚𝑦𝑐𝑖𝑛	 	𝐶𝑦𝑐𝑙𝑜𝑠𝑒𝑟𝑖𝑛𝑒
Table G.1 provides the four alternatives of the reorder point. 
Table G.1: Summary of reorder point alternatives. 
Reorder Point (𝒔) 𝑠G = 𝜇.	×	𝜇/0 + 𝜇.	×	3 = 499	845	 	657	120	 	5	720	427 	𝑠^ = 𝜇.	×	𝜇/0 + 𝜇.	×	4.5 = 549	830	 	722	832	 	6	292	469𝑠 = 𝜇.	×	𝜇/0 + 𝜇.	×	6 = 599	814	 	788	544 	6	864	510𝑠 = 𝜇.	×	𝜇/0 + 3.72 𝜇. +	𝜎/ ^ + 𝜇/0 + 	𝜎.^ =3	382	746	 	4	604	496	 	39	623	974
The two alternatives of the order-up-to-level is provided in Table G.2. 
Table G.2: Summary of order-up-to-level alternatives. 
Order-Up-To-Level (𝑺) 𝑆G = 𝜇.	×	𝜇/0 + 3.72	×	𝜎.×	 𝜇/0 = 	 1	211	877	 	1	773	273	 	14	930	768	𝑆^ = 𝜇.	×	𝜇/0 	×	2.5 = 999	690	 	1	314	240	 	11	440	860
The four alternative values for the reorder frequency is provided in Table G.3. 
Table G.3: Summary of reorder frequency alternatives. 
Reorder Frequency (𝑹) 𝑅G = 1𝑅^ = 2𝑅 = 3𝑅 = 4
Table G.4 provides the three alternatives for the reorder quantity. 
Table G.4: Summary of the reorder quantity alternatives. 
Reorder Quantity (𝑸) 𝑄G =		Exponential smoothing, with 𝛼 = 0.1𝑄^ =		Exponential smoothing, with 𝛼 = 0.5𝑄 =		Exponential smoothing, with 𝛼 = 0.9
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G.1 (s,S) Policy scenarios 
The first set of scenarios will be for the (𝑠, 𝑆)  policy. There are eight possible 
combinations of 𝑠 and 𝑆 for this policy, as provided in Table G.5. 
Table G.5: Summary of (s,S) policy scenarios. 
Policy s S Value of s Value of S 
1 (s,S) 1 s1 S1 499	845	 	657	120	 	5	720	427  1	211	877	 	1	773	273	 	14	930	768	
2 (s,S) 2 s1 S2 499	845	 	657	120	 	5	720	427  999	690	 	1	314	240	 	11	440	860  
3 (s,S) 3 s2 S1 549	830	 	722	832	 	6	292	469  1	211	877	 	1	773	273	 	14	930	768	
4 (s,S) 4 s2 S2 549	830	 	722	832	 	6	292	469  999	690	 	1	314	240	 	11	440	860  
5 (s,S) 5 s3 S1 599	814	 	788	544 	6	864	510  1	211	877	 	1	773	273	 	14	930	768	
6 (s,S) 6 s3 S2 599	814	 	788	544 	6	864	510  999	690	 	1	314	240	 	11	440	860  
7 (s,S) 7 s4 S1 3	382	746	 	4	604	496	 	39	623	974 1	211	877	 	1	773	273	 	14	930	768	
8 (s,S) 8 s4 S2 3	382	746	 	4	604	496	 	39	623	974 999	690	 	1	314	240	 	11	440	860  
G.2 (R,S) Policy scenarios 
The second set of scenarios will be for the (𝑅, 𝑆) policy. There are again eight possible 
combinations of 𝑅 and 𝑆 for this policy, as provided in Table G.6. 
Table G.6: Summary of (R,S) policy scenarios. 
Policy R S Value of R Value of S 
9 (R,S) 1 R1 S1 1 week 1	211	877	 	1	773	273	 	14	930	768	
10 (R,S) 2 R1 S2 1 week 999	690	 	1	314	240	 	11	440	860  
11 (R,S) 3 R2 S1 2 weeks 1	211	877	 	1	773	273	 	14	930	768	
12 (R,S) 4 R2 S2 2 weeks 999	690	 	1	314	240	 	11	440	860  
13 (R,S) 5 R3 S1 3 weeks 1	211	877	 	1	773	273	 	14	930	768	
14 (R,S) 6 R3 S2 3 weeks 999	690	 	1	314	240	 	11	440	860  
15 (R,S) 7 R4 S1 4 weeks 1	211	877	 	1	773	273	 	14	930	768	
16 (R,S) 8 R4 S2 4 weeks 999	690	 	1	314	240	 	11	440	860  
G.3 (R,s,S) Policy scenarios 
The third set of scenarios will be for the (𝑅, 𝑠, 𝑆)  policy. There are 24 applicable, 
possible combinations of 𝑅, 𝑠 and 𝑆 for this policy, as provided in Table G.7. 
Table G.7: Summary of (R,s,S) policy scenarios. 
Policy R s S Value of R Value of s Value of S 
17 (R,s,S) 1 R2 s1 S1 2 weeks 499	845	 	657	120	 	5	720	427  1	211	877	 	1	773	273	 	14	930	768	
18 (R,s,S) 2 R2 s1 S2 2 weeks 499	845	 	657	120	 	5	720	427  999	690	 	1	314	240	 	11	440	860  
19 (R,s,S) 3 R2 s2 S1 2 weeks 549	830	 	722	832	 	6	292	469  1	211	877	 	1	773	273	 	14	930	768	
20 (R,s,S) 4 R2 s2 S2 2 weeks 549	830	 	722	832	 	6	292	469  999	690	 	1	314	240	 	11	440	860  
21 (R,s,S) 5 R2 s3 S1 2 weeks 599	814	 	788	544 	6	864	510  1	211	877	 	1	773	273	 	14	930	768	
22 (R,s,S) 6 R2 s3 S2 2 weeks 599	814	 	788	544 	6	864	510  999	690	 	1	314	240	 	11	440	860  
23 (R,s,S) 7 R2 s4 S1 2 weeks 3	382	746	 	4	604	496	 	39	623	974 1	211	877	 	1	773	273	 	14	930	768	
24 (R,s,S) 8 R2 s4 S2 2 weeks 3	382	746	 	4	604	496	 	39	623	974 999	690	 	1	314	240	 	11	440	860
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25 (R,s,S) 9 R3 s1 S1 3 weeks 499	845	 	657	120	 	5	720	427  1	211	877	 	1	773	273	 	14	930	768	
26 (R,s,S) 10 R3 s1 S2 3 weeks 499	845	 	657	120	 	5	720	427  999	690	 	1	314	240	 	11	440	860  
27 (R,s,S) 11 R3 s2 S1 3 weeks 549	830	 	722	832	 	6	292	469  1	211	877	 	1	773	273	 	14	930	768	
28 (R,s,S) 12 R3 s2 S2 3 weeks 549	830	 	722	832	 	6	292	469  999	690	 	1	314	240	 	11	440	860  
29 (R,s,S) 13 R3 s3 S1 3 weeks 599	814	 	788	544 	6	864	510  1	211	877	 	1	773	273	 	14	930	768	
30 (R,s,S) 14 R3 s3 S2 3 weeks 599	814	 	788	544 	6	864	510  999	690	 	1	314	240	 	11	440	860  
31 (R,s,S) 15 R3 s4 S1 3 weeks 3	382	746	 	4	604	496	 	39	623	974 1	211	877	 	1	773	273	 	14	930	768	
32 (R,s,S) 16 R3 s4 S2 3 weeks 3	382	746	 	4	604	496	 	39	623	974 999	690	 	1	314	240	 	11	440	860  
33 (R,s,S) 17 R4 s1 S1 4 weeks 499	845	 	657	120	 	5	720	427  1	211	877	 	1	773	273	 	14	930	768	
34 (R,s,S) 18 R4 s1 S2 4 weeks 499	845	 	657	120	 	5	720	427  999	690	 	1	314	240	 	11	440	860  
35 (R,s,S) 19 R4 s2 S1 4 weeks 549	830	 	722	832	 	6	292	469  1	211	877	 	1	773	273	 	14	930	768	
36 (R,s,S) 20 R4 s2 S2 4 weeks 549	830	 	722	832	 	6	292	469  999	690	 	1	314	240	 	11	440	860  
37 (R,s,S) 21 R4 s3 S1 4 weeks 599	814	 	788	544 	6	864	510  1	211	877	 	1	773	273	 	14	930	768	
38 (R,s,S) 22 R4 s3 S2 4 weeks 599	814	 	788	544 	6	864	510  999	690	 	1	314	240	 	11	440	860  
39 (R,s,S) 23 R4 s4 S1 4 weeks 3	382	746	 	4	604	496	 	39	623	974 1	211	877	 	1	773	273	 	14	930	768	
40 (R,s,S) 24 R4 s4 S2 4 weeks 3	382	746	 	4	604	496	 	39	623	974 999	690	 	1	314	240	 	11	440	860  
G.4 (s,Q) Policy scenarios 
The fourth set of scenarios will be for the (𝑠, 𝑄)  policy. There are 12 possible 
combinations of 𝑠 and 𝑄 for this policy, as provided in Table G.8. 
Table G.8: Summary of (s,Q) policy scenarios. 
Policy s Q Value of s Value of Q 
41 (s,Q) 1 s1 Q1 499	845	 	657	120	 	5	720	427 𝛼 = 0.1 
42 (s,Q) 2 s1 Q2 499	845	 	657	120	 	5	720	427 𝛼 = 0.5 
43 (s,Q) 3 s1 Q3 499	845	 	657	120	 	5	720	427 𝛼 = 0.9 
44 (s,Q) 4 s2 Q1 549	830	 	722	832	 	6	292	469 𝛼 = 0.1 
45 (s,Q) 5 s2 Q2 549	830	 	722	832	 	6	292	469 𝛼 = 0.5 
46 (s,Q) 6 s2 Q3 549	830	 	722	832	 	6	292	469 𝛼 = 0.9 
47 (s,Q) 7 s3 Q1 599	814	 	788	544 	6	864	510 𝛼 = 0.1 
48 (s,Q) 8 s3 Q2 599	814	 	788	544 	6	864	510 𝛼 = 0.5 
49 (s,Q) 9 s3 Q3 599	814	 	788	544 	6	864	510 𝛼 = 0.9 
50 (s,Q) 10 s4 Q1 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.1 
51 (s,Q) 11 s4 Q2 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.5 
52 (s,Q) 12 s4 Q3 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.9 
G.5 (R,s,Q) Policy scenarios 
The fifth and final set of scenarios will be for the (𝑅, 𝑠, 𝑄)  policy. There are 36 
applicable, possible combinations of 𝑅, 𝑠 and 𝑄 for this policy, as provided in Table G.9. 
Table G.9: Summary of (R,s,Q) policy scenarios. 
Policy R s Q Value of R Value of s Value of Q 
53 (R,s,Q) 1 R2 s1 Q1 2 weeks 499	845	 	657	120	 	5	720	427 𝛼 = 0.1 
54 (R,s,Q) 2 R2 s1 Q2 2 weeks 499	845	 	657	120	 	5	720	427 𝛼 = 0.5 
55 (R,s,Q) 3 R2 s1 Q3 2 weeks 499	845	 	657	120	 	5	720	427 𝛼 = 0.9 
56 (R,s,Q) 4 R2 s2 Q1 2 weeks 549	830	 	722	832	 	6	292	469 𝛼 = 0.1 
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57 (R,s,Q) 5 R2 s2 Q2 2 weeks 549	830	 	722	832	 	6	292	469  𝛼 = 0.5 
58 (R,s,Q) 6 R2 s2 Q3 2 weeks 549	830	 	722	832	 	6	292	469  𝛼 = 0.9 
59 (R,s,Q) 7 R2 s3 Q1 2 weeks 599	814	 	788	544 	6	864	510  𝛼 = 0.1 
60 (R,s,Q) 8 R2 s3 Q2 2 weeks 599	814	 	788	544 	6	864	510  𝛼 = 0.5 
61 (R,s,Q) 9 R2 s3 Q3 2 weeks 599	814	 	788	544 	6	864	510  𝛼 = 0.9 
62 (R,s,Q) 10 R2 s4 Q1 2 weeks 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.1 
63 (R,s,Q) 11 R2 s4 Q2 2 weeks 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.5 
64 (R,s,Q) 12 R2 s4 Q3 2 weeks 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.9 
65 (R,s,Q) 13 R3 s1 Q1 3 weeks 499	845	 	657	120	 	5	720	427  𝛼 = 0.1 
66 (R,s,Q) 14 R3 s1 Q2 3 weeks 499	845	 	657	120	 	5	720	427  𝛼 = 0.5 
67 (R,s,Q) 15 R3 s1 Q3 3 weeks 499	845	 	657	120	 	5	720	427  𝛼 = 0.9 
68 (R,s,Q) 16 R3 s2 Q1 3 weeks 549	830	 	722	832	 	6	292	469  𝛼 = 0.1 
69 (R,s,Q) 17 R3 s2 Q2 3 weeks 549	830	 	722	832	 	6	292	469  𝛼 = 0.5 
70 (R,s,Q) 18 R3 s2 Q3 3 weeks 549	830	 	722	832	 	6	292	469  𝛼 = 0.9 
71 (R,s,Q) 19 R3 s3 Q1 3 weeks 599	814	 	788	544 	6	864	510  𝛼 = 0.1 
72 (R,s,Q) 20 R3 s3 Q2 3 weeks 599	814	 	788	544 	6	864	510  𝛼 = 0.5 
73 (R,s,Q) 21 R3 s3 Q3 3 weeks 599	814	 	788	544 	6	864	510  𝛼 = 0.9 
74 (R,s,Q) 22 R3 s4 Q1 3 weeks 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.1 
75 (R,s,Q) 23 R3 s4 Q2 3 weeks 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.5 
76 (R,s,Q) 24 R3 s4 Q3 3 weeks 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.9 
77 (R,s,Q) 25 R4 s1 Q1 4 weeks 499	845	 	657	120	 	5	720	427  𝛼 = 0.1 
78 (R,s,Q) 26 R4 s1 Q2 4 weeks 499	845	 	657	120	 	5	720	427  𝛼 = 0.5 
79 (R,s,Q) 27 R4 s1 Q3 4 weeks 499	845	 	657	120	 	5	720	427  𝛼 = 0.9 
80 (R,s,Q) 28 R4 s2 Q1 4 weeks 549	830	 	722	832	 	6	292	469  𝛼 = 0.1 
81 (R,s,Q) 29 R4 s2 Q2 4 weeks 549	830	 	722	832	 	6	292	469  𝛼 = 0.5 
82 (R,s,Q) 30 R4 s2 Q3 4 weeks 549	830	 	722	832	 	6	292	469  𝛼 = 0.9 
83 (R,s,Q) 31 R4 s3 Q1 4 weeks 599	814	 	788	544 	6	864	510  𝛼 = 0.1 
84 (R,s,Q) 32 R4 s3 Q2 4 weeks 599	814	 	788	544 	6	864	510  𝛼 = 0.5 
85 (R,s,Q) 33 R4 s3 Q3 4 weeks 599	814	 	788	544 	6	864	510  𝛼 = 0.9 
86 (R,s,Q) 34 R4 s4 Q1 4 weeks 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.1 
87 (R,s,Q) 35 R4 s4 Q2 4 weeks 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.5 
88 (R,s,Q) 36 R4 s4 Q3 4 weeks 3	382	746	 	4	604	496	 	39	623	974 𝛼 = 0.9 
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Appendix H Modelling results 
This appendix provides the modelling results of the 88 scenarios. The appendix is 
divided into three sections, with each section presenting the results for one of the 
formulations. The results are provided according to the performance measures 
introduced in Section 7.1. 
H.1 Modelling results of capreomycin 
This section provides the results of capreomycin for each scenario. Table H.1 
summarises the stock performance of each scenario. 
Table H.1: Capreomycin - Summary of stock performance for the scenarios. 
Policy # R s S Q %BLs 𝜇¿/_ÀÁl 𝑀𝑎𝑥¿/_ÀÁl Total Vol.
(s,S) 1 s1 S1 21.05% 6.91 26 2 337 366 
(s,S) 2 s1 S2 17.37% 7.00 26 2 728 524 
(s,S) 3 s2 S1 15.26% 4.10 13  1 809 564 
(s,S) 4 s2 S2 19.47% 6.23 26  2 617 810 
(s,S) 5 s3 S1 2.63% 2.44 6  1 859 470 
(s,S) 6 s3 S2 2.11% 5.68 14  2 541 754 
(s,S) 7 s4 S1 24.21% 4.25 16  722 871 
(s,S) 8 s4 S2 17.89% 6.49 26  651 444 
(R,S) 1 R1 S1 2.63% 2.44 6  722 871 
(R,S) 2 R1 S2 2.11% 5.68 14  651 444 
(R,S) 3 R2 S1 2.26% 3.89 11  1 006 581 
(R,S) 4 R2 S2 12.63% 4.94 14  1 836 098 
(R,S) 5 R3 S1 1.58% 2.31 5  159 302 
(R,S) 6 R3 S2 5.79% 4.41 13  1 000 613 
(R,S) 7 R4 S1 1.58% 2.57 5  252 229 
(R,S) 8 R4 S2 6.32% 3.23 5  1 249 302 
(R,s,S) 1 R2 s1 S1 23.68% 6.70 33 3 202 857 
(R,s,S) 2 R2 s1 S2 24.74% 9.31 37 3 405 537 
(R,s,S) 3 R2 s2 S1 31.05% 7.89 38 3 387 857 
(R,s,S) 4 R2 s2 S2 28.42% 6.04 26  2 678 197 
(R,s,S) 5 R2 s3 S1 20.00% 5.21 21 2 257 905 
(R,s,S) 6 R2 s3 S2 21.58% 6.20 26  2 769 410 
(R,s,S) 7 R2 s4 S1 5.26% 3.89 11  1 006 581 
(R,s,S) 8 R2 s4 S2 12.63% 4.94 14  1 836 098 
(R,s,S) 9 R3 s1 S1 21.58% 5.36 19  1 628 983 
(R,s,S) 10 R3 s1 S2 33.68% 5.95 24  3 377 107 
(R,s,S) 11 R3 s2 S1 12.63% 5.44 20  1 062 326 
(R,s,S) 12 R3 s2 S2 30.53% 5.50 19  2 461 004 
(R,s,S) 13 R3 s3 S1 23.68% 8.36 27 2 440 469 
(R,s,S) 14 R3 s3 S2 18.42% 4.54 17 2 305 822 
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(R,s,S) 15 R3 s4 S1 1.58% 2.31 5  159 302 
(R,s,S) 16 R3 s4 S2 5.79% 4.41 13  1 000 613 
(R,s,S) 17 R4 s1 S1 10.53% 4.79 17 1 006 652 
(R,s,S) 18 R4 s1 S2 17.37% 4.05 13  2 339 140 
(R,s,S) 19 R4 s2 S1 15.79% 5.11 17  1 519 781 
(R,s,S) 20 R4 s2 S2 20.00% 5.21 21 2 257 905 
(R,s,S) 21 R4 s3 S1 14.74% 4.54 14  2 001 373 
(R,s,S) 22 R4 s3 S2 14.74% 4.53 17  2 072 481 
(R,s,S) 23 R4 s4 S1 1.58% 2.57 5  252 229 
(R,s,S) 24 R4 s4 S2 6.32% 3.23 9  1 249 302 
(s,Q) 1 s1 Q1 27.37% 14.07 57  4 135 590 
(s,Q) 2 s1 Q2 30.53% 10.20 43  4 505 241 
(s,Q) 3 s1 Q3 35.26% 6.26 30  4 105 420 
(s,Q) 4 s2 Q1 21.58% 14.69 53  3 451 015 
(s,Q) 5 s2 Q2 24.21% 11.44 45  3 688 516 
(s,Q) 6 s2 Q3 30.53% 6.16 21 3 803 274 
(s,Q) 7 s3 Q1 21.58% 14.70 57 3 059 089 
(s,Q) 8 s3 Q2 25.26% 7.54 27  3 929 361 
(s,Q) 9 s3 Q3 30.53% 6.16 21  3 803 274 
(s,Q) 10 s4 Q1 10.53% 6.05 16  2 374 224 
(s,Q) 11 s4 Q2 5.26% 3.14 8  1 023 422 
(s,Q) 12 s4 Q3 30.53% 6.16 21  3 803 274 
(R,s,Q) 1 R2	 s1 Q1 26.84% 12 39  4 491 017 
(R,s,Q) 2 R2 s1 Q2 26.84% 12 39  4 491 017 
(R,s,Q) 3 R2 s1 Q3 31.05% 10 27  4 442 105 
(R,s,Q) 4 R2 s2 Q1 32.11% 9 27  4 896 806 
(R,s,Q) 5 R2 s2 Q2 32.11% 9 27  4 896 806 
(R,s,Q) 6 R2 s2 Q3 32.11% 8 24  4 392 562 
(R,s,Q) 7 R2 s3 Q1 31.58% 8 24  4 475 554 
(R,s,Q) 8 R2 s3 Q2 31.58% 8 24  4 475 554 
(R,s,Q) 9 R2 s3 Q3 32.11% 8 24  4 392 562 
(R,s,Q) 10 R2 s4 Q1 7.37% 4 11  1 555 461 
(R,s,Q) 11 R2 s4 Q2 7.37% 4 11  1 555 461 
(R,s,Q) 12 R2 s4 Q3 8.95% 3 9  1 556 844 
(R,s,Q) 13 R3 s1 Q1 35.26% 17 58  4 677 504 
(R,s,Q) 14 R3 s1 Q2 30.53% 8 23  4 160 316 
(R,s,Q) 15 R3 s1 Q3 32.63% 8 33  4 496 983 
(R,s,Q) 16 R3 s2 Q1 34.74% 16 58  4 637 472 
(R,s,Q) 17 R3 s2 Q2 28.42% 7 21  3 556 032 
(R,s,Q) 18 R3 s2 Q3 26.84% 8 22  3 437 803 
(R,s,Q) 19 R3 s3 Q1 34.74% 16 58  4 637 472 
(R,s,Q) 20 R3 s3 Q2 19.47% 7 21  3 078 278 
(R,s,Q) 21 R3 s3 Q3 21.05% 8 22  2 821 514 
(R,s,Q) 22 R3 s4 Q1 35.79% 14 54  4 559 710 
(R,s,Q) 23 R3 s4 Q2 5.79% 4 11  1 258 965 
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(R,s,Q) 24 R3 s4 Q3 4.74% 4 11  876 604 
(R,s,Q) 25 R4 s1 Q1 41.1% 29 75  4 491 281 
(R,s,Q) 26 R4 s1 Q2 41.6% 8 43 5 026 680 
(R,s,Q) 27 R4 s1 Q3 30.5% 9 43  4 425 539 
(R,s,Q) 28 R4 s2 Q1 30.0% 28 71  4 484 190 
(R,s,Q) 29 R4 s2 Q2 38.4% 9 43  5 190 082 
(R,s,Q) 30 R4 s2 Q3 29.0% 9 43  4 210 921 
(R,s,Q) 31 R4 s3 Q1 34.7% 28 71  4 650 234 
(R,s,Q) 32 R4 s3 Q2 30.0% 6 26  4 770 356 
(R,s,Q) 33 R4 s3 Q3 24.2% 5 19  3 791 853 
(R,s,Q) 34 R4 s4 Q1 32.6% 23 73  4 585 716 
(R,s,Q) 35 R4 s4 Q2 7.4% 4 12  1 603 273 
(R,s,Q) 36 R4 s4 Q3 4.7% 3 9  1 003 628 
Table H.2 summarised the order variability performance for each of the scenarios. 
Table H.2: Capreomycin - Summary of order variability performance for the scenarios. 
Policy # R s S Q 𝜎34 𝜎23
Base - - - - 59 466 132 118 
(s,S) 1 s1 S1 67 247 256 203 
(s,S) 2 s1 S2 256 203 205 729 
(s,S) 3 s2 S1 36 996 256 617 
(s,S) 4 s2 S2 256 617 192 787 
(s,S) 5 s3 S1 56 632 94 309 
(s,S) 6 s3 S2 94 309 94 309 
(s,S) 7 s4 S1 275 368 229 375 
(s,S) 8 s4 S2 51 269 275 368 
(R,S) 1 R1 S1  56 632  94 309 
(R,S) 2 R1 S2  94 309  94 309 
(R,S) 3 R2 S1  70 033  89 510 
(R,S) 4 R2 S2  89 510  89 510 
(R,S) 5 R3 S1  83 498  94 524 
(R,S) 6 R3 S2  94 524  94 524 
(R,S) 7 R4 S1  101 674  102 599 
(R,S) 8 R4 S2  102 599  102 599 
(R,s,S) 1 R2 s1 S1  47 785  277 018 
(R,s,S) 2 R2 s1 S2  277 018  233 650 
(R,s,S) 3 R2 s2 S1  90 469  275 298 
(R,s,S) 4 R2 s2 S2  275 298  211 417 
(R,s,S) 5 R2 s3 S1  74 703  214 604 
(R,s,S) 6 R2 s3 S2  214 604  195 895 
(R,s,S) 7 R2 s4 S1  70 033  89 510 
(R,s,S) 8 R2 s4 S2  89 510  89 510 
(R,s,S) 9 R3 s1 S1  77 932  271 853 
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(R,s,S) 10 R3 s1 S2  271 853  230 097 
(R,s,S) 11 R3 s2 S1  67 932  273 173 
(R,s,S) 12 R3 s2 S2  273 173  209 015 
(R,s,S) 13 R3 s3 S1  62 021 263 082 
(R,s,S) 14 R3 s3 S2 263 082  193 342 
(R,s,S) 15 R3 s4 S1  83 498  94 524 
(R,s,S) 16 R3 s4 S2  94 524  94 524 
(R,s,S) 17 R4 s1 S1  72 890  274 002 
(R,s,S) 18 R4 s1 S2  274 002  224 721 
(R,s,S) 19 R4 s2 S1  101 938  274 998 
(R,s,S) 20 R4 s2 S2  274 998  214 604 
(R,s,S) 21 R4 s3 S1  75 911  268 781 
(R,s,S) 22 R4 s3 S2  268 781  193 069 
(R,s,S) 23 R4 s4 S1  101 674  102 599 
(R,s,S) 24 R4 s4 S2  102 599  102 599 
(s,Q) 1 s1 Q1	  11 575  46 945 
(s,Q) 2 s1 Q2  27 731  86 469 
(s,Q) 3 s1 Q3  44 063  100 498 
(s,Q) 4 s2 Q1  11 634  47 068 
(s,Q) 5 s2 Q2  27 731  86 469 
(s,Q) 6 s2 Q3  44 063  100 498 
(s,Q) 7 s3 Q1  11 620  47 124 
(s,Q) 8 s3 Q2  27 731  86 469 
(s,Q) 9 s3 Q3  44 063  100 498 
(s,Q) 10 s4 Q1  11 623  45 102 
(s,Q) 11 s4 Q2  27 731  86 469 
(s,Q) 12 s4 Q3  44 063  100 498 
(R,s,Q) 1 R2 s1 Q1  34 776  65 895 
(R,s,Q) 2 R2 s1 Q2  34 776  65 895 
(R,s,Q) 3 R2 s1 Q3  45 574  84 163 
(R,s,Q) 4 R2 s2 Q1  34 776  65 895 
(R,s,Q) 5 R2 s2 Q2  34 776  65 895 
(R,s,Q) 6 R2 s2 Q3  45 574  84 163 
(R,s,Q) 7 R2 s3 Q1  34 776  65 895 
(R,s,Q) 8 R2 s3 Q2  34 776  65 895 
(R,s,Q) 9 R2 s3 Q3  45 574  84 163 
(R,s,Q) 10 R2 s4 Q1  34 776  65 895 
(R,s,Q) 11 R2 s4 Q2  34 776  65 895 
(R,s,Q) 12 R2 s4 Q3  45 574  84 163 
(R,s,Q) 13 R3 s1 Q1  20 178  46 992 
(R,s,Q) 14 R3 s1 Q2  43 310  68 506 
(R,s,Q) 15 R3 s1 Q3  57 757  82 663 
(R,s,Q) 16 R3 s2 Q1  20 325  46 751 
(R,s,Q) 17 R3 s2 Q2  43 503  67 176 
(R,s,Q) 18 R3 s2 Q3  57 757  82 663 
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(R,s,Q) 19 R3 s3 Q1  20 325  46 751 
(R,s,Q) 20 R3 s3 Q2  43 503  67 176 
(R,s,Q) 21 R3 s3 Q3  57 937  83 277 
(R,s,Q) 22 R3 s4 Q1  20 325  46 751 
(R,s,Q) 23 R3 s4 Q2  43 234  67 612 
(R,s,Q) 24 R3 s4 Q3  57 757  82 663 
(R,s,Q) 25 R4 s1 Q1  21 733  21 733 
(R,s,Q) 26 R4 s1 Q2  54 316  56 552 
(R,s,Q) 27 R4 s1 Q3  75 241  75 241 
(R,s,Q) 28 R4 s2 Q1  21 733  21 733 
(R,s,Q) 29 R4 s2 Q2  54 316  56 552 
(R,s,Q) 30 R4 s2 Q3  75 241  75 241 
(R,s,Q) 31 R4 s3 Q1  21 733  21 733 
(R,s,Q) 32 R4 s3 Q2  54 109  56 373 
(R,s,Q) 33 R4 s3 Q3  75 241  75 241 
(R,s,Q) 34 R4 s4 Q1  21 733  21 733 
(R,s,Q) 35 R4 s4 Q2  53 757  53 757 
(R,s,Q) 36 R4 s4 Q3  75 241  75 241 
The results of the cost performance for each scenario is summarised in Table H.3. 
Table H.3: Capreomycin - Summary of cost performance for the scenarios. 
Policy # R s S Q 𝑪𝑶 𝑪𝑷 𝑪𝑯 Total Cost 
Base - - - - - 43 141 280 18 764 428.20 61 905 708 
(s,S) 1 s1 S1 470 646  40 477 570 34 233 723.26 75 181 939 
(s,S) 2 s1 S2  -    39 521 810  19 346 658.96 58 868 469 
(s,S) 3 s2 S1 226 349  41 688 910  32 146 304.65 74 061 564 
(s,S) 4 s2 S2  1 138 41 168 910 24 779 935.63 65 949 984 
(s,S) 5 s3 S1 534 457  40 143 040  36 024 713.88 76 702 211 
(s,S) 6 s3 S2  1 138 40 008 060  29 726 313.63 69 735 512 
(s,S) 7 s4 S1  -   39 632 701 59 832 890.83 99 465 592 
(s,S) 8 s4 S2  -   39 632 701 38 795 608.27 78 428 309 
(R,S) 1 R1 S1  -    39 632 701 59 832 890.83 99 465 592 
(R,S) 2 R1 S2  -   39 632 701 38 795 608.27 78 428 309 
(R,S) 3 R2 S1  -   39 733 608  52 517 777.36 92 251 385 
(R,S) 4 R2 S2  -   39 733 608 32 753 007.83 72 486 616 
(R,S) 5 R3 S1  -   39 337 908 59 290 396.45 98 628 304 
(R,S) 6 R3 S2  -   39 337 908  39 023 341.20 78 361 249 
(R,S) 7 R4 S1  -    39 733 612 56 526 389.93 96 260 002 
(R,S) 8 R4 S2  -   39 337 908  35 711 409.53 75 049 318 
(R,s,S) 1 R2 s1	 S1 693 741 40 732 350  29 510 007.18 70 936 098 
(R,s,S) 2 R2 s1 S2  1 138 40 366 300  20 207 468.19 60 574 906 
(R,s,S) 3 R2 s2 S1 244 829 40 283 430 29 023 638.43 69 551 897 
(R,s,S) 4 R2 s2 S2  1 138  40 291 070  21 037 813.19 61 330 021 
(R,s,S) 5 R2 s3 S1  -    40 777 260  30 136 908.78 70 914 169 
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(R,s,S) 6 R2 s3 S2  1 138 40 852 050  28 444 321.16 69 297 509 
(R,s,S) 7 R2 s4 S1  -   39 733 608  52 517 777.36 92 251 385 
(R,s,S) 8 R2 s4 S2  -   39 733 608 32 753 007.83 72 486 616 
(R,s,S) 9 R3 s1 S1  -    37 263 130 30 632 477.86 67 895 608 
(R,s,S) 10 R3 s1 S2  1 138  39 753 770  17 186 461.94 56 941 370 
(R,s,S) 11 R3 s2 S1  56 074 40 087 340  44 121 967.54 84 265 382 
(R,s,S) 12 R3 s2 S2  -    40 031 260  24 079 561.22 64 110 821 
(R,s,S) 13 R3 s3 S1 697 426  41 054 920 39 645 248.20 81 397 594 
(R,s,S) 14 R3 s3 S2  -   40 336 040  28 837 488.81 69 173 529 
(R,s,S) 15 R3 s4 S1  -   39 337 908 59 290 396.45 98 628 304 
(R,s,S) 16 R3 s4 S2  -   39 337 908  39 023 341.20 78 361 249 
(R,s,S) 17 R4 s1 S1  24 604 37 508 970  41 869 749.18 79 403 323 
(R,s,S) 18 R4 s1 S2  -    39 121 970  24 511 814.00 63 633 784 
(R,s,S) 19 R4 s2 S1  24 604 37 508 970  41 013 577.96 78 547 152 
(R,s,S) 20 R4 s2 S2  -    40 777 216  30 136 908.78 70 914 125 
(R,s,S) 21 R4 s3 S1  24 604  41 873 380  34 610 303.58 76 508 288 
(R,s,S) 22 R4 s3 S2  -    41 388 890 29 887 589.67 71 276 480 
(R,s,S) 23 R4 s4 S1  -    38 733 612 56 526 389.93 95 260 002 
(R,s,S) 24 R4 s4 S2  -    39 733 612  35 711 409.53 75 445 022 
(s,Q) 1 s1 Q1  -    38 619 594  9 624 144.07 48 243 738 
(s,Q) 2 s1 Q2  -    39 231 874  8 689 738.65 47 921 613 
(s,Q) 3 s1 Q3  -    39 046 015  8 047 223.36 47 093 238 
(s,Q) 4 s2 Q1  -    38 673 448  10 456 718.46 49 130 166 
(s,Q) 5 s2 Q2  -    39 231 874  9 953 762.24 49 185 636 
(s,Q) 6 s2 Q3  -    39 046 015  9 753 940.17 48 799 955 
(s,Q) 7 s3 Q1  -   38 562 878 10 906 833.63 49 469 712 
(s,Q) 8 s3 Q2  -    39 231 874  8 950 306.36 48 182 180 
(s,Q) 9 s3 Q3  -    39 046 015  9 753 940.17 48 799 955 
(s,Q) 10 s4 Q1  -    39 746 974  21 818 965.43 61 565 939 
(s,Q) 11 s4 Q2  -    39 231 874 37 420 785.09 76 652 659 
(s,Q) 12 s4 Q3  -    39 046 015  9 753 940.17 48 799 955 
(R,s,Q) 1 R2 s1 Q1  -    39 194 765  8 883 180.32 48 077 945 
(R,s,Q) 2 R2 s1 Q2  -    39 194 765  8 883 180.32 48 077 945 
(R,s,Q) 3 R2 s1 Q3  -    39 171 271  8 897 468.14 48 068 739 
(R,s,Q) 4 R2 s2 Q1  -    39 194 765  8 863 997.01 48 058 762 
(R,s,Q) 5 R2 s2 Q2  -    39 194 765  8 863 997.01 48 058 762 
(R,s,Q) 6 R2 s2 Q3  -    39 171 271  10 366 956.39 49 538 227 
(R,s,Q) 7 R2 s3 Q1  -   39 194 765  9 989 044.00 49 183 809 
(R,s,Q) 8 R2 s3 Q2  -    39 194 765  9 989 044.00 49 183 809 
(R,s,Q) 9 R2 s3 Q3  -    39 171 271  10 366 956.39 49 538 227 
(R,s,Q) 10 R2 s4 Q1  -    39 194 765 33 072 576.44 72 267 341 
(R,s,Q) 11 R2 s4 Q2  -    39 194 765 33 072 576.44 72 267 341 
(R,s,Q) 12 R2 s4 Q3  -    39 171 271  36 158 736.18 75 330 007 
(R,s,Q) 13 R3 s1 Q1  -    39 653 475  7 804 488.84 47 457 964 
(R,s,Q) 14 R3 s1 Q2  -    38 778 944  8 521 667.01 47 300 611 
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(R,s,Q) 15 R3 s1 Q3  -    38 976 491  8 767 945.81 47 744 437 
(R,s,Q) 16 R3 s2 Q1  -    39 936 146  7 584 196.14 47 520 342 
(R,s,Q) 17 R3 s2 Q2  -    38 451 944  9 831 736.72 48 283 681 
(R,s,Q) 18 R3 s2 Q3  -    38 976 491  10 531 685.93 49 508 177 
(R,s,Q) 19 R3 s3 Q1  -    39 936 146  7 584 196.14 47 520 342 
(R,s,Q) 20 R3 s3 Q2  -    38 451 944  12 101 178.92 50 553 123 
(R,s,Q) 21 R3 s3 Q3  -    38 754 482  13 153 806.64 51 908 289 
(R,s,Q) 22 R3 s4 Q1  -    39 936 146  7 675 582.84 47 611 729 
(R,s,Q) 23 R3 s4 Q2  -    39 019 205 35 908 903.36 74 928 108 
(R,s,Q) 24 R3 s4 Q3  -    38 976 491  41 060 130.52 80 036 622 
(R,s,Q) 25 R4 s1 Q1  -   39 482 690  7 717 469.74 47 200 160 
(R,s,Q) 26 R4 s1 Q2  -    38 590 165  6 318 457.28 44 908 622 
(R,s,Q) 27 R4 s1 Q3  -    39 146 497  8 849 899.28 47 996 396 
(R,s,Q) 28 R4 s2 Q1  -   39 482 690  8 020 257.47 47 502 947 
(R,s,Q) 29 R4 s2 Q2  -    38 590 165  9 067 182.85 47 657 348 
(R,s,Q) 30 R4 s2 Q3  -    38 146 497  9 692 619.78 47 839 117 
(R,s,Q) 31 R4 s3 Q1  -   39 482 690  8 020 257.47 47 502 947 
(R,s,Q) 32 R4 s3 Q2  -   38 682 034  9 245 944.68 47 927 979 
(R,s,Q) 33 R4 s3 Q3  -    39 146 497  11 737 958.70 50 884 456 
(R,s,Q) 34 R4 s4 Q1  -   39 482 690  7 416 402.94 46 899 093 
(R,s,Q) 35 R4 s4 Q2  -   39 438 920  29 372 821.55 68 811 742 
(R,s,Q) 36 R4 s4 Q3  -    39 146 497  36 991 725.98 76 138 223 
H.2 Modelling results of kanamycin 
This section provides the results of kanamycin for each scenario. Table H.4 summarises 
the stock performance of each scenario. 
Table H.4: Kanamycin - Summary of stock performance for the scenarios. 
Policy # R s S Q %BLs 𝜇¿/_ÀÁl 𝑀𝑎𝑥¿/_ÀÁl Total Vol.
(s,S) 1 s1 S1 3.20% 10.40 26  1 402 907 
(s,S) 2 s1 S2 9.60% 4.81 14  1 182 645 
(s,S) 3 s2 S1 2.40% 11.30 26  1 253 054 
(s,S) 4 s2 S2 9.60% 7.69 20  1 029 848 
(s,S) 5 s3 S1 2.40% 11.30 26  1 253 054 
(s,S) 6 s3 S2 17.60% 5.01 23  928 357 
(s,S) 7 s4 S1 0.00% 0.00 0  0 
(s,S) 8 s4 S2 1.60% 3.14 6  310 891 
(R,S) 1 R1 S1 0.00% 0.00 0  0 
(R,S) 2 R1 S2 1.60% 3.14 6  310 891 
(R,S) 3 R2 S1 0.00% 0.00 0  0 
(R,S) 4 R2 S2 1.60% 1.00 1  547 935 
(R,S) 5 R3 S1 0.00% 0.00 0  0 
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(R,S) 6 R3 S2 1.60% 1.00 1  547 935 
(R,S) 7 R4 S1 0.00% 0.00 0  0 
(R,S) 8 R4 S2 2.40% 1.52 2  296 909 
(R,s,S) 1 R2 s1 S1 0.80% 13.50 26  705 119 
(R,s,S) 2 R2 s1 S2 6.40% 2.81 7  1 283 571 
(R,s,S) 3 R2 s2 S1 2.40% 11.30 26  1 253 054 
(R,s,S) 4 R2 s2 S2 8.80% 5.76 16  1 584 887 
(R,s,S) 5 R2 s3 S1 6.40% 6.32 18  1 874 502 
(R,s,S) 6 R2 s3 S2 15.20% 4.34 16  1 050 329 
(R,s,S) 7  R2 s4 S1 0.00% 0.00 0  0 
(R,s,S) 8 R2 s4 S2 1.60% 1.00 1  547 935 
(R,s,S) 9 R3 s1 S1 0.80% 7.00 13  705 119 
(R,s,S) 10 R3 s1 S2 16.80% 4.65 16  2 366 099 
(R,s,S) 11 R3 s2 S1 1.60% 6.57 13  1 032 648 
(R,s,S) 12 R3 s2 S2 7.20% 9.55 29  2 202 031 
(R,s,S) 13 R3 s3 S1 0.80% 7.00 13  705 119 
(R,s,S) 14 R3 s3 S2 10.40% 6.06 16  1 689 513 
(R,s,S) 15 R3 s4 S1 0.00% 0.00 0 0 
(R,s,S) 16 R3 s4 S2 1.60% 1.00 1  547 935 
(R,s,S) 17  R4 s1 S1 7.20% 9.05 22  1 567 366 
(R,s,S) 18 R4 s1 S2 12.00% 3.04 8  2 565 723 
(R,s,S) 19 R4 s2 S1 7.20% 9.51 22  1 567 366 
(R,s,S) 20 R4 s2 S2 6.40% 6.32 18  1 874 502 
(R,s,S) 21  R4 s3 S1 0.80% 11.50 22  705 119 
(R,s,S) 22 R4 s3 S2 12.80% 3.77 16  1 599 355 
(R,s,S) 23  R4 s4 S1 0.00% 0.00 0 0 
(R,s,S) 24  R4 s4 S2 2.40% 1.52 3  296 909 
(s,Q) 1 s1 Q1 9.60% 15.56 47  2 683 523 
(s,Q) 2 s1 Q2 8.00% 11.81 33  2 674 385 
(s,Q) 3 s1 Q3 9.60% 11.74 38  2 693 091 
(s,Q) 4 s2 Q1 7.20% 12.73 31  2 592 497 
(s,Q) 5 s2 Q2 12.00% 9.82 29  2 738 224 
(s,Q) 6 s2 Q3 7.20% 11.88 38  2 043 080 
(s,Q) 7 s3 Q1 12.00% 9.57 29  3 011 095 
(s,Q) 8 s3 Q2 6.40% 8.50 26  2 001 544 
(s,Q) 9 s3 Q3 5.60% 12.66 38  1 813 642 
(s,Q) 10 s4 Q1 1.60% 2.50 4  432 487 
(s,Q) 11 s4 Q2 0.00% 0.00 0  0 
(s,Q) 12 s4 Q3 5.60% 8.50 38  1 813 642 
(R,s,Q) 1 R2	 s1 Q1 13.60% 14 45  3 528 682 
(R,s,Q) 2 R2 s1 Q2 11.20% 10 32  2 859 217 
(R,s,Q) 3 R2 s1 Q3 11.20% 8 23  3 049 787 
(R,s,Q) 4 R2 s2 Q1 13.60% 12 34  3 434 096 
(R,s,Q) 5 R2 s2 Q2 8.80% 9 25  2 805 340 
(R,s,Q) 6 R2 s2 Q3 9.60% 7 18  2 822 867 
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(R,s,Q) 7 R2 s3 Q1 12.80% 12 33  3 299 687 
(R,s,Q) 8 R2 s3 Q2 15.20% 7 21  3 125 870 
(R,s,Q) 9 R2 s3 Q3 6.40% 7 18  2 161 586 
(R,s,Q) 10 R2 s4 Q1 4.80% 8 18  1 450 940 
(R,s,Q) 11 R2 s4 Q2 0.80% 0 0  282 634 
(R,s,Q) 12 R2 s4 Q3 0.00% 0 0 0 
(R,s,Q) 13 R3 s1 Q1 16.80% 17 50  3 752 626 
(R,s,Q) 14 R3 s1 Q2 15.20% 11 29  3 297 102 
(R,s,Q) 15 R3 s1 Q3 13.60% 12 29  3 264 355 
(R,s,Q) 16 R3 s2 Q1 15.20% 16 45  3 717 209 
(R,s,Q) 17 R3 s2 Q2 10.40% 13 30  2 927 042 
(R,s,Q) 18 R3 s2 Q3 12.00% 10 29  2 834 506 
(R,s,Q) 19 R3 s3 Q1 14.40% 15 39  3 164 916 
(R,s,Q) 20 R3 s3 Q2 11.20% 11 29  2 692 339 
(R,s,Q) 21 R3 s3 Q3 12.80% 9 29  2 792 261 
(R,s,Q) 22 R3 s4 Q1 7.20% 12 29  2 253 633 
(R,s,Q) 23 R3 s4 Q2 0.00% 0 0  0 
(R,s,Q) 24 R3 s4 Q3 0.00% 0 0 0 
(R,s,Q) 25 R4 s1 Q1 16.80% 19 48  3 649 091 
(R,s,Q) 26 R4 s1 Q2 8.00% 10 33  2 430 360 
(R,s,Q) 27 R4 s1 Q3 6.40% 10 33  2 309 863 
(R,s,Q) 28 R4 s2 Q1 14.40% 14 45  2 922 409 
(R,s,Q) 29 R4 s2 Q2 28.00% 7 18  4 857 500 
(R,s,Q) 30 R4 s2 Q3 8.80% 16 32  2 559 163 
(R,s,Q) 31 R4 s3 Q1 15.20% 14 51  3 109 141 
(R,s,Q) 32 R4 s3 Q2 8.80% 8 22  2 318 406 
(R,s,Q) 33 R4 s3 Q3 8.80% 6 18  2 635 818 
(R,s,Q) 34 R4 s4 Q1 11.20% 10 28  3 137 629 
(R,s,Q) 35 R4 s4 Q2 2.40% 3 5  1 068 831 
(R,s,Q) 36 R4 s4 Q3 0.80% 0 0  282 634 
Table H.5 summarised the order variability performance for each of the scenarios. 
Table H.5: Kanamycin - Summary of order variability performance for the scenarios. 
Policy # R s S Q 𝜎34 𝜎23
Base - - - - 88 219 173 929 
(s,S) 1 s1 S1  44 350  324 257 
(s,S) 2 s1 S2  324 257  266 167 
(s,S) 3 s2 S1  68 230  340 846 
(s,S) 4 s2 S2  340 846  259 872 
(s,S) 5 s3 S1  68 230  340 846 
(s,S) 6 s3 S2  340 846  222 252 
(s,S) 7 s4 S1  97 627  138 601 
(s,S) 8 s4 S2  138 601  138 601 
(R,S) 1 R1 S1  97 627  138 601 
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(R,S) 2 R1 S2  138 601  138 601 
(R,S) 3 R2 S1  116 653  140 780 
(R,S) 4 R2 S2  140 780  140 780 
(R,S) 5 R3 S1  148 003  150 917 
(R,S) 6 R3 S2  150 917  150 917 
(R,S) 7 R4 S1  152 724  150 005 
(R,S) 8 R4 S2  150 005  150 005 
(R,s,S) 1  R2 s1 S1  44 363  324 258 
(R,s,S) 2 R2 s1 S2  324 258  266 167 
(R,s,S) 3 R2 s2 S1  68 230  340 846 
(R,s,S) 4 R2 s2 S2  340 846  260 150 
(R,s,S) 5 R2 s3 S1  195 768  270 688 
(R,s,S) 6 R2 s3 S2  270 688  222 186 
(R,s,S) 7  R2 s4 S1  116 653  140 780 
(R,s,S) 8 R2 s4 S2  140 780  140 780 
(R,s,S) 9 R3 s1 S1  140 040  333 758 
(R,s,S) 10 R3 s1 S2  333 758  287 562 
(R,s,S) 11 R3 s2 S1  158 160  332 696 
(R,s,S) 12 R3 s2 S2  332 696  371 021 
(R,s,S) 13 R3 s3 S1  175 076  327 777 
(R,s,S) 14 R3 s3 S2  327 777  243 397 
(R,s,S) 15 R3 s4 S1  148 003  150 917 
(R,s,S) 16 R3 s4 S2  150 917  150 917 
(R,s,S) 17  R4 s1 S1  139 989  333 781 
(R,s,S) 18 R4 s1 S2  333 781  287 320 
(R,s,S) 19 R4 s2 S1  158 160  332 696 
(R,s,S) 20 R4 s2 S2  332 696  270 688 
(R,s,S) 21  R4 s3 S1  174 231  329 243 
(R,s,S) 22 R4 s3 S2  329 243  243 317 
(R,s,S) 23  R4 s4 S1  152 724  150 005 
(R,s,S) 24  R4 s4 S2  150 005  150 005 
(s,Q) 1 s1 Q1	  15 876  59 321 
(s,Q) 2 s1 Q2  40 690  119 706 
(s,Q) 3 s1 Q3  62 615  146 092 
(s,Q) 4 s2 Q1  15 890  59 228 
(s,Q) 5 s2 Q2  40 690  119 706 
(s,Q) 6 s2 Q3  62 615  146 092 
(s,Q) 7 s3 Q1  15 890  59 228 
(s,Q) 8 s3 Q2  40 690  119 706 
(s,Q) 9 s3 Q3  62 615  146 092 
(s,Q) 10 s4 Q1  15 869  58 707 
(s,Q) 11 s4 Q2  40 690  119 706 
(s,Q) 12 s4 Q3  62 615  146 092 
(R,s,Q) 1 R2 s1 Q1  19 226  40 434 
(R,s,Q) 2 R2 s1 Q2  52 302  96 437 
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(R,s,Q) 3 R2 s1 Q3  68 876  117 518 
(R,s,Q) 4 R2 s2 Q1  19 241  40 472 
(R,s,Q) 5 R2 s2 Q2  51 974  96 464 
(R,s,Q) 6 R2 s2 Q3  68 876  117 518 
(R,s,Q) 7 R2 s3 Q1  19 319  40 373 
(R,s,Q) 8 R2 s3 Q2  52 228  96 361 
(R,s,Q) 9 R2 s3 Q3  68 876  117 518 
(R,s,Q) 10 R2 s4 Q1  19 509  38 393 
(R,s,Q) 11 R2 s4 Q2  51 974  96 464 
(R,s,Q) 12 R2 s4 Q3  68 876  117 518 
(R,s,Q) 13 R3 s1 Q1  21 477  45 321 
(R,s,Q) 14 R3 s1 Q2  65 816  93 415 
(R,s,Q) 15 R3 s1 Q3  91 097  115 479 
(R,s,Q) 16 R3 s2 Q1  21 526  45 103 
(R,s,Q) 17 R3 s2 Q2  65 816  93 415 
(R,s,Q) 18 R3 s2 Q3  91 097  115 479 
(R,s,Q) 19 R3 s3 Q1  21 477  45 321 
(R,s,Q) 20 R3 s3 Q2  65 816  93 415 
(R,s,Q) 21 R3 s3 Q3  91 097  115 479 
(R,s,Q) 22 R3 s4 Q1  21 701  44 240 
(R,s,Q) 23 R3 s4 Q2  65 416  93 389 
(R,s,Q) 24 R3 s4 Q3  91 097  115 479 
(R,s,Q) 25 R4 s1 Q1  23 194  23 194 
(R,s,Q) 26 R4 s1 Q2  78 362  78 604 
(R,s,Q) 27 R4 s1 Q3  113 583  113 583 
(R,s,Q) 28 R4 s2 Q1  23 194  23 194 
(R,s,Q) 29 R4 s2 Q2  78 362  78 604 
(R,s,Q) 30 R4 s2 Q3  68 324  73 035 
(R,s,Q) 31 R4 s3 Q1  23 194  23 194 
(R,s,Q) 32 R4 s3 Q2  78 551  79 038 
(R,s,Q) 33 R4 s3 Q3  113 583  113 583 
(R,s,Q) 34 R4 s4 Q1  23 194  23 194 
(R,s,Q) 35 R4 s4 Q2  78 022  78 022 
(R,s,Q) 36 R4 s4 Q3  113 583  113 583 
The results of the cost performance for each scenario is summarised in Table H.6. 
Table H.6: Kanamycin - Summary of cost performance for the scenarios. 
Policy # R s S Q 𝐶; 𝐶< 𝐶: Total Cost 
Base - - - - - 21 006 724 7 186 628.40 28 193 353 
(s,S) 1 s1 S1  -    15 739 410  40 010 791.54 55 750 202 
(s,S) 2 s1 S2  -    16 412 520  25 367 851.80 41 780 372 
(s,S) 3 s2 S1  -    18 256 470  37 228 955.10 55 485 425 
(s,S) 4 s2 S2  -    15 781 060 22 885 709.28 38 666 769 
(s,S) 5 s3 S1  -    18 256 470  37 228 955.10 55 485 425 
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(s,S) 6 s3 S2  -    16 778 270  26 363 121.79 43 141 392 
(s,S) 7 s4 S1  -    15 827 879 55 559 061.57 71 386 941 
(s,S) 8 s4 S2  -    15 827 879  33 838 250.12 49 666 129 
(R,S) 1 R1 S1  -    15 827 879 55 559 061.57 71 386 941 
(R,S) 2 R1 S2  -    15 827 879  33 838 250.12 49 666 129 
(R,S) 3 R2 S1  -    15 829 627 56 093 109.86 71 922 737 
(R,S) 4 R2 S2  -    15 829 627  34 387 814.13 50 217 441 
(R,S) 5 R3 S1  -    15 827 875  51 277 975.30 67 105 850 
(R,S) 6 R3 S2  -    15 827 875  29 572 691.23 45 400 566 
(R,S) 7 R4 S1  -    15 829 627  56 497 171.55 72 326 799 
(R,S) 8 R4 S2  -    15 829 627  34 753 711.52 50 583 339 
(R,s,S) 1  R2 s1	 S1  -    15 739 400  39 740 415.61 55 479 816 
(R,s,S) 2 R2 s1 S2  -    16 412 520 25 226 362.53 41 638 883 
(R,s,S) 3 R2 s2 S1  -    18 256 470  37 228 955.10 55 485 425 
(R,s,S) 4 R2 s2 S2  -    15 781 080  23 165 609.44 38 946 689 
(R,s,S) 5 R2 s3 S1  -    16 566 810  23 743 041.20 40 309 851 
(R,s,S) 6 R2 s3 S2  -    16 778 280 23 886 048.70 40 664 329 
(R,s,S) 7  R2 s4 S1  -    15 829 627  56 093 109.86 71 922 737 
(R,s,S) 8 R2 s4 S2  -    15 829 627  34 387 814.13 50 217 441 
(R,s,S) 9 R3 s1 S1  -    16 121 800  37 877 883.00 53 999 683 
(R,s,S) 10 R3 s1 S2  -    16 412 520  18 322 633.84 34 735 154 
(R,s,S) 11 R3 s2 S1  -    16 045 540  32 675 417.01 48 720 957 
(R,s,S) 12 R3 s2 S2  -    16 566 790 20 808 526.20 37 375 316 
(R,s,S) 13 R3 s3 S1  -    15 779 060  34 913 279.97 50 692 340 
(R,s,S) 14 R3 s3 S2  -    15 929 990  21 587 091.53 37 517 082 
(R,s,S) 15 R3 s4 S1  -    15 827 875  51 277 975.30 67 105 850 
(R,s,S) 16 R3 s4 S2  -    15 827 875  29 572 691.23 45 400 566 
(R,s,S) 17  R4 s1 S1  -    16 122 970  30 374 696.70 46 497 667 
(R,s,S) 18 R4 s1 S2  -    16 411 370  21 509 051.76 37 920 422 
(R,s,S) 19 R4 s2 S1  -    16 045 540 30 362 383.68 46 407 924 
(R,s,S) 20 R4 s2 S2  -    16 566 810  23 743 041.20 40 309 851 
(R,s,S) 21  R4 s3 S1  -    15 852 240 40 208 254.92 56 060 495 
(R,s,S) 22 R4 s3 S2  -    15 929 990  25 319 870.92 41 249 861 
(R,s,S) 23  R4 s4 S1  -    15 829 627  56 497 171.55 72 326 799 
(R,s,S) 24  R4 s4 S2  -    15 829 627  34 753 711.52 50 583 339 
(s,Q) 1 s1 Q1  -    15 752 842  8 928 831.17 24 681 673 
(s,Q) 2 s1 Q2  -    15 852 457  12 903 130.12 28 755 587 
(s,Q) 3 s1 Q3  -    15 861 991  12 968 923.45 28 830 914 
(s,Q) 4 s2 Q1  -    15 763 740  10 670 293.09 26 434 033 
(s,Q) 5 s2 Q2  -    15 852 457  14 413 189.50 30 265 647 
(s,Q) 6 s2 Q3  -    15 861 991  15 114 064.54 30 976 056 
(s,Q) 7 s3 Q1  -    15 763 740  11 835 172.53 27 598 913 
(s,Q) 8 s3 Q2  -    15 852 457  16 112 202.58 31 964 660 
(s,Q) 9 s3 Q3  -    15 861 991  17 088 195.58 32 950 187 
(s,Q) 10 s4 Q1  -    15 890 294  25 619 594.46 41 509 888 
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(s,Q) 11 s4 Q2  -    15 852 457  33 897 534.41 49 749 991 
(s,Q) 12 s4 Q3  -    15 861 991  17 088 195.58 32 950 187 
(R,s,Q) 1 R2 s1 Q1  -    15 522 625  9 038 678.35 24 561 303 
(R,s,Q) 2 R2 s1 Q2  -    15 729 830  10 359 318.15 26 089 148 
(R,s,Q) 3 R2 s1 Q3  -    15 826 065  12 281 453.11 28 107 518 
(R,s,Q) 4 R2 s2 Q1  -    15 519 037  9 421 804.83 24 940 842 
(R,s,Q) 5 R2 s2 Q2  -    15 893 193  12 222 718.74 28 115 912 
(R,s,Q) 6 R2 s2 Q3  -    15 826 065  13 944 670.64 29 770 736 
(R,s,Q) 7 R2 s3 Q1  -    15 491 972  11 040 183.02 26 532 155 
(R,s,Q) 8 R2 s3 Q2  -    15 743 597  13 385 232.09 29 128 829 
(R,s,Q) 9 R2 s3 Q3  -    15 826 065  15 816 365.22 31 642 430 
(R,s,Q) 10 R2 s4 Q1  -    15 724 126  19 959 792.13 35 683 918 
(R,s,Q) 11 R2 s4 Q2  -    15 893 193  33 042 697.32 48 935 890 
(R,s,Q) 12 R2 s4 Q3  -    15 826 065 35 095 587.80 50 921 653 
(R,s,Q) 13 R3 s1 Q1  -    15 230 222  7 373 289.23 22 603 511 
(R,s,Q) 14 R3 s1 Q2  -    15 715 627  8 212 758.31 23 928 385 
(R,s,Q) 15 R3 s1 Q3  -    15 818 775  10 586 927.65 26 405 703 
(R,s,Q) 16 R3 s2 Q1  -    15 341 294  8 086 361.83 23 427 656 
(R,s,Q) 17 R3 s2 Q2  -    15 715 627  9 543 430.65 25 259 058 
(R,s,Q) 18 R3 s2 Q3  -    15 818 775  11 707 501.57 27 526 277 
(R,s,Q) 19 R3 s3 Q1  -    15 230 222  8 450 736.86 23 680 959 
(R,s,Q) 20 R3 s3 Q2  -    15 715 627  11 922 360.97 27 637 988 
(R,s,Q) 21 R3 s3 Q3  -    15 818 775  13 237 427.60 29 056 203 
(R,s,Q) 22 R3 s4 Q1  -    15 430 499  11 891 494.74 27 321 994 
(R,s,Q) 23 R3 s4 Q2  -    15 856 881  27 864 157.64 43 721 039 
(R,s,Q) 24 R3 s4 Q3  -    15 818 775  30 413 888.75 46 232 664 
(R,s,Q) 25 R4 s1 Q1  -    15 027 452  7 083 279.50 22 110 732 
(R,s,Q) 26 R4 s1 Q2  -    15 744 060  11 571 364.08 27 315 424 
(R,s,Q) 27 R4 s1 Q3  -    15 826 358  13 247 836.79 29 074 195 
(R,s,Q) 28 R4 s2 Q1  -    15 027 452  8 187 594.90 23 215 047 
(R,s,Q) 29 R4 s2 Q2  -    15 744 060  12 766 363.73 28 510 424 
(R,s,Q) 30 R4 s2 Q3  -    14 065 763  10 771 206.40 24 836 969 
(R,s,Q) 31 R4 s3 Q1  -    15 027 452  8 603 552.67 23 631 005 
(R,s,Q) 32 R4 s3 Q2  -    15 669 900  14 247 511.47 29 917 411 
(R,s,Q) 33 R4 s3 Q3  -    15 826 358  16 110 364.94 31 936 723 
(R,s,Q) 34 R4 s4 Q1  -    15 027 452  10 493 614.01 25 521 066 
(R,s,Q) 35 R4 s4 Q2  -    15 851 004  32 929 537.21 48 780 541 
(R,s,Q) 36 R4 s4 Q3  -    15 826 358  35 521 004.66 51 347 363 
H.3 Modelling results of cycloserine 
This section provides the results of cycloserine for each scenario. Table H.7 summarises 
the stock performance of each scenario. 
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Table H.7: Cycloserine - Summary of stock performance for the scenarios. 
Policy # R s S Q %BLs 𝜇¿/_ÀÁl 𝑀𝑎𝑥¿/_ÀÁl Total Vol.
(s,S) 1 s1 S1 46.67% 8.66 34  83 176 395 
(s,S) 2 s1 S2 39.22% 7.34 36  88 612 986 
(s,S) 3 s2 S1 47.45% 8.71 34  90 381 221 
(s,S) 4 s2 S2 35.29% 5.62 22  82 997 205 
(s,S) 5 s3 S1 28.63% 7.21 25  66 417 405 
(s,S) 6 s3 S2 30.20% 5.96 31  67 878 296 
(s,S) 7 s4 S1 8.63% 5.51 18  38 540 211 
(s,S) 8 s4 S2 13.33% 8.83 29  58 292 077 
(R,S) 1 R1 S1 8.63% 5.51 18  38 540 211 
(R,S) 2 R1 S2 13.33% 8.93 29  58 292 077 
(R,S) 3 R2 S1 9.02% 9.11 35  46 676 508 
(R,S) 4 R2 S2 9.02% 13.18 47  47 928 818 
(R,S) 5 R3 S1 5.88% 11.00 35  36 812 271 
(R,S) 6 R3 S2 13.73% 10.09 40  57 817 621 
(R,S) 7 R4 S1 10.59% 7.68 31  41 238 486 
(R,S) 8 R4 S2 22.35% 6.83 31  76 547 597 
(R,s,S) 1 R2 s1 S1 39.61% 9.89 47  77 683 979 
(R,s,S) 2 R2 s1 S2 24.45% 9.72 39  68 423 989 
(R,s,S) 3 R2 s2 S1 34.51% 10.16 52  77 022 352 
(R,s,S) 4 R2 s2 S2 36.47% 8.08 36  78 022 953 
(R,s,S) 5 R2 s3 S1 35.69% 9.32 43  83 961 230 
(R,s,S) 6 R2 s3 S2 38.04% 8.76 43  76 837 229 
(R,s,S) 7 R2 s4 S1 9.02% 9.11 35  46 676 508 
(R,s,S) 8 R2 s4 S2 9.02% 13.18 47  47 928 818 
(R,s,S) 9 R3 s1 S1 42.75% 9.75 47  80 981 714 
(R,s,S) 10 R3 s1 S2 26.27% 9.24 42  65 266 420 
(R,s,S) 11 R3 s2 S1 29.80% 5.56 22  66 282 991 
(R,s,S) 12 R3 s2 S2 36.08% 6.85 35  80 692 333 
(R,s,S) 13 R3 s3 S1 29.80% 5.56 22  66 282 991 
(R,s,S) 14 R3 s3 S2 32.55% 8.03 40  77 482 121 
(R,s,S) 15 R3 s4 S1 5.88% 11.00 35  36 812 271 
(R,s,S) 16 R3 s4 S2 13.73% 10.09 40  57 817 621 
(R,s,S) 17 R4 s1 S1 30.59% 8.72 41  61 479 860 
(R,s,S) 18 R4 s1 S2 35.29% 8.82 43  80 919 966 
(R,s,S) 19 R4 s2 S1 29.41% 7.08 29  70 442 660 
(R,s,S) 20 R4 s2 S2 35.69% 9.32 43  83 961 230 
(R,s,S) 21 R4 s3 S1 35.29% 7.31 30  75 731 691 
(R,s,S) 22 R4 s3 S2 33.73% 9.23 39  83 498 211 
(R,s,S) 23 R4 s4 S1 10.59% 7.68 31  41 238 486 
(R,s,S) 24 R4 s4 S2 22.35% 6.83 35  76 547 597 
(s,Q) 1 s1 Q1 20.00% 19.47 59  74 677 760 
(s,Q) 2 s1 Q2 20.78% 4.82 49  78 142 881 
(s,Q) 3 s1 Q3 28.63% 9.86 71  91 302 763 
(s,Q) 4 s2 Q1 21.96% 18.68 52  74 753 861 
continued on next page 
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(s,Q) 5 s2 Q2 26.27% 11.95 52  86 246 305 
(s,Q) 6 s2 Q3 18.82% 15.36 57  75 823 651 
(s,Q) 7 s3 Q1 21.57% 17.41 69  73 167 130 
(s,Q) 8 s3 Q2 20.39% 9.58 46  84 310 353 
(s,Q) 9 s3 Q3 22.35% 11.81 44  78 940 628 
(s,Q) 10 s4 Q1 14.12% 10.01 47  65 101 767 
(s,Q) 11 s4 Q2 7.45% 6.08 22  53 111 554 
(s,Q) 12 s4 Q3 5.60% 8.50 38  78 940 628 
(R,s,Q) 1 R2	 s1 Q1 24.71% 24 77  80 040 441 
(R,s,Q) 2 R2 s1 Q2 27.84% 15 51  87 589 007 
(R,s,Q) 3 R2 s1 Q3 22.35% 18 57  73 721 325 
(R,s,Q) 4 R2 s2 Q1 22.75% 21 58  80 234 787 
(R,s,Q) 5 R2 s2 Q2 26.27% 14 47  77 206 440 
(R,s,Q) 6 R2 s2 Q3 20.00% 18 57  73 951 817 
(R,s,Q) 7 R2 s3 Q1 29.02% 19 58  86 130 188 
(R,s,Q) 8 R2 s3 Q2 25.10% 13 47  80 042 713 
(R,s,Q) 9 R2 s3 Q3 24.71% 15 47  79 450 824 
(R,s,Q) 10 R2 s4 Q1 18.43% 20 74  74 513 354 
(R,s,Q) 11 R2 s4 Q2 14.51% 10 38  58 473 269 
(R,s,Q) 12 R2 s4 Q3 11.37% 10 35 55 008 050 
(R,s,Q) 13 R3 s1 Q1 27.06% 31 114  82 928 799 
(R,s,Q) 14 R3 s1 Q2 30.59% 19 73  87 155 846 
(R,s,Q) 15 R3 s1 Q3 23.53% 16 57  72 976 172 
(R,s,Q) 16 R3 s2 Q1 25.10% 31 114  80 180 710 
(R,s,Q) 17 R3 s2 Q2 25.10% 18 52  78 611 972 
(R,s,Q) 18 R3 s2 Q3 24.31% 16 57  74 734 963 
(R,s,Q) 19 R3 s3 Q1 27.84% 31 114  81 535 142 
(R,s,Q) 20 R3 s3 Q2 22.35% 17 68  76 633 355 
(R,s,Q) 21 R3 s3 Q3 24.31% 16 57  74 734 963 
(R,s,Q) 22 R3 s4 Q1 24.31% 30 114  78 593 482 
(R,s,Q) 23 R3 s4 Q2 12.16% 15 49  58 238 857 
(R,s,Q) 24 R3 s4 Q3 9.41% 15 40  53 210 826 
(R,s,Q) 25 R4 s1 Q1 30.98% 35 125  87 737 520 
(R,s,Q) 26 R4 s1 Q2 27.45% 16 50  83 661 572 
(R,s,Q) 27 R4 s1 Q3 30.59% 13 43  91 479 764 
(R,s,Q) 28 R4 s2 Q1 33.73% 36 125  89 229 194 
(R,s,Q) 29 R4 s2 Q2 50.20% 14 41  114 612 732 
(R,s,Q) 30 R4 s2 Q3 21.96% 16 50  83 053 057 
(R,s,Q) 31 R4 s3 Q1 24.24% 36 125  85 136 813 
(R,s,Q) 32 R4 s3 Q2 24.31% 15 53  81 983 954 
(R,s,Q) 33 R4 s3 Q3 33.73% 11 41  91 726 106 
(R,s,Q) 34 R4 s4 Q1 34.90% 32 101  88 781 954 
(R,s,Q) 35 R4 s4 Q2 21.18% 9 47  69 736 558 
(R,s,Q) 36 R4 s4 Q3 17.65% 9 35  71 205 931 
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Table H.8 summarised the order variability performance for each of the scenarios. 
Table H.8: Cycloserine - Summary of order variability performance for the scenarios. 
Policy # R s S Q 𝜎34 𝜎23
Base - - - - 976 715 1 865 129 
(s,S) 1 s1 S1 2 227 686 4 258 829 
(s,S) 2 s1 S2 4 258 829 3 523 724 
(s,S) 3 s2 S1  1 128 154 4 040 870 
(s,S) 4 s2 S2 4 040 870 3 292 663 
(s,S) 5 s3 S1  2 153 086  4 110 091 
(s,S) 6 s3 S2 4 110 091 3 002 954 
(s,S) 7 s4 S1  1 120 426  1 881 802 
(s,S) 8 s4 S2  1 881 802  1 885 686 
(R,S) 1 R1 S1  1 120 426  1 881 802 
(R,S) 2 R1 S2  1 881 802  1 885 686 
(R,S) 3 R2 S1  1 383 606  2 024 841 
(R,S) 4 R2 S2  2 024 841 2 032 348 
(R,S) 5 R3 S1  1 694 425  1 963 972 
(R,S) 6 R3 S2  1 963 972  1 972 002 
(R,S) 7 R4 S1  1 951 608  1 957 691 
(R,S) 8 R4 S2  1 957 691  1 961 676 
(R,s,S) 1 R2 s1 S1 2 585 030 4 529 082 
(R,s,S) 2 R2 s1 S2 4 529 082  3 518 645 
(R,s,S) 3 R2 s2 S1  1 217 499 4 057 245 
(R,s,S) 4 R2 s2 S2 4 057 245 3 275 589 
(R,s,S) 5 R2 s3 S1  1 668 797  3 255 103 
(R,s,S) 6 R2 s3 S2  3 255 103 2 970 890 
(R,s,S) 7 R2 s4 S1  1 389 120 2 029 394 
(R,s,S) 8 R2 s4 S2 2 029 394 2 030 348 
(R,s,S) 9 R3 s1 S1 2 577 835  4 528 512 
(R,s,S) 10 R3 s1 S2  4 528 512  3 488 431 
(R,s,S) 11 R3 s2 S1  1 252 360 4 000 222 
(R,s,S) 12 R3 s2 S2 4 000 222 3 296 693 
(R,s,S) 13 R3 s3 S1  1 252 360 4 000 222 
(R,s,S) 14 R3 s3 S2 4 000 222  3 013 954 
(R,s,S) 15 R3 s4 S1  1 694 425  1 963 972 
(R,s,S) 16 R3 s4 S2  1 963 972  1 972 002 
(R,s,S) 17 R4 s1 S1 3 252 206 4 579 653 
(R,s,S) 18 R4 s1 S2 4 579 653 3 409 336 
(R,s,S) 19 R4 s2 S1  1 282 070 4 060 609 
(R,s,S) 20 R4 s2 S2 4 060 609  3 255 103 
(R,s,S) 21 R4 s3 S1 2 068 930  4 115 789 
(R,s,S) 22 R4 s3 S2  4 115 789  3 104 662 
(R,s,S) 23 R4 s4 S1  1 951 608  1 957 691 
(R,s,S) 24 R4 s4 S2  1 957 691  1 961 676 
(s,Q) 1 s1 Q1	  208 094  821 523 
continued on next page 
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(s,Q) 2 s1 Q2  569 995  1 682 445 
(s,Q) 3 s1 Q3  901 720  1 914 757 
(s,Q) 4 s2 Q1  208 142  823 317 
(s,Q) 5 s2 Q2  569 995  1 682 445 
(s,Q) 6 s2 Q3  901 720  1 914 757 
(s,Q) 7 s3 Q1  208 703  818 010 
(s,Q) 8 s3 Q2  569 995  1 682 445 
(s,Q) 9 s3 Q3  901 720  1 914 757 
(s,Q) 10 s4 Q1  210 363  807 828 
(s,Q) 11 s4 Q2  569 995  1 682 445 
(s,Q) 12 s4 Q3  901 720  1 914 757 
(R,s,Q) 1 R2 s1 Q1  284 907  581 001 
(R,s,Q) 2 R2 s1 Q2  705 988  1 347 708 
(R,s,Q) 3 R2 s1 Q3  946 858  1 758 389 
(R,s,Q) 4 R2 s2 Q1  281 454  593 517 
(R,s,Q) 5 R2 s2 Q2  705 988  1 347 708 
(R,s,Q) 6 R2 s2 Q3  946 858  1 758 389 
(R,s,Q) 7 R2 s3 Q1  281 454  593 517 
(R,s,Q) 8 R2 s3 Q2  705 988  1 347 708 
(R,s,Q) 9 R2 s3 Q3  946 858  1 758 389 
(R,s,Q) 10 R2 s4 Q1  287 315  568 449 
(R,s,Q) 11 R2 s4 Q2  705 988  1 347 708 
(R,s,Q) 12 R2 s4 Q3  946 858  1 758 389 
(R,s,Q) 13 R3 s1 Q1  370 893  802 391 
(R,s,Q) 14 R3 s1 Q2  853 129  1 221 153 
(R,s,Q) 15 R3 s1 Q3  1 189 165  1 557 662 
(R,s,Q) 16 R3 s2 Q1  370 893  802 391 
(R,s,Q) 17 R3 s2 Q2  853 129  1 221 153 
(R,s,Q) 18 R3 s2 Q3  1 189 165  1 557 662 
(R,s,Q) 19 R3 s3 Q1  370 893  802 391 
(R,s,Q) 20 R3 s3 Q2  853 129  1 221 153 
(R,s,Q) 21 R3 s3 Q3  1 189 165  1 557 662 
(R,s,Q) 22 R3 s4 Q1  370 893  802 391 
(R,s,Q) 23 R3 s4 Q2  853 129  1 221 153 
(R,s,Q) 24 R3 s4 Q3  1 189 165  1 557 662 
(R,s,Q) 25 R4 s1 Q1  476 603  476 603 
(R,s,Q) 26 R4 s1 Q2  1 020 224  1 058 420 
(R,s,Q) 27 R4 s1 Q3  1 482 178  1 489 485 
(R,s,Q) 28 R4 s2 Q1  476 603  476 603 
(R,s,Q) 29 R4 s2 Q2  1 014 085  1 052 977 
(R,s,Q) 30 R4 s2 Q3  1 490 715  1 497 665 
(R,s,Q) 31 R4 s3 Q1  476 603  476 603 
(R,s,Q) 32 R4 s3 Q2  1 019 544  1 038 835 
(R,s,Q) 33 R4 s3 Q3  1 482 178  1 489 485 
(R,s,Q) 34 R4 s4 Q1  476 603  476 603 
(R,s,Q) 35 R4 s4 Q2  1 027 680  1 027 680 
(R,s,Q) 36 R4 s4 Q3  1 484 202  1 484 202 
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The results of the cost performance for each scenario is summarised in Table H.9. 
Table H.9: Cycloserine - Summary of cost performance for the scenarios. 
Policy # R s S Q 𝐶; 𝐶< 𝐶: Total Costs 
Base - - - - - 85 200 421 25 382 280 110 582 702 
(s,S) 1 s1 S1  576 229  67 151 870 24 909 804 92 637 903 
(s,S) 2 s1 S2  12 215  69 125 360 14 621 438 83 759 013 
(s,S) 3 s2 S1 586 663 68 167 390 19 372 124 88 126 177 
(s,S) 4 s2 S2  -   69 770 890 18 805 247 88 576 137 
(s,S) 5 s3 S1  576 229  68 156 970 34 150 203 102 883 402 
(s,S) 6 s3 S2  -   69 126 200 22 003 133 91 129 333 
(s,S) 7 s4 S1  576 229 70 642 597 46 507 648 117 726 474 
(s,S) 8 s4 S2  -   70 066 368 26 793 576 96 859 944 
(R,S) 1 R1 S1  576 212  70 642 581 46 507 655 117 726 448 
(R,S) 2 R1 S2  -   70 066 368 26 793 939 96 860 307 
(R,S) 3 R2 S1  576 212  70 642 587 43 890 158 115 108 957 
(R,S) 4 R2 S2  -    70 066 374 27 748 334 97 814 708 
(R,S) 5 R3 S1  576 212  69 615 265 43 182 888 113 374 365 
(R,S) 6 R3 S2  -   69 039 052 24 984 597 94 023 649 
(R,S) 7 R4 S1  576 212  70 716 665 46 260 643 117 553 520 
(R,S) 8 R4 S2  -    70 140 457 25 121 724 95 262 181 
(R,s,S) 1 R2 s1	 S1  583 589  67 327 740 25 352 394 93 263 723 
(R,s,S) 2 R2 s1 S2  12 215  70 152 660 21 997 202 92 162 077 
(R,s,S) 3 R2 s2 S1  576 229 68 372 530 23 308 431 92 257 190 
(R,s,S) 4 R2 s2 S2  -    70 796 150 17 211 507 88 007 657 
(R,s,S) 5 R2 s3 S1  -   70 660 900 17 524 276 88 185 176 
(R,s,S) 6 R2 s3 S2  -    70 796 140 18 890 734 89 686 874 
(R,s,S) 7 R2 s4 S1  576 229 70 642 603 43 890 148 115 108 980 
(R,s,S) 8 R2 s4 S2  -    70 066 374 27 748 334 97 814 708 
(R,s,S) 9 R3 s1 S1  583 589  67 372 730 21 226 877 89 183 196 
(R,s,S) 10 R3 s1 S2  -    66 133 460 23 339 603 89 473 063 
(R,s,S) 11 R3 s2 S1  576 229  67 365 370 28 164 834 96 106 433 
(R,s,S) 12 R3 s2 S2  -   69 768 830 18 343 111 88 111 941 
(R,s,S) 13 R3 s3 S1  576 229  67 365 370 28 164 834 96 106 433 
(R,s,S) 14 R3 s3 S2  -   69 768 830 18 709 381 88 478 211 
(R,s,S) 15 R3 s4 S1  576 229  69 615 281 43 182 875 113 374 385 
(R,s,S) 16 R3 s4 S2  -   69 039 052 24 984 597 94 023 649 
(R,s,S) 17 R4 s1 S1  583 589 67 237 520 33 444 682 101 265 791 
(R,s,S) 18 R4 s1 S2  -    70 140 460 22 023 801 92 164 261 
(R,s,S) 19 R4 s2 S1  576 229  68 372 510 30 056 022 99 004 761 
(R,s,S) 20 R4 s2 S2  -   70 660 900 17 524 276 88 185 176 
(R,s,S) 21 R4 s3 S1 586 663 68 382 970 26 337 257 95 306 890 
(R,s,S) 22 R4 s3 S2  -   70 660 900 17 583 028 88 243 928 
(R,s,S) 23 R4 s4 S1  576 229  70 716 685 46 260 636 117 553 550 
(R,s,S) 24 R4 s4 S2  -    70 140 457 25 121 724 95 262 181 
(s,Q) 1 s1 Q1  -   68 782 909 14 512 255.73 83 295 165 
continued on next page 
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(s,Q) 2 s1 Q2  -    69 851 754 13 773 775.90 83 625 530 
(s,Q) 3 s1 Q3  -    70 261 800 11 199 358.51 81 461 159 
(s,Q) 4 s2 Q1  -    68 788 513 14 282 260.58 83 070 774 
(s,Q) 5 s2 Q2  -    69 851 754 12 517 540.11 82 369 294 
(s,Q) 6 s2 Q3  -    70 261 800 16 360 479.47 86 622 280 
(s,Q) 7 s3 Q1  -    68 864 110 15 206 669.47 84 070 779 
(s,Q) 8 s3 Q2  -    69 851 754 15 608 918.44 85 460 672 
(s,Q) 9 s3 Q3  -    70 261 800 15 032 101.15 85 293 902 
(s,Q) 10 s4 Q1  -    69 115 679 19 746 307.93 88 861 987 
(s,Q) 11 s4 Q2  -    69 851 754 27 271 515.89 97 123 270 
(s,Q) 12 s4 Q3  -    70 261 800 15 032 101.15 85 293 902 
(R,s,Q) 1 R2 s1 Q1  -    67 383 067 13 338 335 80 721 402 
(R,s,Q) 2 R2 s1 Q2  -    68 745 104 12 267 147 81 012 251 
(R,s,Q) 3 R2 s1 Q3  -    68 892 901 17 542 526 86 435 427 
(R,s,Q) 4 R2 s2 Q1  -    67 185 053 14 835 780 82 020 833 
(R,s,Q) 5 R2 s2 Q2  -    68 745 104 14 194 913 82 940 017 
(R,s,Q) 6 R2 s2 Q3  -    68 892 901 17 246 054 86 138 955 
(R,s,Q) 7 R2 s3 Q1  -    67 185 053 13 577 847 80 762 900 
(R,s,Q) 8 R2 s3 Q2  -    68 745 104 14 102 211 82 847 315 
(R,s,Q) 9 R2 s3 Q3  -    68 892 901 14 993 151 83 886 052 
(R,s,Q) 10 R2 s4 Q1  -    67 615 000 14 736 128 82 351 128 
(R,s,Q) 11 R2 s4 Q2  -    68 745 104 23 886 528 92 631 632 
(R,s,Q) 12 R2 s4 Q3  -    68 892 901 27 175 833 96 068 734 
(R,s,Q) 13 R3 s1 Q1  -   65 558 502 12 111 709 77 670 211 
(R,s,Q) 14 R3 s1 Q2  -   68 557 835 12 248 235 80 806 070 
(R,s,Q) 15 R3 s1 Q3  -    68 575 407 14 296 409 82 871 816 
(R,s,Q) 16 R3 s2 Q1  -   65 558 502 12 384 422 77 942 924 
(R,s,Q) 17 R3 s2 Q2  -   68 557 835 13 847 342 82 405 177 
(R,s,Q) 18 R3 s2 Q3  -    68 575 407 13 964 932 82 540 339 
(R,s,Q) 19 R3 s3 Q1  -   65 558 502 12 568 687 78 127 189 
(R,s,Q) 20 R3 s3 Q2  -   68 557 835 15 725 923 84 283 758 
(R,s,Q) 21 R3 s3 Q3  -    68 575 407 13 964 932 82 540 339 
(R,s,Q) 22 R3 s4 Q1  -   65 558 502 12 653 686 78 212 188 
(R,s,Q) 23 R3 s4 Q2  -   68 557 835 23 175 679 91 733 514 
(R,s,Q) 24 R3 s4 Q3  -    68 575 407 28 187 337 96 762 744 
(R,s,Q) 25 R4 s1 Q1  -    63 491 419 12 694 902 76 186 321 
(R,s,Q) 26 R4 s1 Q2  -   68 022 237 13 008 291 81 030 528 
(R,s,Q) 27 R4 s1 Q3  -   68 428 907 12 748 565 81 177 472 
(R,s,Q) 28 R4 s2 Q1  -    63 491 419 13 197 543 76 688 962 
(R,s,Q) 29 R4 s2 Q2  -    68 209 401 12 373 200 80 582 601 
(R,s,Q) 30 R4 s2 Q3  -    68 086 581 14 782 339 82 868 920 
(R,s,Q) 31 R4 s3 Q1  -    63 491 419 13 197 543 76 688 962 
(R,s,Q) 32 R4 s3 Q2  -   68 544 248 14 205 865 82 750 113 
(R,s,Q) 33 R4 s3 Q3  -   68 428 907 13 830 442 82 259 349 
(R,s,Q) 34 R4 s4 Q1  -    63 491 419 11 108 167 74 599 586 
(R,s,Q) 35 R4 s4 Q2  -    68 791 426 21 364 636 90 156 062 
(R,s,Q) 36 R4 s4 Q3  -   68 590 228 24 891 676 93 481 904 
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Appendix I SDM documents 
This appendix provides the SDM documents for all three models. 
I.1 SDM document for Model A 
This section provides the HTML output of the SDM document tool, for Model A. 
Model Assessment Results 
Model Information Result 
Total Number Of 
Variables
20|126 
Total Number Of State 
Variables
5 (25.0%)|51 (40.5%) 
Total Number Of Stocks 4 (20.0%)|39 (31.0%) 
Total Number Of Causal 
Links
20 (11|2|7)|211 (103|24|84) 
Total Number of Rate-
to-rate Links
0 
Time Unit Week 
Initial Time 0 
Final Time 264 
Reported Time Interval TIME STEP 
Time Step 1 
Model Is Fully 
Formulated 
Yes 
Model Defined Groups No 
Potential Omissions Result 
Unused Variables 0 
Supplementary Variables 4 
Supplementary Variables Being Used 0 
Complex Variable 4 
Complex Stock 4 
Variable Types 
L: Level (4 / 39)* SM: Smooth (0 / 0)* DE: Delay (1 / 12)*† LI: Level Initial (0) I: Initial (0 / 0) 
C: Constant (5 / 27) F: Flow (5 / 60) A: Auxiliary (11 / 101) Sub: Subscripts (2) D: Data (0 / 0) 
G: Game (0 / 0) T: Lookup (1 / 1)*†† 
* (State Variables/Total Stocks) † Total Stocks Do Not Include Fixed Delay Variables. †† (Lookup
Tables). 
Views 
View: Cost (5) Variables 
View: Main Model (12) Variables 
Stellenbosch University  https://scholar.sun.ac.za
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Variables 
top (View) Cost (5 Variables) 
    
Group Type Variable Name And Description  
ModelA #5 L Cumulative Total Unit Cost (Dollar) 
Cumulative Total Unit Cost[Formulations,Order Number] = ∫"Total Unit 
Cost"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
Cost 
Used By 
Total Costs 
 
ModelA #13 
F,A 
Normal Orders From Countries (Drugs/Week) 
Normal Orders From Countries[Formulations,Order Number] = Country Demand 
Input[Formulations,Order Number] Present In 2 Views: 
Cost 
Main Model 
Used By 
Normal Orders Supply Line 
Production 
Total Unit Cost 
 
ModelA #17 C Per Unit Cost (Dollar/Drugs) 
Per Unit Cost[Capreomycin,Order Number] = 1,1,1,1 Per Unit Cost[Kanamycin,Order 
Number] = 1,1,1,1 Per Unit Cost[Cycloserine,Order Number] = 1,1,1,1 Present In 2 
Views: 
Not in View 
Cost 
Used By 
Total Unit Cost 
 
ModelA #27 A Total Costs (Dollar) 
Total Costs[Formulations] = SUM(Cumulative Total Unit Cost[Formulations,Order 
Number!]) Present In 1 View: 
Cost 
Used By 
 
ModelA #29 
F,A 
Total Unit Cost (Dollar/Week) 
Total Unit Cost[Formulations,Order Number] = Normal Orders From 
Countries[Formulations,Order Number] * Per Unit Cost[Formulations,Order Number] 
Present In 1 View: 
Cost 
Used By 
Cumulative Total Unit Cost 
 
t
o
p 
(View) Main Model (12 Variables) 
    
G
r
o
u
p 
T
y
p
e Variable Name And Description 
 
M
o
d
el
A 
#
1 
A 
Country Demand Input (Drugs/Week) 
Country Demand Input[Formulations,Order1] = IF THEN ELSE( Uniform[Formulations,Order1] < 
Proportion Of Orders Placed[Formulations,Order1] , Weibull Distribution[Formulations,Order1] , 
0 ) Country Demand Input[Formulations,Order2] = IF THEN ELSE( Country Demand 
Input[Formulations,Order1] > 0 , IF THEN ELSE( Uniform[Formulations,Order2] < Proportion Of 
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Orders Placed[Formulations,Order2] , Weibull Distribution[Formulations,Order2] , 0 ) , 0 ) 
Country Demand Input[Formulations,Order3] = IF THEN ELSE( Country Demand 
Input[Formulations,Order2]>0, IF THEN ELSE( Uniform[Formulations,Order3] < Proportion Of 
Orders Placed[Formulations,Order3] , Weibull Distribution[Formulations,Order3] , 0 ) , 0 ) 
Country Demand Input[Formulations,Order4] = IF THEN ELSE( Country Demand 
Input[Formulations,Order3]>0, IF THEN ELSE( Uniform[Formulations,Order4] < Proportion Of 
Orders Placed[Formulations,Order4] , Weibull Distribution[Formulations,Order4] , 0 ) , 0 ) 
Present In 2 Views: 
Not in View 
Main Model 
Used By 
Normal Orders From Countries 
M
o
d
el
A 
#
1
0 
A
,
D
,
T 
Normal Lead Time Lookup[Formulations,Order Number] (Week) 
Normal Lead Time Lookup[Formulations,Order Number]([(0,0)-
(10,10)],(1,154),(2,154),(3,260),(4,267),(5,155),(6,322),(7,322),(8,274),(9,274),(10,180),(11,180),(12,610),(1
3,364),(14,95),(15,137),(16,186),(17,224),(18,29),(19,273),(20,142),(21,34),(22,74),(23,115),(24,317),(25,6
1),(26,152),(27,128),(28,14),(29,225),(30,105),(31,166),(32,183),(33,313),(34,143),(35,143),(36,285),(37,
226),(38,226),(39,285),(40,194),(41,17),(42,8),(43,16),(44,21),(45,21),(46,21),(47,27),(48,27),(49,30),(5
0,88),(51,171),(52,55),(53,137),(54,32),(55,57),(56,481),(57,481),(58,165),(59,295),(60,44),(61,44),(62,
534),(63,534),(64,194),(65,204),(66,292),(67,193),(68,352),(69,301),(70,195),(71,172),(72,109),(73,10
9),(74,450),(75,450),(76,708),(77,188),(78,118),(79,126),(80,108),(81,108),(82,146),(83,94),(84,55),(85,
143),(86,100),(87,100),(88,82),(89,82),(90,75),(91,207),(92,236),(93,234),(94,34),(95,199),(96,285),(
97,316),(98,271),(99,132),(100,54),(101,35),(102,35),(103,89),(104,146),(105,178),(106,197),(107,245),(1
08,55),(109,61),(110,61),(111,61),(112,61),(113,155),(114,263),(115,128),(116,370),(117,291),(118,291),(119,152),(
120,87),(121,87),(122,155),(123,155),(124,502),(125,502),(126,363),(127,117),(128,59),(129,102),(130,413
),(131,27),(132,419),(133,45),(134,45),(135,239),(136,107),(137,65),(138,19),(139,19),(140,123),(141,123),(14
2,123),(143,305),(144,86),(145,251),(146,251),(147,187),(148,200),(149,187),(150,339),(151,136),(152,348
),(153,105),(154,107),(155,312),(156,312),(157,198),(158,128),(159,127),(160,158),(161,164),(162,367),(163,
205),(164,129),(165,165),(166,264),(167,371),(168,168),(169,301),(170,205),(171,160),(172,278),(173,360
),(174,34),(175,89),(176,92),(177,225),(178,318),(179,366),(180,21),(181,196),(182,397),(183,85),(184,85),(
185,250),(186,266),(187,57),(188,305),(189,305),(190,305),(191,305),(192,305),(193,73),(194,154),(19
5,154),(196,261),(197,258),(198,232),(199,152),(200,363),(201,363),(202,108),(203,174),(204,324),(2
05,324),(206,379),(207,302),(208,156),(209,251),(210,216),(211,255),(212,304),(213,304),(214,267),(
215,267),(216,267),(217,108),(218,39),(219,249),(220,126),(221,183),(222,18),(223,146),(224,223),(22
5,420),(226,38),(227,232),(228,232),(229,232),(230,253),(231,94),(232,204),(233,208),(234,248),
(235,76),(236,204),(237,248),(238,406),(239,134),(240,86),(241,221),(242,264),(243,69),(244,69),(
245,253),(246,166),(247,190),(248,190),(249,145),(250,207),(251,145),(252,207),(253,396),(254,27
8),(255,278),(256,255),(257,255),(258,72),(259,513),(260,394),(261,471),(262,505),(263,505),(26
4,505))  
 
Present In 1 View: 
Main Model 
Used By 
Production 
 
M
o
d
#
11 
L 
Normal Order Drugs Awaiting Dispatch (Drugs) 
Normal Order Drugs Awaiting Dispatch[Formulations,Order Number] = 
∫"Production"["Formulations","Order Number"]-"Normal Orders Fulfilled For 
Countries"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
 
The linked image cannot be displayed.  The file may have been moved, renamed, or deleted. Verify that the link points to the correct file and location.
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el
A 
Main Model 
Used By 
M
o
d
el
A 
#
1
2 
F
,
A 
Normal Order Drugs Received By Countries (Drugs/Week) 
Normal Order Drugs Received By Countries[Formulations,Order Number] = Normal Orders 
Fulfilled For Countries[Formulations,Order Number] Present In 1 View: 
Main Model 
Used By 
Normal Orders Supply Line 
Total Drugs Received By Countries 
 
M
o
d
el
A 
#
1
3 
F
,
A 
Normal Orders From Countries (Drugs/Week) 
Normal Orders From Countries[Formulations,Order Number] = Country Demand 
Input[Formulations,Order Number] Present In 2 Views: 
Cost 
Main Model 
Used By 
Normal Orders Supply Line 
Production 
Total Unit Cost 
 
M
o
d
el
A 
#
1
4 
F
,
A 
Normal Orders Fulfilled For Countries (Drugs/Week) 
Normal Orders Fulfilled For Countries[Formulations,Order Number] = IF THEN ELSE( 
Production[Formulations,Order Number]>0 , Production[Formulations,Order Number] , 0 ) 
Present In 1 View: 
Main Model 
Used By 
Normal Order Drugs Awaiting Dispatch 
Normal Order Drugs Received By Countries 
 
M
o
d
el
A 
#
1
5 
L 
Normal Orders Supply Line (Drugs) 
Normal Orders Supply Line[Formulations,Order Number] = ∫"Normal Orders From 
Countries"["Formulations","Order Number"]-"Normal Order Drugs Received By 
Countries"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
Main Model 
Used By 
 
M
o
d
el
A 
#
2
0 
D
E
,
F
,
A 
Production (Drugs/Week) 
Production[Formulations,Order Number] = DELAY MATERIAL (Normal Orders From 
Countries[Formulations,Order Number] , Normal Lead Time Lookup[Formulations,Order 
Number](Time) , 0 , 0) Present In 1 View: 
Main Model 
Used By 
Normal Order Drugs Awaiting Dispatch 
Normal Orders Fulfilled For Countries 
 
M
o
d
el
A 
#
2
1 
C 
Proportion Of Orders Placed (Dmnl) 
Proportion Of Orders Placed[Capreomycin,Order Number] = 0.574, 0.389, 0.255, 0.263 
Proportion Of Orders Placed[Kanamycin,Order Number] = 0.45, 0.191, 0.287, 0.479 Proportion 
Of Orders Placed[Cycloserine,Order Number] = 0.721, 0.508, 0.412, 0.298 Present In 2 Views: 
Not in View 
Main Model 
Used By 
Country Demand Input 
 
M
o
d
el
A 
#
2
8 
L 
Total Drugs Received By Countries (Drugs) 
Total Drugs Received By Countries[Formulations] = ∫SUM("Normal Order Drugs Received By 
Countries"["Formulations","Order Number!"]) dt + 0.0 Present In 1 View: 
Main Model 
Used By 
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M
o
d
el
A 
#
3
0 
A 
Uniform (Dmnl) 
Uniform[Capreomycin,Order Number] = RANDOM 0 1() Uniform[Kanamycin,Order Number] = 
(RANDOM 0 1()) Uniform[Cycloserine,Order Number] = (RANDOM 0 1()) Present In 2 Views: 
Not in View 
Main Model 
Used By 
Country Demand Input 
 
M
o
d
el
A 
#
3
3 
A 
Weibull Distribution (Drugs/Week) 
Weibull Distribution[Capreomycin,Order Number] = RANDOM WEIBULL( 0 , 448000 , 0.8161 , 
78 , 32500 , 0 ) Weibull Distribution[Kanamycin,Order Number] = RANDOM WEIBULL( 0 , 
882000 ,0.6525 , 0 , 52000 , 1 ) Weibull Distribution[Cycloserine,Order Number] = RANDOM 
WEIBULL( 1500 , 9.4491e+06 , 0.4755 , 1500 , 420000 , 1 ) Present In 2 Views: 
Not in View 
Main Model 
Used By 
Country Demand Input 
 
top (Type) Subscripts (2 Variables) 
    
Group Type Variable Name And Description  
ModelA #7 Sub Formulations () 
Formulations:Capreomycin, Kanamycin, Cycloserine Present In 2 Views: 
Cost 
Main Model 
Used By 
Country Demand Input 
Cumulative Total Unit Cost 
Normal Lead Time Lookup 
Normal Order Drugs Awaiting Dispatch 
Normal Order Drugs Received By Countries 
Normal Orders From Countries 
Normal Orders Fulfilled For Countries 
Normal Orders Supply Line 
Per Unit Cost 
Production 
Proportion Of Orders Placed 
Total Costs 
Total Drugs Received By Countries 
Total Unit Cost 
Uniform 
Weibull Distribution 
 
ModelA #16 Sub Order Number () 
Order Number:Order1, Order2, Order3, Order4 Present In 2 Views: 
Cost 
Main Model 
Used By 
Country Demand Input 
Cumulative Total Unit Cost 
Normal Lead Time Lookup 
Normal Order Drugs Awaiting Dispatch 
Normal Order Drugs Received By Countries 
Normal Orders From Countries 
Normal Orders Fulfilled For Countries 
Normal Orders Supply Line 
Per Unit Cost 
Production 
Proportion Of Orders Placed 
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Total Unit Cost 
Uniform 
Weibull Distribution 
top 
All Variables (20) 
Group Type Variable 
ModelA A Country Demand Input (Drugs/Week) 
ModelA L Cumulative Total Unit Cost (Dollar) 
.Control C FINAL TIME (Week) 
.Control C INITIAL TIME (Week) 
ModelA A,D,T Normal Lead Time Lookup (Week) 
ModelA L Normal Order Drugs Awaiting Dispatch (Drugs) 
ModelA F,A Normal Order Drugs Received By Countries (Drugs/Week) 
ModelA F,A Normal Orders From Countries (Drugs/Week) 
ModelA F,A Normal Orders Fulfilled For Countries (Drugs/Week) 
ModelA L Normal Orders Supply Line (Drugs) 
ModelA C Per Unit Cost (Dollar/Drugs) 
ModelA DE,F,A Production (Drugs/Week) 
ModelA C Proportion Of Orders Placed (Dmnl) 
.Control A SAVEPER (Week ) 
.Control C TIME STEP (Week ) 
ModelA A Total Costs (Dollar) 
ModelA L Total Drugs Received By Countries (Drugs) 
ModelA F,A Total Unit Cost (Dollar/Week) 
ModelA A Uniform (Dmnl) 
ModelA A Weibull Distribution (Drugs/Week) 
top 
Undocumented Variables (18) 
Group Type Variable 
ModelA A Country Demand Input (Drugs/Week) 
ModelA L Cumulative Total Unit Cost (Dollar) 
ModelA Sub Formulations () 
ModelA A,D,T Normal Lead Time Lookup (Week) 
ModelA L Normal Order Drugs Awaiting Dispatch (Drugs) 
ModelA F,A Normal Order Drugs Received By Countries (Drugs/Week) 
ModelA F,A Normal Orders From Countries (Drugs/Week) 
ModelA F,A Normal Orders Fulfilled For Countries (Drugs/Week) 
ModelA L Normal Orders Supply Line (Drugs) 
ModelA Sub Order Number () 
ModelA C Per Unit Cost (Dollar/Drugs) 
ModelA DE,F,A Production (Drugs/Week) 
ModelA C Proportion Of Orders Placed (Dmnl) 
ModelA A Total Costs (Dollar) 
ModelA L Total Drugs Received By Countries (Drugs) 
ModelA F,A Total Unit Cost (Dollar/Week) 
ModelA A Uniform (Dmnl) 
ModelA A Weibull Distribution (Drugs/Week) 
top 
Supplementary Variables (4) 
Group Type Variable 
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ModelA L Normal Order Drugs Awaiting Dispatch (Drugs) 
ModelA L Normal Orders Supply Line (Drugs) 
ModelA A Total Costs (Dollar) 
ModelA L Total Drugs Received By Countries (Drugs) 
top 
Stock Variables (4) 
Group Type Variable 
ModelA L Cumulative Total Unit Cost (Dollar) 
ModelA L Normal Order Drugs Awaiting Dispatch (Drugs) 
ModelA L Normal Orders Supply Line (Drugs) 
ModelA L Total Drugs Received By Countries (Drugs) 
top 
Equations With Embedded Data (5) 
Group Type Variable 
ModelA L Cumulative Total Unit Cost (Dollar) 
ModelA L Normal Order Drugs Awaiting Dispatch (Drugs) 
ModelA L Normal Orders Supply Line (Drugs) 
ModelA L Total Drugs Received By Countries (Drugs) 
ModelA A Weibull Distribution (Drugs/Week) 
top 
Nonmonotonic Lookup Functions (1) 
Group Type Variable 
ModelA A,D,T Normal Lead Time Lookup (Week) 
top 
Equations With If Then Else Functions (2) 
Group Type Variable 
ModelA A Country Demand Input (Drugs/Week) 
ModelA F,A Normal Orders Fulfilled For Countries (Drugs/Week) 
top 
State Variables (5) 
Group Type Variable 
ModelA L Cumulative Total Unit Cost (Dollar) 
ModelA L Normal Order Drugs Awaiting Dispatch (Drugs) 
ModelA L Normal Orders Supply Line (Drugs) 
ModelA DE,F,A Production (Drugs/Week) 
ModelA L Total Drugs Received By Countries (Drugs) 
top 
Variables With Dimensionless Units (2) 
Group Type Variable 
ModelA C Proportion Of Orders Placed (Dmnl) 
ModelA A Uniform (Dmnl) 
top 
Variables without Predefined Min or Max Values (16) 
Group Type Variable 
ModelA A Country Demand Input (Drugs/Week) 
ModelA L Cumulative Total Unit Cost (Dollar) 
Page | 266                                                                          Appendix I: SDM documents 
 
Department of Industrial Engineering   
ModelA A,D,T Normal Lead Time Lookup (Week) 
ModelA L Normal Order Drugs Awaiting Dispatch (Drugs) 
ModelA F,A Normal Order Drugs Received By Countries (Drugs/Week) 
ModelA F,A Normal Orders From Countries (Drugs/Week) 
ModelA F,A Normal Orders Fulfilled For Countries (Drugs/Week) 
ModelA L Normal Orders Supply Line (Drugs) 
ModelA C Per Unit Cost (Dollar/Drugs) 
ModelA DE,F,A Production (Drugs/Week) 
ModelA C Proportion Of Orders Placed (Dmnl) 
ModelA A Total Costs (Dollar) 
ModelA L Total Drugs Received By Countries (Drugs) 
ModelA F,A Total Unit Cost (Dollar/Week) 
ModelA A Uniform (Dmnl) 
ModelA A Weibull Distribution (Drugs/Week) 
 
Units (4/3) 
Units Type Alternates 
$ Basic [Dollar] 
Dmnl Basic  
Drugs Basic  
Week Basic  
$/Drugs Combined [Dollar/Drugs] 
$/Week Combined [Dollar/Week] 
Drugs/Week Combined  
 
Positive Polarity Causal Links (11) 
Cause Effect Polarity 
Country Demand Input Normal Orders From Countries + 
Cumulative Total Unit Cost Total Costs + 
Normal Order Drugs Received By Countries Total Drugs Received By Countries + 
Normal Orders From Countries Normal Orders Supply Line + 
Normal Orders From Countries Total Unit Cost + 
Normal Orders Fulfilled For Countries Normal Order Drugs Received By Countries + 
Per Unit Cost Total Unit Cost + 
Production Normal Order Drugs Awaiting Dispatch + 
TIME STEP SAVEPER + 
Total Unit Cost Cumulative Total Unit Cost + 
Weibull Distribution Country Demand Input + 
top 
Negative Polarity Causal Links (2) 
Cause Effect Polarity 
Normal Order Drugs Received By Countries Normal Orders Supply Line - 
Normal Orders Fulfilled For Countries Normal Order Drugs Awaiting Dispatch - 
 
topFunction-based Polarity Causal Links (7) 
Cause Effect Polarity 
Country Demand Input Country Demand Input If Then Else Switch 
Normal Lead Time Lookup Production Function[DELAYMATERIAL,LOOKUP] 
Normal Orders From 
Countries 
Production Function[DELAYMATERIAL,LOOKUP] 
Production Normal Orders Fulfilled For 
Countries 
If Then Else Switch 
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Proportion Of Orders 
Placed 
Country Demand Input If Then Else Switch 
Time Production Function[DELAYMATERIAL,LOOKUP] 
Uniform Country Demand Input If Then Else Switch 
 
top View-Variable Profile 
View View-Variable Profile 
Cost                                           5 vars (20.8%) 
Main Model                                                                                                       12 vars (50%) 
 
top 
List Of 2 views and their 16 Variables 
  
Cost 
Main 
Model 
  
Total: 5 12 Total: 
Normal Orders Fulfilled For Countries (In 
1 View) 
      Normal Orders Fulfilled For Countries (In 
1 View) 
Proportion Of Orders Placed (In 1 View)       Proportion Of Orders Placed (In 1 View) 
Total Drugs Received By Countries (In 1 
View) 
      Total Drugs Received By Countries (In 1 
View) 
Weibull Distribution (In 1 View)       Weibull Distribution (In 1 View) 
Normal Order Drugs Received By 
Countries (In 1 View) 
      Normal Order Drugs Received By 
Countries (In 1 View) 
Country Demand Input (In 1 View)       Country Demand Input (In 1 View) 
Production (In 1 View)       Production (In 1 View) 
Normal Orders From Countries (In 2 
Views) 
        Normal Orders From Countries (In 2 
Views) 
Normal Lead Time Lookup (In 1 View)       Normal Lead Time Lookup (In 1 View) 
Normal Orders Supply Line (In 1 View)       Normal Orders Supply Line (In 1 View) 
Uniform (In 1 View)       Uniform (In 1 View) 
Normal Order Drugs Awaiting Dispatch 
(In 1 View) 
      Normal Order Drugs Awaiting Dispatch 
(In 1 View) 
Total Unit Cost (In 1 View)       Total Unit Cost (In 1 View) 
Per Unit Cost (In 1 View)       Per Unit Cost (In 1 View) 
Total Costs (In 1 View)       Total Costs (In 1 View) 
Cumulative Total Unit Cost (In 1 View)       Cumulative Total Unit Cost (In 1 View) 
Total: 5 12 Total: 
  
Cost 
Main 
Model 
  
 
Source File: /Users/deonlingervelder/Desk/All/Masters/6. Dynamic Modelling Main 
Models/DAILY/ModelA.mdl (Sat Nov 19 12:10:11 SAST 2016)  
Report Created On Sat Nov 19 12:41:05 SAST 2016 
SDM-Doc Tool Version 1.2.44 
Global Security Sciences Division  
Argonne National Laboratory  
I.2 SDM document for Model B 
This section provides the HTML output of the SDM document tool, for Model B. 
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Model Assessment Results 
 
Model Information Result 
Total Number Of 
Variables 
56|384 
Total Number Of 
State Variables 
16 (28.6%)|165 (43.0%) 
Total Number Of 
Stocks 
10 (17.9%)|93 (24.2%) 
Total Number Of 
Causal Links 
83 (39|8|36)|841 (331|78|432) 
Total Number of 
Rate-to-rate Links 
0 
Time Unit Week  
Initial Time 0 
Final Time 316 
Reported Time 
Interval 
TIME STEP 
Time Step 1 
Model Is Fully 
Formulated 
Yes 
Model Defined 
Groups 
No 
 
Potential Omissions Result 
Unused Variables 0 
Supplementary Variables 2 
Supplementary Variables 
Being Used 
0 
Complex Variable 6 
Complex Stock 0 
 
Variable Types 
 
L: Level (10 / 93)* SM: Smooth (0 / 0)* DE: Delay (6 / 72)*† LI: Level Initial (0) I: Initial (0 / 0) 
C: Constant (10 / 
78) 
F: Flow (13 / 120) 
A: Auxiliary (36 / 
365) 
Sub: Subscripts (2) D: Data (0 / 0) 
G: Game (0 / 0) T: Lookup (1 / 1)*††       
* (State Variables/Total Stocks) † Total Stocks Do Not Include Fixed Delay Variables. †† (Lookup 
Tables).    
Views 
View: Cost (16) Variables 
 
 
View: Main Model (43) Variables 
 
 
 
Variables 
(View) Cost (16 Variables) 
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Top (View) Cost (16 Variables) 
    
Group Type Variable Name And Description  
MODEL 
B 
#14 L Cumulative Purchase Unit Cost (Dollar) 
Cumulative Purchase Unit Cost[Formulations] = ∫Normal Order Purchase 
Cost[Formulations] dt + 0.0 Present In 1 View: 
Cost 
Used By 
Total Costs 
 
MODEL 
B 
#15 L Cumulative Stockpile Replenishment Cost (Dollar) 
Cumulative Stockpile Replenishment Cost[Formulations] = ∫Emergency Order 
Cost[Formulations]+Stockpile Rotation Cost[Formulations] dt + 0.0 Present In 1 
View: 
Cost 
Used By 
Total Costs 
 
MODEL 
B 
#16 L Cumulative Total Obsolescence Cost (Dollar) 
Cumulative Total Obsolescence Cost[Formulations] = ∫Total Obsolescence 
Cost[Formulations] dt + 0.0 Present In 1 View: 
Cost 
Used By 
Total Costs 
 
MODEL 
B 
#22 
A 
Drugs Available For Emergency Orders (Drugs/Week) 
Drugs Available For Emergency Orders[Formulations,Order Number] = MAX(IF 
THEN ELSE( SRS Stock On Hand[Formulations,Order Number]>=Emergency Orders 
From Countries[Formulations,Order Number] , Emergency Orders From 
Countries[Formulations,Order Number] - Obsolete Stock[Formulations,Order 
Number] , SRS Stock On Hand[Formulations,Order Number] - Obsolete 
Stock[Formulations,Order Number] ), 0) Present In 2 Views: 
Cost 
Main Model 
Used By 
Dispatch Emergency Drugs To Countries 
Emergency Order Cost 
SRS Demand 
SRS Stock On Hand 
 
MODEL 
B 
#29 
A 
Drugs To Be Dispatched For Stock Rotation (Drugs/Week) 
Drugs To Be Dispatched For Stock Rotation[Formulations,Order1] = IF THEN ELSE( 
Drugs Available For Stock Rotation[Formulations,Order1] > Processed 
Orders[Formulations,Order1] , Processed Orders[Formulations,Order1] , 0 ) Drugs To 
Be Dispatched For Stock Rotation[Formulations,Order2] = IF THEN ELSE( Drugs To 
Be Dispatched For Stock Rotation[Formulations,Order1]>0 ,IF THEN ELSE( Drugs 
Available For Stock Rotation[Formulations,Order2] - Drugs To Be Dispatched For 
Stock Rotation[Formulations,Order1] > Processed Orders[Formulations,Order2] , 
Processed Orders[Formulations,Order2] , 0 ) ,IF THEN ELSE( Drugs Available For 
Stock Rotation[Formulations,Order2] > Processed Orders[Formulations,Order2] , 
Processed Orders[Formulations,Order2] , 0 ) ) Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order3] = IF THEN ELSE( Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order1] + Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order2] > 0 ,IF THEN ELSE( Drugs Available For Stock 
Rotation[Formulations,Order3] - Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order2] - Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order1] > Processed Orders[Formulations,Order3] , 
Processed Orders[Formulations,Order3] ,0 ) ,IF THEN ELSE( Drugs Available For 
Stock Rotation[Formulations,Order3] > Processed Orders[Formulations,Order3] , 
Processed Orders[Formulations,Order3] , 0 ) ) Drugs To Be Dispatched For Stock 
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Rotation[Formulations,Order4] = IF THEN ELSE( Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order1] + Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order2] + Drugs Available For Stock 
Rotation[Formulations,Order3] > 0,IF THEN ELSE( Drugs Available For Stock 
Rotation[Formulations,Order4] - Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order3] - Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order2] - Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order1] > Processed Orders[Formulations,Order4] , 
Processed Orders[Formulations,Order4] , 0 ) ,IF THEN ELSE( Drugs Available For 
Stock Rotation[Formulations,Order4] > Processed Orders[Formulations,Order4] , 
Processed Orders[Formulations,Order4] , 0 ) ) Present In 3 Views: 
Not in View 
Cost 
Main Model 
Used By 
Drugs Dispatched As Stock Rotation 
Normal Order Purchase Cost 
Processing Drugs For Stock Rotation 
Production & Dispatch To GDF/PA 
MODEL 
B 
#34 
F,A 
Emergency Order Cost (Dollar/Week) 
Emergency Order Cost[Formulations] = SUM(Drugs Available For Emergency 
Orders[Formulations,Order Number!])*Per Unit Cost[Formulations] Present In 1 View: 
Cost 
Used By 
Cumulative Stockpile Replenishment Cost 
 
MODEL 
B 
#56 
F,A 
Normal Order Purchase Cost (Dollar/Week) 
Normal Order Purchase Cost[Formulations] = (SUM(Processed 
Orders[Formulations,Order Number!])-SUM(Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order Number!])) * Per Unit Cost[Formulations] Present In 1 
View: 
Cost 
Used By 
Cumulative Purchase Unit Cost 
 
MODEL 
B 
#57 
F,A 
Normal Orders From Countries (Drugs/Week) 
Normal Orders From Countries[Formulations,Order Number] = Demand 
Input[Formulations,Order Number] Present In 2 Views: 
Cost 
Main Model 
Used By 
Normal Orders Supply Line 
Order Processing 
 
MODEL 
B 
#59 
C,F 
Obsolete Stock (Drugs/Week) 
Obsolete Stock[Formulations,Order1] = QUEUE AGE IN RANGE( SRS Stock On 
Hand[Formulations,Order1] , Expiration Value[Formulations,Order1] , 
NAREPLACEMENT )/TIME STEP Obsolete Stock[Formulations,Order2] = 0 Obsolete 
Stock[Formulations,Order3] = 0 Obsolete Stock[Formulations,Order4] = 0 Present In 
3 Views: 
Not in View 
Cost 
Main Model 
Used By 
Cumulative Obsolete Stock 
Drugs Available For Emergency Orders 
Drugs Available For Stock Rotation 
SRS Demand 
SRS Stock On Hand 
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Total Obsolescence Cost 
MODEL 
B 
#77 
F,A 
Orders Placed To Manufacturer (Drugs/Week) 
Orders Placed To Manufacturer[Formulations,Order Number] = SRS 
Demand[Formulations,Order Number] Present In 2 Views: 
Cost 
Main Model 
Used By 
SRS Supply Line 
 
MODEL 
B 
#78 
C 
Per Unit Cost (Dollar/Drugs) 
Per Unit Cost[Capreomycin] = 5.66 Per Unit Cost[Kanamycin] = 2.59 Per Unit 
Cost[Cycloserine] = 0.55 Present In 2 Views: 
Not in View 
Cost 
Used By 
Emergency Order Cost 
Normal Order Purchase Cost 
Stockpile Rotation Cost 
Total Obsolescence Cost 
 
MODEL 
B 
#81 A Processed Orders (Drugs/Week) 
Processed Orders[Formulations,Order Number] = Order 
Processing[Formulations,Order Number] Present In 2 Views: 
Cost 
Main Model 
Used By 
Drugs To Be Dispatched For Stock Rotation 
Normal Order Purchase Cost 
Production & Dispatch To GDF/PA 
 
MODEL 
B 
#82 
C 
Processing Drugs For Stock Rotation (Drugs/Week) 
Processing Drugs For Stock Rotation[Formulations,Order1] = (Drugs To Be 
Dispatched For Stock Rotation[Formulations,Order1]) + Drugs To Be Dispatched For 
Stock Rotation[Formulations,Order2] + Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order3] + Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order4] Processing Drugs For Stock 
Rotation[Formulations,Order2] = 0 Processing Drugs For Stock 
Rotation[Formulations,Order3] = 0 Processing Drugs For Stock 
Rotation[Formulations,Order4] = 0 Present In 3 Views: 
Not in View 
Cost 
Main Model 
Used By 
SRS Demand 
SRS Stock On Hand 
Stockpile Rotation Cost 
 
MODEL 
B 
#115 
F,A 
Stockpile Rotation Cost (Dollar/Week) 
Stockpile Rotation Cost[Formulations] = SUM(Processing Drugs For Stock 
Rotation[Formulations,Order Number!])*Per Unit Cost[Formulations] Present In 1 
View: 
Cost 
Used By 
Cumulative Stockpile Replenishment Cost 
 
MODEL 
B 
#119 
A 
Total Costs (Dollar) 
Total Costs[Formulations] = Cumulative Purchase Unit Cost[Formulations] + 
Cumulative Stockpile Replenishment Cost[Formulations] + Cumulative Total 
Obsolescence Cost[Formulations] Present In 1 View: 
Cost 
Used By 
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MODEL 
B 
#122 
F,A 
Total Obsolescence Cost (Dollar/Week) 
Total Obsolescence Cost[Formulations] = Per Unit Cost[Formulations] * 
SUM(Obsolete Stock[Formulations,Order Number!]) Present In 1 View: 
Cost 
Used By 
Cumulative Total Obsolescence Cost 
 
(View) Main Model (43 Variables) 
 
Top (View) Main Model (43 Variables) 
    
Group Type Variable Name And Description  
MODEL 
B 
#1 A Country Dispatch Lead Time (Week) 
Country Dispatch Lead Time[Capreomycin,Order1] = RANDOM TRIANGULAR( 3 , 
15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead Time[Capreomycin,Order2] = RANDOM 
TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead 
Time[Capreomycin,Order3] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) 
Country Dispatch Lead Time[Capreomycin,Order4] = RANDOM TRIANGULAR( 3 , 
15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead Time[Kanamycin,Order1] = RANDOM 
TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead 
Time[Kanamycin,Order2] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country 
Dispatch Lead Time[Kanamycin,Order3] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 
35 , 1 ) Country Dispatch Lead Time[Kanamycin,Order4] = RANDOM 
TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead 
Time[Cycloserine,Order1] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country 
Dispatch Lead Time[Cycloserine,Order2] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 
35 , 1 ) Country Dispatch Lead Time[Cycloserine,Order3] = RANDOM 
TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead 
Time[Cycloserine,Order4] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Present 
In 2 Views: 
Not in View 
Main Model 
Used By 
Dispatch Emergency Drugs To Countries 
Drugs Dispatched As Stock Rotation 
QC's & Dispatch To Countries 
 
MODEL 
B 
#13 L Cumulative Obsolete Stock (Drugs) 
Cumulative Obsolete Stock[Formulations,Order Number] = ∫"Obsolete 
Stock"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
Main Model 
Used By 
 
MODEL 
B 
#17 A Demand Input (Drugs/Week) 
Demand Input[Formulations,Order1] = IF THEN ELSE( Uniform[Formulations,Order1] 
< Proportion Of Orders Placed[Formulations,Order1] , Weibull 
Distribution[Formulations,Order1] , 0 ) Demand Input[Formulations,Order2] = IF 
THEN ELSE( Demand Input[Formulations,Order1] > 0 , IF THEN ELSE( 
Uniform[Formulations,Order2] < Proportion Of Orders 
Placed[Formulations,Order2] , Weibull Distribution[Formulations,Order2] , 0 ) , 0 ) 
Demand Input[Formulations,Order3] = IF THEN ELSE( Demand 
Input[Formulations,Order2]>0, IF THEN ELSE( Uniform[Formulations,Order3] < 
Proportion Of Orders Placed[Formulations,Order3] , Weibull 
Distribution[Formulations,Order3] , 0 ) , 0 ) Demand Input[Formulations,Order4] = 
IF THEN ELSE( Demand Input[Formulations,Order3]>0, IF THEN ELSE( 
Uniform[Formulations,Order4] < Proportion Of Orders 
Placed[Formulations,Order4] , Weibull Distribution[Formulations,Order4] , 0 ) , 0 ) 
Present In 2 Views: 
Not in View 
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Main Model 
Used By 
Normal Orders From Countries 
MODEL 
B 
#21 
DE,A 
Dispatch Emergency Drugs To Countries (Drugs/Week) 
Dispatch Emergency Drugs To Countries[Formulations,Order Number] = DELAY 
MATERIAL (Drugs Available For Emergency Orders[Formulations,Order Number], 
Country Dispatch Lead Time[Formulations,Order Number],0, 0) Present In 1 View: 
Main Model 
Used By 
Emergency Order Drugs Received By Countries 
 
MODEL 
B 
#22 A Drugs Available For Emergency Orders (Drugs/Week) 
Drugs Available For Emergency Orders[Formulations,Order Number] = MAX(IF 
THEN ELSE( SRS Stock On Hand[Formulations,Order Number]>=Emergency 
Orders From Countries[Formulations,Order Number] , Emergency Orders From 
Countries[Formulations,Order Number] - Obsolete Stock[Formulations,Order 
Number] , SRS Stock On Hand[Formulations,Order Number] - Obsolete 
Stock[Formulations,Order Number] ), 0) Present In 2 Views: 
Cost 
Main Model 
Used By 
Dispatch Emergency Drugs To Countries 
Emergency Order Cost 
SRS Demand 
SRS Stock On Hand 
 
MODEL 
B 
#23 A Drugs Available For Stock Rotation (Drugs/Week) 
Drugs Available For Stock Rotation[Formulations,Order1] = MAX(0,(QUEUE AGE 
IN RANGE( SRS Stock On Hand[Formulations,Order1] , Rotation Value 
Start[Formulations,Order1] , Rotation Value Stop[Formulations,Order1] )/TIME 
STEP) - Obsolete Stock[Formulations,Order1]) Drugs Available For Stock 
Rotation[Formulations,Order2] = MAX(0,(QUEUE AGE IN RANGE( SRS Stock On 
Hand[Formulations,Order1] , Rotation Value Start[Formulations,Order1] , Rotation 
Value Stop[Formulations,Order1] )/TIME STEP) - Obsolete 
Stock[Formulations,Order1]) Drugs Available For Stock 
Rotation[Formulations,Order3] = MAX(0,(QUEUE AGE IN RANGE( SRS Stock On 
Hand[Formulations,Order1] , Rotation Value Start[Formulations,Order1] , Rotation 
Value Stop[Formulations,Order1] )/TIME STEP) - Obsolete 
Stock[Formulations,Order1]) Drugs Available For Stock 
Rotation[Formulations,Order4] = MAX(0,(QUEUE AGE IN RANGE( SRS Stock On 
Hand[Formulations,Order1] , Rotation Value Start[Formulations,Order1] , Rotation 
Value Stop[Formulations,Order1] )/TIME STEP) - Obsolete 
Stock[Formulations,Order1]) Present In 2 Views: 
Not in View 
Main Model 
Used By 
Drugs To Be Dispatched For Stock Rotation 
 
MODEL 
B 
#27 
DE,A 
Drugs Dispatched As Stock Rotation (Drugs/Week) 
Drugs Dispatched As Stock Rotation[Formulations,Order Number] = DELAY 
MATERIAL (Drugs To Be Dispatched For Stock Rotation[Formulations,Order 
Number], Country Dispatch Lead Time[Formulations,Order Number], 0, 0) Present 
In 1 View: 
Main Model 
Used By 
Normal Order Drugs Received By Countries 
 
MODEL 
B 
#28 
F,A 
Drugs Received From Manufacturer (Drugs/Week) 
Drugs Received From Manufacturer[Formulations,Order Number] = "Production & 
Dispatch To SRS"[Formulations,Order Number] Present In 1 View: 
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Main Model 
Used By 
SRS Supply Line 
MODEL 
B 
#29 A Drugs To Be Dispatched For Stock Rotation (Drugs/Week) 
Drugs To Be Dispatched For Stock Rotation[Formulations,Order1] = IF THEN ELSE( 
Drugs Available For Stock Rotation[Formulations,Order1] > Processed 
Orders[Formulations,Order1] , Processed Orders[Formulations,Order1] , 0 ) Drugs 
To Be Dispatched For Stock Rotation[Formulations,Order2] = IF THEN ELSE( 
Drugs To Be Dispatched For Stock Rotation[Formulations,Order1]>0 ,IF THEN 
ELSE( Drugs Available For Stock Rotation[Formulations,Order2] - Drugs To Be 
Dispatched For Stock Rotation[Formulations,Order1] > Processed 
Orders[Formulations,Order2] , Processed Orders[Formulations,Order2] , 0 ) ,IF 
THEN ELSE( Drugs Available For Stock Rotation[Formulations,Order2] > 
Processed Orders[Formulations,Order2] , Processed Orders[Formulations,Order2] 
, 0 ) ) Drugs To Be Dispatched For Stock Rotation[Formulations,Order3] = IF THEN 
ELSE( Drugs To Be Dispatched For Stock Rotation[Formulations,Order1] + Drugs 
To Be Dispatched For Stock Rotation[Formulations,Order2] > 0 ,IF THEN ELSE( 
Drugs Available For Stock Rotation[Formulations,Order3] - Drugs To Be 
Dispatched For Stock Rotation[Formulations,Order2] - Drugs To Be Dispatched 
For Stock Rotation[Formulations,Order1] > Processed 
Orders[Formulations,Order3] , Processed Orders[Formulations,Order3] ,0 ) ,IF 
THEN ELSE( Drugs Available For Stock Rotation[Formulations,Order3] > 
Processed Orders[Formulations,Order3] , Processed Orders[Formulations,Order3] 
, 0 ) ) Drugs To Be Dispatched For Stock Rotation[Formulations,Order4] = IF THEN 
ELSE( Drugs To Be Dispatched For Stock Rotation[Formulations,Order1] + Drugs 
To Be Dispatched For Stock Rotation[Formulations,Order2] + Drugs Available For 
Stock Rotation[Formulations,Order3] > 0,IF THEN ELSE( Drugs Available For 
Stock Rotation[Formulations,Order4] - Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order3] - Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order2] - Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order1] > Processed Orders[Formulations,Order4] , 
Processed Orders[Formulations,Order4] , 0 ) ,IF THEN ELSE( Drugs Available For 
Stock Rotation[Formulations,Order4] > Processed Orders[Formulations,Order4] , 
Processed Orders[Formulations,Order4] , 0 ) ) Present In 3 Views: 
Not in View 
Cost 
Main Model 
Used By 
Drugs Dispatched As Stock Rotation 
Normal Order Purchase Cost 
Processing Drugs For Stock Rotation 
Production & Dispatch To GDF/PA 
 
MODEL 
B 
#33 A Emergency Input (Drugs/Week) 
Emergency Input[Formulations,Order Number] = IF THEN ELSE( 
Uniform[Formulations,Order Number] < Emergency Proportion Of Orders 
Placed[Formulations,Order Number] , Emergency Weibull 
Distribution[Formulations,Order Number] , 0 ) Present In 1 View: 
Main Model 
Used By 
Emergency Orders From Countries 
 
MODEL 
B 
#35 
F,A 
Emergency Order Drugs Received By Countries (Drugs/Week) 
Emergency Order Drugs Received By Countries[Formulations,Order Number] = 
Dispatch Emergency Drugs To Countries[Formulations,Order Number] Present In 
1 View: 
Main Model 
Used By 
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Emergency Orders Supply Line 
Total Emergency Order Drugs Received 
MODEL 
B 
#36 
F,A 
Emergency Orders From Countries (Drugs/Week) 
Emergency Orders From Countries[Formulations,Order Number] = Emergency 
Input[Formulations,Order Number] Present In 1 View: 
Main Model 
Used By 
Drugs Available For Emergency Orders 
Emergency Orders Supply Line 
 
MODEL 
B 
#37 L Emergency Orders Supply Line (Drugs) 
Emergency Orders Supply Line[Formulations,Order Number] = ∫"Emergency 
Orders From Countries"["Formulations","Order Number"]-"Emergency Order Drugs 
Received By Countries"["Formulations","Order Number"] dt + 0.0 Present In 1 
View: 
Main Model 
Used By 
 
MODEL 
B 
#38 C Emergency Proportion Of Orders Placed (Dmnl) 
Emergency Proportion Of Orders Placed[Capreomycin,Order Number] = 0.106, 0, 
0, 0 Emergency Proportion Of Orders Placed[Kanamycin,Order Number] = 0.086, 
0, 0, 0 Emergency Proportion Of Orders Placed[Cycloserine,Order Number] = 
0.168, 0, 0, 0 Present In 2 Views: 
Not in View 
Main Model 
Used By 
Emergency Input 
 
MODEL 
B 
#41 A Emergency Weibull Distribution (Drugs/Week) 
Emergency Weibull Distribution[Capreomycin,Order Number] = RANDOM 
WEIBULL( 78 , 55255 , 0.6161 , 78 , 32500 , 0 ) Emergency Weibull 
Distribution[Kanamycin,Order Number] = RANDOM WEIBULL( 450 , 46246 
,0.4525 , 450 , 50000 , 1 ) Emergency Weibull Distribution[Cycloserine,Order 
Number] = RANDOM WEIBULL( 1500 , 769160 , 0.4755 , 1500 , 420000 , 1 ) 
Present In 2 Views: 
Not in View 
Main Model 
Used By 
Emergency Input 
 
MODEL 
B 
#44 C Expiration Value (Week) 
Expiration Value[Capreomycin,Order Number] = 56, 0, 0, 0 Expiration 
Value[Kanamycin,Order Number] = 140, 0, 0, 0 Expiration 
Value[Cycloserine,Order Number] = 56, 0, 0, 0 Present In 2 Views: 
Not in View 
Main Model 
Used By 
Obsolete Stock 
 
MODEL 
B 
#49 C Initial Stock On Hand (Drugs) 
Initial Stock On Hand[Capreomycin,Order Number] = 221018, 0, 0, 0 Initial Stock 
On Hand[Kanamycin,Order Number] = 184984, 0, 0, 0 Initial Stock On 
Hand[Cycloserine,Order Number] = 3.07664e+06, 0, 0, 0 Present In 2 Views: 
Not in View 
Main Model 
Used By 
SRS Stock On Hand 
 
MODEL 
B 
#54 L Normal Order Drugs Awaiting Dispatch (Drugs) 
Normal Order Drugs Awaiting Dispatch[Formulations,Order Number] = 
∫"Production & Dispatch To GDF/PA"["Formulations","Order Number"]-"QC's & 
Dispatch To Countries"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
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Main Model 
Used By 
MODEL 
B 
#55 
F,A 
Normal Order Drugs Received By Countries (Drugs/Week) 
Normal Order Drugs Received By Countries[Formulations,Order Number] = "QC's 
& Dispatch To Countries"[Formulations,Order Number] + Drugs Dispatched As 
Stock Rotation[Formulations,Order Number] Present In 1 View: 
Main Model 
Used By 
Normal Orders Supply Line 
Total Normal Order Drugs Received 
 
MODEL 
B 
#57 
F,A 
Normal Orders From Countries (Drugs/Week) 
Normal Orders From Countries[Formulations,Order Number] = Demand 
Input[Formulations,Order Number] Present In 2 Views: 
Cost 
Main Model 
Used By 
Normal Orders Supply Line 
Order Processing 
 
MODEL 
B 
#58 L Normal Orders Supply Line (Drugs) 
Normal Orders Supply Line[Formulations,Order Number] = ∫"Normal Orders From 
Countries"["Formulations","Order Number"]-"Normal Order Drugs Received By 
Countries"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
Main Model 
Used By 
 
MODEL 
B 
#59 
C,F 
Obsolete Stock (Drugs/Week) 
Obsolete Stock[Formulations,Order1] = QUEUE AGE IN RANGE( SRS Stock On 
Hand[Formulations,Order1] , Expiration Value[Formulations,Order1] , 
NAREPLACEMENT )/TIME STEP Obsolete Stock[Formulations,Order2] = 0 
Obsolete Stock[Formulations,Order3] = 0 Obsolete Stock[Formulations,Order4] = 
0 Present In 3 Views: 
Not in View 
Cost 
Main Model 
Used By 
Cumulative Obsolete Stock 
Drugs Available For Emergency Orders 
Drugs Available For Stock Rotation 
SRS Demand 
SRS Stock On Hand 
Total Obsolescence Cost 
 
MODEL 
B 
#64 
DE,A 
Order Processing (Drugs/Week) 
Order Processing[Formulations,Order Number] = DELAY MATERIAL (Normal 
Orders From Countries[Formulations,Order Number], Order Processing Lead 
Time[Formulations,Order Number], 0, 0) Present In 1 View: 
Main Model 
Used By 
Processed Orders 
 
MODEL 
B 
#65 A Order Processing Lead Time (Week) 
Order Processing Lead Time[Capreomycin,Order1] = RANDOM TRIANGULAR( 2 , 
30 , 0 , 4 , 35 , 1 ) Order Processing Lead Time[Capreomycin,Order2] = RANDOM 
TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order Processing Lead 
Time[Capreomycin,Order3] = RANDOM TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order 
Processing Lead Time[Capreomycin,Order4] = RANDOM TRIANGULAR( 2 , 30 , 0 , 
4 , 35 , 1 ) Order Processing Lead Time[Kanamycin,Order1] = RANDOM 
TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order Processing Lead 
Time[Kanamycin,Order2] = RANDOM TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order 
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Processing Lead Time[Kanamycin,Order3] = RANDOM TRIANGULAR( 2 , 30 , 0 , 4 
, 35 , 1 ) Order Processing Lead Time[Kanamycin,Order4] = RANDOM 
TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order Processing Lead 
Time[Cycloserine,Order1] = RANDOM TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order 
Processing Lead Time[Cycloserine,Order2] = RANDOM TRIANGULAR( 2 , 30 , 0 , 
4 , 35 , 1 ) Order Processing Lead Time[Cycloserine,Order3] = RANDOM 
TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order Processing Lead 
Time[Cycloserine,Order4] = RANDOM TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Present 
In 2 Views: 
Not in View 
Main Model 
Used By 
Order Processing 
MODEL 
B 
#77 
F,A 
Orders Placed To Manufacturer (Drugs/Week) 
Orders Placed To Manufacturer[Formulations,Order Number] = SRS 
Demand[Formulations,Order Number] Present In 2 Views: 
Cost 
Main Model 
Used By 
SRS Supply Line 
 
MODEL 
B 
#81 A Processed Orders (Drugs/Week) 
Processed Orders[Formulations,Order Number] = Order 
Processing[Formulations,Order Number] Present In 2 Views: 
Cost 
Main Model 
Used By 
Drugs To Be Dispatched For Stock Rotation 
Normal Order Purchase Cost 
Production & Dispatch To GDF/PA 
 
MODEL 
B 
#82 C Processing Drugs For Stock Rotation (Drugs/Week) 
Processing Drugs For Stock Rotation[Formulations,Order1] = (Drugs To Be 
Dispatched For Stock Rotation[Formulations,Order1]) + Drugs To Be Dispatched 
For Stock Rotation[Formulations,Order2] + Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order3] + Drugs To Be Dispatched For Stock 
Rotation[Formulations,Order4] Processing Drugs For Stock 
Rotation[Formulations,Order2] = 0 Processing Drugs For Stock 
Rotation[Formulations,Order3] = 0 Processing Drugs For Stock 
Rotation[Formulations,Order4] = 0 Present In 3 Views: 
Not in View 
Cost 
Main Model 
Used By 
SRS Demand 
SRS Stock On Hand 
Stockpile Rotation Cost 
 
MODEL 
B 
#86 A Production & Dispatch Lead Time (Week) 
Production & Dispatch Lead Time[Capreomycin,Order1] = RANDOM 
TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead 
Time[Capreomycin,Order2] = RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) 
Production & Dispatch Lead Time[Capreomycin,Order3] = RANDOM 
TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead 
Time[Capreomycin,Order4] = RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) 
Production & Dispatch Lead Time[Kanamycin,Order1] = RANDOM TRIANGULAR( 5 
, 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead Time[Kanamycin,Order2] = 
RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead 
Time[Kanamycin,Order3] = RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) 
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Production & Dispatch Lead Time[Kanamycin,Order4] = RANDOM TRIANGULAR( 
5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead Time[Cycloserine,Order1] = 
RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead 
Time[Cycloserine,Order2] = RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) 
Production & Dispatch Lead Time[Cycloserine,Order3] = RANDOM TRIANGULAR( 
5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead Time[Cycloserine,Order4] = 
RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) Present In 2 Views: 
Not in View 
Main Model 
Used By 
Production & Dispatch To GDF/PA 
Production & Dispatch To SRS 
MODEL 
B 
#98 
DE,F,A 
Production & Dispatch To GDF/PA (Drugs/Week) 
Production & Dispatch To GDF/PA[Formulations,Order Number] = DELAY 
MATERIAL (( Processed Orders[Formulations,Order Number] - Drugs To Be 
Dispatched For Stock Rotation[Formulations,Order Number] ),"Production & 
Dispatch Lead Time"[Formulations,Order Number],0, 0) Present In 1 View: 
Main Model 
Used By 
Normal Order Drugs Awaiting Dispatch 
QC's & Dispatch To Countries 
 
MODEL 
B 
#99 
DE,A 
Production & Dispatch To SRS (Drugs/Week) 
Production & Dispatch To SRS[Formulations,Order Number] = DELAY MATERIAL 
(SRS Demand[Formulations,Order Number] , "Production & Dispatch Lead 
Time"[Formulations,Order Number] , 0 , 0) Present In 1 View: 
Main Model 
Used By 
Drugs Received From Manufacturer 
SRS Stock On Hand 
 
MODEL 
B 
#100 
A,D,T 
Profile (Dmnl) 
Profile([(0,0)-(1,1)],(0,1),(1,1))  
Main Model 
Used By 
SRS Stock On Hand 
 
MODEL 
B 
#101 C Proportion Of Orders Placed (Dmnl) 
Proportion Of Orders Placed[Capreomycin,Order Number] = 0.574, 0.389, 0.255, 
0.263 Proportion Of Orders Placed[Kanamycin,Order Number] = 0.45, 0.191, 
0.287, 0.479 Proportion Of Orders Placed[Cycloserine,Order Number] = 0.721, 
0.508, 0.412, 0.298 Present In 2 Views: 
Not in View 
Main Model 
Used By 
Demand Input 
 
MODEL 
B 
#104 
DE,F,A 
QC's & Dispatch To Countries (Drugs/Week) 
QC's & Dispatch To Countries[Formulations,Order Number] = DELAY MATERIAL 
(IF THEN ELSE( "Production & Dispatch To GDF/PA"[Formulations,Order Number] 
> 0 , "Production & Dispatch To GDF/PA"[Formulations,Order Number] , 0 ) , 
Country Dispatch Lead Time[Formulations,Order Number] , 0 , 0) Present In 1 
View: 
Main Model 
Used By 
Normal Order Drugs Awaiting Dispatch 
Normal Order Drugs Received By Countries 
 
MODEL 
B 
#105 C Rotation Value Start (Week) 
Rotation Value Start[Capreomycin,Order Number] = 16,16,16,16 Rotation Value 
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Start[Kanamycin,Order Number] = 40, 40, 40, 40 Rotation Value 
Start[Cycloserine,Order Number] = 16,16,16,16 Present In 2 Views: 
Not in View 
Main Model 
Used By 
Drugs Available For Stock Rotation 
MODEL 
B 
#108 C Rotation Value Stop (Week) 
Rotation Value Stop[Capreomycin,Order Number] = 36,36,36,36 Rotation Value 
Stop[Kanamycin,Order Number] = 84,84,84,84 Rotation Value 
Stop[Cycloserine,Order Number] = 36,36,36,36 Present In 2 Views: 
Not in View 
Main Model 
Used By 
Drugs Available For Stock Rotation 
 
MODEL 
B 
#112 A SRS Demand (Drugs/Week) 
SRS Demand[Formulations,Order Number] = Drugs Available For Emergency 
Orders[Formulations,Order Number] + Obsolete Stock[Formulations,Order 
Number] + Processing Drugs For Stock Rotation[Formulations,Order Number] 
Present In 1 View: 
Main Model 
Used By 
Orders Placed To Manufacturer 
Production & Dispatch To SRS 
 
MODEL 
B 
#113 A SRS Stock On Hand (Drugs) 
SRS Stock On Hand[Formulations,Order Number] = QUEUE FIFO( "Production & 
Dispatch To SRS"[Formulations,Order Number] , Processing Drugs For Stock 
Rotation[Formulations,Order Number] + Obsolete Stock[Formulations,Order 
Number] + Drugs Available For Emergency Orders[Formulations,Order Number] , 
Profile , Initial Stock On Hand[Formulations,Order Number] , 0 ) Present In 1 View: 
Main Model 
Used By 
Drugs Available For Emergency Orders 
Drugs Available For Stock Rotation 
Obsolete Stock 
 
MODEL 
B 
#114 L SRS Supply Line (Drugs) 
SRS Supply Line[Formulations,Order Number] = ∫"Orders Placed To 
Manufacturer"["Formulations","Order Number"]-"Drugs Received From 
Manufacturer"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
Main Model 
Used By 
Supply Line Position 
 
MODEL 
B 
#116 A Supply Line Position (Drugs/Week) 
Supply Line Position[Formulations,Order Number] = SRS Supply 
Line[Formulations,Order Number]/TIME STEP Present In 1 View: 
Main Model 
Used By 
 
MODEL 
B 
#120 L Total Emergency Order Drugs Received (Drugs) 
Total Emergency Order Drugs Received[Formulations,Order Number] = 
∫"Emergency Order Drugs Received By Countries"["Formulations","Order 
Number"] dt + 0.0 Present In 1 View: 
Main Model 
Used By 
 
MODEL 
B 
#121 L Total Normal Order Drugs Received (Drugs) 
Total Normal Order Drugs Received[Formulations,Order Number] = ∫"Normal 
Order Drugs Received By Countries"["Formulations","Order Number"] dt + 0.0 
Present In 1 View: 
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Main Model 
Used By 
MODEL 
B 
#123 A Uniform (Dmnl) 
Uniform[Capreomycin,Order Number] = RANDOM 0 1() Uniform[Kanamycin,Order 
Number] = (RANDOM 0 1()) Uniform[Cycloserine,Order Number] = RANDOM 0 1() 
Present In 2 Views: 
Not in View 
Main Model 
Used By 
Demand Input 
Emergency Input 
 
MODEL 
B 
#126 A Weibull Distribution (Drugs/Week) 
Weibull Distribution[Capreomycin,Order Number] = RANDOM WEIBULL( 78 , 
448000 , 0.6161 , 78 , 32500 , 0 ) Weibull Distribution[Kanamycin,Order Number] = 
RANDOM WEIBULL( 450 , 882000 ,0.4525 , 450 , 50000 , 1 ) Weibull 
Distribution[Cycloserine,Order Number] = RANDOM WEIBULL( 1500 , 9.4491e+06 , 
0.4755 , 1500 , 420000 , 1 ) Present In 2 Views: 
Not in View 
Main Model 
Used By 
Demand Input 
 
Top (Type) Subscripts (2 Variables) 
    
Group Type Variable Name And Description  
MODEL B #48 Sub Formulations () 
Formulations:Capreomycin, Kanamycin, Cycloserine Present In 2 Views: 
Cost 
Main Model 
Used By 
Country Dispatch Lead Time 
Cumulative Obsolete Stock 
Cumulative Purchase Unit Cost 
Cumulative Stockpile Replenishment Cost 
Cumulative Total Obsolescence Cost 
Demand Input 
Dispatch Emergency Drugs To Countries 
Drugs Available For Emergency Orders 
Drugs Available For Stock Rotation 
Drugs Dispatched As Stock Rotation 
Drugs Received From Manufacturer 
Drugs To Be Dispatched For Stock Rotation 
Emergency Input 
Emergency Order Cost 
Emergency Order Drugs Received By Countries 
Emergency Orders From Countries 
Emergency Orders Supply Line 
Emergency Proportion Of Orders Placed 
Emergency Weibull Distribution 
Expiration Value 
Initial Stock On Hand 
Normal Order Drugs Awaiting Dispatch 
Normal Order Drugs Received By Countries 
Normal Order Purchase Cost 
Normal Orders From Countries 
Normal Orders Supply Line 
Obsolete Stock 
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Order Processing 
Order Processing Lead Time 
Orders Placed To Manufacturer 
Per Unit Cost 
Processed Orders 
Processing Drugs For Stock Rotation 
Production & Dispatch Lead Time 
Production & Dispatch To GDF/PA 
Production & Dispatch To SRS 
Proportion Of Orders Placed 
QC's & Dispatch To Countries 
Rotation Value Start 
Rotation Value Stop 
SRS Demand 
SRS Stock On Hand 
SRS Supply Line 
Stockpile Rotation Cost 
Supply Line Position 
Total Costs 
Total Emergency Order Drugs Received 
Total Normal Order Drugs Received 
Total Obsolescence Cost 
Uniform 
Weibull Distribution 
MODEL B #63 Sub Order Number () 
Order Number:Order1, Order2, Order3, Order4 Present In 2 Views: 
Cost 
Main Model 
Used By 
Country Dispatch Lead Time 
Cumulative Obsolete Stock 
Demand Input 
Dispatch Emergency Drugs To Countries 
Drugs Available For Emergency Orders 
Drugs Dispatched As Stock Rotation 
Drugs Received From Manufacturer 
Drugs To Be Dispatched For Stock Rotation 
Emergency Input 
Emergency Order Drugs Received By Countries 
Emergency Orders From Countries 
Emergency Orders Supply Line 
Emergency Proportion Of Orders Placed 
Emergency Weibull Distribution 
Expiration Value 
Initial Stock On Hand 
Normal Order Drugs Awaiting Dispatch 
Normal Order Drugs Received By Countries 
Normal Orders From Countries 
Normal Orders Supply Line 
Obsolete Stock 
Order Processing 
Order Processing Lead Time 
Orders Placed To Manufacturer 
Processed Orders 
Processing Drugs For Stock Rotation 
Production & Dispatch Lead Time 
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Production & Dispatch To GDF/PA 
Production & Dispatch To SRS 
Proportion Of Orders Placed 
QC's & Dispatch To Countries 
Rotation Value Start 
Rotation Value Stop 
SRS Demand 
SRS Stock On Hand 
SRS Supply Line 
Supply Line Position 
Total Emergency Order Drugs Received 
Total Normal Order Drugs Received 
Uniform 
Weibull Distribution 
 
All Variables (56) 
Group Type Variable 
MODEL B A Country Dispatch Lead Time (Week) 
MODEL B L Cumulative Obsolete Stock (Drugs) 
MODEL B L Cumulative Purchase Unit Cost (Dollar) 
MODEL B L Cumulative Stockpile Replenishment Cost (Dollar) 
MODEL B L Cumulative Total Obsolescence Cost (Dollar) 
MODEL B A Demand Input (Drugs/Week) 
MODEL B DE,A Dispatch Emergency Drugs To Countries (Drugs/Week) 
MODEL B A Drugs Available For Emergency Orders (Drugs/Week) 
MODEL B A Drugs Available For Stock Rotation (Drugs/Week) 
MODEL B DE,A Drugs Dispatched As Stock Rotation (Drugs/Week) 
MODEL B F,A Drugs Received From Manufacturer (Drugs/Week) 
MODEL B A Drugs To Be Dispatched For Stock Rotation (Drugs/Week) 
MODEL B A Emergency Input (Drugs/Week) 
MODEL B F,A Emergency Order Cost (Dollar/Week) 
MODEL B F,A Emergency Order Drugs Received By Countries (Drugs/Week) 
MODEL B F,A Emergency Orders From Countries (Drugs/Week) 
MODEL B L Emergency Orders Supply Line (Drugs) 
MODEL B C Emergency Proportion Of Orders Placed (Dmnl) 
MODEL B A Emergency Weibull Distribution (Drugs/Week) 
MODEL B C Expiration Value (Week) 
.Control C FINAL TIME (Week) 
MODEL B C Initial Stock On Hand (Drugs) 
.Control C INITIAL TIME (Week) 
MODEL B L Normal Order Drugs Awaiting Dispatch (Drugs) 
MODEL B F,A Normal Order Drugs Received By Countries (Drugs/Week) 
MODEL B F,A Normal Order Purchase Cost (Dollar/Week) 
MODEL B F,A Normal Orders From Countries (Drugs/Week) 
MODEL B L Normal Orders Supply Line (Drugs) 
MODEL B F,A Obsolete Stock (Drugs/Week) 
MODEL B A Order Processing Lead Time (Week) 
MODEL B DE,A Order Processing (Drugs/Week) 
MODEL B F,A Orders Placed To Manufacturer (Drugs/Week) 
MODEL B C Per Unit Cost (Dollar/Drugs) 
MODEL B A Processed Orders (Drugs/Week) 
MODEL B A Processing Drugs For Stock Rotation (Drugs/Week) 
MODEL B A Production & Dispatch Lead Time (Week) 
MODEL B DE,F,A Production & Dispatch To GDF/PA (Drugs/Week) 
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MODEL B DE,A Production & Dispatch To SRS (Drugs/Week) 
MODEL B A,D,T Profile (Dmnl) 
MODEL B C Proportion Of Orders Placed (Dmnl) 
MODEL B DE,F,A QC's & Dispatch To Countries (Drugs/Week) 
MODEL B C Rotation Value Start (Week) 
MODEL B C Rotation Value Stop (Week) 
.Control A SAVEPER (Week ) 
MODEL B A SRS Demand (Drugs/Week) 
MODEL B A SRS Stock On Hand (Drugs) 
MODEL B L SRS Supply Line (Drugs) 
MODEL B F,A Stockpile Rotation Cost (Dollar/Week) 
MODEL B A Supply Line Position (Drugs/Week) 
.Control C TIME STEP (Week ) 
MODEL B A Total Costs (Dollar) 
MODEL B L Total Emergency Order Drugs Received (Drugs) 
MODEL B L Total Normal Order Drugs Received (Drugs) 
MODEL B F,A Total Obsolescence Cost (Dollar/Week) 
MODEL B A Uniform (Dmnl) 
MODEL B A Weibull Distribution (Drugs/Week) 
 
Undocumented Variables (54) 
Group Type Variable 
MODEL B A Country Dispatch Lead Time (Week) 
MODEL B L Cumulative Obsolete Stock (Drugs) 
MODEL B L Cumulative Purchase Unit Cost (Dollar) 
MODEL B L Cumulative Stockpile Replenishment Cost (Dollar) 
MODEL B L Cumulative Total Obsolescence Cost (Dollar) 
MODEL B A Demand Input (Drugs/Week) 
MODEL B DE,A Dispatch Emergency Drugs To Countries (Drugs/Week) 
MODEL B A Drugs Available For Emergency Orders (Drugs/Week) 
MODEL B A Drugs Available For Stock Rotation (Drugs/Week) 
MODEL B DE,A Drugs Dispatched As Stock Rotation (Drugs/Week) 
MODEL B F,A Drugs Received From Manufacturer (Drugs/Week) 
MODEL B A Drugs To Be Dispatched For Stock Rotation (Drugs/Week) 
MODEL B A Emergency Input (Drugs/Week) 
MODEL B F,A Emergency Order Cost (Dollar/Week) 
MODEL B F,A Emergency Order Drugs Received By Countries (Drugs/Week) 
MODEL B F,A Emergency Orders From Countries (Drugs/Week) 
MODEL B L Emergency Orders Supply Line (Drugs) 
MODEL B C Emergency Proportion Of Orders Placed (Dmnl) 
MODEL B A Emergency Weibull Distribution (Drugs/Week) 
MODEL B C Expiration Value (Week) 
MODEL B Sub Formulations () 
MODEL B C Initial Stock On Hand (Drugs) 
MODEL B L Normal Order Drugs Awaiting Dispatch (Drugs) 
MODEL B F,A Normal Order Drugs Received By Countries (Drugs/Week) 
MODEL B F,A Normal Order Purchase Cost (Dollar/Week) 
MODEL B F,A Normal Orders From Countries (Drugs/Week) 
MODEL B L Normal Orders Supply Line (Drugs) 
MODEL B F,A Obsolete Stock (Drugs/Week) 
MODEL B Sub Order Number () 
MODEL B A Order Processing Lead Time (Week) 
MODEL B DE,A Order Processing (Drugs/Week) 
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MODEL B F,A Orders Placed To Manufacturer (Drugs/Week) 
MODEL B C Per Unit Cost (Dollar/Drugs) 
MODEL B A Processed Orders (Drugs/Week) 
MODEL B A Processing Drugs For Stock Rotation (Drugs/Week) 
MODEL B A Production & Dispatch Lead Time (Week) 
MODEL B DE,F,A Production & Dispatch To GDF/PA (Drugs/Week) 
MODEL B DE,A Production & Dispatch To SRS (Drugs/Week) 
MODEL B A,D,T Profile (Dmnl) 
MODEL B C Proportion Of Orders Placed (Dmnl) 
MODEL B DE,F,A QC's & Dispatch To Countries (Drugs/Week) 
MODEL B C Rotation Value Start (Week) 
MODEL B C Rotation Value Stop (Week) 
MODEL B A SRS Demand (Drugs/Week) 
MODEL B A SRS Stock On Hand (Drugs) 
MODEL B L SRS Supply Line (Drugs) 
MODEL B F,A Stockpile Rotation Cost (Dollar/Week) 
MODEL B A Supply Line Position (Drugs/Week) 
MODEL B A Total Costs (Dollar) 
MODEL B L Total Emergency Order Drugs Received (Drugs) 
MODEL B L Total Normal Order Drugs Received (Drugs) 
MODEL B F,A Total Obsolescence Cost (Dollar/Week) 
MODEL B A Uniform (Dmnl) 
MODEL B A Weibull Distribution (Drugs/Week) 
 
Supplementary Variables (2) 
Group Type Variable 
MODEL B L Normal Orders Supply Line (Drugs) 
MODEL B L Total Normal Order Drugs Received (Drugs) 
 
Unused Variables (6) 
Group Type Variable 
MODEL B L Cumulative Obsolete Stock (Drugs) 
MODEL B L Emergency Orders Supply Line (Drugs) 
MODEL B L Normal Order Drugs Awaiting Dispatch (Drugs) 
MODEL B A Supply Line Position (Drugs/Week) 
MODEL B A Total Costs (Dollar) 
MODEL B L Total Emergency Order Drugs Received (Drugs) 
 
Stock Variables (10) 
Group Type Variable 
MODEL B L Cumulative Obsolete Stock (Drugs) 
MODEL B L Cumulative Purchase Unit Cost (Dollar) 
MODEL B L Cumulative Stockpile Replenishment Cost (Dollar) 
MODEL B L Cumulative Total Obsolescence Cost (Dollar) 
MODEL B L Emergency Orders Supply Line (Drugs) 
MODEL B L Normal Order Drugs Awaiting Dispatch (Drugs) 
MODEL B L Normal Orders Supply Line (Drugs) 
MODEL B L SRS Supply Line (Drugs) 
MODEL B L Total Emergency Order Drugs Received (Drugs) 
MODEL B L Total Normal Order Drugs Received (Drugs) 
 
Equations With Embedded Data (15) 
Group Type Variable 
MODEL B A Country Dispatch Lead Time (Week) 
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MODEL B L Cumulative Obsolete Stock (Drugs) 
MODEL B L Cumulative Purchase Unit Cost (Dollar) 
MODEL B L Cumulative Stockpile Replenishment Cost (Dollar) 
MODEL B L Cumulative Total Obsolescence Cost (Dollar) 
MODEL B L Emergency Orders Supply Line (Drugs) 
MODEL B A Emergency Weibull Distribution (Drugs/Week) 
MODEL B L Normal Order Drugs Awaiting Dispatch (Drugs) 
MODEL B L Normal Orders Supply Line (Drugs) 
MODEL B A Order Processing Lead Time (Week) 
MODEL B A Production & Dispatch Lead Time (Week) 
MODEL B L SRS Supply Line (Drugs) 
MODEL B L Total Emergency Order Drugs Received (Drugs) 
MODEL B L Total Normal Order Drugs Received (Drugs) 
MODEL B A Weibull Distribution (Drugs/Week) 
 
Equations With If Then Else Functions (5) 
Group Type Variable 
MODEL B A Demand Input (Drugs/Week) 
MODEL B A Drugs Available For Emergency Orders (Drugs/Week) 
MODEL B A Drugs To Be Dispatched For Stock Rotation (Drugs/Week) 
MODEL B A Emergency Input (Drugs/Week) 
MODEL B DE,F,A QC's & Dispatch To Countries (Drugs/Week) 
 
Equations With Min Or Max Functions (2) 
Group Type Variable 
MODEL B A Drugs Available For Emergency Orders (Drugs/Week) 
MODEL B A Drugs Available For Stock Rotation (Drugs/Week) 
 
Complex Variable (Richardson's Rule Threshold = 3) (6) 
Group Type Variable Complexity 
MODEL B F,A Obsolete Stock (Drugs/Week) 4 
MODEL B A Processing Drugs For Stock Rotation (Drugs/Week) 4 
MODEL B A Drugs Available For Stock Rotation (Drugs/Week) 5 
MODEL B DE,F,A QC's & Dispatch To Countries (Drugs/Week) 5 
MODEL B A Drugs Available For Emergency Orders (Drugs/Week) 6 
MODEL B A SRS Stock On Hand (Drugs) 6 
 
State Variables (16) 
Group Type Variable 
MODEL B L Cumulative Obsolete Stock (Drugs) 
MODEL B L Cumulative Purchase Unit Cost (Dollar) 
MODEL B L Cumulative Stockpile Replenishment Cost (Dollar) 
MODEL B L Cumulative Total Obsolescence Cost (Dollar) 
MODEL B DE,A Dispatch Emergency Drugs To Countries (Drugs/Week) 
MODEL B DE,A Drugs Dispatched As Stock Rotation (Drugs/Week) 
MODEL B L Emergency Orders Supply Line (Drugs) 
MODEL B L Normal Order Drugs Awaiting Dispatch (Drugs) 
MODEL B L Normal Orders Supply Line (Drugs) 
MODEL B DE,A Order Processing (Drugs/Week) 
MODEL B DE,F,A Production & Dispatch To GDF/PA (Drugs/Week) 
MODEL B DE,A Production & Dispatch To SRS (Drugs/Week) 
MODEL B DE,F,A QC's & Dispatch To Countries (Drugs/Week) 
MODEL B L SRS Supply Line (Drugs) 
MODEL B L Total Emergency Order Drugs Received (Drugs) 
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MODEL B L Total Normal Order Drugs Received (Drugs) 
 
Variables With Dimensionless Units (4) 
Group Type Variable 
MODEL B C Emergency Proportion Of Orders Placed (Dmnl) 
MODEL B A,D,T Profile (Dmnl) 
MODEL B C Proportion Of Orders Placed (Dmnl) 
MODEL B A Uniform (Dmnl) 
 
Variables without Predefined Min or Max Values (52) 
Group Type Variable 
MODEL B A Country Dispatch Lead Time (Week) 
MODEL B L Cumulative Obsolete Stock (Drugs) 
MODEL B L Cumulative Purchase Unit Cost (Dollar) 
MODEL B L Cumulative Stockpile Replenishment Cost (Dollar) 
MODEL B L Cumulative Total Obsolescence Cost (Dollar) 
MODEL B A Demand Input (Drugs/Week) 
MODEL B DE,A Dispatch Emergency Drugs To Countries (Drugs/Week) 
MODEL B A Drugs Available For Emergency Orders (Drugs/Week) 
MODEL B A Drugs Available For Stock Rotation (Drugs/Week) 
MODEL B DE,A Drugs Dispatched As Stock Rotation (Drugs/Week) 
MODEL B F,A Drugs Received From Manufacturer (Drugs/Week) 
MODEL B A Drugs To Be Dispatched For Stock Rotation (Drugs/Week) 
MODEL B A Emergency Input (Drugs/Week) 
MODEL B F,A Emergency Order Cost (Dollar/Week) 
MODEL B F,A Emergency Order Drugs Received By Countries (Drugs/Week) 
MODEL B F,A Emergency Orders From Countries (Drugs/Week) 
MODEL B L Emergency Orders Supply Line (Drugs) 
MODEL B C Emergency Proportion Of Orders Placed (Dmnl) 
MODEL B A Emergency Weibull Distribution (Drugs/Week) 
MODEL B C Expiration Value (Week) 
MODEL B C Initial Stock On Hand (Drugs) 
MODEL B L Normal Order Drugs Awaiting Dispatch (Drugs) 
MODEL B F,A Normal Order Drugs Received By Countries (Drugs/Week) 
MODEL B F,A Normal Order Purchase Cost (Dollar/Week) 
MODEL B F,A Normal Orders From Countries (Drugs/Week) 
MODEL B L Normal Orders Supply Line (Drugs) 
MODEL B F,A Obsolete Stock (Drugs/Week) 
MODEL B A Order Processing Lead Time (Week) 
MODEL B DE,A Order Processing (Drugs/Week) 
MODEL B F,A Orders Placed To Manufacturer (Drugs/Week) 
MODEL B C Per Unit Cost (Dollar/Drugs) 
MODEL B A Processed Orders (Drugs/Week) 
MODEL B A Processing Drugs For Stock Rotation (Drugs/Week) 
MODEL B A Production & Dispatch Lead Time (Week) 
MODEL B DE,F,A Production & Dispatch To GDF/PA (Drugs/Week) 
MODEL B DE,A Production & Dispatch To SRS (Drugs/Week) 
MODEL B A,D,T Profile (Dmnl) 
MODEL B C Proportion Of Orders Placed (Dmnl) 
MODEL B DE,F,A QC's & Dispatch To Countries (Drugs/Week) 
MODEL B C Rotation Value Start (Week) 
MODEL B C Rotation Value Stop (Week) 
MODEL B A SRS Demand (Drugs/Week) 
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MODEL B A SRS Stock On Hand (Drugs) 
MODEL B L SRS Supply Line (Drugs) 
MODEL B F,A Stockpile Rotation Cost (Dollar/Week) 
MODEL B A Supply Line Position (Drugs/Week) 
MODEL B A Total Costs (Dollar) 
MODEL B L Total Emergency Order Drugs Received (Drugs) 
MODEL B L Total Normal Order Drugs Received (Drugs) 
MODEL B F,A Total Obsolescence Cost (Dollar/Week) 
MODEL B A Uniform (Dmnl) 
MODEL B A Weibull Distribution (Drugs/Week) 
 
Units (4/3) 
Units Type Alternates 
$ Basic [Dollar] 
Dmnl Basic  
Drugs Basic  
Week Basic  
$/Drugs Combined [Dollar/Drugs] 
$/Week Combined [Dollar/Week] 
Drugs/Week Combined  
 
Positive Polarity Causal Links (39) 
Cause Effect Polarity 
Cumulative Purchase Unit Cost Total Costs + 
Cumulative Stockpile Replenishment Cost Total Costs + 
Cumulative Total Obsolescence Cost Total Costs + 
Demand Input Normal Orders From Countries + 
Dispatch Emergency Drugs To Countries Emergency Order Drugs Received By 
Countries 
+ 
Drugs Available For Emergency Orders Emergency Order Cost + 
Drugs Available For Emergency Orders SRS Demand + 
Drugs Dispatched As Stock Rotation Normal Order Drugs Received By Countries + 
Drugs To Be Dispatched For Stock Rotation Processing Drugs For Stock Rotation + 
Emergency Input Emergency Orders From Countries + 
Emergency Order Cost Cumulative Stockpile Replenishment Cost + 
Emergency Order Drugs Received By 
Countries 
Total Emergency Order Drugs Received + 
Emergency Orders From Countries Drugs Available For Emergency Orders + 
Emergency Orders From Countries Emergency Orders Supply Line + 
Emergency Weibull Distribution Emergency Input + 
Normal Order Drugs Received By Countries Total Normal Order Drugs Received + 
Normal Order Purchase Cost Cumulative Purchase Unit Cost + 
Normal Orders From Countries Normal Orders Supply Line + 
Obsolete Stock Cumulative Obsolete Stock + 
Obsolete Stock SRS Demand + 
Obsolete Stock Total Obsolescence Cost + 
Order Processing Processed Orders + 
Orders Placed To Manufacturer SRS Supply Line + 
Per Unit Cost Emergency Order Cost + 
Per Unit Cost Stockpile Rotation Cost + 
Per Unit Cost Total Obsolescence Cost + 
Processed Orders Normal Order Purchase Cost + 
Processing Drugs For Stock Rotation SRS Demand + 
Processing Drugs For Stock Rotation Stockpile Rotation Cost + 
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Production & Dispatch To GDF/PA Normal Order Drugs Awaiting Dispatch + 
Production & Dispatch To SRS Drugs Received From Manufacturer + 
QC's & Dispatch To Countries Normal Order Drugs Received By Countries + 
SRS Demand Orders Placed To Manufacturer + 
SRS Stock On Hand Drugs Available For Emergency Orders + 
SRS Supply Line Supply Line Position + 
Stockpile Rotation Cost Cumulative Stockpile Replenishment Cost + 
TIME STEP SAVEPER + 
Total Obsolescence Cost Cumulative Total Obsolescence Cost + 
Weibull Distribution Demand Input + 
Negative Polarity Causal Links (8) 
Cause Effect Polarity 
Drugs Received From Manufacturer SRS Supply Line - 
Drugs To Be Dispatched For Stock Rotation Normal Order Purchase Cost - 
Emergency Order Drugs Received By Countries Emergency Orders Supply Line - 
Normal Order Drugs Received By Countries Normal Orders Supply Line - 
Obsolete Stock Drugs Available For Emergency Orders - 
Per Unit Cost Normal Order Purchase Cost - 
QC's & Dispatch To Countries Normal Order Drugs Awaiting Dispatch - 
TIME STEP Supply Line Position - 
 
Function-based Polarity Causal Links (36) 
Cause Effect Polarity 
Country Dispatch Lead Time Dispatch Emergency Drugs 
To Countries 
Function[DELAYMATERIAL] 
Country Dispatch Lead Time Drugs Dispatched As Stock 
Rotation 
Function[DELAYMATERIAL] 
Country Dispatch Lead Time QC's & Dispatch To 
Countries 
Undefined(Load) 
Demand Input Demand Input If Then Else Switch 
Drugs Available For Emergency 
Orders 
Dispatch Emergency Drugs 
To Countries 
Function[DELAYMATERIAL] 
Drugs Available For Emergency 
Orders 
SRS Stock On Hand Function[QUEUEFIFO] 
Drugs Available For Stock 
Rotation 
Drugs To Be Dispatched For 
Stock Rotation 
If Then Else Switch 
Drugs To Be Dispatched For 
Stock Rotation 
Drugs Dispatched As Stock 
Rotation 
Function[DELAYMATERIAL] 
Drugs To Be Dispatched For 
Stock Rotation 
Drugs To Be Dispatched For 
Stock Rotation 
If Then Else Switch 
Drugs To Be Dispatched For 
Stock Rotation 
Production & Dispatch To 
GDF/PA 
Function[DELAYMATERIAL] 
Emergency Proportion Of 
Orders Placed 
Emergency Input If Then Else Switch 
Expiration Value Obsolete Stock Function[QUEUEAGEINRANGE] 
Initial Stock On Hand SRS Stock On Hand Function[QUEUEFIFO] 
NAREPLACEMENT Obsolete Stock Function[QUEUEAGEINRANGE] 
Normal Orders From Countries Order Processing Function[DELAYMATERIAL] 
Obsolete Stock Drugs Available For Stock 
Rotation 
Function[MAX,QUEUEAGEINRANGE] 
Obsolete Stock SRS Stock On Hand Function[QUEUEFIFO] 
Order Processing Lead Time Order Processing Function[DELAYMATERIAL] 
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Processed Orders Drugs To Be Dispatched For 
Stock Rotation 
If Then Else Switch 
Processed Orders Production & Dispatch To 
GDF/PA 
Function[DELAYMATERIAL] 
Processing Drugs For Stock 
Rotation 
SRS Stock On Hand Function[QUEUEFIFO] 
Production & Dispatch Lead 
Time 
Production & Dispatch To 
GDF/PA 
Function[DELAYMATERIAL] 
Production & Dispatch Lead 
Time 
Production & Dispatch To 
SRS 
Function[DELAYMATERIAL] 
Production & Dispatch To 
GDF/PA 
QC's & Dispatch To 
Countries 
If Then Else Switch 
Production & Dispatch To SRS SRS Stock On Hand Function[QUEUEFIFO] 
Profile SRS Stock On Hand Function[QUEUEFIFO] 
Proportion Of Orders Placed Demand Input If Then Else Switch 
Rotation Value Start Drugs Available For Stock 
Rotation 
Function[MAX,QUEUEAGEINRANGE] 
Rotation Value Stop Drugs Available For Stock 
Rotation 
Function[MAX,QUEUEAGEINRANGE] 
SRS Demand Production & Dispatch To 
SRS 
Function[DELAYMATERIAL] 
SRS Stock On Hand Drugs Available For Stock 
Rotation 
Function[MAX,QUEUEAGEINRANGE] 
SRS Stock On Hand Obsolete Stock Function[QUEUEAGEINRANGE] 
TIME STEP Drugs Available For Stock 
Rotation 
Function[MAX,QUEUEAGEINRANGE] 
TIME STEP Obsolete Stock Function[QUEUEAGEINRANGE] 
Uniform Demand Input If Then Else Switch 
Uniform Emergency Input If Then Else Switch 
 
View-Variable Profile 
View View-Variable Profile 
Cost                                                       16 vars (26.7%) 
Main 
Model 
                                                                                                                                                43 
vars (71.7%) 
 
List Of 2 views and their 52 Variables 
  
Cost 
Main 
Model 
  
Total: 16 43 Total: 
Total Normal Order Drugs Received (In 1 
View) 
      Total Normal Order Drugs Received (In 1 
View) 
Proportion Of Orders Placed (In 1 View)       Proportion Of Orders Placed (In 1 View) 
Obsolete Stock (In 2 Views)         Obsolete Stock (In 2 Views) 
SRS Stock On Hand (In 1 View)       SRS Stock On Hand (In 1 View) 
Emergency Input (In 1 View)       Emergency Input (In 1 View) 
Processed Orders (In 2 Views)         Processed Orders (In 2 Views) 
Drugs Available For Emergency Orders 
(In 2 Views) 
        Drugs Available For Emergency Orders 
(In 2 Views) 
Production & Dispatch To GDF/PA (In 1 
View) 
      Production & Dispatch To GDF/PA (In 1 
View) 
Normal Orders Supply Line (In 1 View)       Normal Orders Supply Line (In 1 View) 
Uniform (In 1 View)       Uniform (In 1 View) 
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Drugs Available For Stock Rotation (In 1 
View) 
      Drugs Available For Stock Rotation (In 1 
View) 
Emergency Proportion Of Orders Placed 
(In 1 View) 
      Emergency Proportion Of Orders Placed 
(In 1 View) 
Processing Drugs For Stock Rotation (In 
2 Views) 
        Processing Drugs For Stock Rotation (In 
2 Views) 
Profile (In 1 View)       Profile (In 1 View) 
Order Processing Lead Time (In 1 View)       Order Processing Lead Time (In 1 View) 
Emergency Orders Supply Line (In 1 
View) 
      Emergency Orders Supply Line (In 1 
View) 
Rotation Value Stop (In 1 View)       Rotation Value Stop (In 1 View) 
Demand Input (In 1 View)       Demand Input (In 1 View) 
Normal Order Drugs Received By 
Countries (In 1 View) 
      Normal Order Drugs Received By 
Countries (In 1 View) 
Emergency Orders From Countries (In 1 
View) 
      Emergency Orders From Countries (In 1 
View) 
Drugs Dispatched As Stock Rotation (In 1 
View) 
      Drugs Dispatched As Stock Rotation (In 1 
View) 
Country Dispatch Lead Time (In 1 View)       Country Dispatch Lead Time (In 1 View) 
Production & Dispatch To SRS (In 1 View)       Production & Dispatch To SRS (In 1 View) 
Drugs Received From Manufacturer (In 1 
View) 
      Drugs Received From Manufacturer (In 1 
View) 
Order Processing (In 1 View)       Order Processing (In 1 View) 
Expiration Value (In 1 View)       Expiration Value (In 1 View) 
Orders Placed To Manufacturer (In 2 
Views) 
        Orders Placed To Manufacturer (In 2 
Views) 
Weibull Distribution (In 1 View)       Weibull Distribution (In 1 View) 
Drugs To Be Dispatched For Stock 
Rotation (In 2 Views) 
        Drugs To Be Dispatched For Stock 
Rotation (In 2 Views) 
Emergency Weibull Distribution (In 1 
View) 
      Emergency Weibull Distribution (In 1 
View) 
Production & Dispatch Lead Time (In 1 
View) 
      Production & Dispatch Lead Time (In 1 
View) 
SRS Demand (In 1 View)       SRS Demand (In 1 View) 
Normal Orders From Countries (In 2 
Views) 
        Normal Orders From Countries (In 2 
Views) 
Emergency Order Drugs Received By 
Countries (In 1 View) 
      Emergency Order Drugs Received By 
Countries (In 1 View) 
Rotation Value Start (In 1 View)       Rotation Value Start (In 1 View) 
Supply Line Position (In 1 View)       Supply Line Position (In 1 View) 
Cumulative Obsolete Stock (In 1 View)       Cumulative Obsolete Stock (In 1 View) 
Total Emergency Order Drugs Received 
(In 1 View) 
      Total Emergency Order Drugs Received 
(In 1 View) 
SRS Supply Line (In 1 View)       SRS Supply Line (In 1 View) 
QC's & Dispatch To Countries (In 1 View)       QC's & Dispatch To Countries (In 1 View) 
Dispatch Emergency Drugs To Countries 
(In 1 View) 
      Dispatch Emergency Drugs To Countries 
(In 1 View) 
Initial Stock On Hand (In 1 View)       Initial Stock On Hand (In 1 View) 
Normal Order Drugs Awaiting Dispatch 
(In 1 View) 
      Normal Order Drugs Awaiting Dispatch 
(In 1 View) 
Cumulative Stockpile Replenishment 
Cost (In 1 View) 
      Cumulative Stockpile Replenishment 
Cost (In 1 View) 
Cumulative Purchase Unit Cost (In 1 View)       Cumulative Purchase Unit Cost (In 1 View) 
Total Obsolescence Cost (In 1 View)       Total Obsolescence Cost (In 1 View) 
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Stockpile Rotation Cost (In 1 View)       Stockpile Rotation Cost (In 1 View) 
Per Unit Cost (In 1 View)       Per Unit Cost (In 1 View) 
Emergency Order Cost (In 1 View)       Emergency Order Cost (In 1 View) 
Normal Order Purchase Cost (In 1 View)       Normal Order Purchase Cost (In 1 View) 
Total Costs (In 1 View)       Total Costs (In 1 View) 
Cumulative Total Obsolescence Cost (In 
1 View) 
      Cumulative Total Obsolescence Cost (In 
1 View) 
Total: 16 43 Total: 
  
Cost 
Main 
Model 
  
 
Source File: /Users/deonlingervelder/Desktop/All/Masters/6. Dynamic Modelling Main 
Models/DAILY/MODEL B.mdl (Sat Nov 19 12:44:30 SAST 2016)  
Report Created On Sat Nov 19 12:44:48 SAST 2016 
SDM-Doc Tool Version 1.2.44 
Global Security Sciences Division  
Argonne National Laboratory  
I.3 SDM document for Model C 
This section provides the HTML output of the SDM document tool, for Model C. 
Model Assessment Results 
 
Model Information Result 
Total Number Of 
Variables 
51|371 
Total Number Of 
Causal Links 
80 (28|5|47)|931 (307|60|564) 
Total Number of 
Rate-to-rate Links 
0 
Variables without 
Predefined Min or 
Max Values 
47 (92.2%)|367 (98.9%) 
Model Is Fully 
Formulated 
Yes 
Model Defined 
Groups 
No 
 
Potential Omissions Result 
 
Variable Types 
 
L: Level (6 / 72)* SM: Smooth (0 / 0)* DE: Delay (3 / 36)*† LI: Level Initial (0) I: Initial (0 / 0) 
C: Constant (10 / 
87) 
F: Flow (7 / 84) 
A: Auxiliary (35 / 
389) 
Sub: Subscripts (2) D: Data (0 / 0) 
G: Game (0 / 0) T: Lookup (1 / 1)*††       
* (State Variables/Total Stocks) † Total Stocks Do Not Include Fixed Delay Variables. †† (Lookup 
Tables).    
Views 
View: Cost (10) Variables 
 
 
View: Main Model (41) Variables 
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Variables 
 
(View) Cost (10 Variables) 
 
Top (View) Cost (10 Variables) 
    
Group Type Variable Name And Description  
ModelC #21 L Cumulative Total Obsolescence Cost (Dollar) 
Cumulative Total Obsolescence Cost[Formulations,Order Number] = ∫"Total 
Obsolescence Cost"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
Cost 
Used By 
Total Costs 
 
ModelC #22 
L 
Cumulative Total Unit Cost (Dollar) 
Cumulative Total Unit Cost[Formulations,Order Number] = ∫"Total Unit 
Cost"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
Cost 
Used By 
Total Costs 
 
ModelC #61 
F,A 
Normal Orders From Countries (Drugs/Week) 
Normal Orders From Countries[Formulations,Order Number] = Demand 
Input[Formulations,Order Number] Present In 2 Views: 
Cost 
Main Model 
Used By 
Normal Orders Supply Line 
Order Processing 
 
ModelC #63 
C,F 
Obsolete Stock (Drugs/Week) 
Obsolete Stock[Formulations,Order1] = QUEUE AGE IN RANGE( SRS Stock On 
Hand[Formulations,Order1] , Expiration Value[Formulations,Order1] , 
NAREPLACEMENT )/TIME STEP Obsolete Stock[Formulations,Order2] = 0 Obsolete 
Stock[Formulations,Order3] = 0 Obsolete Stock[Formulations,Order4] = 0 Present In 
3 Views: 
Not in View 
Cost 
Main Model 
Used By 
Cumulative Obsolete Stock 
Drugs Available For Dispatch 
SRS Stock On Hand 
Total Obsolescence Cost 
 
ModelC #86 
C 
Per Unit Cost (Dollar/Drugs) 
Per Unit Cost[Capreomycin,Order Number] = 5.66 Per Unit Cost[Kanamycin,Order 
Number] = 2.59 Per Unit Cost[Cycloserine,Order Number] = 0.55 Present In 2 
Views: 
Not in View 
Cost 
Used By 
Total Obsolescence Cost 
Total Unit Cost 
 
ModelC #116 
A 
SRS Demand (Drugs/Week) 
SRS Demand[Formulations,Order Number] = IF THEN ELSE( 
"Reorder?"[Formulations,Order Number]=0 , IF THEN ELSE( Inventory 
Position[Formulations,Order Number]/ TIME STEP<Reorder 
Point[Formulations,Order Number] , (MAX(0,"Order-Up-To-
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Level"[Formulations,Order Number] - Inventory Position[Formulations,Order 
Number]))/TIME STEP, 0 ) , 0 ) Present In 2 Views: 
Cost 
Main Model 
Used By 
Orders Placed To Manufacturer 
Production & Dispatch To SRS 
Total Unit Cost 
ModelC #117 
A 
SRS Stock On Hand (Drugs) 
SRS Stock On Hand[Formulations,Order Number] = QUEUE FIFO("Production & 
Dispatch To SRS"[Formulations,Order Number], Obsolete Stock[Formulations,Order 
Number] + Dispatch Drugs To Countries[Formulations,Order Number] , Profile , 
Initial Stock On Hand [Formulations,Order Number] , 0 ) Present In 2 Views: 
Cost 
Main Model 
Used By 
Drugs Available For Dispatch 
Inventory Position 
Obsolete Stock 
 
ModelC #121 
A 
Total Costs (Dollar) 
Total Costs[Formulations] = SUM(Cumulative Total Unit Cost[Formulations,Order 
Number!]) + SUM(Cumulative Total Obsolescence Cost[Formulations,Order 
Number!]) Present In 1 View: 
Cost 
Used By 
 
ModelC #123 
F,A 
Total Obsolescence Cost (Dollar/Week) 
Total Obsolescence Cost[Formulations,Order Number] = Per Unit 
Cost[Formulations,Order Number] * Obsolete Stock[Formulations,Order Number] 
Present In 1 View: 
Cost 
Used By 
Cumulative Total Obsolescence Cost 
 
ModelC #124 
F,A 
Total Unit Cost (Dollar/Week) 
Total Unit Cost[Formulations,Order Number] = SRS Demand[Formulations,Order 
Number]*Per Unit Cost[Formulations,Order Number] Present In 1 View: 
Cost 
Used By 
Cumulative Total Unit Cost 
 
(View) Main Model (41 Variables) 
 
Top (View) Main Model (41 Variables) 
    
Group Type Variable Name And Description  
ModelC #2 A Backlog Range One (Drugs/Week) 
Backlog Range One[Formulations,Order Number] = QUEUE AGE IN RANGE( Order 
Backlogs[Formulations,Order Number] , QUEUE AGE OLDEST( Order 
Backlogs[Formulations,Order Number] ) , NAREPLACEMENT ) Present In 1 View: 
Main Model 
Used By 
Backlog Reduction MAX(0,Drugs To Be Dispatched[Formulations,Order] - 
Processed Orders[Formulations,Order]) 
Drugs To Be Dispatched IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] > Processed Orders[Formulations,Order1] , 
Processed Orders[Formulations,Order1] , 0 ) 
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Incoming MAX(0,Processed Orders[Formulations,Order] - Drugs To Be 
Dispatched[Formulations,Order]) 
ModelC #3 A Backlog Range Two (Drugs/Week) 
Backlog Range Two[Formulations,Order Number] = QUEUE AGE IN RANGE( Order 
Backlogs[Formulations,Order Number] , 0.5* QUEUE AGE OLDEST( Order 
Backlogs[Formulations,Order Number] ) , QUEUE AGE OLDEST (Order 
Backlogs[Formulations,Order Number] ) - 1 ) Present In 1 View: 
Main Model 
Used By 
Backlog Reduction MAX(0,Drugs To Be Dispatched[Formulations,Order] - 
Processed Orders[Formulations,Order]) 
Drugs To Be Dispatched IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] > Processed Orders[Formulations,Order1] , 
Processed Orders[Formulations,Order1] , 0 ) 
Incoming MAX(0,Processed Orders[Formulations,Order] - Drugs To Be 
Dispatched[Formulations,Order]) 
 
ModelC #4 A Backlog Reduction (Drugs/Week) 
Backlog Reduction[Formulations,Order1] = IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Processed Orders[Formulations,Order1] + 
Order Backlogs[Formulations,Order1] , MAX(0,Drugs To Be 
Dispatched[Formulations,Order1] - Processed Orders[Formulations,Order1]) ,IF 
THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Order 
Backlogs[Formulations,Order1] , Drugs To Be Dispatched[Formulations,Order1] ,IF 
THEN ELSE( Backlog Range One[Formulations,Order1] >0 :AND: Backlog Range 
Two[Formulations,Order1] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order1] + 
Backlog Range Two[Formulations,Order1] + Processed 
Orders[Formulations,Order1], MAX(0,Drugs To Be Dispatched[Formulations,Order1] 
- Processed Orders[Formulations,Order1]),IF THEN ELSE( Backlog Range 
One[Formulations,Order1] >0 :AND: Backlog Range Two[Formulations,Order1] >0 
:AND: Drugs Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] + Backlog Range Two[Formulations,Order1] , Drugs To 
Be Dispatched[Formulations,Order1] ,IF THEN ELSE( Processed 
Orders[Formulations,Order1] > 0 :AND: Backlog Range One[Formulations,Order1] > 
0 :AND:Drugs Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] +Processed Orders[Formulations,Order1] , MAX(0,Drugs 
To Be Dispatched[Formulations,Order1] - Processed Orders[Formulations,Order1]) 
,IF THEN ELSE( Backlog Range One[Formulations,Order1] > 0 :AND: Drugs 
Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] , Drugs To Be Dispatched[Formulations,Order1] ,IF THEN 
ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4]> Processed 
Orders[Formulations,Order1] , MAX(0,Drugs To Be Dispatched[Formulations,Order1] 
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- Processed Orders[Formulations,Order1]) , Drugs To Be 
Dispatched[Formulations,Order1] )) ) ) ) ) ) Backlog Reduction[Formulations,Order2] 
= IF THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Processed Orders[Formulations,Order2] + Order Backlogs[Formulations,Order2] , 
MAX(0,Drugs To Be Dispatched[Formulations,Order2] - Processed 
Orders[Formulations,Order2]) ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Order 
Backlogs[Formulations,Order2] , Drugs To Be Dispatched[Formulations,Order2] ,IF 
THEN ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog Range 
Two[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2] + 
Processed Orders[Formulations,Order2], MAX(0,Drugs To Be 
Dispatched[Formulations,Order2] - Processed Orders[Formulations,Order2]),IF 
THEN ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog Range 
Two[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2] , Drugs To 
Be Dispatched[Formulations,Order2] ,IF THEN ELSE( Processed 
Orders[Formulations,Order2] > 0 :AND: Backlog Range One[Formulations,Order2] 
> 0 :AND:Drugs Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Backlog Range One[Formulations,Order2] + Processed 
Orders[Formulations,Order2] , MAX(0,Drugs To Be 
Dispatched[Formulations,Order2] - Processed Orders[Formulations,Order2]) ,IF 
THEN ELSE( Backlog Range One[Formulations,Order2] > 0 :AND: Drugs Available 
For Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] 
- Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] , Drugs To Be Dispatched[Formulations,Order2] ,IF 
THEN ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Processed Orders[Formulations,Order2] , MAX(0,Drugs To Be 
Dispatched[Formulations,Order2] - Processed Orders[Formulations,Order2]) , 
Drugs To Be Dispatched[Formulations,Order2] )) ) ) ) ) ) Backlog 
Reduction[Formulations,Order3] = IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Processed Orders[Formulations,Order3] + Order Backlogs[Formulations,Order3] , 
MAX(0,Drugs To Be Dispatched[Formulations,Order3] - Processed 
Orders[Formulations,Order3]) ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Order Backlogs[Formulations,Order3] , Drugs To Be 
Dispatched[Formulations,Order3] ,IF THEN ELSE( Backlog Range 
One[Formulations,Order3] >0 :AND: Backlog Range Two[Formulations,Order3] >0 
:AND: Drugs Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order3]+ 
Backlog Range Two[Formulations,Order3] + Processed 
Orders[Formulations,Order3], MAX(0,Drugs To Be 
Dispatched[Formulations,Order3] - Processed Orders[Formulations,Order3]),IF 
THEN ELSE( Backlog Range One[Formulations,Order3] >0 :AND: Backlog Range 
Two[Formulations,Order3] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Backlog Range One[Formulations,Order3]+ Backlog Range 
Two[Formulations,Order3] , Drugs To Be Dispatched[Formulations,Order3] ,IF 
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THEN ELSE( Processed Orders[Formulations,Order3] > 0 :AND: Backlog Range 
One[Formulations,Order3] > 0 :AND:Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Backlog Range One[Formulations,Order3] + Processed 
Orders[Formulations,Order3] , MAX(0,Drugs To Be 
Dispatched[Formulations,Order3] - Processed Orders[Formulations,Order3]) ,IF 
THEN ELSE( Backlog Range One[Formulations,Order3] > 0 :AND: Drugs Available 
For Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Backlog Range One[Formulations,Order3] , Drugs To Be 
Dispatched[Formulations,Order3],IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Processed Orders[Formulations,Order3] , MAX(0,Drugs To Be 
Dispatched[Formulations,Order3] - Processed Orders[Formulations,Order3]) , 
Drugs To Be Dispatched[Formulations,Order3] )) ) ) ) ) ) Backlog 
Reduction[Formulations,Order4] = IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order4] > Processed Orders[Formulations,Order4] + Order 
Backlogs[Formulations,Order4] , MAX(0,Drugs To Be 
Dispatched[Formulations,Order4] - Processed Orders[Formulations,Order4]) ,IF 
THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > Order 
Backlogs[Formulations,Order4] , Drugs To Be Dispatched[Formulations,Order4] ,IF 
THEN ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog Range 
Two[Formulations,Order4] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Backlog Range Two[Formulations,Order4] + Processed 
Orders[Formulations,Order4], MAX(0,Drugs To Be 
Dispatched[Formulations,Order4] - Processed Orders[Formulations,Order4]),IF 
THEN ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog Range 
Two[Formulations,Order4] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Backlog Range Two[Formulations,Order4] , Drugs To Be 
Dispatched[Formulations,Order4] ,IF THEN ELSE( Processed 
Orders[Formulations,Order4] > 0 :AND: Backlog Range One[Formulations,Order4] 
> 0 :AND:Drugs Available For Dispatch[Formulations,Order4] > Backlog Range 
One[Formulations,Order4] + Processed Orders[Formulations,Order4] , 
MAX(0,Drugs To Be Dispatched[Formulations,Order4] - Processed 
Orders[Formulations,Order4]) ,IF THEN ELSE( Backlog Range 
One[Formulations,Order4] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] , Drugs 
To Be Dispatched[Formulations,Order4] ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order4] > Processed Orders[Formulations,Order4] , 
MAX(0,Drugs To Be Dispatched[Formulations,Order4] - Processed 
Orders[Formulations,Order4]) , Drugs To Be Dispatched[Formulations,Order4] )) ) ) ) 
) ) Description: MAX(0,Drugs To Be Dispatched[Formulations,Order] - Processed 
Orders[Formulations,Order]) Present In 2 Views: 
Not in View 
Main Model 
Used By 
Order Backlogs QUEUE FIFO(Incoming[Formulations,Order Number], Backlog 
Reduction[Formulations,Order Number] , Profile , 0 , 0 )QUEUE FIFO ATTRIB( 
_inflow_ , _outflow_ , _attrib_ , _changerate_ , _initprofile_ , _iattribprof_ , 
_inittotal_ , _initattrib_ , _initage_ )QUEUE FIFO ATTRIB( 
Incoming[Formulations,Order Number] , Backlog Reduction[Formulations,Order 
Number] , inatt[Formulations,Order Number] , 1 , Profile , Profile , 0 , -1000 , 0 ) 
ModelC #8 A Country Dispatch Lead Time (Week) 
Country Dispatch Lead Time[Capreomycin,Order1] = RANDOM TRIANGULAR( 3 , 15 
, 0 , 3 , 35 , 1 ) Country Dispatch Lead Time[Capreomycin,Order2] = RANDOM 
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TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead 
Time[Capreomycin,Order3] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country 
Dispatch Lead Time[Capreomycin,Order4] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 
35 , 1 ) Country Dispatch Lead Time[Kanamycin,Order1] = RANDOM TRIANGULAR( 
3 , 15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead Time[Kanamycin,Order2] = RANDOM 
TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead Time[Kanamycin,Order3] 
= RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead 
Time[Kanamycin,Order4] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country 
Dispatch Lead Time[Cycloserine,Order1] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 35 
, 1 ) Country Dispatch Lead Time[Cycloserine,Order2] = RANDOM TRIANGULAR( 3 , 
15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead Time[Cycloserine,Order3] = RANDOM 
TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Country Dispatch Lead 
Time[Cycloserine,Order4] = RANDOM TRIANGULAR( 3 , 15 , 0 , 3 , 35 , 1 ) Present In 
2 Views: 
Not in View 
Main Model 
Used By 
Dispatch 
ModelC #20 L Cumulative Obsolete Stock (Drugs) 
Cumulative Obsolete Stock[Formulations,Order Number] = ∫"Obsolete 
Stock"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
Main Model 
Used By 
 
ModelC #23 A Demand Input (Drugs/Week) 
Demand Input[Formulations,Order1] = IF THEN ELSE( Uniform[Formulations,Order1] 
< Proportion Of Orders Placed[Formulations,Order1] , INTEGER(Weibull 
Distribution[Formulations,Order1]) , 0 ) Demand Input[Formulations,Order2] = IF 
THEN ELSE( Demand Input[Formulations,Order1] > 0 , IF THEN ELSE( 
Uniform[Formulations,Order2] < Proportion Of Orders Placed[Formulations,Order2] 
, Weibull Distribution[Formulations,Order2] , 0 ) , 0 ) Demand 
Input[Formulations,Order3] = IF THEN ELSE( Demand 
Input[Formulations,Order2]>0, IF THEN ELSE( Uniform[Formulations,Order3] < 
Proportion Of Orders Placed[Formulations,Order3] , Weibull 
Distribution[Formulations,Order3] , 0 ) , 0 ) Demand Input[Formulations,Order4] = IF 
THEN ELSE( Demand Input[Formulations,Order3]>0, IF THEN ELSE( 
Uniform[Formulations,Order4] < Proportion Of Orders Placed[Formulations,Order4] 
, Weibull Distribution[Formulations,Order4] , 0 ) , 0 ) Present In 2 Views: 
Not in View 
Main Model 
Used By 
Normal Orders From Countries 
 
ModelC #27 
DE,A 
Dispatch (Drugs/Week) 
Dispatch[Formulations,Order Number] = DELAY MATERIAL (Drugs To Be 
Dispatched[Formulations,Order Number], Country Dispatch Lead 
Time[Formulations,Order Number], 0, 0) Present In 1 View: 
Main Model 
Used By 
Normal Order Drugs Received By Countries 
 
ModelC #28 C Dispatch Drugs To Countries (Drugs/Week) 
Dispatch Drugs To Countries[Formulations,Order1] = Drugs To Be 
Dispatched[Formulations,Order1] + Drugs To Be Dispatched[Formulations,Order2] 
+ Drugs To Be Dispatched[Formulations,Order3] + Drugs To Be 
Dispatched[Formulations,Order4] Dispatch Drugs To 
Countries[Formulations,Order2] = 0 Dispatch Drugs To 
Countries[Formulations,Order3] = 0 Dispatch Drugs To 
Countries[Formulations,Order4] = 0 Present In 2 Views: 
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Not in View 
Main Model 
Used By 
SRS Stock On Hand 
ModelC #32 A Drugs Available For Dispatch (Drugs/Week) 
Drugs Available For Dispatch[Formulations,Order1] = MAX(0, SRS Stock On 
Hand[Formulations,Order1]/TIME STEP - Obsolete Stock[Formulations,Order1]) 
Drugs Available For Dispatch[Formulations,Order2] = MAX(0, SRS Stock On 
Hand[Formulations,Order1]/TIME STEP - Obsolete Stock[Formulations,Order1]) 
Drugs Available For Dispatch[Formulations,Order3] = MAX(0, SRS Stock On 
Hand[Formulations,Order1]/TIME STEP - Obsolete Stock[Formulations,Order1]) 
Drugs Available For Dispatch[Formulations,Order4] = MAX(0, SRS Stock On 
Hand[Formulations,Order1]/TIME STEP - Obsolete Stock[Formulations,Order1]) 
Present In 2 Views: 
Not in View 
Main Model 
Used By 
Backlog Reduction MAX(0,Drugs To Be Dispatched[Formulations,Order] - 
Processed Orders[Formulations,Order]) 
Drugs To Be Dispatched IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] > Processed Orders[Formulations,Order1] , 
Processed Orders[Formulations,Order1] , 0 ) 
Incoming MAX(0,Processed Orders[Formulations,Order] - Drugs To Be 
Dispatched[Formulations,Order]) 
 
ModelC #36 
F,A 
Drugs Received From Manufacturer (Drugs/Week) 
Drugs Received From Manufacturer[Formulations,Order Number] = "Production & 
Dispatch To SRS"[Formulations,Order Number] Present In 1 View: 
Main Model 
Used By 
SRS Supply Line 
 
ModelC #37 A Drugs To Be Dispatched (Drugs/Week) 
Drugs To Be Dispatched[Formulations,Order1] = IF THEN ELSE( Drugs Available 
For Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] 
- Drugs To Be Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Processed Orders[Formulations,Order1] + 
Order Backlogs[Formulations,Order1] , Processed Orders[Formulations,Order1] + 
Order Backlogs[Formulations,Order1] ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Order Backlogs[Formulations,Order1] , Order 
Backlogs[Formulations,Order1] ,IF THEN ELSE( Backlog Range 
One[Formulations,Order1] >0 :AND: Backlog Range Two[Formulations,Order1] >0 
:AND: Drugs Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] + Backlog Range Two[Formulations,Order1] + Processed 
Orders[Formulations,Order1], Backlog Range Two[Formulations,Order1] + Backlog 
Range One[Formulations,Order1] + Processed Orders[Formulations,Order1],IF 
THEN ELSE( Backlog Range One[Formulations,Order1] >0 :AND: Backlog Range 
Two[Formulations,Order1] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order1] + 
Backlog Range Two[Formulations,Order1] , Backlog Range 
Two[Formulations,Order1] + Backlog Range One[Formulations,Order1] ,IF THEN 
ELSE( Processed Orders[Formulations,Order1] > 0 :AND: Backlog Range 
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One[Formulations,Order1] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order1] + 
Processed Orders[Formulations,Order1] , Backlog Range One[Formulations,Order1] 
+ Processed Orders[Formulations,Order1] ,IF THEN ELSE( Backlog Range 
One[Formulations,Order1] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order1] , 
Backlog Range One[Formulations,Order1] ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4]> Processed Orders[Formulations,Order1] , 
Processed Orders[Formulations,Order1] , 0 )) ) ) ) ) ) Drugs To Be 
Dispatched[Formulations,Order2] = IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Processed 
Orders[Formulations,Order2] + Order Backlogs[Formulations,Order2] , Processed 
Orders[Formulations,Order2] + Order Backlogs[Formulations,Order2] ,IF THEN 
ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Order Backlogs[Formulations,Order2] , Order Backlogs[Formulations,Order2] ,IF 
THEN ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog Range 
Two[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2] + 
Processed Orders[Formulations,Order2], Backlog Range 
Two[Formulations,Order2] + Backlog Range One[Formulations,Order2] + 
Processed Orders[Formulations,Order2],IF THEN ELSE( Backlog Range 
One[Formulations,Order2] >0 :AND: Backlog Range Two[Formulations,Order2] >0 
:AND: Drugs Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Backlog Range One[Formulations,Order2] + Backlog Range 
Two[Formulations,Order2] , Backlog Range Two[Formulations,Order2] + Backlog 
Range One[Formulations,Order2] ,IF THEN ELSE( Processed 
Orders[Formulations,Order2] > 0 :AND: Backlog Range One[Formulations,Order2] 
> 0 :AND: Drugs Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Backlog Range One[Formulations,Order2] + Processed 
Orders[Formulations,Order2] , Backlog Range One[Formulations,Order2] + 
Processed Orders[Formulations,Order2] ,IF THEN ELSE( Backlog Range 
One[Formulations,Order2] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] , Backlog Range One[Formulations,Order2] ,IF THEN 
ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Processed Orders[Formulations,Order2] , Processed 
Orders[Formulations,Order2] , 0 )) ) ) ) ) ) Drugs To Be 
Dispatched[Formulations,Order3] = IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Processed Orders[Formulations,Order3] + Order Backlogs[Formulations,Order3] , 
Processed Orders[Formulations,Order3] + Order Backlogs[Formulations,Order3] ,IF 
THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Order Backlogs[Formulations,Order3] , Order 
Page | 300                                                                          Appendix I: SDM documents 
 
Department of Industrial Engineering   
Backlogs[Formulations,Order3] ,IF THEN ELSE( Backlog Range 
One[Formulations,Order3] >0 :AND: Backlog Range Two[Formulations,Order3] >0 
:AND: Drugs Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order3] + 
Backlog Range Two[Formulations,Order3] + Processed 
Orders[Formulations,Order3], Backlog Range Two[Formulations,Order3] + Backlog 
Range One[Formulations,Order3] + Processed Orders[Formulations,Order3],IF 
THEN ELSE( Backlog Range One[Formulations,Order3] >0 :AND: Backlog Range 
Two[Formulations,Order3] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Backlog Range One[Formulations,Order3] + Backlog Range 
Two[Formulations,Order3] , Backlog Range Two[Formulations,Order3] + Backlog 
Range One[Formulations,Order3] ,IF THEN ELSE( Processed 
Orders[Formulations,Order3] > 0 :AND: Backlog Range One[Formulations,Order3] 
> 0 :AND: Drugs Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order3] + 
Processed Orders[Formulations,Order3] , Backlog Range 
One[Formulations,Order3] + Processed Orders[Formulations,Order3] ,IF THEN 
ELSE( Backlog Range One[Formulations,Order3] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Backlog Range One[Formulations,Order3] , Backlog Range 
One[Formulations,Order3] ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Processed Orders[Formulations,Order3] , Processed Orders[Formulations,Order3] , 
0 )) ) ) ) ) ) Drugs To Be Dispatched[Formulations,Order4] = IF THEN ELSE( Drugs 
Available For Dispatch[Formulations,Order4] > Processed 
Orders[Formulations,Order4] + Order Backlogs[Formulations,Order4] , Processed 
Orders[Formulations,Order4] + Order Backlogs[Formulations,Order4] ,IF THEN 
ELSE( Drugs Available For Dispatch[Formulations,Order4] > Order 
Backlogs[Formulations,Order4] , Order Backlogs[Formulations,Order4] ,IF THEN 
ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog Range 
Two[Formulations,Order4] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Backlog Range Two[Formulations,Order4] + Processed 
Orders[Formulations,Order4], Backlog Range Two[Formulations,Order4] + Backlog 
Range One[Formulations,Order4] + Processed Orders[Formulations,Order4],IF 
THEN ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog Range 
Two[Formulations,Order4] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Backlog Range Two[Formulations,Order4] , Backlog Range 
Two[Formulations,Order4] + Backlog Range One[Formulations,Order4] ,IF THEN 
ELSE( Processed Orders[Formulations,Order4] > 0 :AND: Backlog Range 
One[Formulations,Order4] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Processed Orders[Formulations,Order4] , Backlog Range 
One[Formulations,Order4] + Processed Orders[Formulations,Order4] ,IF THEN 
ELSE( Backlog Range One[Formulations,Order4] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] , 
Backlog Range One[Formulations,Order4] ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order4] > Processed Orders[Formulations,Order4] , 
Processed Orders[Formulations,Order4] , 0 )) ) ) ) ) ) Description: IF THEN ELSE( 
Drugs Available For Dispatch[Formulations,Order1] > Processed 
Orders[Formulations,Order1] , Processed Orders[Formulations,Order1] , 0 ) Present 
In 2 Views: 
Not in View 
Main Model 
Used By 
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Backlog Reduction MAX(0,Drugs To Be Dispatched[Formulations,Order] - 
Processed Orders[Formulations,Order]) 
Dispatch 
Dispatch Drugs To Countries 
Incoming MAX(0,Processed Orders[Formulations,Order] - Drugs To Be 
Dispatched[Formulations,Order]) 
ModelC #41 C Expiration Value (Week) 
Expiration Value[Capreomycin,Order Number] = 56, 0, 0, 0 Expiration 
Value[Kanamycin,Order Number] = 140, 0, 0, 0 Expiration Value[Cycloserine,Order 
Number] = 56, 0, 0, 0 Present In 2 Views: 
Not in View 
Main Model 
Used By 
Obsolete Stock 
 
ModelC #46 A Incoming (Drugs/Week) 
Incoming[Formulations,Order1] = IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Processed Orders[Formulations,Order1] + 
Order Backlogs[Formulations,Order1] , MAX(0,Processed 
Orders[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order1]) ,IF 
THEN ELSE( Drugs Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Order 
Backlogs[Formulations,Order1] , Processed Orders[Formulations,Order1] ,IF THEN 
ELSE( Backlog Range One[Formulations,Order1] >0 :AND: Backlog Range 
Two[Formulations,Order1] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order1] + 
Backlog Range Two[Formulations,Order1] + Processed 
Orders[Formulations,Order1], MAX(0,Processed Orders[Formulations,Order1] - 
Drugs To Be Dispatched[Formulations,Order1]),IF THEN ELSE( Backlog Range 
One[Formulations,Order1] >0 :AND: Backlog Range Two[Formulations,Order1] >0 
:AND: Drugs Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] + Backlog Range Two[Formulations,Order1] , Processed 
Orders[Formulations,Order1] ,IF THEN ELSE( Processed 
Orders[Formulations,Order1] > 0 :AND: Backlog Range One[Formulations,Order1] > 
0 :AND: Drugs Available For Dispatch[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3]- 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order1] + Processed Orders[Formulations,Order1] , 
MAX(0,Processed Orders[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order1]) ,IF THEN ELSE( Backlog Range 
One[Formulations,Order1] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order1] , 
Processed Orders[Formulations,Order1] ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] - Drugs To Be Dispatched[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order3]- Drugs To Be 
Dispatched[Formulations,Order4]> Processed Orders[Formulations,Order1] , 
MAX(0,Processed Orders[Formulations,Order1] - Drugs To Be 
Dispatched[Formulations,Order1]) , Processed Orders[Formulations,Order1] )) ) ) ) ) ) 
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Incoming[Formulations,Order2] = IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Processed 
Orders[Formulations,Order2] + Order Backlogs[Formulations,Order2] , 
MAX(0,Processed Orders[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order2]) ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Order 
Backlogs[Formulations,Order2] , Processed Orders[Formulations,Order2] ,IF THEN 
ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog Range 
Two[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2] + 
Processed Orders[Formulations,Order2], MAX(0,Processed 
Orders[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order2]),IF 
THEN ELSE( Backlog Range One[Formulations,Order2] >0 :AND: Backlog Range 
Two[Formulations,Order2] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] + Backlog Range Two[Formulations,Order2] , Processed 
Orders[Formulations,Order2] ,IF THEN ELSE( Processed 
Orders[Formulations,Order2] > 0 :AND: Backlog Range One[Formulations,Order2] 
> 0 :AND: Drugs Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Backlog Range One[Formulations,Order2] + Processed 
Orders[Formulations,Order2] , MAX(0,Processed Orders[Formulations,Order2] - 
Drugs To Be Dispatched[Formulations,Order2]) ,IF THEN ELSE( Backlog Range 
One[Formulations,Order2] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order4] > Backlog Range 
One[Formulations,Order2] , Processed Orders[Formulations,Order2] ,IF THEN 
ELSE( Drugs Available For Dispatch[Formulations,Order2] - Drugs To Be 
Dispatched[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Processed Orders[Formulations,Order2] , MAX(0,Processed 
Orders[Formulations,Order2] - Drugs To Be Dispatched[Formulations,Order2]) , 
Processed Orders[Formulations,Order2] )) ) ) ) ) ) Incoming[Formulations,Order3] = IF 
THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Processed Orders[Formulations,Order3] + 
Order Backlogs[Formulations,Order3] , MAX(0,Processed 
Orders[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order3]) ,IF 
THEN ELSE( Drugs Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Order Backlogs[Formulations,Order3] , 
Processed Orders[Formulations,Order3] ,IF THEN ELSE( Backlog Range 
One[Formulations,Order3] >0 :AND: Backlog Range Two[Formulations,Order3] >0 
:AND: Drugs Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order3] + 
Backlog Range Two[Formulations,Order3] + Processed 
Orders[Formulations,Order3], MAX(0,Processed Orders[Formulations,Order3] - 
Drugs To Be Dispatched[Formulations,Order3]),IF THEN ELSE( Backlog Range 
One[Formulations,Order3] >0 :AND: Backlog Range Two[Formulations,Order3] >0 
:AND: Drugs Available For Dispatch[Formulations,Order3] - Drugs To Be 
Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order3] + 
Backlog Range Two[Formulations,Order3] , Processed 
Orders[Formulations,Order3] ,IF THEN ELSE( Processed 
Orders[Formulations,Order3] > 0 :AND: Backlog Range One[Formulations,Order3] 
> 0 :AND: Drugs Available For Dispatch[Formulations,Order3] - Drugs To Be 
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Dispatched[Formulations,Order4] > Backlog Range One[Formulations,Order3] + 
Processed Orders[Formulations,Order3] , MAX(0,Processed 
Orders[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order3]) ,IF 
THEN ELSE( Backlog Range One[Formulations,Order3] > 0 :AND: Drugs Available 
For Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] 
> Backlog Range One[Formulations,Order3] , Processed 
Orders[Formulations,Order3],IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order4] > 
Processed Orders[Formulations,Order3] , MAX(0,Processed 
Orders[Formulations,Order3] - Drugs To Be Dispatched[Formulations,Order3]) , 
Processed Orders[Formulations,Order3] )) ) ) ) ) ) Incoming[Formulations,Order4] = IF 
THEN ELSE( Drugs Available For Dispatch[Formulations,Order4] > Processed 
Orders[Formulations,Order4] + Order Backlogs[Formulations,Order4] , 
MAX(0,Processed Orders[Formulations,Order4] - Drugs To Be 
Dispatched[Formulations,Order4]) ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order4] > Order Backlogs[Formulations,Order4] , Processed 
Orders[Formulations,Order4] ,IF THEN ELSE( Backlog Range 
One[Formulations,Order4] >0 :AND: Backlog Range Two[Formulations,Order4] >0 
:AND: Drugs Available For Dispatch[Formulations,Order4] > Backlog Range 
One[Formulations,Order4] + Backlog Range Two[Formulations,Order4] + 
Processed Orders[Formulations,Order4], MAX(0,Processed 
Orders[Formulations,Order4] - Drugs To Be Dispatched[Formulations,Order4]),IF 
THEN ELSE( Backlog Range One[Formulations,Order4] >0 :AND: Backlog Range 
Two[Formulations,Order4] >0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] + 
Backlog Range Two[Formulations,Order4] , Processed 
Orders[Formulations,Order4] ,IF THEN ELSE( Processed 
Orders[Formulations,Order4] > 0 :AND: Backlog Range One[Formulations,Order4] 
> 0 :AND: Drugs Available For Dispatch[Formulations,Order4] > Backlog Range 
One[Formulations,Order4] + Processed Orders[Formulations,Order4] , 
MAX(0,Processed Orders[Formulations,Order4] - Drugs To Be 
Dispatched[Formulations,Order4]) ,IF THEN ELSE( Backlog Range 
One[Formulations,Order4] > 0 :AND: Drugs Available For 
Dispatch[Formulations,Order4] > Backlog Range One[Formulations,Order4] , 
Processed Orders[Formulations,Order4] ,IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order4] > Processed Orders[Formulations,Order4] , 
MAX(0,Processed Orders[Formulations,Order4] - Drugs To Be 
Dispatched[Formulations,Order4]) , Processed Orders[Formulations,Order4] )) ) ) ) ) ) 
Description: MAX(0,Processed Orders[Formulations,Order] - Drugs To Be 
Dispatched[Formulations,Order]) Present In 2 Views: 
Not in View 
Main Model 
Used By 
Order Backlogs QUEUE FIFO(Incoming[Formulations,Order Number], Backlog 
Reduction[Formulations,Order Number] , Profile , 0 , 0 )QUEUE FIFO ATTRIB( 
_inflow_ , _outflow_ , _attrib_ , _changerate_ , _initprofile_ , _iattribprof_ , 
_inittotal_ , _initattrib_ , _initage_ )QUEUE FIFO ATTRIB( 
Incoming[Formulations,Order Number] , Backlog Reduction[Formulations,Order 
Number] , inatt[Formulations,Order Number] , 1 , Profile , Profile , 0 , -1000 , 0 ) 
ModelC #50 
C 
Initial Stock On Hand (Drugs) 
Initial Stock On Hand[Capreomycin,Order Number] = 1.19963e+06, 0, 0, 0 Initial 
Stock On Hand[Kanamycin,Order Number] = 1.57709e+06, 0, 0, 0 Initial Stock On 
Hand[Cycloserine,Order Number] = 9.15269e+06, 0, 0, 0 Description: 
7997521.05139e+069.15269e+06 Present In 2 Views: 
Not in View 
Main Model 
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Used By 
SRS Stock On Hand 
ModelC #54 C Inventory Position (Drugs) 
Inventory Position[Formulations,Order1] = SRS Stock On Hand[Formulations,Order1] 
+ SRS Supply Line[Formulations,Order1] -Order Backlogs[Formulations,Order1] - 
Order Backlogs[Formulations,Order2] - Order Backlogs[Formulations,Order3] - 
Order Backlogs[Formulations,Order4] Inventory Position[Formulations,Order2] = 0 
Inventory Position[Formulations,Order3] = 0 Inventory 
Position[Formulations,Order4] = 0 Present In 2 Views: 
Not in View 
Main Model 
Used By 
SRS Demand 
 
ModelC #60 
F,A 
Normal Order Drugs Received By Countries (Drugs/Week) 
Normal Order Drugs Received By Countries[Formulations,Order Number] = 
Dispatch[Formulations,Order Number] Present In 1 View: 
Main Model 
Used By 
Normal Orders Supply Line 
Total Normal Order Drugs Received 
 
ModelC #61 
F,A 
Normal Orders From Countries (Drugs/Week) 
Normal Orders From Countries[Formulations,Order Number] = Demand 
Input[Formulations,Order Number] Present In 2 Views: 
Cost 
Main Model 
Used By 
Normal Orders Supply Line 
Order Processing 
 
ModelC #62 L Normal Orders Supply Line (Drugs) 
Normal Orders Supply Line[Formulations,Order Number] = ∫"Normal Orders From 
Countries"["Formulations","Order Number"]-"Normal Order Drugs Received By 
Countries"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
Main Model 
Used By 
 
ModelC #63 
C,F 
Obsolete Stock (Drugs/Week) 
Obsolete Stock[Formulations,Order1] = QUEUE AGE IN RANGE( SRS Stock On 
Hand[Formulations,Order1] , Expiration Value[Formulations,Order1] , 
NAREPLACEMENT )/TIME STEP Obsolete Stock[Formulations,Order2] = 0 Obsolete 
Stock[Formulations,Order3] = 0 Obsolete Stock[Formulations,Order4] = 0 Present 
In 3 Views: 
Not in View 
Cost 
Main Model 
Used By 
Cumulative Obsolete Stock 
Drugs Available For Dispatch 
SRS Stock On Hand 
Total Obsolescence Cost 
 
ModelC #67 A Order Backlogs (Drugs) 
Order Backlogs[Formulations,Order Number] = QUEUE 
FIFO(Incoming[Formulations,Order Number], Backlog 
Reduction[Formulations,Order Number] , Profile , 0 , 0 ) Description: QUEUE 
FIFO(Incoming[Formulations,Order Number], Backlog 
Reduction[Formulations,Order Number] , Profile , 0 , 0 )QUEUE FIFO ATTRIB( 
_inflow_ , _outflow_ , _attrib_ , _changerate_ , _initprofile_ , _iattribprof_ , 
_inittotal_ , _initattrib_ , _initage_ )QUEUE FIFO ATTRIB( 
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Incoming[Formulations,Order Number] , Backlog Reduction[Formulations,Order 
Number] , inatt[Formulations,Order Number] , 1 , Profile , Profile , 0 , -1000 , 0 ) 
Present In 1 View: 
Main Model 
Used By 
Backlog Range One 
Backlog Range Two 
Backlog Reduction MAX(0,Drugs To Be Dispatched[Formulations,Order] - 
Processed Orders[Formulations,Order]) 
Drugs To Be Dispatched IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] > Processed Orders[Formulations,Order1] , 
Processed Orders[Formulations,Order1] , 0 ) 
Incoming MAX(0,Processed Orders[Formulations,Order] - Drugs To Be 
Dispatched[Formulations,Order]) 
Inventory Position 
ModelC #69 
DE,A 
Order Processing (Drugs/Week) 
Order Processing[Formulations,Order Number] = DELAY MATERIAL (Normal Orders 
From Countries[Formulations,Order Number], Order Processing Lead 
Time[Formulations,Order Number], 0, 0) Present In 1 View: 
Main Model 
Used By 
Processed Orders 
 
ModelC #70 A Order Processing Lead Time (Week) 
Order Processing Lead Time[Capreomycin,Order1] = RANDOM TRIANGULAR( 2 , 
30 , 0 , 4 , 35 , 1 ) Order Processing Lead Time[Capreomycin,Order2] = RANDOM 
TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order Processing Lead 
Time[Capreomycin,Order3] = RANDOM TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order 
Processing Lead Time[Capreomycin,Order4] = RANDOM TRIANGULAR( 2 , 30 , 0 , 
4 , 35 , 1 ) Order Processing Lead Time[Kanamycin,Order1] = RANDOM 
TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order Processing Lead 
Time[Kanamycin,Order2] = RANDOM TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order 
Processing Lead Time[Kanamycin,Order3] = RANDOM TRIANGULAR( 2 , 30 , 0 , 4 , 
35 , 1 ) Order Processing Lead Time[Kanamycin,Order4] = RANDOM TRIANGULAR( 
2 , 30 , 0 , 4 , 35 , 1 ) Order Processing Lead Time[Cycloserine,Order1] = RANDOM 
TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order Processing Lead 
Time[Cycloserine,Order2] = RANDOM TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Order 
Processing Lead Time[Cycloserine,Order3] = RANDOM TRIANGULAR( 2 , 30 , 0 , 4 
, 35 , 1 ) Order Processing Lead Time[Cycloserine,Order4] = RANDOM 
TRIANGULAR( 2 , 30 , 0 , 4 , 35 , 1 ) Present In 2 Views: 
Not in View 
Main Model 
Used By 
Order Processing 
 
ModelC #82 C Order-Up-To-Level (Drugs) 
Order-Up-To-Level[Capreomycin,Order Number] = 1.19963e+06, 0, 0, 0 Order-Up-
To-Level[Kanamycin,Order Number] = 1.57709e+06, 0, 0, 0 Order-Up-To-
Level[Cycloserine,Order Number] = 9.15269e+06, 0, 0, 0 Description: 
7997521.05139e+069.15269e+06 Present In 2 Views: 
Not in View 
Main Model 
Used By 
SRS Demand 
 
ModelC #85 
F,A 
Orders Placed To Manufacturer (Drugs/Week) 
Orders Placed To Manufacturer[Formulations,Order Number] = SRS 
Demand[Formulations,Order Number] Present In 1 View: 
Main Model 
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Used By 
SRS Supply Line 
ModelC #89 A Processed Orders (Drugs/Week) 
Processed Orders[Formulations,Order Number] = INTEGER(Order 
Processing[Formulations,Order Number]) Present In 1 View: 
Main Model 
Used By 
Backlog Reduction MAX(0,Drugs To Be Dispatched[Formulations,Order] - 
Processed Orders[Formulations,Order]) 
Drugs To Be Dispatched IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] > Processed Orders[Formulations,Order1] , 
Processed Orders[Formulations,Order1] , 0 ) 
Incoming MAX(0,Processed Orders[Formulations,Order] - Drugs To Be 
Dispatched[Formulations,Order]) 
 
ModelC #90 
A 
Production & Dispatch Lead Time (Week) 
Production & Dispatch Lead Time[Capreomycin,Order1] = RANDOM TRIANGULAR( 
5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead Time[Capreomycin,Order2] = 
RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead 
Time[Capreomycin,Order3] = RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) 
Production & Dispatch Lead Time[Capreomycin,Order4] = RANDOM TRIANGULAR( 
5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead Time[Kanamycin,Order1] = 
RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead 
Time[Kanamycin,Order2] = RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) 
Production & Dispatch Lead Time[Kanamycin,Order3] = RANDOM TRIANGULAR( 5 
, 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead Time[Kanamycin,Order4] = 
RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead 
Time[Cycloserine,Order1] = RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) 
Production & Dispatch Lead Time[Cycloserine,Order2] = RANDOM TRIANGULAR( 5 
, 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead Time[Cycloserine,Order3] = 
RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) Production & Dispatch Lead 
Time[Cycloserine,Order4] = RANDOM TRIANGULAR( 5 , 45 , 0 , 6 , 70 , 1 ) Present 
In 2 Views: 
Not in View 
Main Model 
Used By 
Production & Dispatch To SRS 
 
ModelC #102 
DE,A 
Production & Dispatch To SRS (Drugs/Week) 
Production & Dispatch To SRS[Formulations,Order Number] = DELAY MATERIAL 
(SRS Demand[Formulations,Order Number] , "Production & Dispatch Lead 
Time"[Formulations,Order Number] , 0 , 0) Present In 1 View: 
Main Model 
Used By 
Drugs Received From Manufacturer 
SRS Stock On Hand 
 
ModelC #103 
A,D,T 
Profile (Dmnl) 
Profile([(0,0)-(1,1)],(0,1),(1,1))  
Main Model 
Used By 
Order Backlogs QUEUE FIFO(Incoming[Formulations,Order Number], Backlog 
Reduction[Formulations,Order Number] , Profile , 0 , 0 )QUEUE FIFO ATTRIB( 
_inflow_ , _outflow_ , _attrib_ , _changerate_ , _initprofile_ , _iattribprof_ , 
_inittotal_ , _initattrib_ , _initage_ )QUEUE FIFO ATTRIB( 
Incoming[Formulations,Order Number] , Backlog Reduction[Formulations,Order 
Number] , inatt[Formulations,Order Number] , 1 , Profile , Profile , 0 , -1000 , 0 ) 
SRS Stock On Hand 
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ModelC #104 
C 
Proportion Of Orders Placed (Dmnl) 
Proportion Of Orders Placed[Capreomycin,Order Number] = 0.574, 0.389, 0.255, 
0.263 Proportion Of Orders Placed[Kanamycin,Order Number] = 0.45, 0.191, 0.287, 
0.479 Proportion Of Orders Placed[Cycloserine,Order Number] = 0.721, 0.508, 
0.412, 0.298 Present In 2 Views: 
Not in View 
Main Model 
Used By 
Demand Input 
 
ModelC #107 
C 
Reorder Frequency (Week) 
Reorder Frequency[Formulations,Order Number] = 1 Present In 1 View: 
Main Model 
Used By 
Reorder? 
 
ModelC #108 
A 
Reorder Point (Drugs/Week) 
Reorder Point[Capreomycin,Order Number] = 399876 + Safety 
Stock[Capreomycin,Order Number] Reorder Point[Kanamycin,Order Number] = 
525696 + Safety Stock[Kanamycin,Order Number] Reorder 
Point[Cycloserine,Order Number] = 4.57634e+06 + Safety Stock[Cycloserine,Order 
Number] Present In 2 Views: 
Not in View 
Main Model 
Used By 
SRS Demand 
 
ModelC #111 A Reorder? (Week) 
Reorder?[Formulations,Order Number] = MODULO( Time , Reorder 
Frequency[Formulations,Order Number] ) Present In 1 View: 
Main Model 
Used By 
SRS Demand 
 
ModelC #112 
C 
Safety Stock (Drugs/Week) 
Safety Stock[Capreomycin,Order Number] = 33323*6 Safety 
Stock[Kanamycin,Order Number] = 43808*3 Safety Stock[Cycloserine,Order 
Number] = 381362*3 Present In 2 Views: 
Not in View 
Main Model 
Used By 
Reorder Point 
 
ModelC #116 
A 
SRS Demand (Drugs/Week) 
SRS Demand[Formulations,Order Number] = IF THEN ELSE( 
"Reorder?"[Formulations,Order Number]=0 , IF THEN ELSE( Inventory 
Position[Formulations,Order Number]<Reorder Point[Formulations,Order Number] , 
(MAX(0,"Order-Up-To-Level"[Formulations,Order Number] - Inventory 
Position[Formulations,Order Number]))/TIME STEP, 0 ) , 0 ) Present In 2 Views: 
Cost 
Main Model 
Used By 
Orders Placed To Manufacturer 
Production & Dispatch To SRS 
Total Unit Cost 
 
ModelC #117 A SRS Stock On Hand (Drugs) 
SRS Stock On Hand[Formulations,Order Number] = QUEUE FIFO("Production & 
Dispatch To SRS"[Formulations,Order Number], Obsolete 
Stock[Formulations,Order Number] + Dispatch Drugs To 
Countries[Formulations,Order Number] , Profile , Initial Stock On Hand 
[Formulations,Order Number] , 0 ) Present In 2 Views: 
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Cost 
Main Model 
Used By 
Drugs Available For Dispatch 
Inventory Position 
Obsolete Stock 
ModelC #118 L SRS Supply Line (Drugs) 
SRS Supply Line[Formulations,Order Number] = ∫"Orders Placed To 
Manufacturer"["Formulations","Order Number"]-"Drugs Received From 
Manufacturer"["Formulations","Order Number"] dt + 0.0 Present In 1 View: 
Main Model 
Used By 
Inventory Position 
 
ModelC #122 
L 
Total Normal Order Drugs Received (Drugs) 
Total Normal Order Drugs Received[Formulations,Order Number] = ∫"Normal 
Order Drugs Received By Countries"["Formulations","Order Number"] dt + 0.0 
Present In 1 View: 
Main Model 
Used By 
 
ModelC #125 
A 
Uniform (Dmnl) 
Uniform[Capreomycin,Order Number] = RANDOM 0 1() Uniform[Kanamycin,Order 
Number] = (RANDOM 0 1()) Uniform[Cycloserine,Order Number] = RANDOM 0 1() 
Present In 2 Views: 
Not in View 
Main Model 
Used By 
Demand Input 
 
ModelC #128 
A 
Weibull Distribution (Drugs/Week) 
Weibull Distribution[Capreomycin,Order Number] = RANDOM WEIBULL( 78 , 
448000 , 0.6161 , 78 , 32500 , 0 ) Weibull Distribution[Kanamycin,Order Number] = 
RANDOM WEIBULL( 450 , 882000 ,0.4525 , 450 , 50000 , 1 ) Weibull 
Distribution[Cycloserine,Order Number] = RANDOM WEIBULL( 1500 , 9.4491e+06 , 
0.4755 , 1500 , 420000 , 1 ) Present In 2 Views: 
Not in View 
Main Model 
Used By 
Demand Input 
 
Top (Type) Subscripts (2 Variables) 
Group Type Variable Name And Description  
ModelC #45 
Sub 
Formulations () 
Formulations:Capreomycin, Kanamycin, Cycloserine Present In 2 Views: 
Cost 
Main Model 
Used By 
Backlog Range One 
Backlog Range Two 
Backlog Reduction MAX(0,Drugs To Be Dispatched[Formulations,Order] - Processed 
Orders[Formulations,Order]) 
Country Dispatch Lead Time 
Cumulative Obsolete Stock 
Cumulative Total Obsolescence Cost 
Cumulative Total Unit Cost 
Demand Input 
Dispatch 
Dispatch Drugs To Countries 
Drugs Available For Dispatch 
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Drugs Received From Manufacturer 
Drugs To Be Dispatched IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] > Processed Orders[Formulations,Order1] , Processed 
Orders[Formulations,Order1] , 0 ) 
Expiration Value 
Incoming MAX(0,Processed Orders[Formulations,Order] - Drugs To Be 
Dispatched[Formulations,Order]) 
Initial Stock On Hand 7997521.05139e+069.15269e+06 
Inventory Position 
Normal Order Drugs Received By Countries 
Normal Orders From Countries 
Normal Orders Supply Line 
Obsolete Stock 
Order Backlogs QUEUE FIFO(Incoming[Formulations,Order Number], Backlog 
Reduction[Formulations,Order Number] , Profile , 0 , 0 )QUEUE FIFO ATTRIB( 
_inflow_ , _outflow_ , _attrib_ , _changerate_ , _initprofile_ , _iattribprof_ , _inittotal_ 
, _initattrib_ , _initage_ )QUEUE FIFO ATTRIB( Incoming[Formulations,Order Number] 
, Backlog Reduction[Formulations,Order Number] , inatt[Formulations,Order Number] 
, 1 , Profile , Profile , 0 , -1000 , 0 ) 
Order Processing 
Order Processing Lead Time 
Order-Up-To-Level 7997521.05139e+069.15269e+06 
Orders Placed To Manufacturer 
Per Unit Cost 
Processed Orders 
Production & Dispatch Lead Time 
Production & Dispatch To SRS 
Proportion Of Orders Placed 
Reorder Frequency 
Reorder Point 
Reorder? 
SRS Demand 
SRS Stock On Hand 
SRS Supply Line 
Total Costs 
Total Normal Order Drugs Received 
Total Obsolescence Cost 
Total Unit Cost 
Uniform 
Weibull Distribution 
ModelC #68 
Sub 
Order Number () 
Order Number:Order1, Order2, Order3, Order4 Present In 2 Views: 
Cost 
Main Model 
Used By 
Backlog Range One 
Backlog Range Two 
Backlog Reduction MAX(0,Drugs To Be Dispatched[Formulations,Order] - Processed 
Orders[Formulations,Order]) 
Country Dispatch Lead Time 
Cumulative Obsolete Stock 
Cumulative Total Obsolescence Cost 
Cumulative Total Unit Cost 
Demand Input 
Dispatch 
Dispatch Drugs To Countries 
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Drugs Received From Manufacturer 
Drugs To Be Dispatched IF THEN ELSE( Drugs Available For 
Dispatch[Formulations,Order1] > Processed Orders[Formulations,Order1] , Processed 
Orders[Formulations,Order1] , 0 ) 
Expiration Value 
Incoming MAX(0,Processed Orders[Formulations,Order] - Drugs To Be 
Dispatched[Formulations,Order]) 
Initial Stock On Hand 7997521.05139e+069.15269e+06 
Inventory Position 
Normal Order Drugs Received By Countries 
Normal Orders From Countries 
Normal Orders Supply Line 
Obsolete Stock 
Order Backlogs QUEUE FIFO(Incoming[Formulations,Order Number], Backlog 
Reduction[Formulations,Order Number] , Profile , 0 , 0 )QUEUE FIFO ATTRIB( 
_inflow_ , _outflow_ , _attrib_ , _changerate_ , _initprofile_ , _iattribprof_ , _inittotal_ 
, _initattrib_ , _initage_ )QUEUE FIFO ATTRIB( Incoming[Formulations,Order Number] 
, Backlog Reduction[Formulations,Order Number] , inatt[Formulations,Order Number] 
, 1 , Profile , Profile , 0 , -1000 , 0 ) 
Order Processing 
Order Processing Lead Time 
Order-Up-To-Level 7997521.05139e+069.15269e+06 
Orders Placed To Manufacturer 
Per Unit Cost 
Processed Orders 
Production & Dispatch Lead Time 
Production & Dispatch To SRS 
Proportion Of Orders Placed 
Reorder Frequency 
Reorder Point 
Reorder? 
SRS Demand 
SRS Stock On Hand 
SRS Supply Line 
Safety Stock 
Total Normal Order Drugs Received 
Total Obsolescence Cost 
Total Unit Cost 
Uniform 
Weibull Distribution 
 
All Variables (51) 
Group Type Variable 
ModelC A Backlog Range One (Drugs/Week) 
ModelC A Backlog Range Two (Drugs/Week) 
ModelC A Backlog Reduction (Drugs/Week) 
ModelC A Country Dispatch Lead Time (Week) 
ModelC L Cumulative Obsolete Stock (Drugs) 
ModelC L Cumulative Total Obsolescence Cost (Dollar) 
ModelC L Cumulative Total Unit Cost (Dollar) 
ModelC A Demand Input (Drugs/Week) 
ModelC A Dispatch Drugs To Countries (Drugs/Week) 
ModelC DE,A Dispatch (Drugs/Week) 
ModelC A Drugs Available For Dispatch (Drugs/Week) 
ModelC F,A Drugs Received From Manufacturer (Drugs/Week) 
ModelC A Drugs To Be Dispatched (Drugs/Week) 
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ModelC C Expiration Value (Week) 
.Control C FINAL TIME (Week) 
ModelC A Incoming (Drugs/Week) 
ModelC C Initial Stock On Hand (Drugs) 
.Control C INITIAL TIME (Week) 
ModelC A Inventory Position (Drugs) 
ModelC F,A Normal Order Drugs Received By Countries (Drugs/Week) 
ModelC F,A Normal Orders From Countries (Drugs/Week) 
ModelC L Normal Orders Supply Line (Drugs) 
ModelC F,A Obsolete Stock (Drugs/Week) 
ModelC A Order Backlogs (Drugs) 
ModelC A Order Processing Lead Time (Week) 
ModelC DE,A Order Processing (Drugs/Week) 
ModelC C Order-Up-To-Level (Drugs) 
ModelC F,A Orders Placed To Manufacturer (Drugs/Week) 
ModelC C Per Unit Cost (Dollar/Drugs) 
ModelC A Processed Orders (Drugs/Week) 
ModelC A Production & Dispatch Lead Time (Week) 
ModelC DE,A Production & Dispatch To SRS (Drugs/Week) 
ModelC A,D,T Profile (Dmnl) 
ModelC C Proportion Of Orders Placed (Dmnl) 
ModelC C Reorder Frequency (Week) 
ModelC A Reorder Point (Drugs/Week) 
ModelC A Reorder? (Week) 
ModelC C Safety Stock (Drugs/Week) 
.Control A SAVEPER (Week ) 
ModelC A SRS Demand (Drugs/Week) 
ModelC A SRS Stock On Hand (Drugs) 
ModelC L SRS Supply Line (Drugs) 
.Control C TIME STEP (Week ) 
ModelC A Total Costs (Dollar) 
ModelC L Total Normal Order Drugs Received (Drugs) 
ModelC F,A Total Obsolescence Cost (Dollar/Week) 
ModelC F,A Total Unit Cost (Dollar/Week) 
ModelC A Uniform (Dmnl) 
ModelC A Weibull Distribution (Drugs/Week) 
 
Undocumented Variables (42) 
Group Type Variable 
ModelC A Backlog Range One (Drugs/Week) 
ModelC A Backlog Range Two (Drugs/Week) 
ModelC A Country Dispatch Lead Time (Week) 
ModelC L Cumulative Obsolete Stock (Drugs) 
ModelC L Cumulative Total Obsolescence Cost (Dollar) 
ModelC L Cumulative Total Unit Cost (Dollar) 
ModelC A Demand Input (Drugs/Week) 
ModelC A Dispatch Drugs To Countries (Drugs/Week) 
ModelC DE,A Dispatch (Drugs/Week) 
ModelC A Drugs Available For Dispatch (Drugs/Week) 
ModelC F,A Drugs Received From Manufacturer (Drugs/Week) 
ModelC C Expiration Value (Week) 
ModelC Sub Formulations () 
ModelC A Inventory Position (Drugs) 
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ModelC F,A Normal Order Drugs Received By Countries (Drugs/Week) 
ModelC F,A Normal Orders From Countries (Drugs/Week) 
ModelC L Normal Orders Supply Line (Drugs) 
ModelC F,A Obsolete Stock (Drugs/Week) 
ModelC Sub Order Number () 
ModelC A Order Processing Lead Time (Week) 
ModelC DE,A Order Processing (Drugs/Week) 
ModelC F,A Orders Placed To Manufacturer (Drugs/Week) 
ModelC C Per Unit Cost (Dollar/Drugs) 
ModelC A Processed Orders (Drugs/Week) 
ModelC A Production & Dispatch Lead Time (Week) 
ModelC DE,A Production & Dispatch To SRS (Drugs/Week) 
ModelC A,D,T Profile (Dmnl) 
ModelC C Proportion Of Orders Placed (Dmnl) 
ModelC C Reorder Frequency (Week) 
ModelC A Reorder Point (Drugs/Week) 
ModelC A Reorder? (Week) 
ModelC C Safety Stock (Drugs/Week) 
ModelC A SRS Demand (Drugs/Week) 
ModelC A SRS Stock On Hand (Drugs) 
ModelC L SRS Supply Line (Drugs) 
ModelC A Total Costs (Dollar) 
ModelC L Total Normal Order Drugs Received (Drugs) 
ModelC F,A Total Obsolescence Cost (Dollar/Week) 
ModelC F,A Total Unit Cost (Dollar/Week) 
ModelC A Uniform (Dmnl) 
ModelC A Weibull Distribution (Drugs/Week) 
 
 
Stock Variables (6) 
Group Type Variable 
ModelC L Cumulative Obsolete Stock (Drugs) 
ModelC L Cumulative Total Obsolescence Cost (Dollar) 
ModelC L Cumulative Total Unit Cost (Dollar) 
ModelC L Normal Orders Supply Line (Drugs) 
ModelC L SRS Supply Line (Drugs) 
ModelC L Total Normal Order Drugs Received (Drugs) 
 
State Variables (9) 
Group Type Variable 
ModelC L Cumulative Obsolete Stock (Drugs) 
ModelC L Cumulative Total Obsolescence Cost (Dollar) 
ModelC L Cumulative Total Unit Cost (Dollar) 
ModelC DE,A Dispatch (Drugs/Week) 
ModelC L Normal Orders Supply Line (Drugs) 
ModelC DE,A Order Processing (Drugs/Week) 
ModelC DE,A Production & Dispatch To SRS (Drugs/Week) 
ModelC L SRS Supply Line (Drugs) 
ModelC L Total Normal Order Drugs Received (Drugs) 
 
Variables without Predefined Min or Max Values (47) 
Group Type Variable 
ModelC A Backlog Range One (Drugs/Week) 
ModelC A Backlog Range Two (Drugs/Week) 
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ModelC A Backlog Reduction (Drugs/Week) 
ModelC A Country Dispatch Lead Time (Week) 
ModelC L Cumulative Obsolete Stock (Drugs) 
ModelC L Cumulative Total Obsolescence Cost (Dollar) 
ModelC L Cumulative Total Unit Cost (Dollar) 
ModelC A Demand Input (Drugs/Week) 
ModelC A Dispatch Drugs To Countries (Drugs/Week) 
ModelC DE,A Dispatch (Drugs/Week) 
ModelC A Drugs Available For Dispatch (Drugs/Week) 
ModelC F,A Drugs Received From Manufacturer (Drugs/Week) 
ModelC A Drugs To Be Dispatched (Drugs/Week) 
ModelC C Expiration Value (Week) 
ModelC A Incoming (Drugs/Week) 
ModelC C Initial Stock On Hand (Drugs) 
ModelC A Inventory Position (Drugs) 
ModelC F,A Normal Order Drugs Received By Countries (Drugs/Week) 
ModelC F,A Normal Orders From Countries (Drugs/Week) 
ModelC L Normal Orders Supply Line (Drugs) 
ModelC F,A Obsolete Stock (Drugs/Week) 
ModelC A Order Backlogs (Drugs) 
ModelC A Order Processing Lead Time (Week) 
ModelC DE,A Order Processing (Drugs/Week) 
ModelC C Order-Up-To-Level (Drugs) 
ModelC F,A Orders Placed To Manufacturer (Drugs/Week) 
ModelC C Per Unit Cost (Dollar/Drugs) 
ModelC A Processed Orders (Drugs/Week) 
ModelC A Production & Dispatch Lead Time (Week) 
ModelC DE,A Production & Dispatch To SRS (Drugs/Week) 
ModelC A,D,T Profile (Dmnl) 
ModelC C Proportion Of Orders Placed (Dmnl) 
ModelC C Reorder Frequency (Week) 
ModelC A Reorder Point (Drugs/Week) 
ModelC A Reorder? (Week) 
ModelC C Safety Stock (Drugs/Week) 
ModelC A SRS Demand (Drugs/Week) 
ModelC A SRS Stock On Hand (Drugs) 
ModelC L SRS Supply Line (Drugs) 
ModelC A Total Costs (Dollar) 
ModelC L Total Normal Order Drugs Received (Drugs) 
ModelC F,A Total Obsolescence Cost (Dollar/Week) 
ModelC F,A Total Unit Cost (Dollar/Week) 
ModelC A Uniform (Dmnl) 
ModelC A Weibull Distribution (Drugs/Week) 
 
Positive Polarity Causal Links (28) 
Cause Effect Polarity 
Cumulative Total Obsolescence Cost Total Costs + 
Cumulative Total Unit Cost Total Costs + 
Demand Input Normal Orders From Countries + 
Dispatch Normal Order Drugs Received By Countries + 
Drugs To Be Dispatched Backlog Reduction + 
Drugs To Be Dispatched Dispatch Drugs To Countries + 
Normal Order Drugs Received By Countries Total Normal Order Drugs Received + 
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Normal Orders From Countries Normal Orders Supply Line + 
Obsolete Stock Cumulative Obsolete Stock + 
Obsolete Stock Drugs Available For Dispatch + 
Obsolete Stock Total Obsolescence Cost + 
Order-Up-To-Level SRS Demand + 
Orders Placed To Manufacturer SRS Supply Line + 
Per Unit Cost Total Obsolescence Cost + 
Per Unit Cost Total Unit Cost + 
Production & Dispatch To SRS Drugs Received From Manufacturer + 
Safety Stock Reorder Point + 
SRS Demand Orders Placed To Manufacturer + 
SRS Demand Total Unit Cost + 
SRS Stock On Hand Drugs Available For Dispatch + 
SRS Stock On Hand Inventory Position + 
SRS Supply Line Inventory Position + 
TIME STEP Drugs Available For Dispatch + 
TIME STEP SAVEPER + 
TIME STEP SRS Demand + 
Total Obsolescence Cost Cumulative Total Obsolescence Cost + 
Total Unit Cost Cumulative Total Unit Cost + 
Weibull Distribution Demand Input + 
 
Negative Polarity Causal Links (5) 
Cause Effect Polarity 
Drugs Received From Manufacturer SRS Supply Line - 
Drugs To Be Dispatched Incoming - 
Inventory Position SRS Demand - 
Normal Order Drugs Received By Countries Normal Orders Supply Line - 
Order Backlogs Inventory Position - 
 
Function-based Polarity Causal Links (47) 
Cause Effect Polarity 
Backlog Range One Backlog Reduction If Then Else Switch 
Backlog Range One Drugs To Be 
Dispatched 
If Then Else Switch 
Backlog Range One Incoming If Then Else Switch 
Backlog Range Two Backlog Reduction If Then Else Switch 
Backlog Range Two Drugs To Be 
Dispatched 
If Then Else Switch 
Backlog Range Two Incoming If Then Else Switch 
Backlog Reduction Order Backlogs Function[QUEUEFIFO] 
Country Dispatch Lead 
Time 
Dispatch Function[DELAYMATERIAL] 
Demand Input Demand Input If Then Else Switch 
Dispatch Drugs To 
Countries 
SRS Stock On Hand Function[QUEUEFIFO] 
Drugs Available For 
Dispatch 
Backlog Reduction If Then Else Switch 
Drugs Available For 
Dispatch 
Drugs To Be 
Dispatched 
If Then Else Switch 
Drugs Available For 
Dispatch 
Incoming If Then Else Switch 
Drugs To Be Dispatched Dispatch Function[DELAYMATERIAL] 
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Drugs To Be Dispatched Drugs To Be 
Dispatched 
If Then Else Switch 
Expiration Value Obsolete Stock Function[QUEUEAGEINRANGE] 
Incoming Order Backlogs Function[QUEUEFIFO] 
Initial Stock On Hand SRS Stock On Hand Function[QUEUEFIFO] 
NAREPLACEMENT Backlog Range One Function[QUEUEAGEOLDEST,QUEUEAGEINRANGE] 
NAREPLACEMENT Obsolete Stock Function[QUEUEAGEINRANGE] 
Normal Orders From 
Countries 
Order Processing Function[DELAYMATERIAL] 
Obsolete Stock SRS Stock On Hand Function[QUEUEFIFO] 
Order Backlogs Backlog Range One Function[QUEUEAGEOLDEST,QUEUEAGEINRANGE] 
Order Backlogs Backlog Range Two Function[QUEUEAGEOLDEST,QUEUEAGEINRANGE] 
Order Backlogs Backlog Reduction If Then Else Switch 
Order Backlogs Drugs To Be 
Dispatched 
If Then Else Switch 
Order Backlogs Incoming If Then Else Switch 
Order Processing Processed Orders Function[INTEGER] 
Order Processing Lead 
Time 
Order Processing Function[DELAYMATERIAL] 
Processed Orders Backlog Reduction If Then Else Switch 
Processed Orders Drugs To Be 
Dispatched 
If Then Else Switch 
Processed Orders Incoming If Then Else Switch 
Production & Dispatch 
Lead Time 
Production & 
Dispatch To SRS 
Function[DELAYMATERIAL] 
Production & Dispatch To 
SRS 
SRS Stock On Hand Function[QUEUEFIFO] 
Profile Order Backlogs Function[QUEUEFIFO] 
Profile SRS Stock On Hand Function[QUEUEFIFO] 
Proportion Of Orders 
Placed 
Demand Input If Then Else Switch 
Reorder Frequency Reorder? Function[MODULO] 
Reorder Point SRS Demand If Then Else Switch 
Reorder? SRS Demand If Then Else Switch 
SRS Demand Production & 
Dispatch To SRS 
Function[DELAYMATERIAL] 
SRS Stock On Hand Obsolete Stock Function[QUEUEAGEINRANGE] 
Time Reorder? Function[MODULO] 
TIME STEP Obsolete Stock Function[QUEUEAGEINRANGE] 
Uniform Demand Input If Then Else Switch 
 
View-Variable Profile 
View View-Variable Profile 
Cost                                       10 vars (18.2%) 
Main 
Model 
                                                                                                                                                      41 
vars (74.5%) 
 
List Of 2 views and their 47 Variables 
  
Cost 
Main 
Model 
  
Total: 10 41 Total: 
Total Normal Order Drugs Received (In 1 
View) 
      Total Normal Order Drugs Received (In 1 
View) 
Proportion Of Orders Placed (In 1 View)       Proportion Of Orders Placed (In 1 View) 
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Obsolete Stock (In 2 Views)         Obsolete Stock (In 2 Views) 
SRS Stock On Hand (In 2 Views)         SRS Stock On Hand (In 2 Views) 
Order-Up-To-Level (In 1 View)       Order-Up-To-Level (In 1 View) 
Processed Orders (In 1 View)       Processed Orders (In 1 View) 
Safety Stock (In 1 View)       Safety Stock (In 1 View) 
Dispatch (In 1 View)       Dispatch (In 1 View) 
Normal Orders Supply Line (In 1 View)       Normal Orders Supply Line (In 1 View) 
Uniform (In 1 View)       Uniform (In 1 View) 
Backlog Range Two (In 1 View)       Backlog Range Two (In 1 View) 
Dispatch Drugs To Countries (In 1 View)       Dispatch Drugs To Countries (In 1 View) 
Backlog Reduction (In 1 View)       Backlog Reduction (In 1 View) 
Profile (In 1 View)       Profile (In 1 View) 
Reorder Point (In 1 View)       Reorder Point (In 1 View) 
Reorder? (In 1 View)       Reorder? (In 1 View) 
Order Processing Lead Time (In 1 View)       Order Processing Lead Time (In 1 View) 
Order Backlogs (In 1 View)       Order Backlogs (In 1 View) 
Demand Input (In 1 View)       Demand Input (In 1 View) 
Normal Order Drugs Received By 
Countries (In 1 View) 
      Normal Order Drugs Received By 
Countries (In 1 View) 
Country Dispatch Lead Time (In 1 View)       Country Dispatch Lead Time (In 1 View) 
Production & Dispatch To SRS (In 1 View)       Production & Dispatch To SRS (In 1 View) 
Reorder Frequency (In 1 View)       Reorder Frequency (In 1 View) 
Drugs Received From Manufacturer (In 1 
View) 
      Drugs Received From Manufacturer (In 1 
View) 
Order Processing (In 1 View)       Order Processing (In 1 View) 
Drugs Available For Dispatch (In 1 View)       Drugs Available For Dispatch (In 1 View) 
Expiration Value (In 1 View)       Expiration Value (In 1 View) 
Orders Placed To Manufacturer (In 1 
View) 
      Orders Placed To Manufacturer (In 1 
View) 
Weibull Distribution (In 1 View)       Weibull Distribution (In 1 View) 
Incoming (In 1 View)       Incoming (In 1 View) 
Production & Dispatch Lead Time (In 1 
View) 
      Production & Dispatch Lead Time (In 1 
View) 
SRS Demand (In 2 Views)         SRS Demand (In 2 Views) 
Normal Orders From Countries (In 2 
Views) 
        Normal Orders From Countries (In 2 
Views) 
Backlog Range One (In 1 View)       Backlog Range One (In 1 View) 
Cumulative Obsolete Stock (In 1 View)       Cumulative Obsolete Stock (In 1 View) 
Inventory Position (In 1 View)       Inventory Position (In 1 View) 
SRS Supply Line (In 1 View)       SRS Supply Line (In 1 View) 
Drugs To Be Dispatched (In 1 View)       Drugs To Be Dispatched (In 1 View) 
Initial Stock On Hand (In 1 View)       Initial Stock On Hand (In 1 View) 
Total Unit Cost (In 1 View)       Total Unit Cost (In 1 View) 
Total Obsolescence Cost (In 1 View)       Total Obsolescence Cost (In 1 View) 
Per Unit Cost (In 1 View)       Per Unit Cost (In 1 View) 
Total Costs (In 1 View)       Total Costs (In 1 View) 
Cumulative Total Unit Cost (In 1 View)       Cumulative Total Unit Cost (In 1 View) 
Cumulative Total Obsolescence Cost (In 
1 View) 
      Cumulative Total Obsolescence Cost (In 
1 View) 
Total: 10 41 Total: 
  
Cost 
Main 
Model 
  
 
I.3 SDM document for Model C  Page | 317 
 
  Stellenbosch University 
Source File: /Users/deonlingervelder/Desktop/All/Masters/6. Dynamic Modelling Main 
Models/DAILY/ModelC.mdl (Sat Nov 19 12:51:13 SAST 2016)  
Report Created On Sat Nov 19 12:52:05 SAST 2016 
SDM-Doc Tool Version 1.2.44 
Global Security Sciences Division  
Argonne National Laboratory  
 
 
